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Abstract
Until now there has been a distinct lack of a truly representative breast cancer 
model. The development of a complex heterologous multi-compartment 
xenograft model incorporating the relevant stromal elements will provide a 
realistic alternative to currently available chimeric xenograft models. The recent 
ability to immortalize primary human mammary endothelial cells and fibroblasts 
by the insertion of the hTERT and a temperature sensitive mutant variant of 
SV40 LT has made this possible. We have commenced the development of an 
organotypic, 3-compartment xenograft model of human breast cancer. The 
immortalized mammary stromal cells provide a viable and much needed tumour 
microenvironment of human origin for tumour proliferation.
Results have confirmed the crucial importance of stromal cell support as 
well as tumour-stromal interactions in tumourigenesis. MCF-7 cells when 
xenografted in numbers insufficient to produce tumours alone, consistently 
produced tumours when combined with stromal cells. Also, heterologous 
xenografts produced not only faster growing but larger tumours than tumour cell 
lines alone. Immunohistochemical analysis using human cell specific markers 
demonstrated that initial tumour growth was supported by the stromal cells 
before the recruitment of host vasculature. The xenografts were composed 
predominantly of proliferating tumour cells, host ECM and vasculature. 
Surprisingly the LT antigen expressing immortalized stromal cells did not 
survive, proliferate or form organized structures in this environment for any 
reasonable time period.
To conclude, these findings parallel observations made in 3-D 
organotypic cultures which indicates that progression of the epithelial cell tumour
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is not cell autonomous. Rather, that tumourigenesis is promoted, and probably 
sometimes induced, by the anomalies in the surrounding stroma and 
microenvironment. With further refinement and adjustments this model can be 
utilized as a credible pre-clinical model for the development and testing of new 
therapeutic strategies, such as those that target breast cancer stroma itself. This is 
very timely as stroma is now emerging as the dominant factor in modulating 
epithelial morphogenesis and mitogenesis.
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Chapter 1 
Introduction
1.1 General introduction
Breast cancer is the most commonly diagnosed form of cancer and the second 
leading cause of cancer deaths in western women. Despite an underlying rise in 
incidence, 5-year survival has improved steadily over the last 25 years due to 
earlier detection and improved treatment. The only way to sustain or even 
accelerate this progress is to develop and test new therapeutic and preventative 
strategies. However, there is still no effective cure for metastatic breast cancer. 
The development of breast cancer models will hopefully facilitate the 
development and testing of novel therapeutic approaches that target metastatic 
breast cancer both in the form of new drugs, vaccines or even gene therapy.
thIn the early 20 century, during the search for the ultimate model of 
human biology, tissue culture and organ modelling was developed when an 
unlikely collaboration between aviator and engineer Charles Lindbergh and 
surgeon Alexis Carrel resulted in the manufacture of a glass perfusion pump that 
was able to prolong the life of animal organs in culture (Carrel and Lindbergh 
1935, 1938). Carrel’s revolutionary work resulted in the Nobel Prize for his 
microvascular surgery techniques (which were critical in his attempts at 
maintaining organs ex vivo) and his recognition as the “father of tissue culture 
science”. The fundamental principles of Carrel’s studies have resulted in the 
tissue culture models of today. However, problems in maintaining human tissues 
and mature organs in vitro (Hayflick and Moorhead 1961, Trowell 1959) 
together with difficulties in interpreting results led to a step back to more
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simplistic first principle models involving cultivation of single cell types. 
Conversely, these models were too simplistic and therefore poorly representative. 
In an attempt to overcome these problems there has been renewed interest in the 
original ideas of Carrel, which involve the development of more complex and 
physiologically relevant systems, by using animal models. Unfortunately, there 
have been no significant improvements in the technology of animal modelling 
since the discovery of the first xenograft model. In order to rectify this situation 
and improve the authenticity of xenograft models there is a pressing need for the 
development of realistic pre-clinical models representative of breast cancer in 
humans. For this to occur we need to develop multi-compartment heterologous 
organotypic xenograft models, either by inserting intact whole tissue xenografts 
and or more human components.
Xenograft of human breast carcinoma cells in experimental animals 
represents the closest model we have to breast cancer in humans. Presently there 
are numerous human xenograft models available for use in breast cancer research 
(Kim et al. 2003). However, currently available human xenograft models are 
very basic and unsophisticated, simply involving the growth of human breast 
cancer cell lines in immunodeficient mice. Xenografted human breast cancer cell 
lines growing in immunodeficient mice; are not very representative, markedly 
differing from human breast cancer in that they contain fewer stromal cells and 
what stroma that does exist is of course murine in origin, resulting in a chimeric 
tumour. The biology of rodent/human tumours can differ significantly from that 
of humans resulting in unpredictable growth, differentiation and metastatic 
patterns (Cardiff 2001).
Breast cancers in humans are not simply comprised of epithelial tumour 
cells but are a heterogeneous mix of stromal cells (endothelial cells, fibroblasts,
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macrophages and lymphocytes), extracellular matrix and its protein. However a 
distinct lack of a truly representative heterologous xenograft model of breast 
cancer exists. The great hurdle impeding the development of more complex 
xenograft models, at the present time, is a lack of readily available stromal cells 
which are relevant and accessible in an easily manipulatable form. With the 
recent ability to immortalize normal human mammary stromal cells, a convenient 
and reliable source of stable stromal cells has been found. However the 
characteristics and behaviour of these immortal cells in vitro and in vivo remains 
to be determined. Therefore, until they are, other sources of human stromal cells 
need to be explored. Furthermore the most effective method of incorporating 
stromal cells as well as their interaction with the host animal needs to be 
investigated. The development of a complex multicellular organotypic 
heterologous xenograft model incorporating the relevant stromal elements will 
provide a realistic alternative to currently available chimeric xenograft models. 
Such a model containing the relevant and essential constituents of a tumour 
microenvironment, human stroma and extracellular matrix, will provide a more 
authentic breast cancer model for the testing of new and emerging therapeutic 
regimes. In order to develop the most accurate model the biology of the human 
breast as well as the pathology of breast cancer must be considered.
28
1.2 The breast
1.2.1 Anatomy
The breast, also known as the mammary gland, is present in both men and 
women, and its structure is essentially similar in both sexes until puberty. It lies 
on the thoracic wall, attached to the pectoralis muscles by fascia over the 2nd and 
6th ribs. The mature female breast is composed of essentially four structures: 
lobules or glands; milk ducts; fat and connective tissue (see Figure 1.1) (Osborne 
2000, Lamarque 1984). Each fully developed adult breast consists of on average 
of 15-20 lobes. The lobes are arranged roughly in a wheel spoke pattern 
emanating from the nipple/areolar area. The distribution of the lobes is not even 
however; there is a preponderance of glandular tissue in the upper outer portion 
of the breast. This is responsible for the tenderness in this region that many 
women experience prior to their menstrual cycle. It is also the most common site 
for breast cancers. Each lobe is subdivided into lobules, which bear numerous 
secretory acini / alveoli. Acini drain into intralobular ducts which in turn drain 
into interlobular ducts, then into separate lactiferous sinuses and from there into 
lactiferous ducts which open onto the nipple. The space between alveoli is filled 
with interstitial tissue that contains varying amounts of adipose tissue as well as 
other cell types such as fibroblasts, lymphatics and blood vessels lined by 
endothelial cells (Osborne 2000, Lamarque 1984).
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Figure 1.1. Gross anatomy of the mature female breast. Diagram from Breast Cancer 
Source website.
1.2.2 Physiology
At birth, the degree of morphological development in the human breast is highly 
variable (Anbazhagan et al. 1995). Maternal hormones may cause transient 
secretory activity in the infant breast during the first few post-natal days, with 
additional secretory developments occurring for a further two months 
subsequently demonstrated by areas of localised hyperplasia.
At puberty the female breast increases in size, mainly due to the 
deposition of interlobular fat, but further ductal and alveolar development is also 
believed to take place (Vorherr 1974). By adulthood the ductal architecture is 
complete, and the breast remains in this mature inactive state with relatively 
limited menstrual cycle associated changes. During the luteal phase, the luminal 
epithelial cells become more columnar and cellular proliferation increases. This
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is followed by abrupt involution and apoptosis shortly before the onset of 
menstruation (Topper et al. 1986, Neville MC 1983, Fanger and Ree 1974).
During pregnancy, in response to hormones initially from the corpus 
luteum. (oestrogen and progesterone), followed by placental hormones 
(oestrogen, progesterone and somatotropin), pituitary hormones (prolactin) and 
adrenocorticoids from the adrenal gland, there is a steep rise in the proliferation 
rate of the breast epithelial cells. This is accompanied by dramatic morphological 
changes, characterised by glandular-alveolar growth, expansion of acini and 
polarisation of luminal epithelial cells (Battersby and Anderson 1988, Vorherr 
1974).
At parturition, an abrupt drop in the level of oestrogen and progesterone 
in blood occurs. For the first few days, the breast secretes colostrum, a milky 
fluid with a low lipid content. Colostrum contains maternal antibodies, 
conferring passive immune protection to the infant. Following the release of 
colostrum, the secretory luminal epithelial cells become fully active, producing 
large volumes of milk. Muscular cells (myoepithelial cells) surrounding the 
alveoli contract to express the milk during lactation. Milk synthesis is maintained 
by prolactin, released from the anterior pituitary in response to a suckling 
stimulus, and the alveolar contents are expressed in response to oxytocin 
( Vorherr 1974). At the end of the suckling period, lactation ceases. Epithelial, cell 
numbers are reduced through apoptosis, and the breast regresses back to the 
mature but inactive stage.
With the onset of the menopause, the levels of circulating ovarian 
hormones fall, and the ductal, elements involute and dense connective tissue 
replaces the intralobular loose connective tissue.
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1.2.3 Biology
The normal human breast gland comprises a branching ductal-lobular system 
lined by an inner layer of luminal epithelial cells which are in direct contact with 
an outer layer of myoepithelial cells separated from the interstitial stroma by an 
intact basement membrane.
The luminal epithelial cells are polarized glandular cells with specialized 
apical and basolateral membrane domains expressing sialomucin and adhesion 
molecules, respectively (Ronnov-Jessen et al. 1996). The function of luminal 
epithelial cells is to synthesise milk. Therefore, those that are capable of 
producing milk proteins such as caseins and lactalbumin are considered 
functionally differentiated. Functional differentiation of luminal epithelial cells 
takes place during pregnancy and lactation. The myoepithelial cells contribute 
significantly to the formation of basement membrane, and their myogenic 
differentiation is responsible for the contractile phenotype mediated by oxytocin 
responsible for the ejection of milk (Murrell 1995). However it was found that 
cellular proliferation in the human breast was virtually confined to luminal cells 
while the myoepithelial cells did not divide when fully mature (Joshi et al. 1986). 
Also that age and parity of women affected the type of parenchymal structures 
present in the breast with nulliparous and older age groups observed to have 
more undifferentiated structures (less ductules per lobular unit) (Russo et al. 
1992).
The two cell populations can easily be distinguished by their different 
phenotypic expression profiles of cytokeratin (CK) 18, CK19, mucin 1 (MUC1), 
epithelial membrane antigen (EMA) and oestrogen receptor (ERa) in luminal 
epithelial cells and expression of CK4, CK14, CK17, cluster differentiation
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antigen (CD) 10 and p4 integrin subunit in myoepithelial cells. The expression of 
these specific markers is associated with phenotypic differentiation, which means 
that the cells have reached the lineage maturity (Suzuki et al. 2000). Once 
phenotypically differentiated, under normal physiology, the expression of these 
markers is stably maintained, and the phenotypically differentiated cells are 
destined to perform their differentiated function. Recently, comprehensive 
expression profiles of these two cell types have been produced using gene 
expression microarray analysis (Jones et al. 2004). New prognostic markers for 
cell survival were identified when the luminal- and myoepithelial-specific 
molecules were evaluated on breast tumour tissue microarrays.
As breast cancer arises mainly in the luminal epithelial compartment on 
the basis that most typical breast cancers express luminal markers (e.g 
cytokeratin 18, 19, EMA etc.), this has been the focus of the majority of studies 
with less attention paid to the role of the surrounding cells in breast function. A 
number of studies have postulated that intact myoepithelial cells are an important 
determinant of normal breast differentiation, and that loss of their functions could 
contribute to induction and/or progression of epithelial cancer (Zou et al. 1994, 
Radice et al. 1997, Stemlicht et al. 1997, Pechoux et al. 1999, Slade et al. 1999). 
Indeed a number of myoepithelial-specific proteins have been shown to inhibit 
epithelial tumour formation and, thus, these cells are postulated to have tumour 
suppressive activities (Gomm et al. 1997, Stemlicht et al. 1997, Shao et al. 1998, 
Sun et al. 1999).
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1.3 Breast Cancer
1.3.1 Epidemiology
With 1 million new cases in the world each year, breast cancer is the commonest 
malignancy in women and comprises 18% of all female cancers. Breast cancer 
has now become the most common cancer in England and Wales. One in nine 
women will develop breast cancer at some point in their lifetime with four in five 
of them being over 50 years old. In 2000 there were almost 36,000 new cases 
diagnosed, comprising 30% of all cancers in women and a rate of 114 per 
100,000 (Office of National Statistics UK, Cancer Research UK). Breast cancer 
incidence is increasing particularly among women aged 50-64 (with four out of 
five new cases being diagnosed in women over the age of 50) with the peak in 
the distribution of new cases in the 50 to 54 age group. This peak may reflect the 
breast screening programme because many of these women will have been 
screened for the first time.
Around 11,500 women died from breast cancer in England and Wales in 
2002, a rate of 30 per 100,000 women making it the most common cause of 
cancer death in women. The age standardised incidence and mortality in the U.K. 
is presently the highest in the world. Men can also get breast cancer but it is very 
rare, with around 300 cases being diagnosed each year.
Although a specific cause for breast cancer has not been identified, there 
are risk factors that increase the likelihood that a woman will develop a breast 
cancer (Baum 2002). Most of the known risk factors for breast cancer relate to a 
woman’s reproductive history such as early first period, late first pregnancy, low 
parity and late menopause. Oral contraceptive use, hormone replacement therapy 
(HRT), obesity and increased alcohol consumption also increase the risk. A
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genetic predisposition has now been discovered involving the germline mutations 
of BRCA1 and BRCA2 genes. The incidence of the mutant BRCAl gene on 
chromosome 17q may be 1 in 800 women. Although the BRCA2 gene on 
chromosome 13q is less frequently mutated it is also associated with early onset 
breast carcinomas. The presence of these genes explains some of the familial 
cases, and may be the aetiology for about 5-10% of breast cancers overall (Eeles 
2000, Cannon-Albright and Skolnick 1996). The overall risk of mutation carriers 
developing (female) breast cancer is estimated to be 80-85% by the age of 80 
years (Ford et al. 1995, Ford et al. 1998). Aside from the genetic predisposition, 
the common factor in many of these risk factors is the increased endogenous 
oestrogen exposure over a long time.
Although more women in the UK are being diagnosed with breast cancer 
than ever before, fewer are now dying from the disease, according to new 
figures. Statistics released by Cancer Research UK reveal that three out of four 
women are surviving for five years or more. Due to earlier detection and 
improved treatment (notably the widespread use of tamoxifen), breast cancer 
death rates in the UK is falling, with around 13,000 women dying from the 
disease in 2001, a 21% decrease over the last decade. This trend is set to 
continue at a rate of around 2% decrease each year.
1.3.2 Diagnosis
Breast cancer is most commonly diagnosed by the patient following the 
discovery of a palpable breast mass and or other signs (e.g. nipple discharge, 
inversion of the nipple, skin tethering, lymphadeopathy etc.). However, a breast 
cancer may have been present for 5 to 10 years before reaching a size (about 1
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cm) that is detectable by palpation. The other common method of diagnosis, in 
the older age group, is mammography (in the UK participation of the National 
Breast Screening Programme). The National Health Service (NHS) offers 
mammograms (breast X-rays) to women between the ages of 50-69, every 3 
years, as part of the National Breast Screening Programme. Although 
mammograms can detect cancer before it can be felt as a lump, its impact on 
survival improvement is considerably less than original studies indicated (Quinn 
and Allen 1995, Baum 2000, Gotzsche and Olsen 2000). Most breast cancers are 
found the upper outer quadrant (50%) probably because this contains a 
significantly larger amount of tissue.
Once referred to a specialised breast clinic a triple assessment is 
performed involving: 1) Clinical evaluation which includes history and physical 
examination of the breast lump and regional lymph nodes, 2) Imaging 
(ultrasound <35 years old or mammography >35 years old) and 3) Cytology (fine 
needle aspiration) or histology (core biopsy or Tru-Cut biopsy). From this 
assessment a diagnosis of malignancy can be made with a relatively high level of 
confidence (-90%) (Drew et al. 1999).
1.3.3 Management of early breast cancer 
Primary treatment
Treatment of breast cancer can take a variety of forms, depending upon the grade 
and stage of the cancer as well as the overall health and wishes of the patient. 
Therapy needs to be appropriate for each individual woman.
The first line of treatment for early breast cancer is surgery. The aims of 
breast cancer surgery are to achieve cure if excised before metastatic spread has
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occurred and to prevent the unpleasant sequelae of local recurrence. Surgical 
options for the breast are a) Breast conserving surgery (BCS) + radiotherapy with 
BCS regarded as either wide local excision, quadrantectomy or segmentectomy, 
b) Simple mastectomy, c) Radical mastectomy which now obsolete and d) 
Mastectomy + reconstruction (immediate or delayed) (Fisher et al. 2002).
Tumours suitable for breast conservation are small single tumours in a 
large breast, peripherally located tumours and tumours with no local 
advancement or extensive nodal involvement. For tumours that are suitable for 
breast conservation there is no difference in local recurrence or overall survival 
when BCS + radiotherapy is compared to mastectomy (Bundred and Downey 
1996, Hortobagyi 1998).
30-40% of patients with early breast cancer have nodal involvement 
determined pathologically, sometimes with the aid of epithelial specific 
immunohistochemistry (e.g. pan-cytokeratin). The aims of axillary surgery are to 
eradicate local disease and determine prognosis to guide adjuvant therapy. 
Clinical evaluation of the axilla is unreliable (30% false positive, 30% false 
negative) with no reliable imaging techniques available; therefore, surgical 
evaluation is important and considered for all patients with invasive cancer. As a 
recently introduced alternative sentinel node biopsy is a technique which aims to 
accurately stage the axilla without the morbidity of axillary clearance. The 
technique is used to identify the first nodes that tumour drains to following 
injection of peritumoural, subdermal or subareolar sites with radioisotope 
labelled colloid, blue dye or usually both. It allows more detailed examination of 
nodes removed. However the prognostic significance of micrometastatic deposits 
identified in sentinel nodes is unclear.
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Secondary treatment
Surgical procedures may be combined with radiation therapy and or 
chemotherapy, depending upon the type of cancer present and hormone receptor 
status. In order to reduce the risk of recurrence, radiotherapy may be prescribed 
following surgery (occasionally only radiotherapy is given without surgery). 
Radiotherapy aims to destroy remaining cancer cells by using high-energy rays, 
and the selective use of irradiation in high-risk patients provides both an 
improvement in local control and an improvement of 8 -10% in the survival rate 
(Taghian and Powell 1999, Small and Lurie 2001). Adjuvant therapy consists of 
drug treatments given after the initial surgery to reduce the risk of recurrence and 
micrometastasis (Fisher 1999). Over the past three decades conventional 
adjuvant chemotherapy regimens have also been employed pre-operatively (neo­
adjuvant or primary chemotherapy) (Smith et al. 2000).
The two main types of adjuvant therapy are hormone therapy and 
chemotherapy. In postmenopausal women with oestrogen receptor (ER) 
positivity and axillary lymph node involvement, the use of hormone therapy 
(tamoxifen for up to 5 years) is the standard treatment (Pinedo and Giaccone 
1997). However, recent results from the ATAC trial (Dec. 2004) demonstrated 
that aromatase inhibitors produced superior results when compared to 
Tamoxifen. Additional chemotherapy may be used depending on factors such as 
the tumour size, tumour grade, hormone receptor status and the extent of lymph 
node involvement. In premenopausal women, chemotherapy is more commonly 
used, although additional tamoxifen has also been shown to be of benefit (Aebi et 
al. 2000, Sugimachi et al. 1999).
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1.3.4 Pathology 
Classification of Breast Cancer
Breast cancers can be classified histologically based upon the types and patterns 
of cells that compose them. Carcinomas can be invasive (extending into the 
surrounding stroma) or non-invasive (confined just to the ducts or lobules) and 
epithelial or mixed tumours.
The WHO Classification of breast cancer is as follows:
• Epithelial
o Non-invasive
■ Ductal carcinoma in situ (DCIS)
■ Lobular carcinoma in situ (LCIS) 
o Invasive
■ Ductal
■ Lobular
■ Mucinous or colloid
■ Papillary
■ Medullary
• Mixed Connective tissue and Epithelial
• Miscellaneous
The great majority of invasive breast cancers are of the ‘ductal’ type (-80%) with 
5-10% lobular and the remainder accounted for by specific types (e.g. mucinous, 
papillary, medullary, tubular).
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Hormone receptor and immunoperoxidase techniques
The hormone receptor status of the breast cancer cells can give very useful 
information for treatment and prognosis. The neoplastic cells can express a 
variety of receptors. The presence of these receptors can provide a means for 
controlling cell growth through hormonal agents.
In general, cancers in which the cells express ER in their nuclei will have 
a better prognosis. This is because such positive neoplastic cells are better 
differentiated, and they can respond to hormonal manipulation. The drug 
tamoxifen is often utilized for this purpose. Almost three-fourths of breast 
cancers expressing ER will respond to this therapy, whereas less than 5% not 
expressing ER will respond (Barnes et al. 1996). The significance of 
progesterone receptor positivity (PR) in a breast carcinoma is less well 
understood (Pichon et al. 1996).
There are other markers that can be identified in breast carcinomas. One 
important marker for breast cancer is erbB2 (HER2), was identified by staining 
around the cytoplasmic membrane of the cells. There is a correlation between 
HER2 (erbB2) positivity and high nuclear grade and aneuploidy, and a specific 
drug (Herceptin, trastuzumab) is available as a therapeutic option with HER2 
positive carcinomas.
Grading of breast cancer
Pathologists further employ grading systems on histopathological samples, in 
order to predict the prognosis of overall and disease free survival (Sloane et al. 
2001). The most widely applied system in the UK is the Scarff-Bloom- 
Richardson system modified and adopted for the European Breast Screening 
Programmes (Elston and Ellis 1991). The grading (of infiltrating carcinoma) is 
based on tubule formation, pleomorphism and mitotic counts. Tubule formation
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is concerned with the proportion of ductal or glandular differentiation, indicated 
by the presence of clearly defined lumina. More than 75% scores 1, between 10- 
75% scores 2 and less than 10% scores 3. Spaces formed as a consequence of 
other mechanisms, such as poor cellular cohesion or cellular necrosis, are 
excluded. For pleomorphism, score 1 represents small, regular nuclei as in 
normal breast epithelial cells with uniform chromatin. Score 2 indicates 
significantly larger nuclei with open vesicules and moderate variability in size 
and shape. The highest score 3 stands for large, vesicular and prominent nuclei 
with a marked variation in size and shape and occasional very large and bizarre 
forms. Mitotic count is obtained according to the European breast screening 
programmes standard. These scores are added together to indicate the Grade 1 
(score 3-5), Grade 2 (score 6-7) and Grade 3 (score 8-9).
Staging of breast cancer
Breast cancers are staged according to the tumour size, lymph node involvement 
and signs of metastasis. The commonly affected lymph nodes are the axillary 
nodes and the nodes along the internal thoracic artery. Ultimately, the metastasis 
may appear in many viscera and in bones. Briefly, in stage I, breast cancers are 
<2cm with no sign of lymph node involvement or distant metastasis. Stage II 
breast cancers are 2-5cm or with lymph node involvement or both, but without 
signs of distant metastasis. In stage III, breast cancers are >5cm, and the lymph 
nodes are usually affected, but there is no sign of metastasis. Stage IV breast 
cancers are of any tumour size, but the lymph nodes are affected and metastasis 
has spread to other parts of the body. It is also important to note that the 5-year 
survival is much poorer for later stage breast cancer: 20% for stage IV at 
presentation compared with 85% for stage I (Quinn and Allen 1995).
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The Nottingham Prognostic Index (NPI)
Out of these prognostic indicators, lymph node status is considered the most 
important pathological factor (Galea et al. 1992, Sloane et al. 2001). However, it 
is a time-dependent factor, not taking account of the innate aggressiveness of 
tumours. Therefore, the three most significant prognostic indicators; tumour size, 
lymph node status and grade have been integrated (NPI) to provide a more 
accurate prognosis {0.2 x size in cm + stage (lymph node, 1-3 by number of 
nodes involved; 0 nodes = 1, 1-3 nodes = 2, >3 nodes = 3) + grade}. According 
to the NPI, the 5 year survival rate of the poor prognostic group (index > 5.4) is 
approximately 20%, whilst moderate prognostic group (index 3.41-5.4) 70% and 
the good prognostic group (index 2.1 <3.4) 95%.
1.3.5 Management of advanced breast cancer
For advanced breast cancer (recurrence and metastasis), the aim of the drug 
treatments is to shrink the existing breast cancers, or to decrease the rate at which 
they grow or spread. Effective treatment relieves symptoms and increases the 
quality and quantity of life.
Hormone therapy
Historically hormone ablation was carried out simply by oophrectomy (Beatson 
1896) and or adrenalectomy, more rarely pituitary ablation. In recent years the 
pharmacological manipulation of endogenous hormones has predominated. 
Tamoxifen (Fisher 1999), most widely used hormone therapy, is effective in 
reducing the risk of recurrence and death when administered to patients with ER- 
positive tumours. The benefit of tamoxifen is significant, irrespective of age, 
menopausal status and whether tamoxifen was given alone or in association with
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chemotherapy (Buzdar and Hortobagyi 1999). There are other selective 
oestrogen receptor modulators (SERMs) available such as Toremifene 
(Fareston), but their superiority in effectiveness or reduction of side effects is 
inconclusive at present (Holli et al. 2000, Buzdar and Hortobagyi 1998). Anti­
oestrogen is the first line of hormone therapy, but if breast cancers do not 
respond, alternatives are as follows: artificial progesterones such as megestrol 
acetate (Megace) and medroxyprogesterone acetate (Farlutal, Provera); 
aromatase inhibitors that block the production of oestrogen in adipose tissues 
such as anastrozole, letrozole and exerestase; pituitary down regulators such as 
goserelin (Zoladex) that reduce the production of oestrogen-stimulating 
hormones. For premenopausal women, permanent surgical removal or 
radiotherapy on the ovaries can also be an effective method for reducing the level 
of oestrogen in the body, although the reversible hormone therapy has been 
considered more preferable in recent years.
Chemotherapy
Chemotherapy is now the first line of treatment for distant metastases affecting 
the liver or lungs. It is also applied if patients do not respond to hormone therapy. 
For advanced breast cancer, the combination of paclitaxel with doxorubicin 
appears highly effective, and taxanes have activity in patients who are refractory 
to anthracyclines (Pinedo and Giaccone 1997).
Need for new therapeutic regimes
The currently available treatments are far from sufficient, failing patients 
particularly with advanced breast cancer (Tannock 1998, Quinn and Allen 1995). 
Hormone therapy (Tamoxifen) is applicable only to patients with breast cancer 
that are positive for ER. Chemotherapy is associated with considerable side 
effects due to the narrow gap between the optimum cytotoxic dosage against
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breast cancer cells and the concurrent damage incurred to normal somatic cells of 
the patients. Furthermore, resistance to treatment can develop following either of 
these therapies.
Therefore, for both preventative and therapeutic purposes, new treatments 
need to be developed. Properties such as a low level of side effects and 
selectivity towards cancer cells compared to normal somatic cells are highly 
desirable. Potential new therapeutic candidates include combination therapy, 
where different treatments may be applied together with the existing hormone 
and or chemotherapeutic agents for synergistic effects and reduction of side 
effects (Huang and Oliff 2001).
Intelligent new drug design
The current best example of intelligent drug design is based on an oncogene 
human epidermal growth factor receptor-2 ERBB2 / HER2 (ErbB2) that is 
amplified in approximately 20% of breast cancers. The transforming effect of 
ErbB2 in vitro and the clinical association with poorer prognosis brought the 
development of a monoclonal antibody Herceptin (Trastuzumab) that targets this 
specific breast cancer marker. Herceptin achieves significant improvement in 
survival of metastatic ErbB2 positive breast cancer patients when combined with 
chemotherapeutic agents (Piccart 2001, Kumar et al. 2000). Another receptor 
specific therapy in development is IRESSA (ZD1389)/epidermal growth factor 
receptor-tyrosine kinase inhibitor (Wakeling et al. 2002, Ranson et al. 2002). 
More recently, dual ErbB-2/EGFR tyrosine kinase inhibitors (572016) are in the 
process of Phase III trials (Rusnak et al. 2001). Whilst the success of the 
intelligent drug design remains statistically significant yet modest (Piccart 2001, 
Kumar et al. 2000), novel genes and proteins are being discovered at an ever- 
increasing pace. Computer aided differential analysis is yielding hundreds of
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potential breast cancer markers from the 30-40,000 genes identified as the human 
genome (Perou et al. 2000). However, it is likely that only a few of these will 
prove therapeutically relevant. To be so, they need to meet two fundamental 
criteria. First, a novel breast cancer marker must be expressed in a sufficiently 
large proportion of patients to engage interest in terms of costly and time- 
consuming drug development. Second, its function must be demonstrated to 
drive the actual tumour progression. Therefore, for these target specific therapies 
to be developed, the thorough understanding of human mammary biology plays a 
crucial role.
With the massive explosion in therapeutic strategies becoming available 
more authentic breast cancer models are urgently required for preclinical trials. 
Only when an authentic and validated model becomes available can we reliably 
consider testing on human patients. Development of better in vitro and in vivo 
models of human breast cancer is of crucial importance in the fight against breast 
cancer mortality. Prime among the factors that need to be considered in this 
context are the tumour microenvironment in vivo and the cells that comprise the 
tumour associated stroma. The objective of this study is to explore different 
methods of recreating the tumour microenvironment in an experimental model 
system.
1.4. Tumour microenvironment
1.4.1 Stroma
The normal human mammary gland, which has a highly structured and 
segregated architecture, contains two distinct tissues: epithelium and
mesenchyme (embryonic) and stroma (postnatal). The mammary ducts are
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formed by a double layer of cells: luminal epithelial cells surrounded by a layer 
of myoepithelial cells, enclosed by the basement membrane. The basement 
membrane separates the epithelial cells from the interstitial stroma. Stroma is 
composed of extracellular matrix (ECM) and mesenchymal cells, which provides 
a structural scaffold and conduit for blood and lymphatic vessels, nerves, and 
leukocytes.
Breast carcinomas are often characterized by a stromal reaction that 
consists of modifications in the composition of both the cellular elements 
(infiltration of fibroblastic cells, endothelial cells and inflammatory cells) and the 
ECM. This reactive stroma actually constitutes a major part of the neoplasm. For 
a long time, only the neoplastic cells were the focus of interest in cancer research 
and the stroma was rather considered a reactive component without major 
significance. However, it has become clear that the stromal cells and their 
products (matrix components, growth factors, proteases, etc.) regulate the 
phenotype of cancer cells. Tumours, therefore, represent a complex ecosystem 
where multiple host cells-ECM and tumour cells-ECM, as well as tumour cells- 
host cells interactions lead to reciprocal influences resulting in tumour promotion, 
invasion and metastasis (Mareel and Leroy 2003).
Although the majority of breast malignancies are epithelial cancers they 
are a complex and relatively unorganized heterogeneous mix of epithelium, 
stromal cells (endothelial cells, fibroblasts), inflammatory cells (e.g. 
macrophages, lymphocytes and mast cells), ECM and its proteins (Ghosh et al.
1980). In breast tumours the epithelial carcinoma cells intermingle with the 
stromal elements in the stroma with tumour angiogenesis producing poorly 
developed and therefore ill defined blood vessels. In contrast, blood vessels are 
well defined and centrally located in the normal mammary gland with epithelial
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cells prevented from coming into contact with fibroblasts and other stromal cells 
as they are separated from them by the basement membrane (Ghosh et al. 1980). 
The stroma provides the vascular supply, specific soluble and ECM molecules 
that are required for tumour growth and progression (Hanahan and Folkman
1996). Growth and dissemination of a breast cancer involves interaction between 
the tumour cells and stromal elements. Two important stromal cells that are 
consistently found in and compose the vast majority of the stromal cells present 
in breast cancer are fibroblasts and endothelial cells.
Fibroblasts
The principal cells of breast stromal tissue are called fibroblasts. Fibroblasts are 
cells of mesenchymal origin with many vital functions during development and 
in adult organisms. Fibroblasts, as they are traditionally defined, comprise a 
diverse class of distinct functional and differentiated cell types separable based 
on their gene expression profiles (Chang et al. 2002). However the label 
fibroblast does not accurately cover their diversity. For example the label 
‘fibroblast’ has also been used loosely to define multipotent cells of mesodermal 
origin that that can give rise to other cells of mesodermal origin such as fat cells, 
bone cells, cartilage cells and smooth muscle cells. In addition it is used as an 
umbrella term to describe other cells such as fibrocytes and myofibroblasts. For 
example, the mixture of cells identified in the stroma of infiltrating breast 
carcinomas have been described as resting fibroblasts, active fibroblasts, early 
myofibroblasts, and mature myofibroblasts (Martinez-Hemandez et al. 1977, 
Schurch et al. 1981). The fibroblasts that comprise the tumour stroma have also 
been termed myofibroblasts, peritumoral fibroblasts, reactive stroma and 
carcinoma-associated fibroblasts .Despite the evidence that the cells we call 
fibroblasts from different stromal sites may comprise a host of distinct
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differentiated cell types, neither the diversity of these cells nor the extent or 
nature of local specificity in their differentiation has been systematically 
examined.
Fibroblasts are usually identified by their spindle-shaped morphology 
containing an abundant and branched cytoplasm surrounding an elliptical and 
speckled nucleus which has one or two nucleoli; their ability to adhere to plastic 
culture vessels; and the absence of markers for other cell lineages. Active 
fibroblasts have abundant rough endoplasmic reticulum and a well developed 
Golgi apparatus characteristic of synthetic cells (Ghosh et al. 1980). Inactive 
fibroblasts, called fibrocytes, are smaller, spindle shaped and have reduced rough 
endoplasmic reticulum, a smaller, elongated nucleus, and are embedded in 
ground substance.
Fibroblasts present in breast stroma, as distinct from multipotent 
fibroblasts that can differentiate into other cell types (cartilage, smooth muscle 
etc.), are considered the least specialized of this family of connective tissue cells, 
making the structural fibres and ground substance of ECM. As the predominant 
cell in the stroma, the fibroblast is responsible for the elaboration of most of the 
components of ECM. They make different collagens, reticular and elastic fibres, 
glycosaminoglycans and glycoproteins found in the extracellular matrix (Tlsty 
and Hein 2001). Collagen is the most abundant protein in the human body and 
90% of that is fibrillar Type I collagen. They are also responsible for the release 
of proteolytic enzymes, proteolytic inhibitors and growth factors. Each organ has 
specialized requirements, and hence fibroblasts from different organs 
demonstrate organ-specific variations of the classes of basic molecules listed 
above. Furthermore, in response to different physiologic signals, be they normal 
or pathologic the fibroblasts of the stroma change accordingly (e.g.
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myofibroblasts and carcinoma associated fibroblasts). Several growth factors can 
induce the activity of fibroblasts. Platelet derived growth factor, PDGF, and 
connective tissue growth factor, CTGF, stimulate chemotactic movement of 
fibroblasts (Takehara 2000). Fibroblast growth factor (b-FGF) is involved in the 
stimulation of fibroblasts during angiogenesis and transforming growth factor 
beta (TGF-B) stimulates fibroblasts to produce matrix proteins (Takehara 2000).
In the normal human mammary gland two distinct stromal areas can be 
identified morphologically (Atherton et al. 1994). Firstly a loose relatively 
cellular stroma (the intralobular stroma) within which the acini of the lobules are 
embedded and secondly the densely collagenous and relatively acellular 
interlobular stroma which surrounds the lobules and their associated intralobular 
stroma. The fibroblast sub-populations found in each of these compartments are 
distinct phenotypically and functionally. The presence of the cell-surface enzyme 
dipeptidyl peptidase IV (DPP-IV) was demonstrated on the cell membranes of 
mammary interlobular fibroblasts, whilst intralobular fibroblasts were DPP-IV- 
negative (Atherton et al. 1992). Fibroblasts isolated from the interlobular and 
intralobular stroma produced similar amounts of type I and IV collagen but the 
interlobular fibroblasts produced 3- to 5-fold more type XIV collagen/undulin 
than intralobular fibroblasts (Atherton et al. 1998). Also phenotypes of 
fibroblasts in the normal mammary gland differs from that present in 
tumourigenic breast stroma. For example, neutral endopeptidase also known as 
CALLA or CD 10, an ectoenzyme from a large family of membrane-associated 
metalloproteases, is not expressed by normal adult breast fibroblasts but is found 
in the stroma associated with over 60% of breast cancers. The maintenance of 
two types of structurally distinct stromas and its components may be important
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during developmental processes in the mammary gland and during 
tumourigenesis.
Myofibroblasts, a sub-population of fibroblasts, are modulated fibroblasts 
which have acquired the capacity to neoexpress a-smooth muscle actin, the actin 
isoform typical of vascular smooth muscle cells, and to synthesize important 
amounts of collagen and other ECM components (Desmouliere et al. 2004). 
Myofibroblasts, normally inconspicuous in healthy tissue, are active during 
tissue development, remodelling, inflammation and repair (Gabbiani 1996) and 
are intimately involved in wound healing. They have more contractile proteins 
(actin and myosin) than fibroblasts and can therefore effectively act to pull 
tissues together after injury. They secrete collagen and their involvement late in 
wound healing can cause excessive scarring. Indeed, the uncontrolled activity of 
myofibroblasts is thought to be involved in the development of fibrosis of the 
liver, kidney, heart and lung (Powell et al. 1999). Myofibroblasts are not only 
capable of remodelling ECM but also interact with epithelial cells and other 
stromal elements and thus may control important functions such as tumour 
invasion and angiogenesis (Desmouliere et al. 2004).
It is important to note that although myofibroblasts are not a component 
of normal breast stroma they are known to be a prominent feature in the stroma 
of infiltrating breast carcinoma (Ghosh et al. 1980) and scirrotic breast cancers 
(Seemayer et al. 1979). Invasive or infiltrating ductal carcinomas, which 
represent the most common type of breast cancer, are characterized by a 
pronounced degree of desmoplasia and are often referred to as scirrhous 
carcinoma. Desmoplasia is a common host response to epithelial tumours and is 
classically described as fibroblast proliferation in conjunction with ECM 
remodelling. The infiltrating process of cancer cells is analogous to wound
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production and healing with continuous granulation tissue and scar formation 
resulting in the characteristic desmoplastic reaction seen in certain breast 
carcinomas. The degree of myofibroblastic proliferation is related to the growth 
pattern of the tumour. The stromal myofibroblast reaction common to many 
invasive and metastatic carcinomas characterized by the production of a dense 
collagen with a contractile state of such tissue may constitute an attempt by the 
host stroma to contain the neoplasm and impede vascular invasion.
Cancer associated fibroblasts (CAF)
Mammary stromal fibroblasts can differentially regulate breast cancer cell 
proliferation. Both the fibroblasts’ tissue source, normal or tumour associated, as 
well as the target tumour cell’s phenotype will determine the extent of the 
proliferative response. This source and target dependency has been reported in 
several studies, (van Roozendaal et al. 1992, van Roozendaal et al. 1996, Brouty- 
Boye and Raux 1993, Dong-Le Bourhis et al. 1997, Gache et al. 1998). Different 
studies have reported different results regarding the varying stimulation or 
inhibition of breast cancer cell lines in vivo by normal or CAF. Fibroblasts are 
thought to affect mammary cells by secreting several classes of compounds 
including: (1) matrix proteins, (2) soluble chemokines, cytokines and growth 
factors, and (3) proteases. Such matrix proteins together with growth factors 
could promote the proliferation of endothelial cells, tumour cells or both (Noel et 
al. 1993, van Roozendaal et al. 1992).
Studies of fibroblasts in the vicinity of the malignant lesion also support a 
role for stromal cells in tumourigenesis (Adam et al. 1994, Dong-Le Bourhis et 
al. 1997, Skobe and Fusenig 1998). The fibroblast is a major cell type of the 
stromal compartment, and as such is intimately involved in orchestrating the 
stromal half of the dialogue in tissue homeostasis. Modification of fibroblasts in
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the stroma immediately adjacent to transformed epithelial cells has been 
documented in several tumour systems (Basset et al. 1990, Chiquet-Ehrismann et 
al. 1986, Singer et al. 1995, Wright et al. 1994, Yee et al. 1991). The different 
phenotypic and genotypic expression patterns of these different CAFs are the 
subject of many studies. For example, Ronnov-Jessen et al. (Ronnov-Jessen et al. 
1996, Ronnov-Jessen et al. 1995) demonstrated that the histology and growth 
characteristics of mammary CAFs were different from those of fibroblasts 
associated with normal breast epithelial cells. They described the presence of 
‘activated’ or abnormal myofibroblasts associated with invasive breast carcinoma 
cells. Other phenotypic changes ascribed to CAFs include abnormal migratory 
behaviour in vitro (Schor et al. 1988) and altered expression of growth factors 
such as platelet-derived growth factor, insulin-like growth factors I and II, 
transforming growth factor-Bl, hepatocyte growth factor/epithelial scatter factor, 
and keratinocyte growth factor (Yee et al. 1991, Ellis et al. 1994, Frazier and 
Grotendorst 1997, Nakamura et al. 1997, Ponten et al. 1994, Yan et al. 1993). 
Although these phenotypic changes have been documented in CAFs, their 
consequences or contributions to tumour growth and development in vivo have 
not yet been investigated.
Endothelial cells
The endothelial cell is a flattened cell type that forms a sheet (the endothelium) 
lining all blood vessels. They, like fibroblasts, represent a structurally and 
functionally heterogeneous population of cells. Endothelial cells may be derived 
from any part of the vascular tree, from large and small veins and arteries, from 
capillaries, or from specialized vascular areas such as the umbilical vein of 
newborns, blood vessels in the brain or from vascularized solid tumours. In 
addition, endothelial cells can also arise from precursor cells called angioblasts
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or haemangioblasts, the latter giving rise not only to endothelial cells but also to 
blood cells.
Although they present many common functional and morphological 
features, they also display remarkable heterogeneity in different organs (Rajotte 
et al. 1998, Trepel et al. 2000). Their complexity and diversity has long been 
recognized, yet very little is known about the molecules and regulatory 
mechanisms that mediate the heterogeneity of different endothelial cell 
populations. However, endothelial cell heterogeneity has now been described at 
the level of morphology, function, antigen composition, and signalling networks 
(Cines et al. 1998, Gerritsen 1987, Page et al. 1992). Each type is uniquely 
adapted to meet the demands of its local environment. Even in the same organ, 
the endothelium of large and small vessels, veins, and arteries exhibits significant 
heterogeneity. An extreme case is the kidney, which contains different types of 
endothelial cells: fenestrated in the peritubular capillaries, discontinuous in 
glomerular capillaries, and continuous in other regions (Risau 1995).
Evidence that endothelium in macro- and microvascular compartments 
arise from distinct embryological origins suggests that a developmentally 
determined phenotype may contribute to the cell’s site-specific function. As an 
important corollary, the embryological origin and local environment of the 
endothelial cell may importantly contribute to both its normal function and its 
response to pathophysiological stimuli. There are two possible mechanisms for 
the development of organ-specific endothelial cell phenotypes. In one case, 
endothelial cells would arise from the mesoderm with a predetermined phenotype 
and migrate to specific vascular beds in an organ, where they subsume site- 
specific function. In the second possibility, all endothelial cells would arise from 
the mesoderm and have a similar generic endothelial cell phenotype that would
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include universal markers such as CD31, but such cells would be devoid of 
vascular bed-specific endothelial cell markers. For this latter hypothesis to be 
correct, multipotent endothelial cells would undergo a terminal differentiation, 
under the influence of inductive signals from the involved organ.
Besides forming a monolayer in every single blood vessel in the 
circulation endothelial cells are actively involved in several regulatory processes 
in the body (Cines et al. 1998, Edgington 1995, Rodgers 1988). Examples 
include: a) the endothelium forms a semi-permeable physical interface between 
blood and surrounding tissue and acts as a functional barrier for the transport of 
blood-borne peptides, proteins, and other soluble molecules to underlying tissue 
to regulate nutrient and blood component traffic (e.g. blood brain barrier); b) via 
the regulated expression of pro- and anti-coagulative activities, endothelium 
actively participates in the haemostatic balance in the body; c) under the 
influence of pro-inflammatory cytokines, endothelial cells up-regulate a variety 
of cellular adhesion molecules to tether and activate leukocytes (leucocyte 
trafficking) and facilitate leukocyte adhesion and transmigration from the blood 
into the tissue; d) endothelial cells play an active role in wound healing and 
tumour angiogenesis.
In the mammary gland several different types of endothelial cells are 
present. These are macro- and microvascular, lymphatic, arterial and venous. 
Although endothelial cells of lymphatic capillaries have many properties in 
common with the endothelium of blood vessels, they also have distinct structural 
characteristics reflecting their specific functions (Daroczy 1988, Skobe and 
Detmar 2000). Lymphatic capillaries lack mural cells and are characterized by an 
incomplete or absent basement membrane. Lymphatic endothelium typically 
contains numerous invaginations and cytoplasmic vesicles as well as
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characteristic overlapping intercellular junctions. Whereas the junctions in blood 
vessels connect adjacent endothelial cells over entire cell boundaries, the 
junctions in lymphatics are generally more sparse. Finally, one of the most 
striking characteristics of the lymphatic capillary is its integration within the 
interstitium; lymphatic endothelial cells are connected to the ECM by fine strands 
of elastic fibres, i.e., anchoring filaments (Leak 1976, Gerli et al. 1990).
Cancer associated endothelium
Like most embryonic tissues, tumours have the ability to build up their own 
blood vessel networks. However, the architecture of tumour vessels is 
fundamentally different from that found in healthy tissues. Tumour vessels are 
usually irregular, heterogeneous, leaky, and poorly associated with mural cells. 
Endothelial cells in tumour vessels are also disorganized and express imbalanced 
surface molecules. These unusual features may provide some molecular and 
structural basis for selective inhibition or even destruction of tumour vessels by 
angiogenesis inhibitors.
It has long been suggested that an organized lymphatic system, as such, is 
not present in tumours (Gullino 1975) with studies in human and animal tumours 
involving injection of tracers into lymphatics revealing that tumours do not have 
an intrinsic lymphatic vascular supply (Zeidman et al. 1955, Tanigawa et al.
1981). However, it has also been agreed that this observation reflects the collapse 
of lymphatics within the tumour due to mechanical stress generated by 
proliferating cancer cells, and that this in turn contributes to increased pressure 
within the tumour interstitium (Leu et al. 2000). Although the lack of 
intratumoural lymphatics appears to be a consistent feature, dilated and engorged 
lymphatics in peritumoural stroma, with occasional penetration into the tumour 
periphery, are features that are observed with equal frequency (Leu et al. 2000,
Hartveit 1990). It has been suggested that these lymphatics are likely to be 
existing lymphatics that have enlarged in response to VEGF-C, rather than new 
lymphatic vessels (Leu et al. 2000).
The presence of tumour cells in peri- or juxtatumoural lymphatics is not 
an uncommon feature for many primary tumours. In a detailed study on breast 
carcinoma, Hartveit (1990) has described the presence of an open lymphatic 
labyrinth in close association with the primary tumour and suggests that tumour 
cells lying free in the periductal lymphatic spaces will be washed with the tide of 
tissue fluid into the labyrinth through the sinuses and on into the lymphatic 
drainage channels
Numerous investigations have focused on the tissue origin of tumour 
endothelial cells (Lin et al. 2000, Asahara et al. 1997) and the individual genes 
that promote the growth and survival of tumour vessels. Tumour cells are 
proposed to mediate tumour angiogenesis by secreting soluble factors that 
enhance endothelial cell proliferation, migration and tube formation as well as by 
direct cellular interactions with endothelial cells. The interactions between 
tumour cells and endothelial cells which are complex, might be analogous to 
those observed during embryonic development and have been hypothesized to be 
important in the process of tumour angiogenesis (Darlandand D’Amore 1999). 
Circulating endothelial progenitors
Traditionally it was believed that tumours recruit neighbouring blood vessels and 
vascular endothelial cells to support their own blood supply. Recent evidence has 
indicated, however, that tumours are also capable of mobilizing bone marrow- 
derived endothelial precursor cells, inducing them to migrate to the tumour and 
become incorporated into the developing vasculature. Tumour-derived 
angiogenic factors promote the recruitment of these cells, which include
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circulating endothelial progenitor cells and haematopoietic stem and progenitor 
cells.
Circulating endothelial progenitor cells (CEP) are highly proliferative 
cells that are derived from bone marrow, foetal liver, umbilical-cord blood and 
cytokine-mobilized peripheral blood and have several characteristics that 
distinguish them from circulating endothelial cells. The latter are mature 
terminally differentiated cells that have sloughed off from the vascular wall and 
enter circulation as a result of shredding or traumatic vascular injury. Mature 
endothelial cells have a low proliferative potential and are less likely than CEPs 
to contribute to tumour neo-angiogenesis (Rafii et al. 2002).
Both CEPs and mature endothelial cells express similar endothelial- 
specific markers, including vascular endothelial growth factor receptor-2 
(VEGFR-2), Tie-1, Tie-2, and vascular endothelial (VE)-cadherin (Rafii et al. 
2002, Peichev et al. 2000). Therefore, these markers do not provide a method in 
which to differentiate between the two populations. Furthermore, identification of 
the differences between CEPs and circulating mature endothelial cells is 
complicated by the fact that haematopoietic stem and CEPs express markers 
similar to those of mature endothelial cells such as VEGFR-1 (Fit-1), platelet 
endothelial cell adhesion molecule (PECAM), Tie-1, Tie-2, and von Willebrand's 
factor (vWF), and they also have the capacity to incorporate acetylated low- 
density lipoprotein (Ac-LDL). However haematopoietic stem and CEPs express 
unique surface markers, such as CD34 and the newly discovered early 
haematopoietic stem cell marker CD 133. Expression of CD 133 diminish with 
maturation and differentiation (Miragliaet al. 1997, Yinet al. 1997).
CD 133 is a novel 120-kd glycosylated polypeptide that contains 5- 
transmembrane domains with an extracellular N-terminus and a cytoplasmic C-
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residue (Miragliaet al. 1997, Yinet al. 1997). The function of CD133, which 
does not share homology with any previously described haematopoietic cell 
surface antigen, is not known. However, isolation of a subpopulation of CD34+ 
cells using monoclonal antibody to human CD 133 has resulted in the 
identification of functional CD34+ population of haematopoietic stem cells. 
Human-derived CD133+ cells were shown to repopulate sheep bone marrow (Yin 
et al. 1997) and, therefore, were considered pluripotent haematopoietic stem 
cells. Expression of CD133 is rapidly down regulated as haematopoietic 
progenitors and stem cells differentiate into more mature post mitotic cells. In 
fact, virtually all mature haematopoietic cells, including mature myeloid, 
megakaryocytes, erythroid, and lymphoid cells and terminally differentiated 
haematopoietic cells, fail to express CD 133 (Miraglia et al. 1997, Yin et al.
1997). Therefore, subsets of CD34+ cells that express CD 133 represented a 
unique phenotypic and functional marker of an immature population of 
haematopoietic stem and progenitor cells. Taken together, these results suggest 
that circulating CD34+ cells expressing CD 133 comprise a functional population 
of CEPs cells that may play a role in postnatal angiogenesis or vasculogenesis.
Several studies have reported that CEPs when inoculated into 
immundeficient mice, incorporate into the vasculature of xenotransplanted 
tumours (Lyden et al. 2001, Reyes et al. 2002, Moore 2002, Asahara et al. 1999, 
Gehling et al. 2000).
Inflammatory cells
One of the responses to breast cancer is an immune response with an influx of 
inflammatory cells. These include macrophages, mast cells, lymphocytes (T and 
B cells), and antibodies, a reflection of immunologic surveillance against 
neoplasia. However inflammatory cells provide a very small contribution to the
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total population of stromal cells present in breast cancer stroma. The function of 
all these different immunocompetent cells has not been clarified as yet. Even so 
the focus of most studies has limited themselves to the lymphocytic infiltration of 
breast cancer.
Ben-Hur et al. (2002) investigated the presence of lymphoid elements in 
the tumourigenesis of human breast cancer. They examined the lymphocytic and 
macrophage content of several different types of breast cancers (fibrocystic 
disease, fibroadenoma, carcinoma in situ, infiltrating ductal and lobular 
carcinoma with high lymphoid infiltration, and infiltrating ductal and lobular 
carcinoma with lymphoid depletion). The two benign conditions showed little 
lymphoid and macrophage infiltration whereas the other malignant conditions, 
with the exception of the lymphoid depleted tumours, showed an extensive 
lymphoid infiltration which were predominantly T-cells. Results demonstrated 
that the host's reaction to the disease was reflected in high correlations between 
the densities of the lymphoid cellular elements as tumourigenesis evolved 
(increased lymphocyte numbers as tumours progressed). It also showed that the 
majority of the stromal immunocompetent cells were T- killer cells which acted 
as a reservoir as it were that eventually crossed into the breast parenchyma and 
joined T helpers and B lymphocytes in the anti-tumour immune response. In later 
stages of cancer the response was exhausted as shown by the decrease in 
lymphocytes and macrophages in the late stage tumours (Ben-Hur et al. 2002).
The different patterns of inflammation and or inflammation associated 
with different histological types of carcinoma have been ignored somewhat, 
probably due to the fact that the significance of inflammation in breast cancer is 
controversial. Lee et al. (1996) looked at the pattern of inflammation in 123 
invasive mammary carcinomas (including 46 lobular), and characterised the
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inflammatory cells by immunohistochemistry. They found different patterns of 
inflammation in ductal and lobular carcinoma. Diffuse inflammation was seen 
more in ductal carcinoma, particularly of high grade, and was predominantly 
composed of macrophages and T cells. Perilobular inflammation was seen most 
frequently in lobular and high-grade ductal carcinomas, particularly at the 
tumour edge. Perivascular inflammation was also largely at the tumour edge, but 
was not more common in any tumour type. In contrast to the diffuse 
inflammation, the perivascular and perilobular inflammation was composed of T 
and B cells (Lee et al. 1996).
The effect of mast cell presence in breast cancer stroma is also unclear. 
Aaltomaa et al. (1993) counted the number of stromal mast cells in 187 breast 
carcinomas specimens. The numbers present were studied in relation to the 
clinical, histological and quantitative prognostic factors and survival 
characteristics. Results showed that a high mast cell count (over 10 g per mm of 
tumour stroma) was related to a favourable prognosis in their survival analysis 
(Aaltomaa et al. 1993). Fisher et al. (1985) also counted the number of mast cells 
within and at the periphery of invasive breast cancers from 424 patients and 
related it to prognosis. No differences in 10 year disease-free survival were 
detected in patients without mast cells and those exhibiting varying numbers of 
such cells. Their information indicates that identifiable mast cells do not 
represent a prognostic pathologic discriminant in patients with breast cancer. 
However, this does not unequivocally exclude a role of mast cell secretory 
products, since only intact and not degranulated or disrupted forms of these cells 
can be counted (Fisher et al. 1985). These two studies contrast as to whether the 
presence of mast cells is favourable or unrelated to breast cancer prognosis.
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In summary, the effect of the presence of immunocompetent cells in the 
stroma of breast is not clear. However they do interact with adjacent stromal cells 
(fibroblasts and endothelial cells) and epithelial cells and so further investigation 
is merited. In order to construct a more realistic breast cancer model, 
immunocompetent cells should be incorporated, however this will only be useful 
once their role in tumourigenesis is clarified.
1.4.2 Extracellular matrix
The extracellular matrix (ECM), often referred to as connective tissue, is a 
complex mesh work of glycoproteins and proteoglycans that determines tissue 
architecture and also modulates breast tissue homeostasis in vivo. It is produced 
in collaboration between stromal fibroblasts and epithelial cells to provide 
structural scaffolding for cells, as well as contextual information. It is composed 
of 3 major classes of biomolecules: 1) structural proteins: collagen and elastin, 2) 
specialized proteins: e.g. fibrillin, fibronectin, and laminin and 3) proteoglycans: 
these are composed of a protein core to which is attached long chains of 
repeating disaccharide units termed glycosaminoglycans forming extremely 
complex high molecular weight components of the ECM.
The breast stroma and its cells communicate with the epithelial cells 
through the ECM with an important function of stromal cells being the 
deposition and remodelling of the ECM (Noel and Foidart 1998). Constituents of 
the ECM produce a large variety of specific signals which directly influences cell 
growth, migration, morphology, proliferation, differentiation, and biosynthetic 
activities (LaFlamme and Auer 1996, Weaver et al. 1997). It has now clear that 
the ECM is made up of specific structural modules that encode information
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interpreted by cells through interactions with specific plasma membrane 
receptors, mostly of the integrin family (LaFlamme and Auer 1996). Integrins, a 
family of adhesion receptors used by cells to interact with their ECM, function as 
signalling receptors integrating information from the ECM and other 
environmental cues including growth factors and hormones. Signals triggered by 
integrins direct cell adhesion and regulate other aspects of cell behaviour 
including cell proliferation and differentiation as well as determine cell survival. 
In addition, the ECM plays an essential role in normal epithelial cell survival, 
and loss of contact with the ECM and its components results in apoptosis termed 
anoikis (Frisch and Francis 1994). For example several studies have revealed the 
importance of the basement membrane in the morphogenesis and differentiation 
of mammary epithelial cells (Roskelley and Bissell 1995, Weaver et al. 1997).
Although the precise mechanisms of matrix effects remain to be 
elucidated, there is considerable evidence that the ECM influences cell properties 
and behaviour by modification of cytoskeletal organization and activation of 
second messenger and protein kinase pathways (LaFlamme and Auer 1996). In 
addition, the ECM is a site of sequestration of various factors that are likely to 
affect cell activity such as growth factors, mobility factors, natural proteases and 
their inhibitors.
In addition to functioning as a structural scaffold the ECM produces 
matrix macromolecules for cell adhesion and migration to exert profound effects 
on cell behaviour by a variety of mechanisms. Common matrix constituents elicit 
signal transduction cascades as a result of their ligation by integrin receptors, and 
that these matrix induced signalling networks share many common pathways 
with their cytokine induced counterparts (Juliano 1996). Cytokines and matrix 
macromolecules have a bi-directional co-modulatory effect on each other’s
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synthesis. Cytokines affect the expression of matrix molecules, matrix receptors 
and matrix degrading enzymes, whereas matrix macromolecules modulate the 
synthesis of cytokines and their respective cell surface receptors (Schor 1994). In 
addition, the effects of cytokines on cell behaviour may be mediated by the 
matrix macromolecules whose synthesis they regulate. In other words the 
observed cellular response to a cytokine may be a secondary consequence of the 
bioactivity of the matrix macromolecules whose expression is under primary 
cytokine control. Also, matrix macromolecules bind cytokines and present them 
to cell surface receptors in a functionally optimal state (Streuli 1999). Finally, 
matrix macromolecules modulate cellular response to cytokines (i.e. the nature of 
the macromolecular matrix to which the cells are adherent determines cellular 
response to cytokines) (Schor 1994, Lee and Streuli 1999).
Breast carcinomas are characterized by a stromal reaction that consists of 
modifications in the composition of both the cellular elements (infiltration of 
fibroblastic cells, endothelial cells, inflammatory cells) and the ECM. Disruption 
of communication between the epithelium and stroma can lead to alterations in 
the ECM which can both induce and promote breast cancer. Alterations in cell- 
ECM interactions are a consistent feature of mammary tumours in vivo and in 
culture (Petersen et al. 1992, Bemfield et al. 1993, Zutteret al. 1993, Sympson et 
al. 1994, Bergstraesser and Weitzman 1993, Howlett et al. 1995). The stromal 
cells surrounding tumours have increased or altered expression of many ECM 
proteins which change with cancer progression (Ronnov-Jessen et al. 1996, 
Rabinovitz and Mercurio 1996, Ziober et al. 1996). Tumour associated fibroblast 
stroma has been shown to produce ECM molecules such as fibronectin and 
tenascin that influence cell adhesion and proliferation. Tenascin, known to 
reduce epithelial cell adhesiveness, is absent in normal breast, its expression
being restricted to embryonic and malignant tissues (Kadar et al. 2002). Thus we 
can see that the ECM is involved in both normal and pathological processes.
Desmoplasia is a good example of ECM remodelling during 
tumourigenesis. The desmoplastic stromal reaction is characterized by both 
quantitative and qualitative modifications in the composition of connective tissue 
matrix (Dvorak 1986, Gregoire and Lieubeau 1995, Wemert 1997). An excessive 
accumulation of ECM components including different types of collagen (types I, 
III, V), fibronectin, elastin and proteoglycans is often observed. In addition, non 
basement membrane type IV collagen was shown to be increased in elastotic 
breast tumour tissues (Verhoeven et al. 1990). Interestingly bone sialoprotein, a 
bone matrix protein involved in hydroxy apatite crystal formation is ectopically 
expressed in human breast cancers and results in the formation of 
microcalcifications which can be detected in early lesions (Bellahcene et al. 
1996).
1.4.3. Tumour-stromal interactions
To achieve a better understanding of cancer we must study the function of the 
complex tumour microenvironment and not just focus on the genes involved. It is 
clear now that the heterotypic interactions between cancer cells and their 
recruited normal neighbours as well as the associated ECM have a crucial role in 
tumour progression and so it is no longer sufficient to just understand 
intracellular signalling (Shekhar et al. 2001).
As described above breast carcinomas are composed of not only tumour 
epithelial cells but also of associated endothelial cells, fibroblasts, macrophages, 
and lymphocytes (Ghosh et al. 1980, Gregoire and Lieubeau 1995). Several lines
64
of evidence indicate that breast stromal cells play a central role, via the ECM 
(remodelling, growth factors, proteases etc.), in tumour invasion and 
dissemination (Camps et al. 1990, Picard et al. 1986, Grey et al. 1989). 
Perturbations in crosstalk between the mammary epithelium and stroma together 
with alterations in the ECM can, therefore, lead to the induction and promotion 
of breast cancer.
Stroma is well known to support and respond to tumourigenesis, directly 
influencing the tumour process (Noel and Foidart 1998). This was demonstrated 
by culturing primary breast tumours cells, in combination with stromal elements 
(fibroblasts), in 3-D collagen type 1 matrices. The addition of stromal fibroblasts 
caused the tumour to spread and become invasive, with greater concentrations of 
stromal elements having a proportional effect on tumour growth (Ronnov-Jessen 
et al. 1995). The exact mechanism of tumour-stromal interactions is not clear at 
present but it has now been established that fibroblasts by modulating the ECM, 
and/or by their direct influence on tumour cells are crucial.
As the predominant cell in the stroma, the fibroblast is responsible for the 
elaboration of most of the components of the ECM in addition to several other 
important factors (proteases, matrix proteins, chemokines, cytokines and growth 
factors). Proteases that remodel the ECM play an important role in the 
progression of neoplasia (Werb 1997). Excessive protease activity can lead to 
major changes within the microenvironment of tumour tissue to promote cell 
migration, and it thereby contributes to metastasis. Moreover, subtle changes in 
the levels and activities of proteases can expose cryptic sites in ECM molecules 
that alter integrin usage, and release matrix-bound growth factors, which both 
potentiate proliferation and survival of tumour cells, and induce angiogenesis 
(Streuli 1999, Vu et al. 1998, Stetler-Stevenson 1999). Thus, several of the
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hallmarks of tumour progression occur as a result of alteration in protease 
activity within the extracellular environment of a progressing tumour (Hanahan 
and Weinberg 2000). Direct evidence that inappropriate expression of both 
matrix metalloproteinases (MMPs) and serine proteases, the two main classes of 
ECM-degrading proteases, is involved in tumour progression comes from mis- 
expression studies in genetically altered mice (Wilson et al. 1997, Johnsen et al. 
1998, Stemlicht et al. 1999).
The regulation of ECM-degrading proteases is normally kept under tight 
control. Tissue inhibitors of MMPs suppress the activity of MMPs, whereas 
serpins are a class of serine protease inhibitor. The expression of these protease 
inhibitors is closely regulated in developmental morphogenetic processes. For 
example, tissue inhibitors of MMPs control ECM remodelling during mammary 
gland development, suppressing excess MMP activity and therefore preventing 
matrix remodelling from occurring prematurely in post-lactational involution 
(Talhouk et al. 1992, Fata et al. 2001). However, there can be severe 
consequences if the expression of matrix proteinase suppressing enzymes is 
misregulated. Just as over-expression of MMPs and serine proteases can 
contribute to carcinogenesis, so can down-regulation of their inhibitors. Levels of 
one such inhibitor of serine proteases, namely maspin, are frequently reduced or 
even absent in invasive cancer (Zou et al. 1994).
Information from ultrastructural, immunohistochemical and biochemical 
analyses have demonstrated that the mammary stroma is altered in critical 
aspects during the neoplastic process. Several studies have documented an 
acquired expression of a-smooth-muscle actin, vimentin, smooth muscle myosin, 
calponin, tenascin and desmin in tumour stroma (van den Hooff 1988, Ronnov- 
Jesson et al. 1996). Myofibroblastic differentiation of fibroblasts with the
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activation of a partial smooth muscle differentiation programme and the 
excessive elaboration of collagen types III and V in the area of a neoplastic 
lesion occurs in the desmoplastic reaction. The above described proteins are also 
often expressed as a response to wound healing or inflammation, as 
myofibroblasts orchestrate the repair response (Sappino et al. 1990). In addition, 
the distribution of laminin, a molecule critical for the architectural integrity of 
undisturbed tissue, is reduced and altered in ECM found associated with 
malignant cells (van der Hooff 1988). More recent studies documented 
alterations in dipeptidyl peptidase IV, MMPs, inhibitors of metalloproteinases, 
growth factors and collagens (Basset et al. 1990, Atherton et al. 1992, Garin- 
Chesa et al. 1990, Nakamura et al. 1997a, Rasmussen and Cullen 1998). These 
numerous alterations in the mammary stroma drive the tumourigenic process.
Growth and progression of breast cancers are accompanied by increased 
neovascularization (angiogenesis) (Ausprunk and Folkman, 1977, Nicosia etal. 
1982, Hanahan 1988, Hanahan and Folkman 1996). Most of the available data is 
concerned with fibroblast-epithelial cell interactions in breasts cancer. However 
endothelial cells in the stroma also play a major role in tumourigenesis in 
particular angiogenesis (Rak et al. 1996). Accumulating evidence points to the 
local environment particularly interaction with adjacent cells and ECM, as being 
a major factor in endothelial cell differentiation (Kubitza et al. 1999). 
Heterogeneity of mature endothelial cell phenotypes is proof different organs 
produce different endothelial phenotypes. The study of how changes in stroma 
can affect tumour formation represents a new direction in tumour therapeutics. A 
variety of factors, including hypoxia and genetic changes in the tumour epithelial 
cells, contribute to increased production of angiogenic factors (Boudreau and 
Myers 2003). Furthermore, cells within the activated tumour stroma also
contribute to the increase in production of vascular endothelial growth factor and 
other angiogenic factors, including basic fibroblast growth factor and platelet- 
derived growth factor (Kern and Lippman 1996, Kushlinskii and Gershtein 
2002). The contribution of the microenvironment to tumour-induced 
angiogenesis is underscored by findings that breast tumours implanted into 
different tissue sites show marked differences in the extent and nature of the 
angiogenic response (Boudreau and Myers 2003). These findings have important 
implications for designing anti-angiogenic therapies.
The fact that while normal stroma can be protective in delaying or 
preventing tumour formation (Shekhar et al. 2001, Hayashi and Cunha 1991, 
Cooper and Pinkus 1977), abnormal stroma can promote tumourigenesis, 
underlines the crucial importance/role of stroma in tumourigenesis. Shekhar et al. 
(2001) showed that, while normal reduction mammoplasty fibroblasts could 
inhibit or retard the morphological transformation of both normal MCFlOAand 
preneoplastic EIII8 breast epithelial cells, respectively, tumour-derived breast 
fibroblasts could override or enhance genetic constraints imposed by MCF10A or 
EIII8 cells, respectively, causing them to undergo ductal-alveolar morphogenesis. 
However the stromal (cell) effect may be organ type specific. A study by 
Moinfar et al. (2000), using a 3-D cell culture model with Matrigel, showed that 
only breast fibroblasts, but not soft tissue sarcoma-derived malignant 
mesenchymal cells, normal lung, or embryonal 3T3 fibroblasts, could confer 
morphogenesis inducing effects on primary mammary epithelial cells. Therefore, 
although the cultures were performed in Matrigel, a reconstituted basement 
membrane matrix containing a variety of ECM molecules, induction of breast 
epithelial growth and morphogenesis appeared to be mediated by the ECM that 
was laid down by organ-specific mesenchyme.
A recent report has shown that stromal alteration(s) can precede the 
malignant conversion of tumour cells (Moinfar et al. 2000). Following 
examination of multiple human breast tumours they found a high frequency (up 
to 75%) of alleic loss (loss of heterozygosity) in mesechymal mammary stromal 
cells (fibroblasts) close to the cancer cells which were not present in normal 
breast tissue. Moreover, the genetic alterations found in the tumour associated 
fibroblasts preceded the genotypic changes found in the epithelial cells. In an 
alternative approach, a study by Olumi et al. (1999) reported, using both an in 
vitro co-culture and an in vivo tissue recombinant system, that prostate 
carcinoma-associated fibroblasts but not their normal equivalents were able to 
stimulate tumourigenesis in non-tumourigenic prostatic epithelial cells. 
Oncogenic signals from tumour derived fibroblast can change non-malignant 
epithelial cell populations to malignant ones. Furthermore only transient 
stimulation is required to transform cells into tumourigenic lesions. This 
evidence from a similar cancer system clearly shows that the surrounding stroma 
has a functional role in tumour development. Similarly in a mouse mammary 
model, only irradiated mammary stroma of the fat pad and not its normal 
equivalent was shown to give rise to tumours when non-tumourigenic mammary 
epithelial cells grafted into the mammary fat pad (Barcellos-Hoff and Ravani 
2000).
Oncogenic mechanisms of stromal cells
Genetic change in the form of Toss of heterozygosity’ (LOH) may be the trigger 
in the development of breast cancer. A study by Kurose et al. (2002) analyzed 50 
breast tissue samples taken from epithelial and stromal tumours looking for LOH 
in two known tumour suppressor genes, TP53 and PTEN. Altered forms of both
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genes have been associated with the development of breast cancer. Half of the 
tumour samples contained mutated TP53 genes: 11 samples had mutations in the 
epithelium alone, nine had mutations in the stroma alone and five had mutations 
in both tissue layers. Nearly one-third of the breast cancer samples contained 
PTEN mutations. However these alterations were found in either the stroma or 
the epithelium; only one breast tissue sample contained PTEN mutations in both 
tissue compartments. In addition to finding variations in the frequency and 
distribution of genetic mutations, the researchers also discovered that, with the 
exception of two samples, PTEN and TP53 mutations did not occur together in 
the same tissue compartment. Yet when genetic mutations were found in both 
tissue compartments, at least three of the samples had different types of 
mutations between epithelium and the respective stroma. This effectively ruled 
out the possibility of cross contamination between the tissues. Their exclusive 
nature and the presence of discordant mutations even within the same gene 
suggest that genetic alterations occur independently in the stroma and the 
epithelium. Put simply, a mutation could first occur in the stroma, rather than in 
the epithelium. These mechanisms are not limited to breast cancer with similar 
genetic changes occurring in other solid tumours.
The knowledge that stromal cells have the ability to stimulate 
oncogenesis has been taken a step further by recent data suggesting that stroma 
may develop oncogenic properties independently even in the absence of a 
tumour. Four possible mechanisms are; carcinogen induced mutations, use of 
enzymes (matrix metalloproteinases), recruitment of inflammatory markers and 
viral alterations of stromal signals.
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I. Carcinogen induced oncogenesis
Carcinogens in addition to promoting tumourigenesis by directly damaging 
epithelia, can also promote tumourigenesis by altering the surrounding stroma. 
Barcellos Hoff and Ravani (2000) showed that irradiated murine mammary 
stroma promoted tumour progression of transformed normal murine epithelial 
cells. Also these mammary epithelial cells developed tumours faster and more 
often and reached a greater size than the same cells transplanted with un­
irradiated stroma. This effect has also been clearly documented with skin and 
bladder tissue where carcinogen treated stroma combined with untreated 
epithelial cells resulted in enhanced tumour formation (Billingham et al. 1951, 
Hodges et al. 1977, Uchida et al. 1990).
II. Recruitment of matrix metalloproteinases (MMP)
MMPs have many functions and activities. They can degrade ECM as well as 
being involved in the promotion of inflammatory responses, normal tissue 
remodelling, wound healing and angiogenesis. These enzymes, however, also 
have an important function in malignancy. The sustained presence of these 
proteinases in the tumour microenvironment, produced both by cancer and 
activated cells, leads to the degradation of normal ECM. Breakdown of ECM 
stimulates both proliferative and apoptotic mechanisms, which can lead to the 
selection of apoptosis-resistant carcinoma cells and an enhanced invasive 
potential (Sethi et al. 1999, Mitsiades et al. 2001). In some tumours direct 
association of MMPs with specific ECM receptors provide spatial control of 
MMP activity and directional signals to the invading tumour cells. Alterations in 
epithelial tissues together with disrupted intercellular signals, found in wounding 
for example, can promote inflammation. This process when unregulated or 
persistent can lead to upregulation of enzymes such as MMPs by stromal
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fibroblasts that can disrupt the ECM causing invading immune cells to 
overproduce factors that promote abnormal proliferation. Consequently this can 
cause epithelial cells present in the microenvironment, which already possess 
tumourigenic potential, to be activated or promote genomic instability within 
nearby epithelial cells leading to tumourigenesis.
Emerging new data underlines the fact that matrix remodelling enzymes 
like MMPs can affect mammary stroma, so that it directly influences the 
carcinogenic potential of neighbouring epithelial cells. Several studies have 
indicated that over activity of these MMPs can not only promote carcinogen 
induced mammary tumourigenesis but also spontaneous mammary tumour 
formation. Conversely reduced MMP activity levels can even suppress 
tumourigenesis. Data has suggested that transgenic expression of the 
metalloproteinase MMP-3/stromelysin-l in murine mammary epithelia is 
sufficient for tumour formation. Prior to tumour formation stromelysin-1 
expression leads to the development of reactive stroma implying alterations in 
the stroma have an important role in tumour formation. Also tumours formed 
after a given time period lose the transgenic expression of MMP-3 to gain 
specific genomic alterations (Sympson et al. 1995, Rudolph-Owen and Matrisian 
1998, Thomasset et al. 1998, Stemlicht et al. 1999). Also a new gene coding for 
the enzyme stromelysin-3 (ST-3), has been identified, that is expressed 
specifically in stromal cells surrounding invasive breast carcinomas. ST-3 is a 
new member of the family of metalloproteinase enzymes which degrades the 
ECM. ST-3 is postulated to play an important role in the progression of 
epithelial malignancies (Schor and Schor 2001). Two very important facts to 
consider have arisen from these studies; a) in the absence of a previously formed
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tumour, altered MMP expression is causative of the neoplastic phenotype, and b) 
aberrant expression of a mutated MMP can generate genetically altered cells.
III. The recruitment of inflammatory cells
Tumour development, similar to inflammation, involves the recruitment of 
inflammatory cells. Research using a transgenic mouse model that expresses the 
human papilloma virus-16 in basal keratinocytes to study tumour development 
demonstrated inflammatory stromal cell infiltration during tumourigenesis. The 
infiltrating stromal cells were mast cells, observed to activate matrix 
metalloproteinase-9 by the release of serine proteins. These findings were 
significant because tumour models with mast cell deficient mice coincided with a 
lack of pre-malignant angiogenesis, an important marker for tumourigenesis. 
This suggested that neoplastic progression involves the exploitation of an 
inflammatory response to tissue disruption or aberrations (Coussens et al. 1999, 
Coussens et al. 2000)
IV. Stromal signals transformed by viruses
The study of viral associated cancers has raised the possibility that viral 
affected non malignant stromal cells may stimulate tumourigenesis in normal 
cells which eventually produce tumours. For example, multiple myeloma 
research has shown that viral sequences for the cytokine interleukin-6 (IL-6), 
coded by the human herpes virus, were present in the stromal dendritic cells. As 
dendritic cells are well known to influence the growth control of haemopoietic 
cells in a paracrine pathway, it was suggested that abnormal regulation of IL-6 
expression in stromal cells may promote tumourigenesis in haemopoietic cells 
leading to multiple myeloma. Also a similar theory has been proposed regarding 
HIV and Karposi’s sarcoma (McGrath et al. 1995). Here IL-6 produced by virus 
infected stromal cells, macrophages, is thought to trigger the initial sequence for
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tumourigenesis in the neighbouring cells. In both cases virus and viral sequences 
were absent from the malignant cells. This evidence together with the presence 
of viral expression in tumour associated stromal cells; macrophages and dendritic 
cells provides good evidence of the correlation between viral induced cytokine 
expression in stromal cells with the appearance of transformed cells (Coussens et 
al. 1999).
With the increasingly recognised fact that tissue microenvironment is 
very important in the regulation of normal cell function, we need to develop 
models to test how structural and biochemical cues provided by the tissue 
microenvironment play critical roles in the suppression of tumourigenic 
phenotypes (Bissell et al. 1982). These extracellular cues themselves influence 
intracellular gene expression that in turn results in fundamental alterations in the 
composition of the microenvironment (Bissell et al. 1982). Inappropriate 
alterations of cell-microenvironment interactions can result in abnormal cellular 
behaviour, as seen in tumour progression (Ronnov-Jessen et al. 1996).
Targeting stroma as potential therapies
Vascular endothelial cells are already the focus of intense therapeutically 
relevant research, but tumour-associated fibroblasts, macrophages, neutrophils, 
lymphendothelial cells, etc. provide additional largely unexplored territory in the 
ongoing search for efficient countermeasures against invasive cancer.
Better understanding of breast cancer biology has lead to the realisation 
that tumour stromal interactions are also of crucial importance in cancer biology. 
Understanding the effect these interactions have on cell growth and 
morphogenesis as well as the complex signalling pathways between the two 
offers the possibility of revealing new potential therapeutic targets, such as those 
that target breast cancer stroma itself. Stroma appears to be the dominant factor
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in modulating and controlling epithelial morphogenesis and mitogenesis, and 
therefore direct targeting of stroma may result in a more efficient method of 
tumour regression and treatment (Camps et al. 1990, Picard et al. 1986, Grey et 
al. 1989). For example it is now recognized that tumour fibroblasts, which 
behave differently to mature tissue fibroblasts, offer a potential target for anti­
tumour therapy (Mersmann et al. 2001). Moreover, the study by Moinfar et al. 
(2000) reported that stromal alterations (fibroblasts) precede the malignant 
conversion of mammary epithelial cells.
Also the discovery of a cell surface antigen called fibroblast activation 
protein (FAP), present on reactive tumour stromal fibroblasts found in epithelial 
cancers and in granulation tissue during wound healing, presents a potentially 
attractive stromal target. Reactive stromal fibroblasts found in injured/healing 
tissue and epithelial tumours characteristically induce the formation of FAP a 
type II integral membrane protein that belongs to the serine protease gene family 
(Garin-Chesa et al. 1990, Niedermeyer et al. 1998, Scanlan et al. 1994, Park et al. 
1999). It is absent from most normal adult human tissues, with resting fibrocytes 
in normal tissue generally lacking detectable FAP expression (Garin-Chesa et al. 
1990, Rettig et al. 1988). FAP-positive stromal fibroblasts are seen in the stroma 
of over 90% of malignant breast, ovarian, colorectal, lung, skin and pancreatic 
tumours. A proportion of bone and soft tissue sarcoma tumour cells are also FAP 
positive (Rettig et al. 1988). Some reports have shown that FAP expression may 
be an independent prognostic factor in certain tumours such as breast cancer 
(Ariga et al. 2001).
The targeting of antigens selectively expressed on tumour stroma or 
tumour capillary endothelial cells with monoclonal antibodies has emerged as a 
novel targeting approach for immunotherapy (Burrows and Thorpe 1994, Old
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1996, Scott and Cebon 1997). The FAP antigen, mentioned above, is an attractive 
antigenic target because it has broad applicability to several common and as yet 
poorly treatable cancer types, and it also displays a restricted expression pattern 
in normal tissue (Garin-Chesa et al. 1990). Welt et al. (1994) using the F I9 
monoclonal antibody to FAP and recently Tahtis et al. (2003) using a different
| T 1
I-labeled humanized anti-FAP monoclonal antibodies (BIBH-7) to target 
human FAP-expressing tumour xenografts, established in a human skin/SCID 
mouse chimeric model, demonstrated specific binding to the stromal components 
of the tumour.
However as animal models and in vivo studies are costly and complex 
with problems of unpredictable characteristics and ethical approval, 
physiological 3-D model systems using human cells to create an authentic model 
is an obvious choice. With the recent advances in tissue engineering 3-D cultures 
are now more morphologically and functionally differentiated (lobulo-alveolar 
structures that express and secrete milk). In addition 3-D models can be produced 
in larger quantities as a result of greater control over culture composition, new 
bioreactors and greater choice in the method of inducing 3-D growth. The great 
hurdle impeding model development is a lack of a readily available supply of 
organ-specific stromal cells such as fibroblasts and endothelial cells. However, 
recent advances in genetic engineering have allowed the generation of cells with 
immortal growth to be produced.
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1.5 Immortalization
1.5.1 Immortalization of normal human cells
Normal human somatic cells undergo a limited number of divisions before 
entering an irreversible growth-arrest state defined as senescence (Hayflick et al. 
1961). However genetic alterations can allow some cells to escape senescence. 
These cells pass through a ‘crisis’ phase, which is usually accompanied by 
extensive cell death, after which they become immortalized and continue to 
proliferate indefinitely. They may then progress and acquire the characteristics of 
cells that are fully cancerous or ‘transformed’ through additional mutations in 
tumour-suppressor genes or oncogenes (genes that cause cancer when mutated). 
Unlike normal cells, transformed cells can survive without growth factors, and 
they do not need to be anchored to a solid support. The acquisition of unlimited 
proliferative potential defined as true immortality is probably a critical step 
during tumourigenesis (Newbold et al. 1982).
In normal human somatic cells the progressive shortening of telomeres 
with each cell division has been demonstrated as the single key factor 
determining the length of the cell cycle (Allsopp et al. 1992). Telomeres are short 
repetitive DNA sequences that define the ends of chromosomes and are 
synthesized by the enzyme telomerase (Blackburn and Gall 1978, Harley et al. 
1990). With each round of cell division, the DNA at each telomere gets 
progressively shorter (~50 base pairs per division) (de Lange 1994), leading, in 
turn, to shortening of the whole telomeric structure. Adult somatic cells lack 
functional telomerase, a multi-component enzyme comprising a template RNA 
plus an essential catalytic subunit of human telomerase (hTERT), telomeres are 
not regenerated (Zhu et al. 1999, Meyerson et al. 1997, Lingner et al. 1997,
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Harrington et al. 1997, Kilian et al. 1997, Nakamura et al. 1997b, Counter et al.
1998). Several observations suggested that this process of telomeric erosion 
could impose the limits on cellular lifespan. Normal human tissues have low 
levels of telomerase. In contrast, many tumour cells and immortalized cell lines 
have up-regulated telomerase activity, suggesting a mechanism by which cells 
may escape normal ageing controls. To overcome telomere shortening and 
bypass senescence and crisis, it has been demonstrated that artificial expression 
of hTERT can immortalize normal human cells (fibroblasts and epithelial cells) 
(Bodnar et al. 1998, Vaziri and Benchimol 1998, Yang et al. 1999, Ouellette et 
al. 2000). However, O’Hare et al. (2001) reported that hTERT alone could not 
immortalize primary human mammary fibroblasts or endothelial cells. On the 
other hand a combination of hTERT and the oncogene SV40 Large T antigen 
when transduced by amphotropic retroviruses into primary human mammary 
endothelial cells and fibroblasts consistently generated stable immortal human 
cells in a reproducible and convenient manner (O’Hare et al. 2001) and thereby 
providing potential components of a multi-compartment tumour-stromal model 
system. The value of these cells very much depends on whether they retain 
normal cell function and do not exhibit transformed characteristics.
T ransformation
Tumourigenesis is a multi-step process involving the accumulation of genetic 
alterations and mutations, of genes controlling cell proliferation and survival, 
which allow tumour cells to overcome cellular hurdles on its way. Normal 
human cells have a number of intrinsic mechanisms, involving molecular 
‘gatekeepers’, to protect them from going out of control and forming tumours. 
For example, mutations of the p53 tumour suppressor gene have been reported to 
be present in over half of all breast tumours (Ozbun and Butel 1995). Breast
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cancers also frequently carry mutations that deregulate the retinoblastoma protein 
(pRB) pathway including loss of expression of pRB or pl6INK4a (Varley et al. 
1989, Brenner et al. 1996) or amplification or over-expression of cyclin D1 
(Gillett et al. 1994). Breast carcinoma cells also commonly acquire alterations in 
the Ras-signaling pathway (Clark and Der 1995), which may occur by several 
mechanisms, most notably amplification or over-expression of the ERBB2 gene 
(Slamon et al. 1989). C-myc is also frequently amplified or over-expressed (Escot 
et al. 1986).
It has been shown that hTERT immortalized cells (normal human 
mammary epithelial cells, mammary fibroblasts and hepatocytes) (Hahn et al. 
1999, Elenbass et al. 2001) can be fully transformed into a malignant phenotype 
by adding two well known oncogenes. The first is an activated ras gene (H- 
rasV12), which although is rarely mutated in breast cancers (-5% of cases) 
(Clark and Der 1995) is mutated in many human tumours. The second is a viral 
oncoprotein, the simian virus 40 large-T antigen. This protein is involved in 
transforming normal host cells into tumour cells by inhibiting two central 
growth-control factors; the tumour-suppressor proteins p53 and pRB (Varley et 
al. 1989, Brenner et al. 1996, Ozbun and Butel 1995, Hahn et al. 1999). When 
Hahn et al. (1999) introduced the ras oncogene alone, the human cells became 
senescent (as previously reported for mouse cells). This senescence could not be 
overcome by combining ras with introduction of hTERT. But cells expressing 
large-T and hTERT became immortalized, and when these proteins were 
combined with ras expression increased growth of the cells was observed (Hahn 
et al. 1999). Hahn et al (1999) demonstrated that these different cells formed 
colonies in soft agar, a simple, in vitro test for transformation and were 
tumourigenic in nude mice. The results clearly showed that only the combination
of all three genetic elements was sufficient to cause efficient tumour growth. 
Therefore in tumourigenic human cells, mutations/alterations causing telomerase 
to become active can cooperate with other mutations in oncogenes to induce 
transformation.
The findings by Hahn et al. (1999) indicated that at least 3 distinct 
pathways were involved in genetically manipulating normal human cells so that 
they are transformed into a fully tumourigenic cell. These are: 1) expression of 
the telomerase enzyme (hTERT) to overcome telomere shortening and maintain 
length, 2) expression of the large-T protein inactivating both the pRB and p53 
pathways and 3) the expression of the ras oncogene to induce transformation to a 
cancerous state.
1.6 In vitro tumour models
Since human in vivo models are not ethically available, the development of more 
relevant models has relied upon in vitro systems. These have been based on both 
cell lines derived from breast tumours and normal human mammary epithelial 
cells. Problems of authenticity with in vitro systems are caused by acquisition of 
any number of additional events, all of which contribute to transformation.
1.6.1 Two and three dimensional tissue culture models
At present in vitro tissue culture of breast cancer cell lines is the most widely 
used experimental model system of breast cancer (Suzuki et al. 2001). Although 
simple and convenient to use, this model is far from satisfactory in that it 
represents a very artificial environment. Important physiological processes that 
are lacking in vitro include three dimensional (3-D) structure, tumour-stromal
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interaction and angiogenesis (presence or lack of circulating activating/inhibiting 
factors) with its influence on tumour development and tumour growth, and 
metastatic spread to other tissues.
Two dimensional culture models
Until the last 10 years, 2-D monolayer cultures together with organ cultures have 
been the most popular in vitro models for breast cancer research. Monolayer 
culture models are easy and convenient to set up with good viability of cells in 
culture but they lack some major elements such as the 3-D microenvironment of 
intact tissue in particular stroma; this being important as stroma of the mammary 
gland accounts for greater than 80% of the resting breast volume (Drife 1996). 
Due to their lack of structural architecture they are also faced with transport 
limitations resulting in the quality of the monolayer being strongly influenced by 
the physicochemical properties of the support. Moreover, growth of normal 
epithelial cells as monolayers on artificial supports leads to partial loss of the 
original epithelial cell characteristics resulting in observations that normal 
epithelial cells when grown in 2-D monolayers are highly plastic and express 
many characteristics displayed by tumour cells in vivo (Bissell 1981, Petersen et 
al. 1992). In addition, not all normal epithelial cell types are able to adhere and 
grow well on artificial substrata. In contrast, the microenvironment of tumours 
remains intact in organ cultures. This is of vital importance as cell-cell, cell- 
matrix interactions and interstitial fluid affect differentiated cell function within 
the 3-D environment. However organ culture is not without its own problems; 
with difficulty in obtaining specimens and poor viability of the tissues in culture 
being major obstacles encountered.
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Three dimensional tissue culture models
It has not been long that 3-D culture models, in the form of multicellular 
spheroids, have replaced 2-D models as more representative and complex in vitro 
culture models. The advantages 3-D cultures have over 2-D monolayers are their 
well defined geometry, which makes it possible to directly relate structure to 
function and in turn enable theoretical analyses. Their close resemblance with 
micrometastases and initial avascular regions of metastatic tumours augments 
their authenticity. In addition, 3-D cultures are composed of cells with different 
phenotypes such as proliferating, non-proliferating and necrotic cells very similar 
to the situation within intact human tumours. Phenotypes present, therefore, more 
closely resemble those present in vivo. Cellular heterogeneity within these 
tumour models caused by mass transport limitations, resembling the multiple 
phenotypes found in solid epithelial tumours, is far more realistic than the 
cellular homogeneity found in monolayer cultures. The majority of 3-D cultures 
used were in the form of multicellular tumour spheroids.
3-D multicellular tumour spheroids
Multicellular tumour spheroids are very small spheroids consisting of cells 
(epithelial or a mixture of epithelial and stromal cells) organized in a 3-D 
spheroidal arrangement. Many cells types, present in 3-D multicellular spheroids, 
were found to assume a more or less normal cellular architecture and exhibit 
gene expression profiles that were reflective of an authentic differentiated 
phenotype (Stoker et al. 1990, Kleinman et al. 1987). 3-D spheroids also contain 
extensive ECM that differs in the relative amount and assembly from the 
corresponding monolayer cultures. The complex 3-D network of cell-cell and 
cell-matrix interactions is not only relevant in the penetration and action of drugs 
but it also affects the distribution and function of physiologically occurring
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factors. These biological effectors such as hormones and growth factors 
fundamentally determine the regulatory mechanisms of cell growth, 
differentiation and death. For example, human mammary epithelial cells, isolated 
from reduction mammoplasty, grown in culture on reconstituted basement 
membrane form polarized acinus type structures capable of gland specific 
function such as milk production (Stoker at al. 1990). These results were also 
reproduced using primary mouse epithelial cells isolated from pregnant mice. 
However the same cells grown in a different substrate, Type 1 Collagen, show 
altered integrins, abnormal cellular polarity and disorganization emphasising the 
importance of matching cell type with appropriate substrata (Howlett et al. 
1995). As mentioned above 3-D spheroids have been shown to recapitulate the 
drug sensitivity patterns of tumour cells in vivo. MDA-MB-231 breast tumour 
cells exhibited a much lower IC50 to cis-platinum when plated in monolayer 
cultures than as suspended spheroids. In a study by Ohmori et al. (1998) up- 
regulation of TGF-ps in breast tumour cells, has been shown to be protective 
against cytotoxic agents such as cis-platinum. Treatment of MDA-MB-231 
spheroids, but not MDA-MB-231 monolayers, with cis-platinum induced up- 
regulation of TGF-pi mRNA and protein which is highly predictive of the 
patterns of drug response of tumour cells in vivo.
With its many advantages over conventional monolayer cultures, 3-D 
cultures more closely resemble the in vivo situation with regard to cell shape and 
its environment. This is important as it is recognised that cell shape and 
environment can determine the behaviour and gene expression of the cell. For 
example, K-ras mutations frequently found in colorectal tumours, have been 
noted to occur more consistently during transition from early to intermediate
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adenoma stage which coincides at what time tumours acquire 3-D growth 
patterns (Rak et al. 1995).
Heterologous 3-D co-culture models
Currently heterotypic co-cultures of luminal and myoepithelial cells; tumour and 
fibroblasts; and tumour and endothelial cells are available. This is important as 
human breast cancers are now well recognised as a heterogeneous mix of stromal 
and epithelial cells and also because it has been demonstrated that the presence 
of stromal cells promotes cell differentiation and structure formation. For 
example it has been reported that human mammary epithelial cells when injected 
alone, without stromal cells (fibroblasts), into mammary fat pads do not support 
complex differentiated structures (e.g. ductal structure formation (Sheffield 
1988)).
Three mandatory requirements are necessary to develop human tissue; 1. 
co-localization of different cell types with cell-cell interactions and the exchange 
of growth factors and other biological effectors; 2. manufacture of an 
extracellular matrix (ECM) to provide a 3-D scaffold for mechanical stability and 
to regulate cell function; 3. synthesis of interstitial fluid containing the necessary 
nutrients and biological effectors required for tissue differentiation and 
maturation. Heterologous 3-D co-culture models incorporating stroma satisfy 
these three broad requirements and so produce credible and reliable preclinical 
tumour models.
As 3-D cultures support co-cultivation of multiple cell types, interaction 
between epithelial and stromal cells which regulate normal and neoplastic 
development can be studied. For example, the value of experimental culture 
models using normal epithelial cells often depends on the degree of epithelial cell 
polarization as well as other critical features observed in natural tissues,
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including the formation of tight junctions, desmosomes and membrane 
interdigitations. As the control of epithelial cell polarity is one of the important 
functions of the stroma, inclusion of stroma and its elements is vital for 
maintaining authenticity. Indeed loss of epithelial cell polarity has been proven to 
lead to increased cell proliferation and tumourigenesis.
Breast tumour epithelial cells found in human breast cancer are apolar, 
exhibit disorganized cell-cell junctions, contain distorted cell nuclei, and fail to 
organize into ductal structures. Cell shape and tissue architecture is partly 
dependent on various adhesion molecules, and so any alterations in these 
molecules have been implicated in cancer progression (Alford and Taylor- 
Papadimitrou 1996). Heterologous 3-D models, therefore, can recreate or 
maintain these vital cell-cell adhesion interactions preserving the tissue 
architecture. For example, tumour cell adherence and migration in spheroid co­
cultures reflect the distinct metastatic potential of (different) breast tumour cells. 
Given the crucial importance of the tumour-stromal interaction in cancer biology, 
a more realistic environment is created better able to elicit an in vivo like 
response to cancer therapies.
With the microenvironment of normal tissue and tumours being of crucial 
importance in the control of growth and development it is vital to clarify the 
origin of the ECM present within in vitro and in vivo model systems. The ECM 
produced and present in the majority of 3-D in vitro tumour model systems is 
predominantly of tumour cell origin. In heterologous (tumour-stromal) model 
systems incorporating stromal cells such as fibroblasts, ECM is also produced by 
these stromal elements. However the situation present in vivo with animal models 
is very different. In xenograft and transgenic models it is the host cells that 
produce the ECM; this being significant as it is of rodent non-epithelial tumour
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tissue origin. This raises serious implications and issues regarding tumour- 
stromal cell interactions as well as cell signalling.
1.6.2 3-D cell culture techniques and models
The concept of the 3-D in vitro co-culture system was invented due to the many 
advantages it gave to cancer research. These models can reproducibly reflect the 
distinct invasive behaviour of breast tumour cells, mimic the cell-stromal 
interactions of breast carcinomas and allow for systematic investigation into the 
multiple unknown regulatory feedback mechanisms between breast tumour and 
stromal cells in a well defined 3-D environment. Multicellular tumour spheroids 
have a well organized spherical symmetry of morphological and physiological 
features including complex cell-cell and cell-matrix interactions resembling 
avascular tumour sites and or micrometastatic regions in vivo and thus are a very 
useful model in tumour biology.
The most popular methods used to manufacture 3-D spheroids are 
spontaneous aggregation, liquid overlay cultures, spinner flasks and more 
recently the NASA developed Rotary Cell Culture System (Kim et al. 2004). As 
an alternative, 3-D prefabricated biodegradable scaffold based cultures, and pre­
engineered collagen scaffold have been developed. The scaffold based culture 
system is gaining in popularity as the 3-D matrix is used to promote multilayer 
growth of cells derived from breast cancers. The design of the Rotary Cell 
Culture System is a vast improvement on the spinner flask in that larger more 
morphologically and functionally differentiated breast cancer spheroids can be 
produced. The individual merits of each method are discussed in more detail in 
Chapter 5
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1.7 In vivo model systems
1.7.1 Animal model systems
Many of our medical advances over the last century have been made using 
animals. Our extended lifespan, treatments for heart disease, cancer, diabetes, 
vaccinations, and many other things are all a testament to the benefits of animal 
models in research. Animal tumour models of the past have led us to the drugs of 
the present. Not only are they used in the discovery and screening of drugs, they 
are used for therapeutic development such as predicting drug efficacy, safety and 
learning about the mechanism of action. They also have major role in improving 
our understanding of tumour biology such as cell proliferation, progression and 
apoptosis. Furthermore, as patients bearing tumours of a given type do not 
necessarily provide a perfectively predictive model for others with the same 
tumour type, in vivo models may provide a more consistent and reliable 
indicator.
As with any disease prevention is the key, more so with breast cancer as 
it frequently occurs in women without established major risk factors. Great 
advances in other areas of breast cancer research have led us to some very 
exciting ideas as well as therapeutic strategies with enormous potential. 
Therefore we clearly need suitable models for initial preclinical testing of these 
new preventative and therapeutic strategies. Development and testing of 
preventative strategies is very important in understanding the controls of normal 
mammary gland development, differentiation and involution, and genetic and 
epigenetic changes/developments that are associated with precancerous 
proliferative breast disease. Further research into developing better in vitro and in 
vivo models of human breast cancer is urgently required. Animal models used in
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preclinical studies should possess genetic and other biomarker abnormalities 
similar to their human counterparts. These include animal xenograft models, 
human precancerous cell lines, and in vivo human precancerous models for long 
term study.
Animal models are a vast improvement on in vitro cell culture systems 
which are limited in that they represent tissues taken out of the body. Cells in 
culture do not behave normally when removed from the blood, immune system, 
nervous system and neighbouring tissues that help make them what they are. In 
addition, even cells for culture must come from an animal initially. Sometimes, 
however, an animal model is too complex and a cell culture system or computer 
model allows a more effective study of a single aspect of the disease. Moreover, 
an animal model can’t be created until patients are studied and the disease is 
described and defined.
With the massive explosion in therapeutic strategies becoming available 
an authentic breast cancer model is urgently required for preclinical trials. Only 
when an authentic and validated model becomes available can we reliably 
consider testing on human patients. Development of better in vivo models of 
human breast cancer is of crucial importance in the fight against breast cancer 
mortality.
The mutant nude mouse
The introduction of the immunodeficient (Foxnl) mice in the 1960s opened a 
brand new era of cancer research enabling the development of xenograft models 
of human breast and other cancers. The absence of a functional immune response 
has made it possible to transplant and grow foreign tissues with very little 
interference and complications. Prior to the discovery of the immunodeficient 
mouse, syngeneic transplantable mouse tumour systems or autochtonous rat
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tumours were employed as the main or only tool in the development of anti­
tumour agents. Sometimes complex procedures were used to render wild type 
mice immunodeficient, involving a combination of surgery (thymectomy), 
radiation and/or drug treatments; however the specialised techniques used meant 
that this approach was not widely used.
Today the nude (.Foxnl) and severe combined immunodeficiency (SCID) 
mice, which have naturally occurring single gene mutations which affect their 
immune system, are the most commonly used research models in xenograft 
experiments. Nude mice have a naturally occurring autosomal recessive mutation 
in chromosome 11 which causes failure of hair growth and other defects, 
including thymic epithelial dysgenesis, which renders them T cell deficient 
(Kindred 1971). The thymus remains rudimentary and produces reduced numbers 
of mature T cells. This means nude homozygotes (animals with identical mutant 
genes at corresponding chromosome loci) do not reject allografts and often do 
not reject xenografts (tissue from another species). The discovery that human 
neoplasms (tumours) could be grown in nude mice was immediately recognized 
as an important research tool. Thus, the spontaneous mutation of Foxnl among 
laboratory mice was a serendipitous development that led to the nude mouse 
becoming the first animal model of a severe immunodeficiency. The first 
successful transplantation of a human malignant tumour into nude mice was 
reported in 1968 (Pantelouris 1968). In the decades since, the nude mouse has 
been widely utilized by researchers studying factors regulating transplantable 
human tumour growth and cancer metastasis. Although it lacks T cells, the nude 
mouse has a normal complement of bone-marrow-dependent B cells. It thus 
presented a unique tool for the study of the role of the thymus on lymphocyte 
differentiation, investigations of B cell functions (including interactions with
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other immune cells) and other immune cells, including the natural killer (NK) 
cells. Nude mice have been used extensively in studies of the tumourigenesis of 
in vitro cultured cells. They are also widely utilized in evaluating anticancer 
agents prior to human clinical trials.
1.7.2 Xenograft models of breast cancer
The breast cancer xenograft model exploits the fact some human breast cancer 
cell lines formed tumours in immunodeficient mice. Unfortunately human breast 
cancer is one of the more difficult tumours to transplant directly into 
experimental animals. Primary human breast cancer has proven to be among the 
least likely of human tumours to grow progressively in immunodeficient mice, 
with relatively low rates of tumour take, and few forming spontaneous 
metastases (Price 1996). The reported success (take rate) for invasive human 
breast cancer (primary metastatic cells) is 7%-20% (Mehta et al. 1993). The 
differences are accounted for by site of implantation (orthotopic being better) the 
age and strain of mice used, and whether or not hormonal supplementation is 
used (nude mice have low oestrogen levels compared with humans). In 
comparison the success rates of pancreatic/colonic, renal cell, lung and urological 
carcinomas have been reported as 40-60%, 40%, 38-51% and 56% respectively 
(Cui et al. 2001, Angevin et al. 1999, Mourad and Vallieres 1995, Mattem et al. 
1985, Okada and Yoshida 1984). Serially transplantable breast xenografts are 
much rarer still (Mehta et al. 1993). Paradoxically, better success has been 
reported with pre-invasive disease samples e.g. ductal carcinoma in situ (Gandhi 
et al. 2000, Chan et al. 2002).
90
Directly established mammary tumour xenograft lines with the capacity 
to metastasize were not developed until the early 1990s (Hurst et al. 1993), 
although prior and subsequent to this a number of established in vitro lines have 
been adapted to xenograft cultures. Some such lines are able to locally invade or 
metastasize, sometimes as the result of further genetic engineering to a more 
aggressive phenotype. Of the generally available human breast cancer cell lines, 
only MDA-MB-435 reliably forms spontaneous metastases after implantation 
into the mammary fat pad of immunodeficient mice (Price 1990).
Advantages of xenograft models
No single disease model can accurately reflect all features of the disease being 
tested. One must therefore select the model type which most closely mimics that 
aspect of the disease required by the hypothesis. Currently several different 
classes of animal based breast cancer models exist, these include rat models 
(chemically induced tumours), human tumour xenografts, syngeneic, transgenic 
(gain), and knockout mice. The chief advantage the xenograft models convey 
over other model systems is that it represents a model system of human origin 
allowing the use of fresh surgical patient material and or human tumour 
engraftments. Human breast cancer cells that grow progressively in nude mice 
generally retain their karyotypic, morphologic and histologic appearances as well 
as their production of specific enzymes and antigens, thus providing more 
opportunities to study the tumour cells in vivo rather than only in vitro (Fogh et 
al. 1977).
Human tumour xenograft and tissue transplant models are thus powerful 
tools for analyzing the complexities of organ function, especially when results 
can be reciprocally tested and scrutinized in simpler 3-D in vitro culture models. 
As with any model the similarity with the original is of paramount importance.
Therefore incorporating more human components such as the relevant stromal 
cells will only improve the authenticity and credibility of xenograft models. 
Orthotopic vs heterotopic xenotransplanation
Over the last decade opinion has differed with respect to the optimum site of 
tissue transplantation within the animal and its preparation. For example, does the 
outgrowth of human mammary epithelium from immunodeficient subcapsular 
kidney transplantations truly represent normal mammary events or does the 
mammary fat pad provide a more relevant environment for outgrowth? Indeed, it 
has long been recognised that mouse mammary epithelial cells display 
differential developmental responses depending upon their site of delivery 
(Miller et al. 1981, Neville et al. 1998). In addition, it is now widely accepted 
that tumours grown subcutaneously are less successful in terms of take rates and 
metastases than those grown in the anatomically correct site (i.e. mammary fat 
pad) (Price 1990). Furthermore orthotopic implantation of breast tumour cells 
encourages the development of both lung and lymphatic metastases (Killion et al. 
1998, Fidler 1999). For example, this is seen with the MDA-MB-231 model of 
human breast cancer metastatic to the bone (Yoneda et al. 1994), human 
colorectal cancer lines metastatic to liver, melanoma lines metastatic to nodes, 
prostate lines metastatic to nodes and bone, and pancreatic lines metastatic to 
liver and many other syngeneic and xenogeneic models.
1.7.3 Alternative models of breast cancer
It is important to note that other animal models of breast cancer exist. These 
reflect various aspects of breast cancer biology, but despite their non-human 
origin, have been widely and successfully used. They fall into three groups: the
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chemically induced (rat) models, syngeneic, and models generated by genetic 
manipulations (transgenic gain and knockout mice).
Naturally each of the models has its specific uses, disadvantages and 
advantages. The majority of non-xenograft mouse models involve both in vitro 
and in vivo models which have utilized rodent cell systems, often in conjunction, 
with mutant rodent oncogenes. The results obtained from these models, therefore 
have questionable relevance to the human disease of breast cancer. For example, 
manipulation of a single gene can lead to high tumour incidence in transgenic 
and knockout mice; however this is very different to the mechanism of tumour 
formation in humans as multiple genetic and epigenetic changes are evident in 
human tumours and even in some benign breast lesions (Millikan et al. 1995, 
Dietrich et al. 1995, Simpson et al. 2005). These models, therefore, may more 
adequately reflect inherited beast cancers, since the altered genetic events are 
present from foetal life. On the top of these problems, unfortunately the 
expressed transgene is generally expressed throughout the mammary epithelium, 
which probably does not occur in the majority of sporadic human breast cancers 
(Clarke 2000). There may be additional problems of interpretation when the 
transgene is not controlled by a tissue-specific promoter but is expressed in every 
cell in the animal.
Chemically induced models
Chemically induced and oncogenic virus derived mouse mammary tumours (e.g. 
mouse mammary tumour virus) were not ideal models for human cancer in that 
they were highly immunogeneic, failed to metastasise, and were not hormonally 
responsive as human cancers. Researchers began to recognize the importance of 
using strictly syngeneic inbred strains and the fact that spontaneous tumours may
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be closer to their human counterparts than those induced with strongly oncogenic 
chemicals and viruses. As such these models are now rarely used.
Syngeneic mice
Syngeneic mice are strains of mice produced by repeated inbreeding (over 20 
generations), in order to eliminate heterozygocity, so that each pair of autosomes 
within an individual is identical (Shi et al. 2001). They are virtually genetically 
identical (over 98% genetically identical) in addition to being immunologically 
compatible so as to allow tissue transplantation. Therefore they allow the study 
of the immune response in the absence of other variables caused by genetic 
differences (i.e. MHC haplotype, immunoglobulins (Ig) idiotype). Ig from one 
animal can be injected into another animal of the same inbred strain with out 
eliciting an immune response. Furthermore specific cells (e.g. tumour cells) can 
be transferred without rejection.
Syngeneic mouse tumour models have a somewhat limited role in cancer 
research because the biology of the rodent and their tumours can differ 
significantly from that of human cancer. To begin with, the difference in 
developmental programmes of mouse and humans will manifest in many ways 
with size being an obvious example. As a consequence the cellular targets for 
oncogenic transformation are present in vastly reduced numbers in mouse tissues 
than in their human counterparts. This is coupled with the fact that mice have a 
much shorter lifespan than humans, and so tumours that occur in mice must have 
an accelerated programme of progression. In addition a smaller number of 
genetic changes are required for rodent cell transformation in vitro, so it follows 
that this situation will be mimicked in vivo. These fundamental differences 
between humans and mice will undoubtedly have an influence on tumour 
formation. It therefore comes to no surprise to learn that the tumours formed
9 4
differ as well. For example, most human breast cancers are hormone dependent, 
whilst the vast majority of mouse tumours are hormone independent with much 
lower levels of oestrogen/progesterone receptors (Nandi et al. 1995). Another 
point of note is that although similar morphological patterns of lesions appear in 
both species, the morphology of most mouse tumours does not resemble the 
common human breast cancers (Cardiff 2001). Finally to round things off the 
metastatic pattern between the two species is also very different. Breast cancer in 
humans involves either regional spread, by lymphatic channels to local lymph 
glands, or haematogenous systemic spread. In contrast mouse mammary cancers 
metastasize almost exclusively to the lung (Cheung et al. 1997). A major 
technical problem with using syngeneic models involves studies where 
monoclonal antibodies against human antigens failed to cross react with the 
rodent equivalent.
Although human tumour xenografts are now the preferred model, 
applications requiring an intact immune system still present uses for syngeneic 
mouse models. In addition, as metastasis is more readily observed in syngeneic 
models they are still useful for such specific studies.
Transgenic gain and knockout mice.
The development of techniques for introducing foreign DNA into the germ line 
of mice by microinjection and those of engineering embryonic stem cells prior to 
injection into mouse blastocytes has yielded two powerful experimental tools: the 
ability to over-express or suppress genes in specific tissues of a mouse 
(transgenic gain mice), and the power to ablate specific gene expression in the 
whole mouse or in a tissue specific (knock out mice). Since the establishment of 
these technologies, their use has allowed the exploration of the role of a variety
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of genes during development, as well as the importance of these genes for certain 
physiological and biochemical processes and for the development of disease.
Transgenic mice result from genetically altered embryos: introduction of 
a foreign or synthetic gene (called a transgene) or combination of genes by 
microinjection into developing oocytes. This results in a chimeric mouse with a 
gain of a gene with the genetic alteration affecting the germ plasm, and 
subsequently can be transmitted to their progeny (heterozygous progeny).The 
transgene inserts randomly into the genome (non-homologous recombination). 
Through selective breeding, it then is possible to maintain a strain of mice 
consisting of individuals with particular traits of interest. A specific trait, such as 
a predisposition to develop a particular type of tumour, can be introduced into a 
mouse strain by injecting an oncogene into the embryo. Transgenic mice can 
therefore permit the study of cancer in specific tissues including their initial 
development.
The knock out mouse is generated in a very similar manner to the 
transgenic gain mice except in this case a normal gene is replaced with a mutant 
gene resulting in the loss of a gene or function (thus allowing the investigation of 
that specific gene function).
To determine the value of genetically engineered mice (GEM) we must 
look closer at the biology and genetics. It is well recognised that cancer involves 
the accumulation of genetic abnormalities within a cell with sporadic cancers 
arising when the initiating mutation affects a single cell in an otherwise normal 
microenvironment. However oncogene bearing transgenic mice and tumour 
suppressor gene knockouts do not mimic sporadic tumour development because 
the initiating mutation is present throughout the body or a particular tissue. As a 
consequence the functions of the microenvironment in either stimulating or
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inhibiting tumour growth can be impaired. Following on from this other side 
effects such as the induction of mechanisms that balance the effects of the 
mutation and tumourigenesis outside the tissue of interest can occur. This 
situation more closely resembles rare familial cancer syndromes in humans. 
Another major limitation of transgenic and knockout mice is their dependency on 
promoters that are ultimately sensitive to hormonal stimulation.
Currently most genetically engineered mice transgenes are placed behind 
promoters that have some target tissue specificity, with MMTV-LTR (mouse 
mammary tumour virus long terminal repeat) and WAP (whey acidic promoter) 
being the most commonly used promoters. These promoters have hormone 
regulated enhancer elements that are stimulated by various hormones and so are 
not the natural promoters for the activated oncogenes associated with human 
breast cancer. Therefore these and other promoters can result in tumours with 
strange biologies very different to the human situation. As a consequence it is 
difficult to assess the interaction between oncogene coupled signalling pathways 
and the action of endocrine hormones. For example tumourigenesis can be 
enhanced in pregnancy with both promoters, whereas in humans pregnancy tends 
to be protective (Cardiff 2001).
1.8 Aims of the thesis
The aim of this thesis was to develop a more authentic xenograft model of breast 
cancer by incorporating the relevant and essential constituents of a tumour 
microenvironment: human stromal cells and extracellular matrix. Ideally this 
would be an organotypic, 3-compartment xenograft model of human breast 
cancer in mice comprising solely of human cells. The development of a complex
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multi-compartment heterologous xenograft model incorporating the relevant 
stromal elements will provide a realistic alternative to currently available 
chimeric xenograft models. If successful this model can be utilized as an accurate 
and credible preclinical model for the development and testing of new 
therapeutic strategies, such as those that target breast cancer stroma itself
The great hurdle impeding multi-compartment xenograft model 
development has been the lack of readily available human stromal cells. The 
required cells have to be robust enough and in sufficient supply to be 
incorporated into these model systems. With the recent availability of a series of 
immortalized human mammary stromal cell lines (O’Hare et al. 2001) it is has 
now become possible to commence development of a multi-compartment breast 
tumour model. There are two broad components to this thesis: in vitro and in 
vivo.
In vitro
The first objective was to characterize each of the cell lines by comparing their 
growth properties against each other and also their equivalent normal cells in 
order to select the cell line or cell lines most suitable for incorporation into the 3- 
compartment xenograft models (Chapter 3). Next, the vascularization of the 
xenografts was investigated by determining the ability of the human endothelial 
cells to interact and integrate with host (mouse) endothelial cells, in vitro, to 
form chimeric vasculature (Chapter 4). Prior to in vivo xenografting, the ability 
of the immortalized stromal cell lines, with the aid of new 3-D tissue culture 
techniques, to interact and form viable complex heterologous tumours in vitro 
was investigated (Chapter 5). If successful, the goal was to xenograft these pre­
formed heterologous in vitro tumours directly into immunodeficient mice in 
order to streamline model development.
In vivo
The first objective was to investigate whether the available cell lines survived in 
vivo and for what period of time. The next objective was to examine the extent to 
which surviving cells formed organised structures (e.g. blood vessels) and 
whether they proliferated. Once the basic parameters of survival, growth and 
differentiation had been established, the appropriate stromal cell lines were co­
grafted with different breast epithelial tumour cell lines (e.g. VEGF over­
expressing mammary epithelial tumour cell lines) and with primary breast 
tumour cells (Chapter 6). The last part of the thesis describes experiments in 
which an alternative source of stromal cells, in the form of circulating endothelial 
progenitor cells, was investigated as regards to their suitability for use in this 
model system (Chapter 7).
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Chapter 2 
Materials and methods
2.1 Routine cell culture
2.1.1 General tissue culture methods
All cell culture procedures were carried out using aseptic technique in a laminar 
flow cell culture hood with the operator wearing protective clothing and nitrile 
gloves. Surface decontamination was achieved with 70% (v/v) ethanol, and any 
cell contaminated or potential pathogen containing liquids drained into 10% (v/v) 
‘Chloros’ solution (Sodium Hypochlorite, Haychlor Hayes Chemicals) (See 
appendix I for details of all sources). All vessels, flasks and pipettes used were 
left to soak in Chloros solution for >12 hours prior to being discarded in 
appropriate yellow bags or containers for incineration.
Cells were grown in 25cm2, 75cm2, or 175cm2 Nunc® tissue culture 
flasks (Nalge Nunc International) in an atmosphere of 5% (v/v) carbon dioxide 
(CC>2)/air in 37°C or 33.5°C humidified incubators. Cells were monitored daily 
and passaged at 80-90% confluency by trypsinisation. The culture medium was 
drained and the cells washed once with phosphate buffered saline (PBS, 
Biowhittaker) and then twice using PBS containing 0.02% (w/v) ethylene 
diaminetetra-acetic acid (EDTA) (disodium salt) (PBS/EDTA), to chelate 
calcium ions. This PBS was then drained and ~1 ml of thawed bovine trypsin 
(1 mg/ml, Sigma) in 0.02% (w/v) EDTA was added to the flask, and the flask 
incubated at 37°C for approximately 1-2 minutes to disrupt cell-cell and cell- 
flask attachment. Intermittent removal of the flask from the incubator and 
rocking of its contents to assess cell detachment from the flask surface was
carried out to prevent over trypsinisation of the cells. Detached cells were 
washed from the flask with air buffered L I5 medium (Biowhittaker) containing 
10% (v/v) of foetal calf serum (FCS, First Link), pelleted by centrifugation for 3 
minutes at approximately 300xg (1500 revolutions per minute (rpm)) and then 
re-plated as required. All cell lines were routinely passaged at a split ratio of 1:6.
2.1.2 Freezing, thawing and storage of cells
Cells to be used in xenograft experiments were previously grown up in bulk and 
stored in dedicated liquid nitrogen (N2) tissue culture banks in replicate 
ampoules. Cells to be frozen were trypsinised from their flasks as previously 
described, centrifuged into a pellet and then resuspended at a cell density of 
approximately 5 xlO6 cells/ml in freezing medium which contained 10% (v/v) 
dimethyl sulphoxide (DMSO, Sigma) as a cryoprotectant in LI 5 medium 
containing 10% (v/v) FCS. The cell suspension was then aliquoted into 1ml 
cryotubes (Nalge Nunc International) and frozen in a liquid N2 vapour phase 
freezing head using a two stage freezing protocol. After freezing, the tubes were 
stored under liquid N2 in dedicated tissue storage facilities. Cells were thawed by 
placing the frozen cryotubes in a 37°C water bath immediately after removal 
from the liquid N2 . Once the contents were fully thawed the cell suspension was 
transferred to 5-10 ml of growth medium. The cells were pelleted by 
centrifugation for 3 minutes at approximately 300xg (1500 rpm), resuspended in 
5ml of growth medium and plated out in a 75 cm2 flask containing the appropriate 
medium. After 24 hours the medium was changed to remove dead cells, debris 
and any remaining traces of DMSO.
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2.1.3 Culture conditions for different cell lines used
The cells used in this study are summarised in Table 2.1. The individual culture 
conditions are described below.
Temperature sensitive 
33.5 °C
N on-temperature 
sensitive 
37 °C
Human mammary HMME2 HMME
endothelial cells HMME7 HMME 7wt (wild type)
Human mammary HMF 3A HMF
fibroblasts HMF 3B* HMF 3wt (wild type)
HMF 3C 
HMF 3D
HMF 3wt ras
Human breast tumour MCF-7
cell lines MCF-7 V I2
T47D
ZR-75-1
Table 2.1. Table showing all the cells and cell lines used together with their 
temperature sensitivities. (* derived with the temperature sensitive LT construct but 
lacking temperature sensitivity).
Human breast cancer cell lines
Four established oestrogen sensitive breast tumour cell lines were used; these 
were MCF-7 V12 (VEGF over-expressing variant of the MCF-7 cell line from 
Professor Adrian Harris, Institute of Molecular Medicine, Oxford), MCF-7, T- 
47D and ZR-75-1 (originally obtained from the American Type Culture 
Collection, ATCC).
Banked cell lines of MCF-7, ZR-75-1, T-47-D, and MCF-7 V12 from 
frozen stocks were thawed as described in section 2.1.2. The contents of a frozen 
vial were transferred by pipette into a 75 cm2 culture vessel containing a 1:1 mix 
of Dulbecco's Modified Eagle's medium (DMEM, Biowhittaker)/Ham’s F-12
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medium (Biowhittaker) containing 10% (v/v) FCS, 2mM L-glutamine (Gibco), 
lOOU/ml penicillin (Gibco) and lOOpg/ml streptomycin (Gibco). The flasks were 
then placed on a horizontal incubator shelf in a humidified atmosphere of 5% 
(v/v) CO2 at 37°C. The cells were allowed to settle and attach to the surface of 
the culture flask. Feeding of the cells in culture was carried out at regular 
intervals depending on the culture conditions and the apparent pH as denoted by 
the change in colour of the phenol red. When the cell population had reached 80- 
90% confluency across the tissue culture flask surface the cells were either used 
for experiments or passaged further. All experiments were carried out within 5- 
10 passages of original thawed stocks.
Human mammary stromal cells and immortalized cell lines
Unaltered human mammary fibroblasts and endothelial cells (non-transformed) 
and immortalized human mammary stromal cell lines (temperature sensitive and 
non-temperature sensitive, derived by O’Hare et al. (2001) used are shown in 
Table 2.1. All stromal cell lines used with the exception of the unaltered cells 
(HMF and HMME) were immortalized by the insertion of the catalytic subunit of 
human telomerase (hTERT) and a temperature sensitive mutant (U19tsA58) 
variant of the Simian virus 40 large T antigen (SV40 LT). The HMF variants A- 
D differed in the timing and order of the immortalizing gene transfection. The 
HMME variants were derived in a similar manner from two separate donors. 
Wild type (non-temperature sensitive) large T (LT) variants of each cell type 
(HMF 3wt, HMME 7wt) were also created by insertion of a wild type LT antigen 
in cells previously engineered to express hTERT. HMF 3wt ras was derived by 
transfection of the wild type HMF 3wt cell line with the activated (VI2) ras 
oncogene.
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Human mammary fibroblasts (HMF). HMF 3A, HMF 3B, HMF 3C, HMF 3D,
HMF 3wt, HMF 3wt ras, HMF were obtained from Prof. Mike O’Hare, UCL.
HMF 3A, HMF 3B, HMF 3C, HMF 3D are the four conditionally 
immortalized human mammary fibroblasts lines. The condition being that they 
are temperature sensitive with the permissive growth temperature being 33.5 °C. 
HMF 3wt, and HMF 3wt ras are wild type LT variants of HMF 3D and unlike 
the temperature sensitive (ts) lines grow well at 37 °C. HMFs are the unaltered 
sub-cultures of primary human mammary fibroblasts.
The HMF cells and HMF cell lines were cultured in growth medium 
consisting of DMEM, 2 m M  glutamine, 10% (v/v) heat-inactivated FCS, 50 
units/ml penicillin, and 50 pg/ml streptomycin at either 37 °C or 33.5 °C in a 
humidified incubator in an atmosphere of 5% (v/v) CO2 + 95 % air. Flasks were 
examined daily during the first week.
Human mammary endothelial cells (HMME). HMME 7, HMME 2, HMME 
7wt, HMME were obtained from Prof. Mike O’Hare, UCL.
HMME 7 and HMME 2 are the two conditionally immortalized human 
mammary endothelial cell lines which grow only at 33.5°C. HMME 7wt is a wild 
type LT variant, with HMME being the sub-cultured unaltered endothelial cells.
The HMME cells were cultured in a specially optimized microvascular 
endothelial medium EGM-2™ - Endothelial Growth Medium-2 (EGM-2 Bullit 
kit, Biowhittaker) consisting of basal growth medium developed for normal 
human microvascular endothelial cells in a low serum environment with a final 
serum concentration of 2% (v/v). The complete medium (500ml) contained 
various supplements and growth factors. These were heparin 0.5ml, 
hydrocortisone (HC) 0.2ml, human fibroblast growth factor (hFGF) 2ml, 
vascular endothelial growth factor (VEGF) 0.5ml, insulin like growth factor R -
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IGF-1 0.5ml, ascorbic acid (aa) 0.5ml, human epidermal growth factor (hEGF) 
0.5ml, gentamicin and amphotericin (GA-1000) 0.5ml, and foetal bovine serum 
(FBS) 10ml (precise concentrations of the additives are not supplied by the 
manufacturer). All cultures were kept in a humidified incubator in 5% (v/v) CO2 
at their respective optimum temperature of 37°C or 33.5°C.
2.1.4 Culture conditions for freshly isolated cells 
Mouse microvascular endothelial cells
Murine microvascular endothelial cells (isolation method described in section 
2.3.1) were serially sub-cultured at 37°C in a humidified atmosphere with 5% 
(v/v) CO2 in DMEM supplemented with 2mM glutamine, lOOU/ml penicillin, 
lOOpg/ml streptomycin, ImM sodium pyruvate (Gibco), 20mM HEPES (Gibco), 
1% non-essential amino acids (Gibco), 50mM 2-mercaptoethanol (Gibco), 
freshly added 20% (v/v) heat inactivated FCS, 150pg/ml EC growth supplement 
(Sigma) and 12U/ml heparin (Sigma). They were cultured in either fibronectin 
(1 mg/ml) or 2% (w/v) gelatin (type B from bovine skin, Sigma) coated tissue 
culture flasks (see section 2.2.1 for coating method). At confluence the 
endothelial cells were detached from the culture flasks using a solution of 
0.125% (w/v) bovine trypsin (Sigma) in 0.02% (w/v) EDTA and then passaged. 
In some experiments, enzyme free cell dissociation solution was used. Cells were 
washed twice with PBS containing 0.02% (w/v) EDTA and mechanically 
disrupted by gentle tapping of the tissue culture flasks.
Circulating human endothelial progenitor cells (CEPs)
Immediately following isolation (for method see Chapter 2.3.2) approximately 
lxlO5 CD34+CD133+ enriched circulating endothelial progenitor cells were
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plated on fibronectin coated 25cm2 tissue culture flasks (see Chapter 2.2.1 for 
coating method). Growth factors required for CEPs differentiation and expansion 
have been identified as VEGF, bFGF, IGF, EGF as noted by Kalka et al. (2000) 
and so were incorporated into the growth medium.
Cells were grown in 60% (v/v) low-glucose DMEM and 40% (v/v) 
MCDB-201 (all from Sigma), supplemented with lx insulin-transferrin-selenium, 
lx linoleic acid-BSA, 10 8 M dexamethasone, 10^ M ascorbic acid 2-phosphate 
(all from Sigma), 100 U/ml penicillin and 100 pg/ml streptomycin, lOng/ml 
VEGF, bFGF-2 lng/ml, 2ng/ml IGF-1, and 10% (v/v) FBS (Sigma) as described 
by Reyes et al. (2002). Cultures were maintained at 37°C in a humidified 
atmosphere of 5% (v/v) CO2 with medium changes every 4-5 days.
2.2 Specialized culture methods
2.2.1 Fibronectin and gelatin coating of tissue culture flasks 
Fibronectin
Fibronectin coating helps cells maintain native differentiated characteristics and 
functions as well aid attachment to the tissue culture plastic. 2ml of human 
fibronectin solution (1 mg/ml, BD Laboratories) was added to 25cm tissue 
culture flasks. The flasks were then transferred to an incubator and the coating 
solution was allowed to sit for a minimum of two hours or overnight. The excess 
coating solution was then drained from the flasks. The flasks were then allowed 
to dry flat in the hood for at least one hour. The coated flasks were stored at room 
temperature for use within 1 month. A similar procedure was followed for 
preparing all culture flasks and culture dishes for growing and culturing freshly
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isolated murine microvascular endothelial cells and circulating endothelial 
progenitor cells.
Gelatin
Sufficient amount of 2% (w/v) gelatin (Sigma) was added to culture vessel so 
that it completely covered the bottom. Approximately 3 ml per 25cm flask or 7- 
8 ml per 25cm flask was used. The gelatin solution was left to sit in contact with 
the plastic for at least 20 minutes at room temperature. The excess gelatin 
solution was then aspirated off and the remainder was allowed to evaporate by 
leaving the container sitting open in the hood until no traces of the liquid 
remained. The cap was then replaced once the surface had dried. Gelatinized 
flasks were stored at room temperature or at 4°C for up to 2 weeks maintaining 
sterility until use.
2.2.2 Preparation of ECM-related substrates for differentiation
assays and liquid overlay cultures
Matrigel
BD Matrigel™ Matrix is a solublized basement membrane preparation extracted 
from EHS mouse sarcoma, a tumour rich in extracellular matrix proteins. Its 
major component is laminin, followed by collagen IV, heparan sulfate 
proteoglycans, and entactin. At room temperature, BD Matrigel™ Matrix 
polymerizes to produce biologically active matrix material resembling the 
mammalian cellular basement membrane. Two varieties of matrigel were used: 
Matrigel and growth factor reduced Matrigel (GFR) (Table 2.2).
Matrigel was stored at -80°C, after aliquoting into vials. Vials of Matrigel 
were thawed by placing on ice or at 4°C for 24 hours. The thawed matrigel was
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mixed to homogeneity using pre-chilled pipettes. A required amount of Matrigel 
(300pl/well for 96-well plates and 1 ml/well for 48-well plates (both from Nalge 
Nunc International) was placed in the multiwell plates to obtain an even spread. 
The plates then were placed in an incubator for 30 minutes at 37°C to gel the 
matrix. Media was added and incubated for 24 hours to elute any residues and 
toxic contaminants.
Amounts of Growth Factors (GF) Present in BD Matrigel™ Matrix vs. GFR
BD Matrigel™ Matrix
Growth
Factor
Range of GF 
Concentration in 
BD Matrigel Matrix
Average GF 
Concentration in 
BD Matrigel Matrix
Typical GF 
Concentration in GFR 
BD Matrigel Matrix
EGF 0.5-1.3 ng/ml 0.7 ng/ml < 0.5 ng/ml
bFGF < 0.1-0.2 pg/ml n.a.* n.d.**
NGF < 0.2 ng/ml n.a.* < 0.2 ng/ml
PDGF 5-48 pg/ml 12 pg/ml < 5 pg/ml
IGF-1 11-24 ng/ml 16 ng/ml 5 ng/ml
TGF-p 1.7-4.7 ng/ml 2.3 ng/ml 1.7 ng/ml
* n.a. - not applicable **n.d. - not determined
ECM Composition of BD Matrigel™ Matrix vs. GFR 
Matrigel Matrix
Basement
Membrane
Matrigel
Component
Percent in 
BD Matrigel™ 
Matrix
Percent in GFR 
BD Matrigel™ 
Matrix
Laminin 56% 61%
Collagen IV 31% 30%
Entactin 8% 7%
Table 2.2. Table summarizing the constituents of growth factor reduced and 
standard Matrigel (data supplied by manufacturers product specifications).
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Agarose gels
Purified low-melting-point agarose powder (A-4018; Sigma Type VII: low 
gelling temperature, Sigma-Aldrich) was mixed with PBS in a glass beaker to 
obtain the desired concentration (1-1.5% (w/v) agarose) and then sterilized by 
autoclaving. The beaker was then heated in a water bath until all the agarose had 
completely melted. After cooling the solution to about 40°C, 100 pi of 1.5% 
agarose was pipetted for 96-well plates, 300pl for 48-well plates and 500pl for 
24-well plates.
Fibrin gels
Human fibrinogen (Sigma) was dissolved in PBS to give a solution of 30mg/ml. 
lml of this solution was added to 10 ml of MCDB 131 medium (Biowhittaker). 
This solution was dialysed using medium sized dialysis tubing (25kD) against 
MCDB 131 medium for 24 hours while stirring at 4°C to remove any residues 
and contaminants. Following dialysis 10% (v/v) FCS and 2mM glutamine were 
added to the mixture. For the manufacture of liquid overlay cultures, 500pl of the 
fibrinogen solution was added to the wells of a 48-well plate. The fibrinogen was 
solidified into fibrin by adding 5pi of thrombin (Sigma) (lpl of thrombin for 
lOOpl of fibrinogen solution). Once the fibrinogen had solidified it was then 
placed at 37°C for 2 hours for the fibrin gel to fully form before cells were 
plated. For multiple layer cultures this process was repeated on the top of the 
seeded cells.
Collagen gels
Rat tail collagen, Type 1 (3.82 mg/ml) (Collaborative Biomedical Products) was 
used to prepare solid gels in microwell plates. The collagen solution was diluted 
to 50pg/ml using 0.02N acetic acid and then neutralized with 0.1M NaOH. 200pl 
of the diluted collagen material was added to each micro well of a 96-well plate.
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The micro well plates were then incubated at 37°C where the gels polymerized in 
60 minutes. The plates were then rinsed well using PBS to remove the acid and 
air dried. They were then stored at 2-8°C for up to one week under sterile 
conditions before use.
2.3 Cell separation techniques
2.3.1 Isolation of mouse endothelial cells
The isolation and long term culture of murine endothelial cells has often proven a 
difficult task. A quick and efficient magnetic bead separation protocol outlined 
by Dong et al. (1997) was adopted for the isolation of microvascular endothelial 
cells from murine tissues.
Animals
Female NCr (nu/nu) mice (original stocks from National Cancer Institute) aged 4 
to 6 weeks bred in on site facilities were used. The ethical guidelines that were 
followed met the standards required by the UKCCCR Guidelines for the Welfare 
of Animals in Experimental Neoplasia (Workman et al. 1998).
Preparation of tissue
Tissues (murine lungs and hearts) from 8 mice were dissected out and removed 
aseptically, rinsed in 30ml of Hanks' balanced salt solution (HBSS, Biowhittaker) 
containing lOOU/ml penicillin and lOOpg/ml streptomycin, minced into small 
pieces ( 1 x 2  mm squares) in a 60mm tissue culture dish using sterilized razor 
blades, and then enzymatically digested in 20ml of 1 ml/mg collagenase A 
(Sigma) in L I5 medium and 1 mg/ml of bovine trypsin at 37°C for 45 minutes 
with occasional agitation. Following digestion, DMEM with 10% (v/v) FCS was 
added and centrifuged for 3 minutes at approximately 300xg (1500 rpm) to form
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a pellet. The pellet was then resuspended in 5ml of DMEM with 10% (v/v) FCS 
and then the cellular digest was filtered sequentially through sterile 40pm and 
31pm nylon meshes (Falcon, Becton Dickinson Labware) to remove clumps of 
cells, centrifuged at 400 *g for 10 minutes to pellet cells, and washed twice in 
DMEM medium with 10% (v/v) FCS. The cell pellet was then resuspended in 4 
ml of DMEM with 10% (v/v) FCS prior to Dynabead separation.
Preparation of antibody coated magnetic beads for endothelial cell isolation 
Dynabeads (Dynal Biotech) coated with sheep anti-rat IgG (30pl aliquot per 5ml 
tube) were washed three times with serum free DMEM and then incubated with 
rat anti-mouse PECAM-1 monoclonal antibody (MEC13.3, BD Pharmingen) 
overnight at 4°C (10pl/50pl beads in DMEM). Following incubation, beads were 
washed three times with DMEM containing 10% (v/v) FCS, centrifuged at 300*g 
(1500 rpm) for 5 minutes and re-suspended in 5ml of the same medium. 
Separation of cells
lml of cell suspension (from digested murine tissues) was added to the tube 
containing beads that had been pre-coated with anti-PECAM-1 as described 
above. After affinity binding for 30 minutes at 4°C with occasional agitation, the 
bead-bound cells were recovered using magnetic bead separation (Dynal 
magnetic particle concentrator MPC-1, Dynal Biotech), washed five times with 
DMEM containing 10% (v/v) FCS and once with FCS free DMEM, and then 
digested for 5 to 10 minutes at 37°C in lml of 1 mg/ml of trypsin/ 0.02% (w/v) 
EDTA to release the cells. The bead-free cells were centrifuged at 300*g for 5 
minutes in DMEM containing 10% (v/v) FCS and then re-suspended in 7 ml of 
growth medium (described in Chapter 2.1.4) for culture. This solution was then 
plated in a 25cm2 fibronectin pre-coated tissue culture flask.
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2.3.2 Isolation of circulating endothelial progenitor cells 
Separation of mononuclear cells from bone marrow aspirates and cytokine 
mobilized blood (buffy coats)
Bone marrow. After informed consent, bone marrow samples (20-50ml) 
collected from healthy donors for allogeneic bone marrow transplantation, were 
placed in sterile tubes containing preservative-free lithium heparin (20U/ml) in 
preparation for layering on a Ficoll-Hypaque gradient (specific gravity 
1 -077 g/ml, Sigma). Low-density mononuclear cells (LD-MNCs) were isolated 
from the bone marrow sample by density gradient centrifugation over 15ml of 
Ficoll-Hypaque for 25 minutes at 500xg. The LD-MNCs at the interface were 
carefully harvested using a Pasteur pipette. The harvested cells were then re­
suspended in 10ml of PBS (containing 1-5% (v/v) FCS) and washed 3 times, at 
18-20°C, by centrifuging at 300xg for 3 minutes and re-suspending each time. 
After washing the cells were then centrifuged sequentially at 200 xg, 300 xg, and 
500xg for 10 minutes each to remove platelets. The LD-MNCs were then washed 
twice in 20ml of HBSS and re-suspended in 10ml of Iscove’s modified 
Dulbecco's medium (IMDM, Biowhittaker) supplemented with 10% (v/v) FBS 
and 5mmol/l EDTA.
Peripheral blood mononuclear cell isolation. Cytokine mobilized 
(Granulocyte-macrophage colony-stimulating factor) pheripheral buffy coat 
residues rich in mononuclear cells were obtained from the National Blood 
Transfusion Unit, London. 25 ml of the anti-coagulated blood was mixed with 
25ml of PBS (containing 1-5% (v/v) FCS) in a 50 ml tube at room temperature. 2 
volumes of diluted blood (30ml of diluted blood mixture) were carefully layered 
over 1 volume of Ficoll Hypaque (15ml). This solution was centrifuged (low
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acceleration and deceleration in a non-braked centrifuge) at 800-1000xg for 30 
minutes in a swinging motor at room temperature. The LD-MNCs at the interface 
were carefully harvested using a Pasteur pipette. The harvested cells were then 
re-suspended in 50ml of PBS (containing 1-5% (v/v) FCS) and centrifuged at 
290xg for 10 minutes at 18-20°C and the supernatant discarded. This washing 
process was repeated twice. The LD-MNCs were then washed twice in 20ml of 
HBSS and filtered through a 50pm nylon mesh to remove clumps before being 
re-suspended in 10ml of IMDM supplemented with 10% (v/v) FBS and 5mmol/l
o
EDTA. A 500ml bag of buffy coat residue provided a yield of approximately 10 
cells.
Positive selection of CD133+ cells by magnetic cell sorting
The haemopoietic stem/progenitor cells were isolated by positive selection of 
CD133+ expressing cells using the AC 133 Cell Isolation Kit (Miltenyi Biotec) 
and the MS Magnet (MiniMACS™, Miltenyi Biotec). Briefly LD-MNCs were 
added to CD133+ monoclonal antibody conjugated super paramagnetic 
microbeads (AC 133 Cell Isolation Kit) to attach, washed and processed through a 
MACS magnetic separation column to obtain a pure population of CD133+ 
(Figure 2.1).
highly pure  
C D 1 3 3 +  cells
Figure 2.1. Isolation of CD133* cells using the MACS AC 133 Cell Isolation Kit.
Modified diagram taken from Miltenyi Biotec protocol instructions sheet.
Density gradient 
separation (d = 1 .0 7 7 ) 
or leukapheresis
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Standard buffer used for washing the LD-MNCs was made from PBS (pH 7.2), 
supplemented with 0.5% (w/v) bovine serum albumin (BSA, Sigma) and 2 mM 
EDTA. The buffer was kept cold (4°- 8°C) at all times. lOOpl of FcR blocking
o
reagent provided was added to a total cell count of 10 LD-MNCs cells 
suspended in 300pl of buffer solution, to inhibit unspecific or Fc-receptor 
mediated binding of antibodies to non-target cells. The LD-MNCs were then
labelled by adding in lOOpl of CD133+ coated microbeads (500pl of beads
8 8 perlO total cells) producing a final volume of 500pl perlO total cells. The cells
were mixed well and incubated for 30 minutes at 4-8°C. The cells were then
washed by adding 10-20 times the labelling volume of buffer solution and
centrifuged at 300xg for 10 minutes. The supernatant was then pipetted off and
the cell pellet was re-suspended in 500pl of buffer. In the meantime a MS
column was prepared by placing it in the high-gradient magnetic field of an MS
magnet and rinsing with 500pl of buffer. Following two washes the cell
suspension was applied and the negative cells were allowed to flow through the
column. The column was then washed four times with 500pl of buffer solution
followed by another lml of buffer. After removing the column from the magnet
the positive fraction with the magnetically labelled cells was firmly flushed out
using the supplied plunger to obtain purified CD 133+cells. These cells was then
plated in a 25cm tissue culture flask pre-coated with fibronectin containing
either the endothelial cell growth medium EGM-2 or the specialized medium
described in Chapter 2.1.4.
Cytospin slide preparation for staining of CEPS
Glass slides, filter cards (Shandon #190005 thick white) and funnels (0.5ml 
capacity, Shandon) were set up in the Shandon Cytospin-2 device. 0.2ml aliquots 
of diluted cell suspensions were placed into the chamber. Another device was
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placed opposite for counter balance. The Cytospin-2 device was set at 100 
revolutions per minute for 5 minute at high acceleration. The funnel and filter 
were then discarded from the glass slide and the cell preparation was allowed to 
air dry overnight, protecting it from dust. Immunofluorescence staining was 
performed on the slide.
2.4 Cell labelling techniques
In this study both cytoplasmic and membrane marking dyes were evaluated. The 
cytoplasmic dyes were the CellTracker™ dyes (Molecular Probes) and the 
membrane labelling dyes were the fluorescent liphophilic Vybrant Cell-Labeling 
Solutions (Molecular Probes). Emission spectrum information for both types of 
dye is shown in Figure 2.2.
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Figure 2.2. Normalized fluorescence emission spectra of DiO (3,3- 
dioctadecyloxacarbocyanine perchlorate), Dil (l,l'-dioctadecyl-3,3,3',3'- 
tetramethylindocarbocyanine perchlorate), DiD (l,T-dioctadecyl-3,3,3',3'- 
tetramethylindodicarbocyanine perchlorate), DiR dyes (bound to phospholipid 
bilayer membranes) and the green and orange CellTracker dyes (taken from 
instruction protocol, Molecular Probes).
2.4.1 CellTracker™ Dyes
5mg of CellTracker fluorescent probes; either Orange CellTracker™ CMTMR 
(5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethylrhodamine) or Green 
CellTracker™ CMFDA (5-chloromethylfluorescein diacetate) were dissolved in 
10% (v/v) DMSO to obtain a stock solution with a final concentration of lOmM. 
The stock solution was diluted to a final working solution of 0.5 to 25pM in
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serum free DMEM medium. Cells were grown in tissue culture flasks containing 
the appropriate medium until the desired confluency was reached. The medium 
was removed from the flask by decanting and pre-warmed (37°C) probe- 
containing (0.5 to 25pM) medium was added. The flask was placed horizontally 
and the cells were incubated for 45 minutes at 37°C or 33.5°C (depending on 
cell) in 5% (v/v) CO2 . The loading solution was then replaced with fresh pre­
warmed medium and incubated for another 30 minutes at 37°C to ensure 
complete integration of the probe. The cells were then washed again. 10% (v/v) 
DMSO alone without dye was used as the control.
2.4 2 Fluorescent liphophilic dyes
Vybrant Dil (l,T-dioctadecyl-3,3,3',3'- tetramethylindocarbocyanine perchlorate), 
DiD (l,T-dioctadecyl-3,3,3',3'- tetramethylindodicarbocyanine perchlorate), and 
DiO (3,3'-dioctadecyloxacarbocyanine perchlorate) cell-labelling solutions were 
supplied in units of 1 ml. The solutions containing ImM Dil, DiO or DiD were 
sterile filtered through 0.2pm polycarbonate filters.
The staining solution was prepared by adding 5 pi of the supplied 
labelling dye solution to 1 ml of normal growth medium. Trypsinised cells at a 
density of lx l0 6/ml were suspended in serum-free DMEM culture medium. 5pi 
of the cell-labelling solution supplied was added for each ml of cell suspension. 
The suspension was mixed well by gentle pipetting and then incubated for 20 
minutes at 37°C. The optimal incubation time varied depending on cell type. The 
labelled suspension tubes were then centrifuged at 1500 rpm for 5 minutes at 
37°C. The supernatant was then removed and the cells were gently re-suspended
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in warm (37°C) medium. This wash procedure was repeated three times. 10 
minutes recovery time was allowed before fluorescence observations were made.
2.5 In vitro growth and differentiation assays
2.5.1 Flask growth assays
r 'y #
A required number of cells (1x10 ) were plated in 25cm flasks in their 
respective growth medium and cultured for various time points. Cells were then 
trypsinised, centrifuged into a pellet and then gently re-suspended in an 
appropriate volume of medium ensuring a unicellular suspension was achieved. 
Cell numbers were determined using a haemocytometer. Experiments were either 
carried out at single time points after plating, or replicate flasks were harvested at 
intervals (multi-point assays).
Haemocytometer counting
The haemocytometer (improved Neubauer® chamber) and cover slip were 
cleaned first with distilled water, then by 70% (v/v) ethanol and wiped dry with a 
lens tissue. A lightly moistened coverslip was placed squarely on top of the 
haemocytometer before being gently pressed into position. Pressure was applied 
until it had firmly stuck with ‘Newton’s rings’ visible. Cells were gently 
redistributed throughout the medium through repeated re-suspension using a 
pipette. The haemocytometer was then loaded by placing a drop of suspension 
near the edge of the coverslip. Every count was duplicated by analyzing two 
ruled counting areas. Using the 20X objective of a microscope, the upper left 
primary squares of each grid (10 primary squares) was located and a counter was 
used to count the cells in 10 primary square using the following conventions: 
Each large square of the grid equals a volume of 10'4 cm3 or 10-4 ml (as 1 cm3 =
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1 ml). Multiplying the number of cells in a large square by the dilution factor (if 
the sample was diluted) and then multiplying by 10,000 will determine the total 
number of cells per ml. At least 200 cells were counted for each measurement.
2.5.2 Microwell growth assays
24-well plates (Nalge Nunc International) were used for micro well growth 
assays. The required numbers of cells (1x10 ) were plated in wells of a 24-well 
plate and cultured in 1-2 ml of medium containing various growth factors and 
serum concentrations as described in the results (Chapter 3.2.2). Cell numbers 
were determined by a methylene blue staining assay.
Methylene blue staining
The methylene blue staining assay was used for estimating the number of fixed 
adherent cells present in a micro-culture (Oliver et al. 1989). The assay is 
dependent on the binding of methylene blue to a fixed monolayer at pH 8.5, and 
after washing, the release of the dye by lowering the pH and then measuring dye 
absorbance with an automated vertical light-path microplate photometer. This 
assay is rapid, highly reproducible and easy to perform, making it ideal for 
screening large numbers of samples.
The methylene blue staining assay was conducted with minor changes to 
a previously described protocol (Oliver et al. 1989). Borate buffer stock solution 
(2x) was prepared by dissolving 38.1 g of Di-sodium tetraborate (AnalaR® BDH 
Laboratory supplies) in 5 litres of Millipure water and the pH adjusted to 8.5 by 
adding ~ 120 - 140 ml of 1M hydrochloloric acid (HC1). Methylene blue dye was 
prepared by dissolving 1 g of methylene blue powder (BDH Laboratory supplies) 
in 100 ml of 1 x borate buffer and filtered through Whatman filter paper prior to
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use to remove undissolved particulate. Saker elutant was prepared by admixing 
98% (v/v) ethanol with 0.1M HCL in 1:1 proportions.
Following microwell growth assay experiments the cells were washed 
twice with PBS and then fixed with 4% (v/v) formaldehyde in PBS and stored at 
4°C. These fixed 24-well plates were inverted to remove excess PBS and tapped 
dry on to absorbent paper towel. 300pl of methylene blue solution was placed in 
each of the 24 wells using a Gilson pipette. The plate was left at ambient 
temperature for 1 hour for the cells to take up the methylene blue dye. Excess 
methylene blue solution was poured off and the plate was then submerged in 5 
consecutive plastic containers of borate buffer, to remove all traces of 
unincorporated methylene blue. The plate was once again tapped dry, and 300ml 
of Saker elutant was added to each well. The plate was then left on a shaker 
platform (Luckham model 804) for 1 hour for elution to take place.
The 24-well plate format was chosen so as to accommodate a reasonable 
starting cell number (1><103) and also to allow the wells to be easily observed 
using a phase contrast microscope. However the available microplate reader did 
not accommodate 24-well plates. Hence eluted dye samples from the 24-well 
plates were transferred in replicate to 96-well plates before measurements were 
made.
For each 24-well plate, a 96-well plate was labelled and prepared with the 
first blank row filled with 1 OOpl of Saker elutant. The furthest row on the left of 
each plate was used as the plate reader standard. Its value was subtracted from 
the reading of the rest of the rows. The eluted dye solution from each well was 
transferred in triplicate into a 96 well plate at lOOpl/well (e.g. the contents of 
each well of the 24 well plate was transferred into 3 wells of a 96-well plate. If 
the colour was found to be too intense for the plate reader to measure the eluted
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cell solution was diluted by a factor of 4 or 8, and lOOpl of the diluted elutant 
was added to the 96-well plates in triplicate. The 96-well plates were then 
returned to the platform shaker for a further 10 minutes to ensure adequate 
mixing of diluted solutions and to remove any bubbles created during the 
pipetting process. To check that all bubbles had been removed the plates were 
viewed on a light box (Kenro® lightbox -  Swindon). The plates were then 
loaded onto a microplate reader (Dynatech laboratories MRX) and the relative 
absorbance of light at 650 nm wavelength measured against the Saker elutant as 
standard. The numerical output from the plate reader was analysed with a 
spreadsheet package in Microsoft Excel.
2.5.3 Co-culture growth assays
To investigate the effect of tumour-stromal interactions, in an in vitro setting, a 
series of co-culture experiments were performed using a cell culture insert and 
multi well system (cells were deposited into two compartments in each well). The 
method used was as follows:
The cell culture inserts consisted of 0.4pm pore sized polyethylene 
terephthalate membranes (1.6xl06 pores /cm2) (BD Falcon™) with cells 
deposited on and below the membrane in each well. The pore size chosen 
prevents physical contact by inhibiting migration of cells from the upper to the 
lower chamber but allows free exchange of nutrients and growth factors (Figures
2.3 and 2.4).
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Figure 2.3. Diagram of the co-culture tissue culture dish. Co-culture inserts are 
constructed of plastic sides with a microporous membrane on the base which is made of 
polyethylene terephthalate. The insert is suspended inside the corresponding culture 
dish by means of a lip/flange at the top. (taken from diagram in the instructions protocol, 
Nalge Nunc International).
Figure 2.4. Co-culture assays. Separate populations of cells can be grown on the 
upper surface of the insert and on the base of the culture dish, kept physically separated 
but allowing the passage of macromolecules through the porous membrane, (taken from 
diagram in the instructions protocol, Nalge Nunc International).
Prior to seeding, lml of pre-warmed culture medium was added to each well of 
the 24-well plate. The plate was then placed in either a 37°C or 33.5°C incubator 
with a humidified atmosphere of 5% (v/v) CO2 for 20 minutes before seeding to 
equilibrate the pH. Cells were added to the pre-warmed culture media in the 24- 
well plates and left for minimum of 2 hours to attach.
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Cell culture inserts were rehydrated in 2ml of DMEM for 2 hours at room 
temperature prior to use. Following rehydration, the medium was removed and 
the required numbers of cells (depending on experiment, usually 1><10 cells 
/insert) were added into each insert chamber in 1ml of its appropriate medium. 
The seeded inserts were then gently placed in corresponding wells of the 24-well 
plate. After 24 hours, medium was removed from each compartment and 
replaced with fresh medium, and thereafter every 2 days. All the experiments 
were carried out in triplicate. Controls consisted of wells with cells seeded in the 
lower compartment and cell culture inserts without cells. The end point was 
determined when the cells, in the lower chamber below the inserts, in whichever 
experimental condition resulted in the most rapid growth to become 80-90% 
confluent. All target cells in the lower compartment were then washed and fixed 
in 4% (v/v) formaldehyde in PBS for 20 minutes after the inserts containing the 
effector cell had been removed. Cell numbers were measured by the modified 
methylene blue staining method. All measurements were done in triplicate 
(described in Chapter 2.5.2)
2.5.4 In vitro endothelial cell differentiation assays
To investigate the differentiation properties of the unaltered and immortalized 
human mammary endothelial cells, in vitro assays were performed to assess the 
ability of the cells to form primitive microcapillaries on Matrigel.
Aliquoted vials of frozen matrigel and growth factor reduced Matrigel 
(GFR) were defrosted on ice at 4°C overnight. The required numbers of wells of 
a 24 well plate were coated with 300pl of Matrigel ensuring all air bubbles were 
removed (using a heated needle). The Matrigel was left to gel for 30 minutes at
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37°C. The total volume was made up to 500pl with media and the plates were 
incubated for up to 72 hours at 37°C in a humidified atmosphere of 5% (v/v) CO2 
with regular media changes to remove residue and toxic contaminants.
o #
Endothelial cells were plated out at densities of 1-3x10 cells/well onto either 
GFR Matrigel or Matrigel in complete EGM-2 endothelial growth media. The 
wells were visualised under a phase contrast light microscope at hourly time 
points and images were recorded electronically.
2.6 Manufacture of heterologous 3-D co-culture models 
and tumour spheroids
To investigate direct cell-cell interactions various 3-D cell culture methods were 
used. They included microcarrier beads, liquid overlay cultures, a rotary cell 
culture system and prefabricated 3-D scaffolds.
2.6.1 Microcarrier beads
Cytodex-3 microcarrier beads (Sigma) are dextran beads (133-215pm) coated 
with denatured porcine-skin collagen bound to the surface. Before use the beads 
were prepared by swelling and hydrating in 50ml/g of calcium and magnesium 
free phosphate-buffered saline (CMF-PBS, Biowhittaker) and autoclaved at 
120°C. The beads were then sterilized overnight in 70% (v/v) ethanol. Prior to 
use, the beads were washed three times in CMF-PBS and once in growth culture 
medium.
5 x 106 cells were added to 5 ml of bead containing solution (1.5 X 105 
beads). The beads and cells were transferred to a 125-ml Wheaton Magna Flex 
Spinner Flask (Wheaton Scientific), containing 75 ml of complete medium, and
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incubated under constant stirring 30 revolutions per minute (rpm) in a humidified 
atmosphere of 5% (v/v) CO2 at 37°C overnight to attach. The medium was 
replaced with fresh medium every fourth day by letting the beads settle and 
changing 50ml of medium. To create a heterologous co-culture spheroid other 
cell types were added either in free cell suspension or as pre-seeded microcarrier 
beads.
2.6.2 Liquid overlay cultures
Simple liquid overlay plates and cultures were prepared by inserting 500pi, 
300pl, or lOOpl of agarose, fibrin, collagen or matrigel into wells of a 24, 48 or 
96-well plate (Becton Dickinson Labware) respectively. The preparations of 
individual substrates are described in Chapter 2.2.2. Substrates were allowed to 
gel and solidify before the required cells were plated. Cells were counted using a 
haemocytometer and were added to the substrate-coated wells and allowed to 
attach for 4 to 5 hours at 37°C. For heterologous spheroid manufacture, cell 
suspensions (approx. lxlO4 cells) or pre-seeded microcarrier beads (lxlO4 cells 
seeded on 5xl03 beads) were added and mixed with the substrates (500pl) before 
being allowed to gel and finally applied to a 24-well plate. Then 2ml of growth 
medium was added to produce the liquid overlay. Following an overnight 
incubation with the liquid overlay, media were replaced daily. For extended 
cultures (>2 weeks); a further 2ml of fresh medium was added on the second day. 
This allowed for replacement of spent medium at the air liquid interface without 
disturbing the cellular layer on the gel surface.
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2.6.3 Prefabricated 3-D scaffolds
*2
Small (approximately 5mm x 3mm x 0.039 cm in size) 3-D biodegradeable pre­
engineered scaffolds (BD™ Three Dimensional Open-Cell Polylactic Acid 
(OPLA®) Scaffolds, BD Biosciences) were seeded with cells using two different 
methods: still and dynamic.
For the still seeding method a cell suspension containing approximately 
5.0x104-  2.5x105 cells in 250pl of growth medium (of each cell type) was added 
to a scaffold placed in a 30ml universal container. The scaffolds which had 
adsorbed the medium plus cells were gently transferred to 96-well plates 
containing 250pl of growth medium. In some experiments the seeded scaffolds 
were coated in Matrigel or serum. 200pl of liquid Matrigel at 4°C was added to 
the seeded scaffolds before being transferred to the wells.
For dynamic seeding the tube containing the scaffold was seeded with 
cells and then incubated with gentle agitation (-50-100 rpm) on an orbital shaker 
(Stuart Scientific) at 37°C in a gassed incubator for between 2-24 hours 
depending on the cell type. To maintain the pH during incubation a further 250pl 
of medium was added after 8 hours. After incubation with agitation was 
completed, the seeded scaffold was gently placed into a well of a 96-well plate 
containing 250pl of media for the remainder of the experiment.
Seeded scaffolds were also placed in liquid overlay culture, to further 
promote growth and differentiation. 5.0 x 104 cells were seeded onto the 
scaffolds using the dynamic seeding method and then mixed with 300pl of 
Matrigel before being solidified in wells of a 48-well plate. Liquid overlays were 
made as described in Chapter 2.6.2. Medium was changed every other day. At
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fixed time points scaffolds were removed and fixed in 4% (w/v) formaldehyde 
for sectioning and immunohistochemistry.
2.6.4 Rotary cell culture system
Rotary cell culture system RCCS-4D (Cellon), 10ml and 50ml high aspect ratio 
vessel bioreactors were used for the manufacture of heterologous tumour 
spheroids (Figure 2.5). 5x 106 cell suspension or 1.5xl05 cells pre-seeded on 
Cytodex-3 microcarrier beads (depending on study group) were inserted into 
either a 50ml or 10ml cylindrical culture vessel. This was then filled completely 
with growth medium making sure all air bubbles were removed. The vessel was 
then attached to the rotator base and rotated about the horizontal axis. The 
disposable vessels were rotated at 26rpm at 37 °C in a humidified atmosphere of 
5% (v/v) CO2 and 95% air. Oxygen supply and carbon dioxide removal was 
achieved through a gas permeable silicone rubber membrane that forms one 
surface of the cylindrical vessel. Cells were cultured for fixed time points or 
alternatively until the desirable spheroid sizes were manufactured. Spheroids 
meeting the size criteria (1-4 mm) were carefully removed from the culture 
vessel through access ports using a syringe. Spheroids were either fixed in 10% 
formaldehyde or snap frozen for histology. They were also used for liquid 
overlay and in vivo studies. The cryopreserved or fixed spheroids were processed 
for immunohistochemistry as described in Chapter 2.7.
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Figure 2.5. Rotary Cell Culture System. Microgravity bioreactor allows the growth of 
complex three-dimensional tissue models. Picture taken from Synthecon™ showing 
power source, complete assembly and on the right the harvesting of spheroids from a 
vessel using a syringe.
2.7 Xenotransplantation
2.7.1 Animals and husbandry 
Experimental animals
The mice used in all xenograft experiments were bred on site in the facilities of 
the Institute of Cancer Research Biological Services Unit from existing 
populations of nu/nu mice. The mice were separated into single sex family 
groups and only female mice were used for the purposes of the study. The mice 
were kept in purpose built cages in Maximised laminar flow cages and were 
allowed free access to food and water.
6 week old female NCr-nii athymic nude mice from existing stocks were 
acclimatized in the laboratory 1 week before experimentation. The animals were 
housed in microisolator cages, four per cage, in a 12 hour light/dark cycle. The 
animals received filtered sterilized water and sterile rodent food ad libitum. The 
animals were observed daily and any abnormal clinical signs noted.
1 2 8
Inhalational halothane, delivered with 100% (v/v) oxygen in a purpose 
built veterinary anaesthetic trolley with adequate facilities for scavenging and 
safely absorbing waste gases was used to provide anaesthesia.
To support the growth of the oestrogen-dependent breast tumour cell 
lines, animals were implanted under anaesthesia with control release pellets 
containing 0.72-mg 1713-estradiol 60-day release pellets (Innovative Research of 
America) subcutaneously in the dorsal neck region, under strict asepsis, one week 
prior to tumour inoculation. This allowed enough time for the mice to recover 
and for a constant level of oestrogen to be established.
2.7.2 Preparation of cell suspensions and spheroids for 
inoculation of mice 
Cell suspensions
Sub-confluent cells in the exponential growth phase were trypsinised as 
previously described and collected by centrifugation at 300xg for 3 minutes. 
Normally, unless stated, 5x106 cells were counted on a haemocytometer and 
resuspended in either a 1:1 mix of Matrigel and serum free medium (SFM) or 
SFM alone depending on the study group. For threshold cell number xenografts 
(i.e. cell numbers that will consistently take as a xenograft), MCF-7 cells were 
inoculated at 5x106 cells /site. For sub-threshold experiments lxlO5 cells /site 
were inoculated. Each animal received 50pl inoculations bilaterally either 
subcutaneously or into the mammary fat pad. Cells lines were injected in either 
SFM or together with matrigel in a 1:1 mix of Matrigel and SFM depending on 
the study group. Anaesthetized mice were injected using a sterile 30-gauge 
needle under a dissecting microscope into the mammary fat pad or
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subcutaneously in the flanks while avoiding leakage from the injection site by 
pinching the skin at the injection site.
Spheroids
Two methods were used for the manufacture of 3 compartment spheroids to be 
xenotransplanted into mice; the Rotary cell culture system (RCCS) and liquid 
overlay cultures. Heterologous 3 compartment spheroids manufactured in the 
rotary cell culture system were carefully removed from the RCCS vessel at 7 and 
14 day time points. Spheroids ranging in size from 1mm to 6mm in diameter 
were produced and resuspended in either a 1:1 mix of Matrigel and SFM or SFM 
alone depending on the study group, and inoculated in 50pl/site as described 
above.
2.7.3 Harvesting and processing of xenografts 
Xenograft tissue harvests
The mice were sacrificed by rapid cervical dislocation. Tumours were carefully 
dissected out whole and removed of skin under aseptic conditions. The tumours 
were then immediately fixed in either 4% (w/v) formaldehyde for 8-10 hours for 
preparation of paraffin sections or cryopreserved (snap frozen in liquid nitrogen 
cooled isopentane) for frozen sectioning. Some xenografts were fixed in 2.5% 
(v/v) glutaraldehyde for 2-5 hours for preparation of ultra thin sections. For 
control purposes tissue from other sites were harvested and fixed in a similar 
manner.
Processing of xenograft tissue for paraffin sections.
A standard dehydration and paraffin wax embedding procedure was performed to 
process the tumours. The tumours sections were cut on a microtome (Anglia
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Scientific AS300 Microtome) set to 3-5jam at room temperature. A standard 
procedure was used to dewax and rehydrate the tissue sections prior to staining 
and immunohistochemistry.
Preparation of paraffin blocks. Following fixation the tissue specimens were 
loaded onto dedicated cassettes and processed through an automated processor 
(Shandon Citadel 2000 processor) which takes the cassettes through a series of 
graded alcohol baths to dehydrate the tissues and then into a clearing agent 
xylene. Hot paraffin was then allowed to permeate the tissues. Tissues processed 
into paraffin were melted by placing them in a 65°C paraffin bath for 15 minutes. 
Block molds were warmed on a hot plate. Hot paraffin was then poured into the 
molds with the melted tissues placed in the molds (Tissue Tek II Wax 
Embedding Center). Heated forceps were used to prevent the tissues from 
sticking. When the tissues were in the desired orientation the molds were placed 
on a cooling plate and the cassette backing was placed on top as a lid. After 30 
minutes the hard paraffin block was popped out of the mold. Tissue blocks were 
stored at room temperature prior to sectioning.
Sectioning paraffin blocks. Formaldehyde fixed paraffin embedded blocks to be 
sectioned were prepared by placing face down on an ice block for 10 minutes. A 
water bath of fresh deionized water was also prepared by preheating to 40°C. 
Following chilling on ice, the block was inserted into the microtome chuck so 
that the wax block faced the blade and was aligned in the vertical plane. A fresh 
blade was placed in the microtome and the dial was set to 4pm cut. The block 
was “faced” by cutting down to the desired tissue plane with the paraffin ribbon 
discarded. Once the block had began ribboning well then another four sections 
were cut, picked up with forceps or brush and floated on the surface of the water 
bath. 3-6 pm thick tissue sections were cut from the paraffin-embedded
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blocks.The sections were carefully floated onto the surface of clean Vectabond™ 
(Vector Laboratories) coated glass slides. If the block was not ribboning well 
then it was placed back on the ice block to cool and hydrate. Sections were 
allowed to dry overnight at room temperature or 40°C 
Processing of xenograft tissue for frozen sections
Freshly harvested tumours were immediately flash frozen by plunging the tissue 
specimens into isopentane (BDH Laboratory Supplies) cooled in liquid nitrogen. 
The frozen specimens were then stored in liquid nitrogen banks prior to 
processing.
A small mound of Optimal Cutting Temperature compound (OCT, 
Tissue-Tek) was placed on the cryostat chuck taking care to avoid bubbles. The 
base of the OCT was then frozen using Cyto-Cool freeze spray before placing 
another small mound of OCT on top. The tissue specimen was then embedded in 
the OCT making certain it was completely covered and thus protected from 
freeze-drying. Another drop of OCT was then added to ensure full coverage. The 
chuck was then frozen by immersing it and the specimen mounted upon it in 
liquid nitrogen or pre-cooled isopentane. Once the liquid nitrogen had stopped 
boiling the specimen was solidly frozen and ready to be sectioned. The position 
of the block was adjusted to align the block with the knife blade. Before cutting 
sections, the temperature of the block was allowed to equilibrate with the 
temperature of the cryostat (-20°C) (Bright Cryostat). The tissue block was cut 
until the desired tissue was exposed. Sections were cut at the desired thickness 
(usually 3-5 pm) and then transferred directly to clean Vectabond™ coated glass 
slides. The slides were air dried at room temperature for 1 hour before being 
covered in aluminium foil and stored at -40°C. Generally, the technically best-
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preserved section out of three adjacent sections processed from each block was 
selected for subsequent staining.
Processing of xenograft tumours for ultra thin sections
Freshly dissected tumours were rinsed in PBS and then cut into very small pieces 
(l-2mm ) in fresh electron microscope grade 2.5% (v/v) glutaraldehyde and 
fixed for a total of 2.5 hours. The tissue samples were then post fixed in 2% 
osmium tetroxide in lOOmM cacodylate buffer (1 hour on ice).The tissue was 
then embedded in Epon resin and cut (0.5pm) in an ultramicrotome before being 
stained with 0.6% toluidene blue in 0.3% (w/v) sodium bicarbonate.
Coating of glass slides
Vectabond™ (Vector Laboratories) treated slides were used to significantly 
enhance the adherence of frozen sections, paraffin-embedded tissue sections and 
cell preparations to glass slides and coverslips. This product does not coat slides 
with a glue or denatured protein, but chemically modifies the glass to form a 
highly adherent surface.
High quality glass slides (BDH Laboratory Supplies) were thoroughly 
cleaned in detergent and then rinsed in water before being placed in metal slide 
racks (25 slots). The slides were then immersed in 400ml of acetone (BDH 
Laboratory Supplies) for 5 minutes. Vectabond™ Reagent solution was prepared 
just prior to use by adding 7ml of Vectabond™ Reagent treatment solution 
(entire contents) to 350ml of acetone and stirring well. Slides were removed from 
acetone; the rack was tapped several times to drain and immediately placed in the 
pre-prepared Vectabond™ Reagent solution for 5 minutes. The slides were then 
removed and excess reagent was eliminated by gently dipping the rack several 
times over 30 seconds in deionized or distilled water taking care not to create 
bubbles. The water was changed after every 5 racks. The rack of slides was then
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removed for drying. Gentle agitation or tapping of the rack before drying was 
performed to decrease water droplets and their resulting spots. The slides were 
air dried thoroughly at room temperature or at 37°C. Slides were used 
immediately after drying, or stored in a box at room temperature for later use. 
The 357ml of Vectabond™ Reagent mixture was sufficient to treat at least 500 
slides.
2.8 Immunohistochemistry
2.8.1 Haematoxylin and eosin staining
Formaldehyde fixed paraffin embedded sections were deparaffinized in 3 
changes of xylene (BDH Laboratory Supplies) for 2 minutes each. They were 
then rinsed in 2 changes of 100% (v/v) ethanol for 1 minute each followed by 
95% (v/v) and 80% (v/v) ethanol for 1 minute each. They were then washed 
thoroughly in cold running tap water for 1 minute. The sections were then 
immersed in Harris’s Haematoxylin solution (BDH Laboratory Supplies) for 2 
minutes followed by rinsing in cold running tap water for 1 minute. This was 
followed by immersion in Acid alcohol (76.6% (v/v) ethanol, 1/300 (v/v) HC1 
(230ml 100% (v/v) ethanol, 70 ml H2 O, 1ml of 1M HC1)) for 5-10 seconds 
before being washed in cold running tap water for 5 minutes The sections were 
then dehydrated in 80% (v/v) ethanol followed by a 30 second immersion in 
Eosin Y solution (Sigma) for 15 seconds. Dehydration was completed in 2 
changes of 95% (v/v) and 100% (v/v) ethanol, 1 minute each. The sections were 
finally cleared in 3 changes of xylene for 2 minutes each. Sections remained in 
the xylene until they were coverslipped.
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2.8.2 Section preparation
Formaldehyde fixed paraffin embedded tissue sections
Prior to deparaffinization, the sections were placed in a 55°C oven for ten 
minutes to melt the paraffin. The slides were deparaffinized in two changes of 
xylene for 5 minutes each, 100% (v/v) ethanol two changes for 3 minutes each 
and finally transferred to 95% (v/v) ethanol for 3 minutes. Following this the 
endogenous peroxidase activity was blocked by incubating sections in 10% (v/v) 
H2O2 solution (BDH Laboratory Supplies) in methanol for 10 minutes. The slides 
were then rinsed twice in PBS for 5 minutes each time. The sections were now 
ready for antigen retrieval.
Frozen tissue sections
Frozen sections were removed from the -40°C fridge, allowed to thaw and rinsed 
twice in PBS to remove the tissue freezing matrix. Care was taken to avoid 
dehydration of the sections, before being fixed in ice cold 100% (v/v) methanol 
for 7 minutes. The slides were then washed twice in PBS for 5 minutes each time.
2.8.3 Antigen retrieval techniques
Antigen retrieval mechanisms works by causing either acid- or base-catalysed 
hydrolysis of methylene cross-links between protein molecules, which are 
introduced by fixation in formaldehyde, and possibly also by removing calcium 
ions (citrate and EDTA are common ingredients of retrieval solutions). Most 
antigens are retrieved by heating in either acidified (pH 1) or alkaline (pH 8-10) 
water, some by either or neither of these. Less extreme pH levels (e.g. 6) are 
often effective and less likely to cause section losses.
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Enzymatic digestion
For enzymatic digestion, 0.1% (w/v) chymotrypsin (Sigma) and 0.1% (w/v) 
calcium chloride (Sigma) were dissolved in distilled water and the pH of the 
solution was adjusted to 7.8 using 0.1N sodium hydroxide. 50ml of the solution 
was then poured into a Coplin jar and warmed to 37°C in a water bath. Once the 
temperature of the solution had stabilized at 37°C the slides were transferred into 
the jar and incubated at 37°C for 10 minutes. The slides were then washed in 
cold running tap water.
Heat treatment
Two methods were adopted in this study. The first method involved the use of a 
simple commercially available pressure cooker (John Lewis). Slides were slotted 
into a metal slide rack and placed in the open pressure cooker containing 3000ml 
of vigorously boiling citrate buffer (pH of 6.0). The lid of the pressure cooker 
was the replaced and heated until the pressure indicator signal was turned on 
(115°C). Once this had occurred the slides were left for 2 minutes of pressure 
cooking before the pressure was released and the slides were washed in cold 
running tap water.
The second method involved the use a standard commercially available 
700 kW microwave. Slides for staining were placed in a metal slide rack and 
then place in a microwaveable plastic container containing 700ml of citrate 
buffer at a pH of 6.0. The container was sealed with a piece of Clingfilm and 
then pierced with a fork several times. The container was placed in the 
microwave (Sharp) and heated for 18 minutes at full power (700kW). Following 
this the container was removed from the microwave and left to cool for 20 
minutes at room temperature with the Clingfilm taken off. The slides were then 
washed in cold running tap water.
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2.8.4 Antigen visualization method
Immunoperoxidase staining
Immunoperoxidase staining was performed using a modified version of the 3 
step protocol described in the Vectastain Universal Elite kit (Vector 
Laboratories). If antibody staining required antigen retrieval to unmask the 
antigenic epitope it was performed as described above, the method used being 
dependent on the antigen/antibody combination chosen.
Following antigen retrieval the slides were labelled with a solvent 
resistant pen and the tissue sections were demarcated with a grease pen (Dako). 
To overcome the problem of non specific staining the sections were blocked for 
20 minutes by applying 200pl of a diluted solution of normal horse serum (50pi 
of normal horse serum, provided in the kit, mixed with 1ml of PBS) to the 
sections and then tipping off without washing.
Primary antibody was diluted in antibody diluent (PBS with 10% (v/v) 
FCS) until the desired working concentration was obtained. 200pi of the diluted 
antibody solution was applied to each tissue sections on the slide. The sections 
were incubated for 1 hour at room temperature in a humidified chamber taking 
care not to allow the sections to dry out. The sections were then rinsed 3 times in 
PBS, 2 minutes each time.
After washing, the Universal biotinylated secondary antibody solution 
(prepared by adding lOOpl of normal horse serum and lOOpl of biotinylated 
antibody, both provided in the kit, to 1ml of PBS) was applied to the tissue 
sections on the slide (200pl/section) and incubated for 45 minutes at room 
temperature. Again sections were rinsed 3 times in PBS, 2 minutes each time. In 
the third step an Avidin-Complex Solution (prepared by adding lOOpl of reagent
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A and lOOpl of reagent B, both provided, to 1ml of PBS) prepared at least 30 
minutes prior, was applied to the tissue sections on the slide and incubated for 45 
minutes at room temperature. Again sections were rinsed 3 times in PBS, 2 
minutes each time.
Finally the diaminobenzidene substrate solution (DAB) was prepared by 
adding 1 drop of DAB chromogen (50fig) to every 1 ml of DAB buffer. Slides 
were allowed to incubate for 5 minutes or until the desired colour intensity was 
reached. The sections were then washed thoroughly in cold running water. The 
slides were then counterstained in Harris’s haematoxylin solution for 60 seconds 
before being rinsed in water and then dipped quickly twice in acid alcohol. 
Finally the sections were dehydrated through 4 changes of ethanol (95%, 95%, 
100% and 100%) and cleared in 3 changes of xylene. The slides were mounted 
with a 22x50mm coverslips (BDH Laboratory Supplies) using lOpl of a 1:1 
mixture of Hydromount (National Diagnostics) and Citifluor antifadant AF1 
(Citifluor Ltd). Excess mounting media was removed with fibre-free paper, 
without disturbing the coverslip. The primary antibodies were omitted to provide 
a negative control, and human tonsil sections were used as positive controls.
2.8.5 Indirect immunofluorescence 
Incubation with primary antibodies
The primary antibody was diluted to the appropriate desired concentration in 
antibody diluent (PBS with 10% (v/v) FCS). 200pi of the primary antibody 
solution was applied to each section in a humid chamber taking care not to allow 
sections to dry out and incubated for 1 hour at room temperature. Primary 
antibodies used were either mouse or rat monoclonals. Source and details of all
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primary antibodies used are given in Chapter 3. Following incubation the 
antibody solution was then removed and the sections were washed three times in 
PBS, 5 minutes each wash.
For the examination of two or three different antigens in the same cell, a 
double or triple immunofluorescence procedure was used. Sections were 
incubated simultaneously with the required number of primary antibodies, 
provided they were monospecific and could be distinguished with secondary 
antibodies conjugated to different fluorochromes (or with primary antibodies 
directly conjugated to different fluorochromes).
Incubation with secondary antibodies
The sections were now incubated with secondary antibodies conjugated to a 
fluorochrome; e.g. anti-mouse IgG FITC or TRITC, depending on the donor 
species of the primary antibody and the desired fluorochrome. Conjugated 
secondary antibodies cross-adsorbed against human tissue to minimize non­
specific binding and affinity-purified against the appropriate primary antibody 
isotype were used. The type and source of the secondary antibodies used are 
given in Table 2.3. The secondary antibody was diluted to the appropriate 
working concentration in antibody diluent and 200pi of the diluted antibody 
solution was applied to each section. The sections were incubated for 1 hour at 
room temperature and then washed again three times in PBS, 5 minutes each 
wash. Single antibody staining controls consisted of sections stained with only 
the secondary antibody (no first antibody). Secondary antibodies of different 
species and antibody subclasses were chosen so that the primary antibody 
staining could be separately detected.
Detection and visualization of multiple antigens were performed using 
appropriate mixtures of species, isotype or subclass specific fluorophore
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conjugated secondary antibodies. Controls for multiple antigen visualization 
involved omitting individual primary antibodies as well as sections stained only 
with the combination of secondary antibodies.
Species Species
specificity
Class Fluorochrome Dilution Source
Sheep mouse IgGl FITC 1:64 Sigma
Sheep mouse IgGl TRITC 1:100 Dako
Goat rat IgG2a FITC 1:500 Serotec
Table 2.3. Table showing the secondary antibodies used.
2.8.6 Direct immunofluorescence
A direct immunofluorescence system was also used (Zenon, Molecular Probes) 
(Figure 2.6). This consists of a kit whereby a primary antibody can be directly 
conjugated with an Alexa fluorophore of choice. Zenon™ Human IgG Labeling 
Kits contains a Zenon human IgG labelling reagent (Component A) and a Zenon 
blocking reagent (human IgG) (Component B). Subclass specific Zenon reagents 
for mouse IgGl and IgG2a were used in the study. Alexa fluors emitting at 
488nm (FITC equivalent) and 555 nm (TRITC equivalent) were used.
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Figure 2.6. The Zenon antibody labelling scheme. An unlabelled IgG is incubated 
with the Zenon labelling reagent, which contains a fluorophore-labeled Fab fragment (A). 
The labeled Fab fragment binds to the Fc portion of the IgG antibody (B), and excess 
Fab fragment is neutralized by the addition of a nonspecific IgG (C). The addition of 
nonspecific IgG prevents cross-labeling of the Fab fragment in experiments where 
multiple primary antibodiesof the same type are present, (diagram modified from a 
picture taken from the product information sheet, Molecular Probes).
1 pg of the required primary antibody was diluted in PBS to make an approximate 
total antibody solution of 5-1 Opl. 5pi of the Zenon class specific mouse IgG 
labelling reagent (Fab, Component A) was added to the antibody solution. This 
mixture was incubated for 5 minutes at room temperature. Then 5 pi of the Zenon
B
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blocking reagent was added (Fcr, Component B) to the reaction mixture. Again 
the solution was incubated for 5 minutes at room temperature. The reaction 
mixture was then diluted to the appropriate working concentration in antibody 
diluent equivalent to an antibody concentration of 0.5-0. lpg/ml and applied to 
sections within 30 minutes of manufacture.
Frozen tissue sections to be labelled with the Zenon reagents were fixed 
in 4% (w/v) formaldehyde solution in PBS for 15 minutes at room temperature 
prior to antibody labelling. The sections were then washed two times with PBS 
for 5 minutes each. The tissue sections were then permeabilized by incubating in 
PBS containing 0.1% (v/v) Triton® X-100 (Sigma) for 5 minutes at room 
temperature. The pre-prepared Zenon labelling complex was diluted to the 
desired working concentration in antibody diluent, and applied in sufficient 
volume (200pi) to immerse the cell sample. The slides were incubated for 40-60 
minutes at room temperature in the dark protecting from light during the 
incubation. When labelling was complete, the sections were washed twice with 
PBS for 5 minutes each. When staining with more than one Zenon labelling 
complex, all complexes were combined into a single staining solution.
Following antibody labelling, a second fixation of the section was 
performed in 4% (w/v) formaldehyde solution in PBS for 15 minutes at room 
temperature. When the fixation was complete, the sections were washed twice 
with PBS for 5 minutes each. This second fixation step was carried out because 
the Zenon Fab fragment is not covalently coupled to the primary antibody and so 
can dissociate with time and even transfer to another primary antibody in 
multicolour applications.
Following this the sections, if required, were counterstained with a DNA 
stain Hoechst 33258 (5pg/ml) and washed with PBS after any additional staining
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procedures. Controls consisted of sections that were stained with the Zenon 
reagents only (A + B) (no primary antibody added). The sections were mounted 
with coverslips using lOpl of a 1:1 mixture of Hydromount (National 
Diagnostics) and Citifluor antifadant AF1 (Citifluor Ltd). Excess mounting 
media was removed with fibre-free paper, without disturbing the coverslip.
2.8.7 Fluorescence staining of live cells on coverslips
Live cells for labelling were plated onto sterile coverslips (13mm, BDH 
Laboratory Supplies) placed in 24-well plates at a density of 4x104 cells in 2ml 
of their respective growth medium. When the cells reached approximately 80% 
confluency, they were washed twice in 2ml of PBS/well, fixed with cold 
methanol (-20°C) for 7 minutes, washed three times with 2ml of PBS and stored 
in PBS at 4°C.
Prior to antibody labelling the PBS was drained from the 24-well plates. 
The cells were first blocked with 500pl /well of 0.5% (w/v) BSA in PBS for 30 
minutes at 37°C to minimize non-specific adsorption of the antibodies to the 
coverslips. The blocking buffer was removed by holding each coverslip on its 
edge with forceps and draining it onto a sheet of fibre-free paper. Fixed cells 
were stained by both indirect and direct immunofluorescence as described above.
The coverslips were mounted by inverting then onto a slide containing 
lOpl of mounting media consisting of a 1:1 mixture of Hydromount and Citifluor 
antifadant AF1. The edges of each coverslip were sealed with regular transparent 
nail polish and allowed to dry for 3 minutes to provide semi-permanent 
preparations. Image data sets depicting immunofluorescence labelling were 
collected and processed as described in Chapter 2.8.7.
143
2.8.8 Visualisation and image processing 
Light microscopy
Brightfield. Image data files of H&E and immunoperoxidase labelled specimens 
were collected with a high resolution Leaf camera (ISS) mounted over an 
Axiophot microscope (Zeiss) fitted with a xlO NA 0.3 ,a x20 NA 0.5 or x40 NA 
0.75 objective as described elsewhere (Entwistle 1998, Entwistle 2003). The 36 
bit data (3 channels of 12 bits each) generated by the sensor of the camera was 
truncated to the most significant 8 bits for each channel and transferred to the 
computer through a SCSI interface using proprietary software supplied with the 
camera which ran as a TWAIN 32 plug-in with Image-Pro Plus (Media 
Cybernetics). Following calibration, the software was used to collect image data 
sets using a routine that ensured that the brightest pixels were not quite saturated 
without generating conflict with the balance of colours. Where required, 
correction of any spatial shading effects was made after two data sets had been 
collected, one describing a region of interest and the other a nearby empty field 
of view. Correction of spatial shading was implemented by dividing each pixel 
value in the empty field of view and multiplying the product by 250, for each of 
the three channels, using Adobe Photoshop (Adobe Systems Inc). The resulting 
data set was then subjected to contrast stretching and saved as the 24 bit RGB 
TIFF files.
Phase contrast. A Nikon camera connected to an inverted Zeiss light 
microscope fitted with xlO NA 0.3 and x20 NA 0.5 phase contrast objectives was 
used to take greyscale pictures of cells in culture and endothelial differentiation 
assays using Technical Pan Film (Kodak).
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Fluorescence microscopy
Image data files depicting immunofluorescent staining were collected as a matrix 
of 1024 x 1024 elements, each with a bit depth of 12, on a Coolview 12 cooled 
Charge Coupled Device (CCD) camera mounted over an Axiophot microscope 
fitted with a xlO NA 0.3, x20 NA 0.5 or a x40 NA 0.75 objective. The readout 
from the CCD camera was transferred to a Snapper frame grabber card mounted 
in a personal computer running under Windows 95 by proprietary software 
(Photonic Science) controlled by Image Pro Plus v 4.01. The fluorophores were 
visualised with various filter combinations, or modes, as follows: Hoechst 33258 
using a using a blue bandpass emission filter and ultraviolet illumination, 
fluorescein isothiocyanate (FITC), using a green bandpass emission filter and 
blue illumination and tetramethylrhodamine isothiocyanate (TRITC) using a red / 
near infrared bandpass emission filter and green illumination. The emission from 
each fluorophore into the other modes, crosstalk, was insignificant, <0.1% (A 
Entwistle, personal communication). Images depicting multiple 
immunofluorescences labelling with additional Hoechst 33258 staining were 
generated by assigning green to the emissions from FITC, red to emissions from 
TRITC and blue to Hoechst 33258. Images displaying triple immunofluorescent 
labelling with additional Hoechst labelling were made by assigning the emissions 
from: Hoechst (exclusively nuclear) to blue, red to TRITC and green to FITC. 
The contrast in the colour data sets was adjusted so that the information that 
could be perceived in the final images corresponded as closely as possible to the 
data sets presented on a computer monitor screen that had been balanced against 
a colour test card. The protocol used in this study conforms to and meets the 
requirements of a criterion set in a recently published review on the correct use 
of a light microscope (Dell and Vale 2004).
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Time lapse microscopy
In some experiments sequential phase contrast, brightfield and 
immunofluorescence images were recorded using an automated time lapse 
system (Olympus CK2 microscope) controlled by Image Pro plus 4.0 microscopy 
program. These images were collated to produce short sequential movies 
visualized on Real Media Player.
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Chapter 3 
Characterisation of immortalized human 
mammary stromal cell lines
3.1 Introduction
Tumour-stromal interaction studies have to date relied on the continuous 
collection and explanation of biopsies, a relatively time consuming process. In 
addition, normal breast biopsies are limited in supply and long term experiments, 
or experiments requiring larger quantities of cells, have also been hampered by 
the difficulty of expanding the different cell populations, especially stromal cells. 
To overcome the problems of using normal primary tissue, methods to extend the 
lifespan of the explanted cells have been developed. Ectopic expression of the 
catalytic subunit of human telomerase (hTERT), as well as Simian virus (SV40) 
large T antigen oncogene, has been shown to extend life of normal human 
somatic cells, including fibroblasts and endothelial cells to confer immortality 
(Hahn et al. 1999, Elenbass et al. 2001). The immortalized human mammary 
stromal cell lines used in this study were cells previously derived by O’Hare et 
al. (2001) using the above method.
Derivation and properties of the immortalized stromal cell lines
The transduction and establishment of conditionally immortalized human 
mammary stromal cell lines by O’Hare et al. (2001), from primary cells, are 
explained in Figures 3.1 and 3.2. Primary mammary microvascular endothelial 
cells (1° HMME) were immunomagnetically isolated, from normal reduction 
mammoplasties (two donors), by using the QBEND-40 monoclonal antibody 
against thrombomodulin, a marker of endothelial cells. The primary mammary
147
interlobular fibroblasts (1° HMF) were established from ‘fines’ (40|im filter 
passing single cells and small cell clumps) from an enzymatically dissociated 
normal reduction mammoplasty (one donor). Fibroblasts were separated from 
other cell populations in the digested mix by selective growth in a medium 
(DMEM /FCS) which did not support the growth of mammary endothelial or 
epithelial cells. The conditionally immortalized cell lines were generated by 
transduction of a temperature sensitive (tsLT) mutant (U19tsA58) of SV40 LT 
antigen, whereas the wild type variants were generated by transduction of a wild 
type LT antigen (U19). The conditionally immortalized cell lines varied in the 
timing and order of the oncogene transductions. The variations in order and 
timing of transduction, however, did influence the genomic stability with the 
cells differing slightly in properties (Table 3.1). None of the cell lines displayed 
anchorage independent growth, a characteristic of transformed cells at early 
passage. However HMF 3B, unlike the other early passage cells, grew at 37°C. 
HMF 3C became spontaneously transformed at about 60 population doublings 
(PD) as demonstrated by its capacity after this time to grow in soft agar. HMF 
3 A remained stable maintaining temperature sensitivity with no evidence of overt 
transformation. HMF 3D lost this temperature sensitive status at late passage 
(>60PD) but did not show anchorage independent growth. HMF 3wt and HMME 
7wt have been passaged in excess of 100 PD without evidence of transformation 
as have the temperature sensitive endothelial cell lines (HMME 2 and HMME 7).
Recent data (PS Jat, personal communication) have shown that the HMF 
B line but not HMF D has lost the temperature sensitive A58 (tsA58) mutation, 
probably as the result of a reverse transcriptase caused back mutation, thus 
explaining its loss of temperature sensitivity.
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wtLT -----► HMME 7wt
HMME 7
donor — hTERT --------  tsLT — ------ ► HMME7
HMME 2
donor -------  tsLT — ---------- hTERT -— ► HMME2
Figure 3.1. Derivation of the immortalized human mammary endothelial cell lines 
(HMME). The immortalized endothelial cells were derived from two donors. The cell lines 
differed in the order and timing of the oncogene transductions. HMME 7wt is a wild type 
LT variant of HMME 7 which grows well at 37.5°C.
----  tsLT ---------—  hTERT -----► HMF 3A
-----  tsLT ---------— hTERT -----► HMF 3B
HMF 3
donor HMF 3C
-  hTERT ----- ----  tsLT ------- ►
— hTERT ----- ----  tsLT ------- ► HMF 3D
wtLT ------------- ► HMF 3wt
Figure 3.2. Derivation of the immortalized human mammary fibroblast cell lines 
(HMF). The immortalized fibroblasts were derived from normal breast tissue removed 
from one donor-HMF 3. The cell lines differed in the order and timing of the oncogene 
transductions. HMF 3wt is a wild type LT variant of HMF-3 which grows well at 37.5°C.
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Immortalized 
Stromal Cell Line
Temperature sensitivity Anchorage Independent 
Growth
HMF3A YES NO
HMF3B NO NO
HMF3C YES NO (<60PD) -» YES
HMF 3D YES (<60PD) NO NO
HMF 3wt NO NO
HMF 3wt ras NO YES
HMME 2 YES NO
HMME 7 YES NO
HMME 7wt NO NO
Table 3.1. Table summarizing the temperature sensitivity and transformation 
status of the immortalized stromal cell lines.
The properties of immortalized cell lines, such as their genotypic and karyotypic 
stability, may vary depending upon the method of immortalization (e.g. hTERT 
vs SV40 LT vs HPV viral oncogene) and/or on the order of genetic events (Fauth 
et al. 2004). Furthermore the oncogenes inserted to generate these immortal cell 
lines have other properties and abilities which can have a significant effect on the 
genome of the cell and its phenotype. For example the inactivation of 
retinoblastoma (pRB) and p53 tumour suppressor genes (TP53) produced by 
SV40 LT antigen insertion could alter their properties. The abrogation of Rb/p53 
cell cycle check point controlling genes release check points so that cells 
continue to cycle. In addition p53 also senses mutation damage and may trigger 
apoptosis of damaged cells. Thus its abrogation by T antigen might result in the
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accumulation of genomic damage in such cells. The T antigen has recently been 
reported to have the ability to cause chromosomal aberrations, aneuploidy and 
transformation by its interaction with Bubl and Bub3, both components of the 
spindle checkpoint complex (Cotsiki et al. 2004). On the face of it, hTERT, 
which stabilises telomeres and prevents cell senescence by telomere erosion, 
should be a milder method of immortalizing human adult somatic cells which 
lacks this activity. However it has been shown, repeatedly, that adult human 
mammary fibroblasts and endothelial cells do not successfully immortalize with 
hTERT alone. Consequently a combination of hTERT and SV40 LT antigen was 
used to generate immortalized lines for these cell types.
Characterisation of the immortalized stromal cell lines
The aim of the experiments described in this chapter was to determine whether 
these cells had retained basic characteristics of normal cellular growth or whether 
the immortalization procedure had transformed the cells in full or in part. Cells 
had already been tested for anchorage independent growth which was negative in 
all early passage cells. However anchorage independent growth represents a 
relatively extreme aberration and there remained the possibility that the lines 
were altered in less obvious ways. Tests were carried out to investigate some of 
the other characteristics of transformation. Some generic characteristics of 
transformed cells are listed in Table 3.2 (Chang 1986, Hahn et al. 1999).
151
Criteria of transformation in vitro
Increased growth rate 
Growth factor insensitivity
Higher confluent density (loss of contact inhibition of growth) 
Cellular overlapping (loss of contact inhibition of movement) 
Loss of serum dependence
Acquisition of anchorage independent growth (high colony
formation in soft agar)________________________________
Ability to produce tumours in immunodeficient mice
Table 3.2. Summary of the characteristics representative of transformation. The
characteristics are listed with the most extreme phenotypes last.
Significant alterations in their growth properties would imply that their cellular 
phenotypes had changed to a degree no longer representative of normal 
mammary fibroblasts and endothelial cells. Therefore the experiments outlined 
below should provide an indication of whether these stromal cell lines have 
essentially normal human characteristics or whether they had become 
tumourigenic as result of partial or full (tumourigenic) transformation. In 
addition, the results reported in this chapter will help answer the question of 
whether these cell lines are suitable for use as normal fibroblasts and endothelial 
cells in the proposed 3 compartment xenograft model and if one or other line is a 
better model of normality in this context.
Furthermore, monolayer co-culture growth assays together with 3-D in 
vitro differentiation assays were performed to investigate the reciprocal effects of 
tumour-stromal interactions between the immortalized cell lines and breast 
tumour epithelial cells. These studies were carried out to confirm the well
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recognised reports that tumour-stromal interactions are stimulatory on both 
growth and differentiation and to establish the extent to which these cell line 
models reproduce these effects. The ability of these cell lines to survive and form 
tumours in vivo is described later (Chapter 6).
3.2 Growth kinetics
The questions of growth rate, growth factor dependency and serum requirements 
were addressed in the current study by performing a series of monolayer growth 
experiments in a variety of growth medium supplements.
3.2.1 Simple growth assays
A series of monolayer growth assays were performed to examine the growth 
properties of the immortalized endothelial cell lines; HMME 7, HMME 2, 
HMME 7wt and fibroblasts; HMF 3A, HMF 3B, HMF 3C, HMF 3D, HMF 3wt, 
HMF 3wt ras. HMF and HMME are unaltered subcultures of primary fibroblasts 
and endothelial cells respectively. The HMF 3wt ras was derived by transducing 
the HMF 3wt with an activated ras oncogene as described in Chapter 2.1.3. The 
main purpose of these experiments was to look for alterations in growth rates, in 
comparison to unaltered stromal cells, as these are often taken to be one of the 
criteria representative of transformation (Chang 1986).
Flask assays were used for multipoint growth measurements, as described 
in Chapter 2.5.1. l x03 cells of each of the cells and cell lines were plated in 
25cm2 flasks, in triplicate, in their respective growth medium and conditions. 
Cells were harvested at intervals of 2, 4, 6, 8, 10 and 12 days and counted using a 
haemocytometer. A minimum of 200 cells were counted for each determination.
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The results were tabulated and graphically represented in Figures 3.3 and 3.4. All 
cell lines were tested were early passage cells (less than passage 30) equivalent 
to <100 population doublings. Unaltered fibroblasts and endothelial cells were 
tested at passage 3-6 (<20 PD).
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Figure 3.3. M ulti-point g rap h ica l rep rese n ta tio n  of th e  grow th  ra te s  o f th e  im m ortalized 
hum an  m am m ary en d o th e lia l cell lines ov er a  tw o w eek  period . HMME and the HMME 7wt 
cell line were cultured at 37.5°C with HMME 2 and 7 cell lines grown at 33.5°C. Data shown are 
m eans +/- standard deviation (n=3) (shown a s  error bars) of triplicate m easurem ents.
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Figure 3.4. M ultipoint g rap h ica l re p re se n ta tio n  of th e  grow th ra te s  of th e  im m ortalized 
hum an m am m ary fib ro b la s t lin es  o v e r a tw o w eek  period. HMF, HMF 3wt and HMF 3wt ras
cell lines were cultured a t 37.5 °C with HMF 3A-D cell lines grown at 33.5°C. Data shown are 
m eans +/- standard deviation (n=3) (shown a s  error bars) of triplicate m easurem ents.
1 5 5
The wild type LT variants of both the human mammary endothelial cell and the 
fibroblast lines produced the fastest growth rates with the unaltered cells showing 
the slowest growth rates. In fact, all the immortalized stromal cell lines 
demonstrated significantly faster growth rates in comparison to their respective 
unaltered cells including the temperature sensitive cell lines grown at 33.5°C.
3.2.2 Growth factor requirements
The dependency of the immortalized stromal cell lines on various growth factors 
and supplements was also investigated as another criterion of transformation. 
This was analysed by monolayer growth in microwell plates performed as 
described in Chapter 2.5.2. Cell numbers were determined by the methylene blue 
staining assay also described in Chapter 2.5.2.
Calibration of the Dynatech Laboratories MRX plate reader 
Prior to use the linearity of the Dynatech Laboratories MRX plate reader was 
investigated to determine the relationship between absorbance of the dye and cell 
number in the methylene blue assay. Various known cell numbers were plated in 
96-well plates, allowed to attach for several hours, and assayed using the 
methylene blue staining method described above. The absorbance reading was 
taken at each of the fixed cell numbers and tabulated. The results (Figure 3.5) are 
graphically represented and show a near linear relationship between dye intensity 
and cell numbers over the range tested, which represented the range encountered 
in the actual experiments.
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Methylene Blue Calibration
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Figure 3.5. Calibration of the Dynatech Laboratories MRX plate reader. Error bars 
signify the standard deviation (n=3). Line of best fit calculated by the formula y = ax + b 
where a is the slope and b is the intercept (using Microscoft Excel).
Endothelial cells
The growth factors present in the commercially available endothelial cell growth 
medium EGM-2 Bullet kit (Biowhittaker) were used. These are the growth 
factors that have been identified as necessary for the optimal growth of normal 
human endothelial cells. These were heparin (hep), hydrocortisone (HC), human 
fibroblast growth factor (hFGF), vascular endothelial growth factor (VEGF), 
insulin like growth factor (IGF-1), ascorbic acid (AA) and human epidermal 
growth factor (hEGF). With the possible exception of VEGF and heparin the 
‘endothelial’ growth supplements are also reported to act on many different cell 
types and were therefore also tested on the fibroblast lines.
1 x 103 cells were plated in 24-well plates in the basal endothelial cell 
medium (EGM-2) containing 2% (v/v) FBS with the addition of each of the
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2% (v/v) FBS without any growth supplements added. The cells were grown at 
their respective optimal temperatures and then fixed at three selected time points; 
7, 12 and 15 days. The influence of the individual growth factors on different cell 
lines was compared to growth in basal medium alone (control, EGM-2) and was 
calculated as a percentage of controls. All experiments were carried out in 
triplicate. Results for the unaltered endothelial cells are shown in Figure 3.6, with 
its corresponding immortalized lines HMME 2 (Figure 3.7A), HMME 7 (Figure 
3.7B) and HMME 7wt (Figure 3.7C).
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Figure 3.6. Effect of individual growth supplements on the growth of the unaltered 
human mammary endothelial cells. Control was defined as 100% (basal media 
containing serum with no supplements). The growth effect of the supplements was 
calculated as a percentage increase/decrease compared to control. Data shown as 
means +/- standard deviation (n=3) shown as error bars. Statistically significant results 
are marked with (*) where p  £ 0.05 using the Students t-test in Excel’s statistical 
package.
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Unaltered endothelial cells were stimulated by all the growth factors with HC, 
hFGF and VEGF being particularly potent (Figure 3.6). However, AA had an 
inhibitory effect as a single addition. The dependency of the unaltered cells to 
growth factor stimulation is in line with expectation as the commercial medium 
used (EGM-2) has been optimized for human endothelial cells.
Data for the corresponding experiments on the endothelial cell lines 
HMME 2, HMME 7 and HMME 7wt are shown in Figure 3.7.
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Figure 3.7. Effect of individual growth supplements on the growth of the 
immortalized human mammary endothelial cell lines (a) HMME 2, (b) HMME 7 and 
(c) HMME 7wt. Control was defined as 100% (basal media containing serum with no 
supplements). The growth effect of the supplements was calculated as a percentage 
increase/decrease compared to control. Data shown as means +/- standard deviation 
(n=3) shown as error bars. Statistically significant results are marked with (*) where p £ 
0.05 using the Students t-test in Excel’s statistical package.
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Overall, the effects of individual growth factors were much smaller than with the 
unaltered cells. Furthermore, at least in the shorter time points, a number of the 
supplements were inhibitory. The only supplement to be consistently stimulatory 
in all the cell lines was HC. The decreased growth rate did not appear to be due 
to cell death, since little or no cell debris was seen in the culture medium.
Fibroblasts
A similar experiment was carried with the unaltered fibroblasts and immortalized 
fibroblast cell lines with the exception that measurements were made a single 
time point. The result is shown in Figure 3.8.
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Figure 3.8. Effect of individual growth supplements on the growth of the human 
unaltered and immortalized mammary fibroblast cell lines. Cells were grown for 7 
days at 37°C HMF. Control was (growth in basal media containing serum but no growth 
supplements) defined as 100%. The effect of growth supplements on cell growth is 
shown as a percentage increase/decrease in comparison to control. Data shown as 
means +/- standard deviation (n=3)-error bars). Statistically significant results are 
marked with (*) where p < 0.05 using the Students t-test in Excel’s statistical package.
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Most of the ‘endothelial’ growth supplements had dramatic stimulatory effects 
on the unaltered fibroblasts increasing growth rates considerably (Figure 3.8). 
The increase in growth produced by the various factors ranged from 50-150%. 
Even VEGF stimulated the cells and the only factor that did not was heparin. The 
fibroblast lines, by contrast all showed relatively minimal effects, compared with 
the unaltered cells. However, such mainly stimulatory effects as were noted were 
also somewhat greater than had been observed in the endothelial lines (e.g. 
experiments with HMF 3 A and HMF 3B)
In summary the growth factor dependency of all the immortalized stromal 
cells was significantly less than that of the unaltered cells. The stimulatory 
effects of the growth supplements varied throughout both the endothelial and 
fibroblast lines underscoring their individuality. It should be noted that the wild 
type lines were grown at 37°C unlike the others.
3.2.3 Effect of serum on growth rates
Human microvascular endothelial cells in culture normally require a serum 
content of 10-20% (Iijimata et al. 1991, Hohenwarter et al. 1992, Lassalle et al. 
1992, Fickling et al. 1992) when growing in relatively simple medium, or as in 
the case with EGM-2 medium 2% with specific growth factors.
Serum contains many endogenous growth factors. The fact that, as shown 
in the previous section, the immortalized endothelial cells have significantly 
reduced growth factor requirements compared to unaltered cells could be due to 
both the growth promoting activity of the SV40 LT and to the presence of 
endogenous growth factors in the 2% serum to provide optimal conditions. To 
ascertain whether any major growth factor responses were retained by the cell
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lines, they were retested with growth factors at reduced serum concentrations. 
Growth assays in microwell plates were performed, as previously described.
Endothelial cell lines were grown in 3 different reduced serum 
concentrations: 0.2%, 0.4%, 1% and 2% FBS (i.e. 10%, 20%, 50% and 100%) of 
the normal foetal bovine serum concentration (2% v/v) present in the basal 
endothelial cell medium. 1 x 103 cells were plated in wells of a 24-well plate in 
endothelial cell basal medium (EGM-2) containing one of the four serum 
concentrations with the addition of each of the growth factors provided in the 
EGM-2 bullet kit medium. Controls for each serum concentration consisted of 
basal medium containing the appropriate serum concentration without any 
growth supplements. The cells were grown at their optimal temperature and 
conditions for 7 days before being fixed in 4% (w/v) formaldehyde in PBS. Cell 
numbers were determined by the modified methylene blue staining assay as 
described in Chapter 2.5.2.
The effect of different serum concentrations on the growth rates of the 
unaltered endothelial cell HMME and immortalized cell lines HMME 2, HMME 
7 and HMME 7wt are shown in Figure 3.9.
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Figure 3.9. Effect of serum concentration on the growth of unaltered and 
immortalized human mammary endothelial cells in medium without growth 
factors. Control consists of the normal serum concentration of 2% v/v and is shown as 
100%. The effect of serum on cell growth is shown a percentage increase/decrease in 
comparison to control. Data shown as means +/- standard deviation (n=3,-error bars) of 
triplicate measurements.
All the cells tested, both the unaltered and immortalized cell lines, were strongly 
dependent on serum concentration in the absence of the additional growth 
factors.
The effect of the individual growth factors at different serum 
concentrations on the unaltered endothelial cells is shown in Figure 3.10.
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Figure 3.10. Effect of serum concentration on the influence of individual growth 
supplements on the growth of the unaltered human mammary endothelial cells.
Cells were grown in 4 different serum concentrations in the presence of each of the 
growth factors for a period of 7 days. Data shown as means +/- standard deviation (n=3- 
error bars). Statistically significant results are marked with (*) where p < 0.05 using the 
Students t-test in Excel’s statistical package.
In the unaltered cells the responsiveness to individual growth factors was 
increased as the serum concentration was decreased (Figure 3.10). This effect 
was most noticeable with hydrocortisone.
The results of the endothelial cell lines HMME 2, HMME 7 and HMME 
7wt are shown in Figure 3.11.
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Figure 3.11. Effect of growth supplements in different serum concentrations on 
the growth of the (a) HMME 2, (b) HMME 7 and (c) HMME 7wt endothelial cell lines.
Cells were grown in 4 different serum concentrations in the presence of each of the 
growth factors for a period of 7 days. Data shown as means +/- standard deviation (n=3- 
error bars). Statistically significant results are marked with (*) where p ^ 0.05 using the 
Students t-test in Excel’s statistical package.
HMME 7 and HMME 7wt behaved like the unaltered cells with enhanced growth 
factor responsiveness at the lower serum concentrations, although the effects 
were not progressive as with the unaltered cells but only become strongly evident 
at the lowest serum level (0.2% v/v). Again hydrocortisone was the most 
consistently active individual growth factor. It was noteworthy that ascorbic acid 
did not promote growth under low serum conditions, in contrast to the results 
with 2% (v/v) serum. HMME 2 did not show consistent evidence of growth 
factor response even at the lowest serum concentrations. As shown previously
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(Figure 3.11 A) this line was the least growth factor sensitive at normal serum 
concentrations.
In summary the effect of growth factors was most significant at low 
serum concentration (seen with the unaltered endothelial cells HMME and lines 
HMME 7 and HMME 7wt) However HMME was the exception again with 
growth factor responsiveness staying similar throughout the different serum 
concentrations. Once again the individuality of the cell lines is demonstrated.
3.3 Co-culture growth assays
Tumour-stromal interactions are now emerging as a crucial factor in 
tumourigenesis. To investigate the effect of tumour-stromal interactions, in an in 
vitro setting, a series of co-culture experiments were performed using a cell 
culture insert and multiwell system (cells were separated into two compartments 
in each well). The method used is described in Chapter 2.5.3. The following 
interactions were studied: effect of tumour on stromal cell growth, effect of 
stroma on tumour growth and finally endothelial cell-fibroblast interaction.
3.3.1 Effect of tumour cells on the stromal cell growth
As a preliminary study the wild type (non-temperature sensitive cell lines) were 
tested with MCF-7 cells. Firstly the effect of different numbers of breast tumour 
cells (MCF-7) on the growth of immortal fibroblasts and endothelial cells was 
studied. Results are presented in Figure 3.12. The cells to be studied were plated 
on the bottom of the wells with the effector cells (i.e. MCF-7 cells) plated on the
membrane of the cell culture inserts. The cell culture inserts consisted of 0.4pm
6 2pore sized polyethylene terephthalate membranes (1.6x10 pores/cm ) with cells
168
deposited into two separate compartments in each well to prevent physical 
contact by inhibiting migration of cells from the inserts in the upper chamber to 
the lower chamber. Controls consisted of wells with cells seeded on the lower 
compartment and cell culture inserts without cells. The end point was determined 
when the cells, in the lower chamber below the inserts, in which ever 
experimental condition resulted in the most rapid growth to become 80-90% 
confluent. The temperature sensitive cell lines were not tested because they were 
unlikely to provide a satisfactory system for future in vivo studies, but the ras 
variant of HMF 3wt was included as a ‘transformed’ control.
169
In both endothelial cells and fibroblasts increasing numbers of MCF-7 tumour 
cells inhibited stromal cell growth. However the unaltered and wild types ras 
fibroblast demonstrated slight stimulation when cultured in 1 x 103 tumour cells 
before being progressively inhibited at higher tumour numbers (Figure 3.12b). 
HMF 3wt was inhibited with all the tumour cell numbers.
Next the unaltered HMME and HMF cells and their corresponding wild 
type lines were co-cultured with 4 different human breast epithelial tumour cell 
lines to determine whether the effects of tumour cells on the growth rates of the 
stromal cells were to any extent tumour cell type specific (Figure 3.13).
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Figure 3.13. Endothelial cell (a) and fibroblast (b) growth rates in co-culture with 4 
different breast tumour cell lines. Growth was measured over a 7 day period with 104 
cells seeded in the top compartment of the microwell inserts. Results are calculated as a 
percentage inhibition/stimulation of control (culture inserts with no added cells). Data 
shown as means +/- standard deviation (n=3-error bars). Statistically significant results 
are marked with (*) where p < 0.05 using the Students t-test in Excel’s statistical 
package.
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Results (Figure 3.13) showed that the tumour-stromal interactions were on the 
whole inhibitory. In the case of the unaltered endothelial cells wild type 
endothelial line, all the tumour cell lines were inhibitory to roughly the same 
extent although the cell line did appear more sensitive. This was even the case 
when the tumour cells were the VEGF over-expressing variant of MCF-7 (MCF- 
7 V12).
In the case of the fibroblasts the lines were again inhibited but to slightly 
different extents in respect of individual tumour cell lines, with ZR-75-1 being 
the most active in this respect. The unaltered fibroblasts were less sensitive to 
inhibition and in some instances activities actually showed enhancement of 
growth, for example when co-cultured with MCF-7 V I2 and T-47D. This 
stimulatory effect demonstrates that the inhibition seen with the cell lines is 
probably not simply a consequence of generally adverse conditions (i.e. over 
acidity) caused by the tumour cells.
In summary therefore, in so far as the stromal cells are concerned the 
presence of breast tumour cells was inhibitory in all cases, but MCF-7 was the 
least inhibitory in this system.
3.3.2 Effect of stromal cells on tumour cell growth
The unaltered HMME and HMF cells and their corresponding lines were next co­
cultured with the 4 human breast epithelial tumour cell lines, following a similar 
protocol as Chapter 3.3.1 but with the compartments reversed (i.e. tumour cells 
in the bottom and HMME/HMF cells in the inserts, to determine the effects of 
stromal cells on the growth rates of 4 different tumour cells. In order to avoid 
potential problems of over-acidity and other toxic media effects the medium was
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changed every day. Results for both endothelial and fibroblasts are shown in 
Figure 3.14.
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Figure 3.14. Breast tumour cell line growth rates in co-culture with human 
mammary stromal cells. Growth was measured over a 7 day period with 104 cells 
seeded in the top compartment of the microwell inserts. Controls were tumour cells 
alone. Results are calculated as a percentage inhibition/stimulation of control (culture 
inserts with no added cells). Data shown as means +/- standard deviation (n=3-error 
bars). Statistically significant results are marked with (*) where p < 0.05 using the 
Students t-test in Excel’s statistical package.
The results clearly demonstrated that the stromal cells tested, both the unaltered 
and their corresponding fibroblasts and endothelial cell lines, had inhibitory 
effects on the growth of all the 4 different breast tumour cell lines. The 
fibroblasts and endothelial cells inhibited the 4 different tumour cell lines to
1 7 4
different extents. The stromal cells inhibited the growth of the MCF-7 cell line 
most with T47D showing the least inhibition.
3.3.3 Effect of fibroblast-endothelial cell interaction
Lastly, the effect of the presence of fibroblasts (HMF, HMF 3wt, HMF 3wt ras) 
on the growth of the human mammary endothelial cells (HMME, HMME 7wt) 
and vice versa was investigated, using the cell culture insert and multiwell 
system (see Chapter 2.5.3). Results are shown in Figure 3.15.
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Figure 3.15. Growth rates of (a) human mammary fibroblasts in co-culture with human 
mammary endothelial cells and (b) endothelial cells in co-culture with human 
mammary fibroblasts. G rowth w as  m e asu red  over a  7 day  period with 104 cell s e e d e d  in 
the  top com partm ent of th e  microwell inserts. C ontrols w ere  endothelial cells or fibroblasts 
cultured alone. R esu lts  a re  ca lcu la ted  a s  a  p e rc en ta g e  inhibition/stimulation of control 
(culture inserts  with no a d d e d  cells). D ata show n a s  m e an s  +/- s tan d ard  deviation (n=3-error 
bars). Statistically significant resu lts  a re  m arked with (*) w here  p < 0 .05 using the  S tuden ts t- 
te s t in Excel’s  statistical pack ag e .
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Both the unaltered and its corresponding wild type endothelial cell line were 
inhibited when co-cultured with the fibroblasts (Figure 3.15a). However the 
immortalized endothelial cells were inhibited to a greater extent when compared 
to the unaltered cells.
Results (Figure 3.15b) showed that the fibroblasts were greatly stimulated 
when co-cultured with the unaltered and wild type endothelial cells 
demonstrating markedly enhanced growth, in excess of 200% in some cases. The 
wild type fibroblast lines were also stimulated but to a lesser extent with the 
‘transformed’ HMF 3wt ras showing noticeably greater stimulation than the 
HMF 3wt line.
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A summary o f all the co-culture data is shown in Tables 3.3-3.5
Effector HMF
3wt
HMF
3wt
ras
HMF T47D ZR-
75-1
MCF-
7
MCF- 
7 V12
Target HMME 1 4 4 4 4 4 4
HMME
7wt 4 4 4 4 4 4 4
Table 3.3. The effect of breast tumour cell lines and fibroblasts on endothelial cell 
growth
Effector HMME HMME
7wt
T47D ZR-75-
1
MCF-7 MCF-7
V12
Target
HMF
3wt T T 4 4 4 4
HMF 
3wt ras T T 4 4 4 4
HMF T T T 4* 4 T
Table 3.4. The effect of breast tumour cell lines and endothelial cells on fibroblast 
growth
Effector HMME HMME 7 
wt
HMF 3wt HMF 3wt 
ras
HMF
Target
T47D — — — — 4
ZR-75-1 4 4 4 4 4
MCF-7 4 4 4 4 4
MCF-7
V12 4 4 4 4 4
Table 3.5. The effect of stromal cells on breast tumour cell line growth.
Inhibitory * P=0.013
Stimulatory
— = No change p> 0.4
All results p < 0.01 Calculated using the Students T-test assuming unequal 
variance-two tailed
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3.4 Endothelial cell differentiation assays
The ability of human mammary endothelial cells to undergo terminal 
differentiation and morphogenesis can be determined by its growth on the 
basement membrane preparation, Matrigel. Basement membranes are thin 
extracellular matrices underlying epithelial cells and separating them from 
connective tissue. BD Matrigel™ Matrix is a solubulized basement membrane 
preparation extracted from EHS mouse sarcoma, a tumour rich in extracellular 
matrix proteins. Its major component is laminin, followed by collagen IV, 
heparan sulfate proteoglycans, and entactin. Matrigel can be used to coat tissue 
culture surfaces, where cell growth can promote tissue like morphogenesis and 
tissue specific cell differentiation and function, thus providing an in vitro model 
for in vivo tissue morphogenesis. ‘Transformed’ cells can show reduced 
morphogenesis on Matrigel, apparent as a loss of organisation and the failure to 
produce any recognisable structure. Due to the differences observed between 
normal and transformed cells’ differentiation and morphogenesis, a 
differentiation assay using matrigel was performed to assess endothelial cell 
phenotype.
The ability of the immortalized human mammary endothelial cells to 
proliferate, differentiate and form tubular structures in vitro was therefore 
investigated. In addition the effect of growth factors, either exogenous or those 
produced from tumours, on endothelial cell proliferation and differentiation was 
determined.
To investigate the ability of the immortalized endothelial cells to 
differentiate in vitro on extracellular matrix with minimal growth factor support, 
differentiation assays on GFR Matrigel were carried out (Figure 3.16).
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Figure 3.16. Phase contrast micrographs showing (a) unaltered and (b) immortal 
human mammary endothelial cells plated on GFR Matrigel with complete 
endothelial medium EGM-2 Bullit kit after 24 hours. No signs of primitive 
microcapillary like differentiation. Similar results were observed with the other 
endothelial cell lines including the temperature sensitive lines when grown at 33.5°C. 
Magnification *80.
Both the unaltered and HMME endothelial cell lines failed to differentiate and 
produce primitive capillary networks on the GFR Matrigel (Figure 3.16).
To further investigate tumour stromal interactions, assays were repeated this time 
including in either fibroblasts or tumour cells with the endothelial cells when plating of 
GFR Matrigel. Results are shown in Figure 3.
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Figure 3.17. Phase contrast micrographs taken after 24 hours showing primitive 
microcapillary networks produced by the endothelial cell line HMME 7wt when 
incubated with (a) immortalized human mammary fibroblasts and (b) tumour 
epithelial cells (MCF-7). The unaltered endothelial cells, HMME 2 and HMME 7 
produced very similar results. Taken at *80 magnification.
In contrast both unaltered and immortalized endothelial cells differentiated and 
produced capillary structures when cultured on GFR Matrigel in the presence of 
either fibroblasts or tumour (Figure 3.17), suggesting that the addition of the 
tumour cells/fibroblasts provided the necessary factors to promote endothelial 
cell differentiation. Therefore, the presence of tumour cells/fibroblasts had a 
stimulatory influence on endothelial cell differentiation. A point of note is that in 
this experiment the tumour cells/fibroblasts were in direct contact with the 
endothelial cells.
In summary, the immortal human mammary endothelial cells displayed 
the same differentiation characteristics and properties as the unaltered endothelial
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cells on Matrigel. Fibroblasts and tumour epithelial cells provided the necessary 
growth supplements lacking in GFR matrigel to promote endothelial cell 
differentiation. Tumour-stromal stromal interactions were key to providing the 
necessary support.
3.5 Cell labelling
3.5.1 Introduction
The aim of this section was to investigate cell labelling techniques and systems 
in order to select a suitable system for identifying live individual cell types in 
mixed populations of stromal and tumour cells in in vitro cell culture 
experiments. In addition to identifying different cell types, the dyes would be 
used to assist in the clarification of cell position in relation to each other. Success 
would allow us to follow the different live cell types in heterologous co-culture 
experiments, endothelial cell differentiation assays, heterologous co-culture 
spheroids and more importantly xenograft studies.
To serve as an effective tracer of cell morphology or location, a probe 
must have the capacity for localized introduction into a cell or organelle and 
subsequent long term retention within that structure. The tracer should also be 
biologically inert. Ideally cells should remain viable for at least 24 hours after 
loading and persist through several cell divisions so they can be utilised for in 
vivo studies.
The cellular labelling ability of two different classes of dyes was 
investigated. These were the cytoplasmic (CellTracker™) and membrane 
(Vybrant lipophilic) labelling dyes. To test the manufacturer’s claims, together 
with a view to using in in vitro and in vivo location studies, a series of
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experiments were devised to assess the duration of labelling and to determine 
whether, as claimed, all dyes would stably label individual cells and would not 
be transferred to adjacent cells by release and re-uptake. (See Chapter 2.4 for 
details of labelling)
3.5.2 CellTracker™ dyes
The first experiment used cytoplasmic CellTracker™ dyes as they should 
produce stronger fluorescence compared with the membrane labelling dyes. 
CellTracker™ dyes are reported by the manufacturer (Molecular Probes) to be 
retained in living cells through several generations and also inherited by daughter 
cells after cell division (Cumberledge and Krasnow 1993). These dyes contain a 
chloromethyl group that reacts with thiols, probably in a gluthathione S- 
transferase-mediated reaction. The reagents diffuse freely through the 
membranes of live cells. Once inside the cell, these probes undergo a reaction to 
produce a membrane-impermeant glutathione-fluorescent dye adduct, although 
other experiments suggest that they may also react with other intracellular 
components (Zang et al. 1992). Furthermore, unlike the free dyes, the peptide- 
fluorescent dye adducts contain amino groups and can therefore be covalently 
linked to surrounding biomolecules by fixation with formaldehyde or 
glutaraldehyde.
To investigate the ability of these dyes to provide a reliable method of 
cellular labelling for the tracing of the three cell types in mixed in vitro cell 
cultures and eventually in an in vivo setting the studies described below were 
performed.
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Three different cell types, MCF-7, HMF 3wt and HMME 7wt, were each 
loaded with the orange CellTracker™ CMTMR (5-(and-6)-(((4- 
chloromethyl)benzoyl)amino) tetramethylrhodamine)) or green CellTracker™ 
dyes CMFDA (5-chloromethylfluorescein diacetate), one at a time (see Chapter 
for 2.4.1). They were then cultured in their respective growth medium and 
examined at 1, 3, 5, 7, 10, 12 and 14 day time points to assess their fluorescence 
intensity. This was undertaken at two different cell densities: cells plated at 
confluency and non confluent rapidly proliferating cells to assess how much cell 
division diluted fluorescence intensity.
Using the fluorescein filter set on the fluorescence microscope, both 
green CellTracker™ and orange CellTracker™ could be detected with the cells 
showing diffuse cytoplasmic staining with both dyes (Figure 3.18).
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A) Orange CellTracker
B) Green CellTracker
Figure 3.18. HMME 7wt endothelial cell line labelled with (a) the orange 
CellTracker™ and (b) HMF 3wt fibroblast line labelled with the green 
CellTracker™. Images taken at day 2 post labelling at *80 and *160 magnification.
Fluorescence intensity was stably maintained for 5 days but after this time staining 
decreased rapidly until by 14 days it was barely visible (Figure 3.19). Colour 
intensity decreased much more rapidly in non-confluent rapidly dividing cells in
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comparison to slowly dividing confluent cells and by 5 days fluorescence intensities 
were very low, compared with confluent cells.
14 days
5 days 14 days
Figure 3.19. (a) Green CellTracker™ labelled HMF 3wt fibroblast line at different 
time points, (b) Orange CellTracker™ labelled HMME 7wt endothelial cell line at 
different time points. Difference in fluorescence intensity is dramatic with endothelial 
cells barely visible after 15 days. Images taken *160 magnification.
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The ability of the two CellTracker™ dyes to be retained without leakage or transfer 
in a mixed population of cells was tested as follows. Two different cell types (5xl04 
of endothelial cells and fibroblasts) were plated on a coverslip in 24-well plates, one 
previously labelled with a dye and the other unlabelled. The labelled cells had been 
thoroughly washed to remove any excess un-incorporated dye. The combined cells 
were cultured for 5 days and then examined. Each cell type could be identified by its 
characteristic morphology (Figures 18 & 19).
Figure 3.20. Leakage of the orange CellTracker™ from endothelial cells to 
surrounding unlabelled fibroblasts. Taken at *80 ar>d *160 magnifications.
187
Figure 3.21. Leakage of the green CellTracker™ from fibroblasts to surrounding 
unlabelled endothelial cells. Taken at *80 magnification.
The orange (Figure 3.20) CellTracker™ dye can be seen to be released from the 
endothelial cells labelling adjacent fibroblasts whilst the green CellTracker™ dye 
(Figure 3.21) can be seen labelling adjacent endothelial cells.
To examine whether dye transfer occurred by direct cell-cell contact or 
by simple leakage and re-uptake a second experiment was carried out. Medium 
from CellTracker™ labelled cells that had been cultured for 5 days were added to 
non-labelled cells and cultured for 2-3 days. These cells were then examined to 
determine whether they had taken up dye from the conditioned medium.
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Figure 3.22. Staining of unlabelled endothelial cells from conditioned medium 
harvested from orange Celltracker™ labelled fibroblasts. Cells were incubated for 
48 hours. Taken at *80 magnification.
Medium harvested from orange Celltracker™ labelled cells did stain unlabelled 
cells, whereas medium from the green CellTracker™ labelled cells resulted in 
minimal staining.
In summary, therefore while green CellTracker™ did provide a stable 
marker for the cells tested, the orange CellTracker™ did not. Therefore, a 
combination of these two cytoplasmic dyes is not an effective means of 
following differently labelled cells for more than 5 days.
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3.5.3 Fluorescent lipophilic membrane dyes
Cell membranes provide a convenient conduit for loading live and fixed cells 
with lipophilic dyes. Not only can cells tolerate a high concentration of dye, but 
lateral diffusion of the dye within the membrane can serve to stain the entire cell, 
even if the dye is applied locally. Lipophilic carbocyanine tracers like Dil 
(Vybrant Cell-Labeling Solutions) are claimed to be ideal labels for long-term 
cell tracing in vivo and in vitro, including studies of cell migration and 
transplantation. Dil labelling does not appreciably affect cell viability, 
development or basic physiological properties (Honig and Hume 1986, Honig 
and Hume 1989). A range of long-chain dialkylcarbocyanines with a variety of 
spectroscopic and cellular labelling properties; DiO, DiL and DiD were tested 
(emission spectre shown in Chapter 2.4).
The same methods used to assess the CellTracker dyes were adopted to 
assess the suitability of the lipophilic membrane dyes for labelling fibroblasts 
and endothelial cells. DiO (green) could be detected using the fluorescein optical 
filter set on the fluorescence microscope. Dil (orange) and DiD (red) dyes could 
be detected with the rhodamine optical filters. All cells showed homogenous 
membrane staining after 40-60 minutes staining with all these dyes. Again 
fluorescent intensity was stably maintained for 5 days but after this time staining 
decreased rapidly until by 14 days it was barely visible. Colour intensity 
decreased much more rapidly in non-confluent rapidly dividing cells in 
comparison to slowly dividing confluent cells.
All three tracers demonstrated equal stability displaying similar 
characteristics in regards to retention, leakage and re-uptake. MCF-7, HMF 3wt 
and HMME 7wt did show detectable uptake from dye present in the conditioned
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medium from labelled cells, but to a much lesser extent compared with the 
orange CellTracker. No one dye emerged as being superior to the others. In 
conclusion the red emitting DiD tracer could be effectively used with the green 
CellTracker™ for in vitro co-culture studies of up to 5 days duration. The 
red/green combination was selected as it was more easily visualized than a 
green/blue pairing.
Dyes Duration of 
constant level 
of
fluorescence
Retention Leakage
CMFDA
CellTracker™
(green)
5days + + + +
CMTMR
CellTracker™
(orange)
5days + + +  +
DiD (red)
5days + + + +
DiO (green)
5days + +  + +
Dil (orange)
5 days + +  + +
Table 3.6. Table summarizing the properties of the various cell labelling dyes 
tested. Emission colours are shown in brackets.
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3.6 Conclusion and discussion
3.6.1 Growth assays and transformation
Cells can become immortal as the result of transformation in vivo, spontaneous 
immortalization and by in vitro manipulation of normal cells to generate cell 
lines. However spontaneous immortalization of adult human cells is very 
infrequent (less than one in 109 cells). Therefore genetic manipulation of normal 
cells is necessary to generate human cell lines. The acquisition of an unlimited 
proliferative potential defined as true immortality is probably a critical step 
during tumourigenesis often associated with several genetic alterations (e.g. 
expression of the ras oncogene). The study of immortalization and other 
alterations associated with neoplastic transformation of mammary stromal cells is 
important to understanding the development of human mammary tumours. 
Because stromal cells are important regulators of associated epithelial cells, 
alterations in the regulation of stromal cell proliferation that influence epithelial 
cells may also contribute to the development of mammary carcinomas. To study 
the phenotypic alterations associated with immortalization on the growth 
properties of human mammary stromal cells, established human mammary 
stromal cells immortalized with SV40 Large T antigen and hTERT were used. 
Role of SV40 LT antigen in cellular transformation
SV40 large T antigen (LT) is a powerful oncoprotein capable of transforming a 
variety of cell types (Hahn et al. 1999, Bryan and Reddel 1994). The 
transforming activity of LT is due in large part to its ability to bind and inactivate 
the retinoblastoma (pRB) and p53 tumour suppressor proteins (Ozer 2000). 
These two tumour suppressor pathways are also perturbed in the majority of 
human cancers through mutation and methylation of the genes controlling
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various components of these pathways (Levine 1997, Sellers and Kaelin 1997). 
Consequently, expression of the LT antigen can lead to the transformation of a 
cell from a normal to a growth-deregulated state. Alterations in growth suggest 
modifications in growth regulation, caused by changes in growth factor 
sensitivity, or increased autocrine productions of growth factors (see Table 3.2). 
Changes in growth properties, in vitro, associated with transformation towards a 
tumourigenic phenotype are often indicative of a more robust phenotype. 
Weinberg (2002) reported that in addition to the disruption of pRB and p53 
tumour suppressor pathways, complete transformation of some human cells 
required the additional perturbation of protein phosphatase 2A by small T 
antigen. Expression of ST in this setting stimulated cell proliferation, permitted 
anchorage-independent growth, and conferred increased resistance to nutrient 
deprivation. These facts begin to clarify and even delineate a set of intracellular 
pathways whose disruption, in aggregate, appears to be necessary to generate 
tumourigenic human cells.
Therefore, as SV40 LT immortalization is involved in the process of 
transformation, immortal cells would be expected to have altered properties 
(inactivation of pRB and p53 among other things). In addition, immortalization 
achieved with SV40 large T antigen can also introduce variability into cell lines 
both as a consequence the site of integration of the LT antigen gene into the host 
cell genome and also the number of copies integrated. Integration may disrupt or 
deregulate normal gene function, while the copy number determines the level of 
SV40 large T expression. SV40 large T antigen itself is transforming if present at 
high levels, and results in the genetic instability of cell lines (Chang 1986).
The fact that SV40 Large T antigen itself can be transforming dependent 
on the level of its expression is now well recognised. Low levels are required for
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immortalization while high levels are required for transformation (Price et al. 
1994, Stewart and Bacchetti 1991, Ray et al. 1990). Price et al. (1994) compared 
the effects of low and high levels of T antigen expression in human fibroblasts. 
High levels of LT antigen expression resulted in cultures with a high rate of 
proliferation, an extended in vitro life span, a loss of contact inhibition of growth 
and a morphology characteristic of SV40-transformed cells. Low but detectable 
levels of the LT protein was accompanied by a 50% or greater reduction in the 
proliferative rate and restoration of cell morphology and contact inhibition 
similar to that found in non-transfected cells. These results demonstrate that low 
amounts of LT antigen are sufficient to maintain cell viability and prevent the re­
expression of the senescent phenotype seen in the absence of LT antigen. 
Similarly, the ability of LT antigen to extend the in vitro life span is not 
dependent on high level expression of LT antigen. In contrast, the rate of 
proliferation of human cells as well as the cell morphology and contact inhibition 
are dependent on the amount of LT antigen present. Many of the cellular effects 
can be minimised or reversed by reducing LT antigen expression.
Furthermore, LT binds to several other cellular factors, interacting with 
and perturbing the function of proteins that are components of other cellular 
regulatory circuits (Ali and DeCaprio 2001, Flint and Shenk 1997, Pipas and 
Levine 2001). These include the transcriptional co-activators p300 and the 
related protein CBP, which may contribute to its transformation function (Eckner 
et al. 1996, Avantaggiati et al. 1996). Several other features of LT that appear to 
contribute to its full transformation potential are yet to be completely understood. 
Therefore, as the human mammary stromal cells studied were immortalized by 
SV40 LT (with hTERT), a certain level of genetic instability and phenotypic 
variability is to be expected.
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Growth assays
The main purpose of this chapter was to determine how closely the immortalized 
stromal cell lines behaved in comparison to unaltered cells derived from primary 
cultures. This was in order to assess which of the immortalized cell lines, alone 
or in conjunction with the tumour cell lines, could provide the best model system 
for future in vivo experiments.
The significantly increased growth rates, a criterion of transformation in 
vitro, of the immortalized cells in comparison to the unaltered cells suggest that 
they must have adopted or changed to a more robust phenotype. The 
immortalization process had partially transformed/altered the stromal cell lines 
(fibroblast and endothelial cells) enhancing their growth properties to provide a 
significant growth advantage in vitro. A possible reason for the difference in 
growth rates may be attributed to cells being grown at different temperatures and 
thus having different metabolic rates. However, even when the temperature 
sensitive cell lines were grown at a lower temperature (33.5°C) than the 
unaltered cells (37.5°C) they still had greater growth rates.
In addition to the increased growth rate, the growth factor dependency of 
all the immortalized endothelial cells was significantly less than the unaltered 
cells at normal serum levels. Furthermore, the wild type LT variant HMME 7wt 
was even less dependent than the two temperature sensitive cell lines HMME 2 
and 7. However, at low serum concentrations (0.02% v/v) all the immortalized 
endothelial cells behaved in a manner very similar to the unaltered endothelial 
cells. With the absence of dead cells and cellular debris in the serum dependent 
growth assays on microscopic examination, the difference in growth rates 
between the cell lines can be confidently attributed to be differential growth 
rather than differential survival due to cell death. Hie immortalized fibroblasts
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lines also demonstrated reduced growth factor sensitivity with growth factors 
producing a minimal effect in comparison to the unaltered fibroblasts at normal 
serum concentrations. In contrast, the immortalized stromal cell lines also 
displayed properties consistent with normal cells such as anchorage-dependent 
growth and endothelial cell differentiation on Matrigel.
To summarise the results, all the immortalized stromal cell lines tested 
had undergone partial transformation evident from the results of the growth 
assays. All the fibroblast and endothelial cell lines were passaged in excess of 
100 population doublings without evidence of cell senescence or crisis. The 
enhanced ability of the immortalized stromal cells to grow in vitro may suggest a 
higher chance of survival as well as enhanced growth when xenografted in vivo.
In order to define the effect the immortalization process had on the 
transformation status of each of the cell lines an attempt at a semi-quantitative 
analysis was carried out using the in vitro criteria of transformation previously 
listed in Table 3.2. Each criterion was assigned an arbitrary numerical score 
dependent on the degree of transformation. The higher the score obtained, the 
closer the cells were deemed to be to the fully transformed phenotype. Thus, 
fully transformed cells with a tumourigenic phenotype in vivo would be assigned 
a score of 5, while cells deviating from normal with an enhanced growth rate 
would be scored as 1. Intermediate values were assigned to other in vitro 
transformation characteristics. In compiling the final score the highest numerical 
score was summated with all the lower scores as the acquisition of a strong 
transformation phenotype (i.e. anchorage independent growth) is usually 
associated with concurrent expression of all the weaker features. Although not 
tested in all cases this was seen to be the case with the cell lines tested, for 
example HMF 3wt ras.
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Criteria of transformation in vitro T ransformation 
score
I) Increased growth rate 1
II) Growth factor insensitivity 
NORMAL SERUM
1
III) Growth factor insensitivity 
LOW SERUM
2
IV) Higher confluent density (loss of contact 
inhibition of growth)
2
V) Cellular overlapping (loss of contact 
inhibition of movement)
2
VI) Loss of serum dependence 3
VII) Acquisition of anchorage independent 
growth (high colony formation in soft agar)
4
VIII) Ability to produce tumours in 
immunodeficient mice
5
Table 3.7. Arbitrary numerical scoring system to grade transformation
Immortalized stromal cells T ransformation
score
NORMAL CELLS 0
Unaltered fibroblasts- HMME
Unaltered fibroblasts- HMF
HMF 3A 4
HMF 3B
HMF 3D (Positive for
HMF 3wt criteria I, II &
IV)
HMME 7
HMME 7wt
HMME 2 6
(Positive for
criteria I, II III
&IV)
HMF 3C (at late passage >60PD) 15
HMF 3wt ras
(Positive for
criteria I-VII)
TUMOUR CELLS 20
Table 3.8. Assessment of cellular transformation. Cells and ranked by summating 
the transformation score (Table 3.7).
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Figure 3.23. Diagrammatical representation of the transformation status of each of 
the immortalized human mammary stromal cells. The immortalized stromal cell lines 
demonstrated some of the hallmarks of transformed cells such as enhanced growth 
rates and reduced growth factor sensitivity at normal serum concentrations.
With the exception of HMF 3C and HMF 3wt ras, the remaining cell lines 
showed a similar transformation status; this phenotype being much closer to the 
normal phenotype than a fully transformed tumourigenic phenotype (Table 3.8 
and Figure 3.23). However, although the remaining cell lines were transformed 
to a similar ‘degree’ they each also had subtle differences which made then 
unique. For example, HMF 3D lost their temperature sensitivity at late passage 
whereas HMF 3B did not express temperature sensitivity from the outset even 
though they were transduced with tsLT. HMF 3A and HMF 3wt, however, 
remained stable even at late passage (>100PD). HMF 3C as mentioned before 
was transformed at late passage to an anchorage independent phenotype. Also the 
cell lines differed in their growth factor sensitivities. For example, the wild type
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LT variant HMF 3wt demonstrated reduced growth factor sensitivity in 
comparison to the tsLT transduced fibroblast lines.
With the endothelial cell lines the wild type LT variant HMME 7wt 
demonstrated significantly enhanced growth rates followed by the HMME 2 cell 
line with HMME 7 having the slowest growth rate. Both HMME 7 and HMME 
7wt demonstrated reduced growth factor sensitivity at normal serum 
concentrations, however they behaved in a similar manner to the unaltered 
endothelial cells at low serum concentrations demonstrating growth factor 
responsiveness. HMME 2, by contrast, showed little evidence of growth factor 
responsiveness at normal and even low serum concentrations. These individual 
characteristics clearly demonstrate that these lines do differ even though the 
differences may be small.
In summary, the immortalized stromal cell lines displayed some of the 
hallmarks of transformation in vitro, although they also retained many of the 
characteristics of normal cells. Therefore, although they can not be regarded as 
normal cells they are also by no means fully transformed. In fact they were much 
closer phenotypically to normal cells than fully transformed cells. The results in 
this chapter also demonstrate that the each of immortalized human mammary 
stromal cell lines tested was unique, with each possessing slightly different 
phenotypic properties. Therefore one can conclude that the characteristics of the 
cell lines were not just a manifestation of LT antigen expression alone, but had 
gained other additional properties which made then individual.
Thus it seems we have useful cell lines: cells that possess an immortal 
growth potential which function essentially like normal cells without being fully 
transformed into tumourigenic phenotypes. They can therefore provide a readily 
available source of essentially normal human mammary stromal cells potentially
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able to support a tumour microenvironment when xenografted in vivo. They thus 
provide a valid model for more complex culture systems and in vivo experiments. 
However, with the results available it was not possible to select a particular cell 
line as being better suited or a superior model for future in vivo studies. Their 
individual characteristics meant that each would have to be tested separately.
3.6.2 Tumour-stromal interactions
In the mammary gland, mesenchymal-epithelial interactions are of paramount 
importance during normal development and tumourigenesis (Cunha 1994, 
Silberstein 2001, Bissell and Radisky 2001). Positive regulation of normal and 
tumoural mammary epithelial cell proliferation by fibroblasts in co-culture are 
now well recognised. A number of published studies have provided evidence that 
stromal and epithelial components surrounding tumour cells are undoubtedly 
involved in tumour growth regulation and differentiation. The stromal-tumour 
co-culture experiments in this chapter were carried out to determine whether the 
immortalized stromal cells function like normal stromal cells in their interaction 
with tumour cells. As shown in the results (Chapter 3.3.1) the interaction of all 
the stromal cells with the tumour lines were similar, with no obvious distinction 
between either normal unaltered fibroblasts and immortalized lines, on the one 
other hand, or between immortalized lines and a ras transformed variant on the 
other.
Results from the co-culture experiments showed that the tumour-stromal 
interactions were on the whole inhibitory. Increasing concentrations of the breast 
tumour cell line, MCF-7, produced increasing inhibition of both the unaltered 
and wild type LT variants of the immortalized endothelial cells and fibroblasts.
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Three different well established breast tumour cell lines acted in a similar manner 
also inhibiting both the unaltered and immortalized stromal cell lines. Even the 
VEGF over-expressing cell line MCF-7 V12 failed to stimulate the unaltered and 
immortalized endothelial cells. Furthermore, the stromal cell lines inhibited the 
growth of the 4 tumour breast cell lines when co-cultured in a similar manner. 
Both the unaltered fibroblasts and the transformed HMF 3wt ras fibroblast cell 
line inhibited tumour cell line growth. In addition, from investigation of 
fibroblast-endothelial cell interactions, it was found that the fibroblasts inhibited 
the endothelial cells whereas the endothelial cells greatly stimulated the 
fibroblasts (see Figure 3.15). The latter result demonstrates that growth 
stimulation can be detected with the chosen growth assay.
The results of the present study are contrary to current general 
perceptions which are that stromal-tumour interactions have a stimulatory effect 
on growth both in vitro (van Roozendaal et al. 1992, van den Hoof 1991) and in 
vivo (Shekhar et al. 2001). Several studies have shown that stromal-tumour 
interactions promote growth, differentiation and also invasion of human 
mammary tumour cells when studied in co-culture experiments similar to those 
carried out here (Ronnov-Jessen et al. 1995, Schor et al. 1994, Camps et al. 
1990). Furthermore there are numerous studies comparing normal and tumour 
associated stroma, in particular fibroblasts, showing that in most cases both have 
a stimulatory influence on tumour cell proliferation and differentiation (van 
Roozendaal et al. 1996, Lefebvre et al. 1995, Gache et al. 1998, Ryan et al. 1993, 
Adam et al. 1994). Therefore the present results are not consistent with the 
majority of similar experiments. However it is worth noting that none of the 
above studies involved SV40 LT expressing stromal cell lines. In one study 
however (Dong-Le Bourhis et al. 1997), it was claimed that normal fibroblasts
inhibited tumour growth while tumour associated fibroblasts had no effect. 
Details of studies are shown in Table 3.9.
The experimental protocol used here was carefully defined to exclude 
factors and conditions which could have resulted in non-specific effects. For 
example cultures were inspected on a daily basis for signs of apoptosis, over 
confluency and extreme media conditions such as over-acidity. Medium was 
changed daily or as required. Experiments were repeated three times and gave 
similar results. In the present study the unaltered stromal cells (both fibroblasts 
and endothelial cells) from primary cultures also inhibited the growth of the 
mammary tumour cell lines and therefore it appears that the effects observed here 
are not solely associated with LT expressing cells.
202
Reference Target cell Cell-cell
contact
Effect
Fibroblast
type
Normal, 
immortalized 
& transformed 
cell lines
Present study MCF -7, 
MCF-7 V I2, 
T47D, ZR- 
75-1
No, co-culture 
insert system
All types 
inhibitory
Normal &
tumour-
associated
Valenti et al. 
2001
MCF -7 No,
conditioned
media
Both types 
stimulatory
Normal &
tumour-
associated
Gache et al. 
1998
MCF -7, 
MDA- 
MB231, 
T47D, and 
BT-20
No, co-culture 
insert system
Both types 
stimulatory
Normal &
tumour-
associated
Dong-Le 
Bourhis et 
al.1997
MCF -7 No, co-culture 
insert system
Normal-
inhibitory,
tumour
associated-no
effect
Normal &
tumour-
associated
Lefebvre et al. 
1995
MCF -7 Yes Both types 
stimulatory
Normal &
tumour-
associated
van
Roozendaal et 
al. 1996
MCF -7 No,
conditioned
media
Both types 
stimulatory
Normal &
tumour-
associated
Adam et al. 
1994
MCF -7 No, co-culture 
insert system
Both types 
stimulatory
Table 3.9. Studies that have examined fibroblast/mammary tumour cell 
interactions using co-culture systems. This study and those referenced are listed.
However, some studies do report inhibitory effects similar to the present study. 
Dong-Le Bourhis et al. (1997) demonstrated that fibroblasts originating from 
normal breast tissue inhibited the proliferation of MCF-7 cells in co-culture 
experiments, while serum free conditioned medium produced by primary stromal 
cells did not affect MCF-7 cell growth. These results suggest that epithelial 
cancer cells could induce, through the secretion of diffusible factors, normal
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fibroblasts to produce tumour growth inhibitory factors. Indeed, it has been 
reported that TGF-B released from tumour associated fibroblasts induces 
production of short-lived apoptosis-inducing factors in normal fibroblasts 
(Jurgensmeier et al. 1994, Wehrle et al. 1994). The apoptosis inducing signal in 
turn acts specifically on tumour cells leading to apoptosis. It was proposed that 
this complex and dynamic interaction may constitute a growth regulatory 
mechanism whereby normal stromal elements react to the presence of tumour 
cells and contribute to the repression of tumourigenesis.
The comparison in effect between normal and carcinoma associated 
fibroblasts on tumour cells are often carried out as part of the same experiment 
(see Table 3.9). Dong-Le Bourhis et al. (1997) reported that when fibroblasts 
from tumour tissue were used no effect was observed on the proliferation of 
MCF-7 cell in co-culture experiments. Lefebvre et al. (1995) used direct co­
culture experiments allowing membrane contacts between the different cell types 
and showed stimulation of tumour growth. Thus, a possible reason for the 
discrepancy in results found in this chapter with those reported may be due to the 
fact that the immortalized stromal cells required actual physical contact in order 
to provide growth stimulation. The cells in the present study are not in direct 
physical contact but communicate through free exchange of growth and other 
soluble factors. These data suggest that, unlike normal tissue derived fibroblasts, 
tumour tissue derived fibroblasts as well as partially transformed fibroblasts may 
require cell-cell contact in order to act upon the proliferation of breast cancer 
epithelial cells. Direct contact may be a crucial criterion for promotion of growth 
and differentiation. Otherwise, as shown in our results, factors that inhibit tumour 
growth may be dominant.
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However, Gache et al. (1998) studied the paracrine growth regulation of a 
variety of breast epithelial cells in co-culture with normal and tumour associated 
breast fibroblasts. They showed that all fibroblasts stimulated the proliferation of 
the hormono-responsive breast carcinoma MCF-7 cell line, suggesting that cell 
contacts were not indispensable for the paracrine stimulation of MCF-7 cell 
growth by fibroblasts. Moreover, the proliferation of a variety of other breast 
carcinoma cells (MDA-MB231, T47D, and BT-20) was also stimulated by 
fibroblasts. However, the amplitude of the proliferative response seemed to be 
dependent on the carcinoma cell line considered. Furthermore, the proliferative 
response of normal mammary epithelial cells to the presence of fibroblasts was 
shown to be significantly higher than the tumour cell response. The nature of the 
tissue of fibroblast origin, normal or tumour did not influence the growth 
response of the epithelial cells, in this study.
To investigate the disparity in results between the present study and the 
various other studies the method of co-culture was examined and compared. 
Factors such as length of experiment period, size of membrane pores, method of 
assessing cell numbers, medium used, cell numbers used and also the stage of 
cell growth could affect the outcome of the study. For example, the cell number 
used as well as the stage of growth, whether cells are proliferating or nearing 
senescence will affect cell-cell interactions. Gache et al. (1998) used a near 
identical cell co-culture method as the present study also using culture inserts 
with 0.4mm pore sizes. Cells were only co-cultured for 2 days in a serum-free or 
a 5% FBS-supplemented DMEM/F12 culture medium. Passage numbers were 
not stated, but the study suggests primary cultures with low passage numbers 
were used. A constant number of epithelial cells (5x 103—1 x 104 cells/cm2) was 
seeded either alone or in the presence of a constant number of fibroblasts
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according to a fibroblast/epithelial cell ratio of 2. Cell proliferation was evaluated 
by measuring the incorporation of 3H-thymidine.
Dong-Le Bourhis et al. (1997) who produced similar results as the present 
study plated 5x103 epithelial cells on the membranes with 5xl03- 5xl04 stromal 
cells in the lower chamber in a 10:1 fibroblast/MCF-7 ratio (same as present 
study). No pore size was stated. Both cell types were plated in DMEM/F12 
culture medium containing 10% FCS which was changed every other day. Cell 
proliferation was evaluated by measuring the endogenous lysosomal 
hexosaminidase or the incorporation of 3H-thymidine. Passage numbers were not 
stated, but the study suggests primary cultures of early passage were used. Cells 
were co-cultured for 8 days (similar experiment period). This co-culture 
experiment is much closer to the one used in this chapter. Hence it may explain 
why a similar set of results were obtained.
The effect of tumour cells on the growth of stromal components is not 
very well described in the literature. In one reported study Valenti et al. (2001) 
showed that conditioned medium (CM) from the MCF-7 cell line induced 
myofibroblastic differentiation as defined by increased smooth muscle actin 
formation, decreased cell proliferation, and increased apoptosis in cultured 
normal fibroblasts but not in fibroblasts from malignant breast tissue. These data 
suggest that structural and functional differences exist between stromal 
fibroblasts from normal breast and breast cancer with respect to the 
responsiveness to soluble factors present in the CM. They hypothesized that the 
lack of in vitro sensitivity to CM shown by tumour fibroblasts was the result of 
an in vivo inherent and stable phenotypic change on the fibroblasts surrounding 
breast tumour cells occurring via a paracrine mechanism. This study provides
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evidence of tumour cell inhibition of normal fibroblast growth as found in the 
present study.
The present study also investigated tumour-endothelial growth 
interactions something, as far as we are aware, that has not been previously 
reported as distinct from effects on differentiation (i.e. tubule/vessel formation). 
Again mutual inhibitory effects were observed. Moreover, the investigations of 
stromal-stromal interactions described in this chapter involving fibroblasts and 
endothelial cells are unique. The growth of the unaltered fibroblasts HMF, 
immortalized fibroblast line HMF 3wt and the fully transformed ras transfected 
fibroblast cell line HMF 3wt ras were all stimulated by the presence of 
endothelial cells (both immortal and unaltered cells) in the co-culture 
experiments. However this stimulation was not bi-directional, as the unaltered 
and immortalized endothelial cells were inhibited by the 3 different fibroblasts 
mentioned above.
Overall the inhibitory effects observed in the study did not differ 
markedly between the different cell lines and therefore the experiments did not 
assist in selecting any specific line as more appropriate for in vivo studies.
3.6.3 Live cell labelling
Testing of cell labelling systems for the identification of different viable cell 
types in mixed populations of cells was not successful in that no one reliable long 
term labelling system was identified. The cellular labelling ability of two 
different classes of dyes, the cytoplasmic (CellTracker™) and membrane 
(Vybrant lipophilic) labelling system was investigated. Results showed that the 
all the dyes failed to provide an adequate level of cellular labelling in vitro after a
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period of 5 days. However, the green CellTracker™ and red emitting DiD did 
provide a reliable method for labelling and separating two different cell types. 
Many previous studies using these dyes have been limited to hours or at most 2-3 
days (Duffield et al. 2001, Kespichayawattana et al. 2000, Finnegan et al. 2001). 
As these dyes have been shown in the present study to be reasonably stable for 
up to 5 days, the problems encountered in the present study may have not 
occurred in the shorter time frame. However the longer term loss of staining 
intensity and transfer of dye noticeably with the orange CellTracker™ clearly 
precludes their use in longer term xenograft studies.
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Chapter 4 
Interaction of human and mouse endothelial 
cells in vitro
4.1 Introduction
For human tumour cell xenografts to survive and proliferate they must acquire a 
blood supply. It is well recognised that host derived vasculature provides this 
function. Recently, with the ability to incorporate human endothelial cells 
directly into xenograft models we can now determine whether these human 
endothelial cells can form the necessary vasculature alone or whether they 
cooperate with the host vascular system to form a chimeric vasculature. In other 
words do human endothelial cells interact with mouse endothelial cells in vitro to 
form organized structures -  immature capillary networks. Successful integration 
of human and murine cells in vitro will allow us to further analyse the 
mechanism of complex vascular organization as well as develop pre-engineered 
vascular beds that can be used to perfuse transplanted human tissue.
It has been reported that human endothelial cell capillary 
networks/tubules formed in vitro when implanted in vivo (SCID mice) connect 
with mouse vessels to become perfused by the mouse circulation (Schechner et 
al. 2000, Nor et al. 1999, 2000, 2001). Human dermal microvascular endothelial 
cells transplanted into SCID mice on biodegradable polymer matrices 
differentiated into functional human microvessels that anastomosed with mouse 
vasculature (Nor et al. 2001). A matrix of collagen type 1 and human fibronectin 
supported the organization of human endothelial cells into primitive capillary 
like structures by 18-24 hours in culture and led to the development of human
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endothelial cell lined microvessels perfused by mouse circulation after 
implantation. No significant mouse neo-vascularization or inflammation was 
associated with these constructs, indicating that a suitable balance had been 
achieved between sustaining human vessels and minimizing the host response. 
The human endothelial cells became invested by perivascular smooth muscle a- 
actin-expressing mouse cells 21 days after implantation. However, apoptosis of 
the primary endothelial cells was a problem in these studies. We therefore tested 
whether the potentially more stable immortalized human mammary endothelial 
cell lines could provide a better system to utilize in the formation of chimeric 
vasculature.
Mouse endothelial cells have in the past proven difficult to isolate and 
maintain in culture. The most useful techniques have either involved the infusion 
of target organs with digestive enzymes or the digestion and/or homogenization 
of an entire organ (O’Connell and Edidin 1990, DeBault et al. 1979). These 
methods are technically demanding and time consuming and generally yield 
relatively impure endothelial cells populations. Consequently, overgrowth of 
contaminating non-endothelial cells may occur in culture. In addition, a large 
number of mice are required for these endothelial cell preparations. Recently, 
methodological advances, such as the use of flow cytometry and Dynabeads 
together with monoclonal antibodies or appropriate lectins, have provided new 
ways to improve the purity of endothelial cell cultures (Sahagun et al. 1989, 
Jackson et al. 1990). However, these cell separation techniques have rarely been 
used to isolate mouse endothelial cells directly from tissue homogenates 
(Modzelewski et al. 1994). On top of this, long-term maintenance of normal 
mouse endothelial cells remains a difficult task. As an alternative, 
immortalization (e.g. with the polyoma middle-sized T antigen, PmT) has been
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used to obtain mouse microvascular endothelial cultures from different tissues 
(Garlanda et al. 1994, Williams et al. 1988, Hahne et al. 1993). However, these 
immortalized mouse cells are transformed and tumourigenic and can differ 
considerably from their normal counterparts, as illustrated, for instance, by recent 
results of in vitro versus in vivo expression of the long pentraxin PTX3 
(prototypic acute phase reactants that serve as indicators of inflammatory 
reactions). PTX3 expressed by normal mouse endothelial cells in vitro and in 
vivo in response to inflammatory cytokines/markers was not expressed by 
transformed endothelial cells (Introna et al. 1996). Immortomouse (Jat et al. 
1991, Noble et al. 1995) endothelial cell lines could have been used in the 
construction of chimeric vessels in vitro, however it was decided to use normal 
mouse endothelial cells despite the labour isolating them, because they would be 
the best model for the interaction of human endothelial lines with hosts cells in 
vivo.
The aim of this section of the experimental programme, therefore, was to 
isolate fresh mouse endothelial cells to determine whether human endothelial 
cells, in the form of immortalized endothelial cell lines, can interact with mouse 
endothelial cells in vitro to form organized structures (i.e. immature capillary 
networks).
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4.2 Isolation, culture and characterization of mouse 
endothelial cells
4.2.1 Isolation of mouse endothelial cells
A quick and efficient magnetic bead separation protocol outlined by Dong et al. 
(1997) was adopted and modified for the isolation of micro vascular endothelial 
cells from mouse tissues as described in Chapter 2.3.1.
In brief, the lungs and hearts from 8 mice were dissected out, minced into 
small pieces (1 x 1mm squares) and digested in collagenase. The digested mix 
was then filtered to obtain a cell suspension ready for Dynabead 
immunomagnetic separation. The cell suspension was mixed with sheep anti-rat 
IgG coated Dynabeads bound to a rat anti-mouse PEC AM-1 monoclonal 
antibody (MEC13.3, BD Pharmingen) for affinity binding.
Although precise cell numbers were not determined at this stage the size 
of the visible cell pellet isolated indicated that >106 cells were potentially 
present. The isolation procedure was attempted 3 times with similar results. Each 
time the lungs and hearts of 8 mice, using mouse specific anti-CD31 conjugated 
Dynabeads, provided a small yield of approximately 1 x 104- 5 x 104 rosetted cells 
representing <1% of the initial digested cell suspension. The rosetted cells were 
lightly trypsinised to remove the Dynabeads. The immunomagnetically sorted 
cells were then cultured.
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Figure 4.1. Dynabead rosettes of mouse microvascular endothelial cells labelled 
with an anti-mouse CD31 (arrows). M agnification ><220
4.2.2 Culture of freshly isolated mouse endothelial cells
Immunomagnetically separated cells using the Dynabead separation method were 
plated in a 25cm2 tissue culture flask containing 7ml of a specialized medium 
consisting of DMEM supplemented with 2mM glutamine, lOOU/ml penicillin, 
lOOpg/ml streptomycin, ImM sodium pyruvate, 20mM HEPES, 1% non- 
essential amino acids, 50mM 2-mercaptoethanol, freshly added 20% (v/v) heat 
inactivated FCS, 150pg/ml endothelial cell growth supplement and 12U/ml 
heparin (Marelli-Berg et al. 2000). They were cultured in either fibronectin 
(1 mg/ml) or 2% (w/v) gelatin coated tissue culture flasks (see Chapter 2.2.1) at 
37°C in a humidified atmosphere with 5% (v/v) CO2.
Following isolation, trypsinisation and culture the cells initially attached 
and formed clusters which then spread out over 24-48 hours (Figure 4.2a) and
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proliferated until they formed confluent monolayers within 10-14 days (Figure 
4.2b). At this stage they showed contact inhibition of growth and the 
‘cobblestone’ morphology also seen with primary human endothelial cell 
cultures. When confluent the mouse endothelial cells were serially sub-cultured 
by detaching from the culture flasks using a solution of 0.125% (w/v) bovine 
trypsin in 0.02% (w/v) EDTA and then re-passaged at a ratio of 4:1. In some 
experiments, enzyme free cell dissociation solution was used. This method 
involved washing twice with PBS containing 0.02% (w/v) EDTA and 
mechanically disrupting the monolayer by gentle tapping of the tissue culture 
flasks. In total the cells lasted for 3-4 months in culture, arresting after about 10 
passages.
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Figure 4.2. Phase contrast micrographs of the Dynabead sorted mouse 
microvascular endothelial cells in culture at 2 (a) and 14 (b) days. Following plating 
and two days in culture in th e  m edium  d esc rib ed  above  m o u se  m icrovascular 
endothelial cells fo rm ed ch a rac te ris tic  'sp in d le  s h a p e d ’ cells (a) before a typical 
cobblestone m orphology w a s  o b se rv e d  a t co n flu en ce  14 d a y s  (b), also  s e e n  with 
primary hum an endothelial cells. M agnification *80 (left) and  *160 (right).
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4.2.3 Characterization of mouse endothelial cells
To confirm that the cells were truly differentiated endothelial cells and not 
simply contaminated with other cell types, cells harvested between passages 4-10 
were immunophenotypically characterized. The mouse specific endothelial 
marker PECAM-1/CD31 that was originally used to sort the cells was used to 
label the mouse endothelial cells after they been in culture for between 14 and 50 
days. Visualization was carried out by indirect immunofluorescence using 
secondary antibodies conjugated with either a FITC or TRITC fluorophore. 
Results are shown in Figure 4.3. Similar positive labelling of almost all cells 
(>95%) was observed with all cultures tested between passage 4 and 10. Previous 
chapters have demonstrated that this mouse specific anti-CD31 antibody was a 
reliable method of identifying mouse endothelial cells and vasculature in vivo. As 
confirmation of their mouse origin, Hoechst 33258 nuclear stain produced the 
characteristic punctuate staining pattern of this species (Figure 4.3d).
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Figure 4.3. Immunofluorescence labelling of mouse endothelial cells using the 
mouse specific anti-CD31 antibody. Cells tha t had been  in culture for 21 days 
(passage 1) w ere labelled using a rat anti-m ouse CD31 m onoclonal antibody (FITC & 
TRITC secondaries) (a-c). H oechst 33258 nuclear staining of m ouse endothelial cell (d) 
- note the punctuate nuclei which a re  unique to  m ouse cells differentiating them  from 
human cell nuclei. Magnification a)*220, b)*220, c)*180, d)*220.
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4.3 Human and mouse endothelial cell differentiation 
assays
In order to investigate the interaction between human and mouse microvascular 
endothelial cells in an in vitro environment a simple differentiation assay was 
performed. Mouse endothelial cells that had been isolated from mouse tissues 
and cultured in vitro for between 21-35 days (as described in Chapter 4.2) were 
labelled using an orange CellTracker™ dye (see Chapter 2.4.1). The wild type 
human mammary endothelial cell line HMME 7wt was labelled with the green 
CellTracker™ dye. Although these dyes (in particular the orange CellTracker™) 
were not suitable for long term studies (see Chapter 3.5.2) the present experiment 
involved labelling of short term cultures only. Roughly equal numbers (5><104) of 
both labelled cells were then plated on prepared Matrigel in 24 well-plates and 
incubated at 37°C in a humidified atmosphere with 5% (v/v) CO2 under a light 
microscope. Sequential images were then captured at 30 minute intervals for over 
a 24 hour period using an automated time lapse camera.
Collation of all the images showed that the human and mouse endothelial 
cells do interact and integrate with each other to form primitive micro-capillaries. 
Results are shown in Figures 4.4a-d.
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B)
C)
(See next page for figure legend)
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Figure 4.4. Immunofluorescence and brightfield images of chimeric capillary like 
networks formed by human and mouse endothelial cells. Human mammary 
endothelial cell line HMME 7wt was labelled with the green CellTracker™ dye whilst 
mouse endothelial cells were with labelled orange CellTracker™. Images on the left are 
fluorescence and on the right their corresponding brightfield images, (a) shows the two 
differently labelled cells plated on Matrigel. (b) & (c) are images taken after 24 hours of 
incubation on Matrigel. The two cell types have clearly integrated to form primitive micro­
capillaries. Magnification *80.
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When initially plated the individual cells could be seen labelled green or orange 
(Figure 4.4a). Both cell types commenced aggregation within 1 hour and by 12 
hours had formed long capillary like extensions (Figures 4.4b and c). 
Intermingling of both cell types followed by combined capillary network 
formation was then evident. On formation o f capillary like networks, mouse and 
human endothelial cells could be clearly identified throughout the capillary 
networks as separately coloured cells. This experiment was repeated three times 
using mouse endothelial cells at a similar passage number from three different 
Dynabead sorts. Unfortunately as expected from previous results (Chapter 3.5.2) 
clear separation of labelling disappeared soon after this time, although the 
primitive capillary like structures did persist for several days (Figure 4.5).
Figure 4.5. Phase contrast and darkfield images of primitive networks of 
microcapiilaries consisting of both human (HMME 7wt) and mouse endothelial 
cells after 3 days of culture on Matrigel. M agnification *80
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4.4 Conclusion and discussion
A modification of Dong et al. (2000)’s method for isolating mouse 
microvascular endothelial cells from mouse tissue provided a quick and an 
efficient method of producing a pure population of mouse microvascular 
endothelial cells. The resulting endothelial cells produced a good source of viable 
cells for further in vitro studies.
Results from the differentiation assays on matrigel showed that human 
and mouse endothelial cells do interact in vitro to differentiate and form micro­
capillary like networks. These results are very promising as they suggest that the 
xenografted immortalized human mammary endothelial cell lines could interact 
with mouse endothelial cells in vivo and hopefully integrate into the vasculature 
of the proposed heterologous xenograft models.
The major limitation encountered with the construction and maintenance 
of human synthetic microvessels in vitro and in vivo has been the apoptosis of 
cultured human endothelial cells (Ilan et al. 1998). Both Schechner et al. (2000) 
and Nor et al. (1999) noticed the increasing presence of mouse microvessels in 
the implants over time. This was probably attributable to the fact that some of the 
endothelial cells underwent apoptosis, because transduction of endothelial cells 
with a modified (caspase-resistant) form of Bcl-2 protein delayed apoptosis 
allowing the consistent incorporation into the mouse circulatory system with an 
increased density of human cell-lined vessels. With our readily available source 
of immortalized human mammary endothelial cells this problem could be 
reduced by the greater robustness of the cell lines as compared with primary 
cells. Furthermore, it would be relatively straightforward to introduce a stable 
Bcl-2 over-expression in such lines if necessary. Due to the immortality of the
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endothelial cell lines they should persist indefinitely as immortal cells. 
Incorporation of such human endothelial cell lined microvessels into our 
proposed 3-D organotypic breast tumour xenograft model may therefore improve 
tumour viability and proliferation. Successful integration of human and mouse 
cells will allow us to further analyse the mechanism of complex vascular 
organization as well as develop engineered vascular beds that can be used to 
perfuse transplanted human tissue.
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Chapter 5 
Three-dimensional heterologous co-culture 
models
5.1 Introduction
To investigate the pathobiology of human breast cancer, it is necessary to 
maintain or recreate the characteristic three-dimensional (3-D) architecture of the 
tumour tissue in culture. More specifically, to create 3-D heterologous in vitro 
co-cultures involving tumour cell interaction with stromal cells; endothelial cells, 
fibroblasts and immunocompetent cells. In previous years the study of normal 
human breast physiology and breast cancer has been significantly impaired by 
limitations inherent to available model systems, specifically two-dimensional 
models (2-D).
2-D monolayer culture models are easy and convenient to set up with 
good viability of cells in culture but they lack the 3-D microenvironment of 
intact tissue. In contrast organ cultures have a ready made tumour 
microenvironment which remains intact. This is of vital importance as cell-cell, 
cell-matrix interactions and interstitial fluid affect differentiated cell function 
within the 3-D environment. However organ culture is not without its own 
problems; with difficulty in obtaining specimens and poor viability of the tissues 
in culture being major obstacles.
The concept of the multicellular tumour spheroid was developed to 
overcome this very problem. Spheroid cultures mimic both the 3-D organization 
and differentiated function of intact tissues to a much greater extent than cell 
monolayers (Becker et al. 1993). Multicellular tumour spheroids were
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specifically manufactured for cancer research and for the testing of the effects of 
radiation (Wheldon 1994) and new chemotherapeutic agents (Mueller-Klieser 
1997, Yuhas et al. 1978). They were generally formed from robust tumour cell 
lines which aggregated homotypically to produce solid tumour cell spheroids 
(Yuhas et al. 1977). They probably grew well in avascular conditions as they 
were originally from anoxic tumours.
With recent advances in 3-D cell culturing techniques, spheroid-like 3-D 
heterologous in vitro co-culture systems can now be manufactured. With these 
individually designed models many important variables can be accurately 
controlled (e.g. cell types, numbers and experiment duration). These model 
systems can in principle reproducibly reflect the distinct invasive behaviour of 
breast tumour cells, mimic the tumour-stromal cell interactions of breast 
carcinomas and allow for systematic investigation into the multiple unknown 
regulatory feedback mechanisms between breast tumour and stromal cells in a 
well defined 3-D environment (Petersen et al. 1992, Bergstraesser and Weitzman 
1993, Kunz-Schughart et al. 2001). Multicellular tumour spheroids have a well 
organized spherical symmetry of morphological and physiological features 
including complex cell-cell and cell-matrix interactions resembling avascular 
tumour sites and or micrometastatic regions in vivo and thus are a very useful 
model in tumour biology (Sutherland 1988).
In principle, 3D spheroids can be manufactured either by exploiting 
spontaneous cell aggregation, generating more or less spherical cellular 
conglomerates, or by culturing cells on artificial substrates that induce cellular 
differentiation and maintain cellular function. Cells can either adhere to each 
other (homotypic aggregation) or other cells (heterotypic aggregation) as well as 
to endothelial cells and exposed basement membrane. Some breast cancer and
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breast cell lines will spontaneously aggregate during cell culture, to form tissue­
like spheroids. For example, it is well documented that the human breast 
carcinoma cell line MDA-MB-435 undergoes homotypic cell aggregation 
(Glinsky et al. 2000) and the breast carcinoma cell line DU4475 grows in 
suspension to form clusters and cords which are attached chiefly by desmosomes 
(Langlois et al. 1979).
The aim of this chapter was to investigate which of the available tissue 
culture techniques was most suitable to manufacture a 3-D heterologous spheroid 
using the immortalized stromal cells as components. Therefore having selected, 
tailored and optimised the most suitable technique the final goal was to recreate a 
heterologous spheroid model closely resembling a ‘metastatic avascular in vivo 
tumour’ to xenograft into immunodeficient mice. If successful the advantages of 
this specific model will be two-fold. Firstly the spheroid will consist of both 
human tumour and stromal cells and secondly, the problem of cell dispersion on 
injection in vivo can be overcome by maintaining cells in close proximity. 
Furthermore tumour-stromal interaction within these heterologous tumour 
spheroids should provide the immortalized human mammary stromal cells with 
the best possible chance of survival and proliferation, not only in vitro but also in 
vivo.
To assist in the manufacture of heterologous spheroids in the present 
study, using immortalized human stromal cell lines, several different techniques 
were successively tested. These were a) use of microcarrier beads, b) liquid 
overlay cultures, c) 3-D biodegradable pre-engineered scaffolds and d) the 
Rotary Cell Culture System (RCCS). It may also be advantageous to use a 
combination of techniques to produce the best results.
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Microcamer beads were introduced to provide support as the tumour and 
stromal cell lines used depended on attachment and did not spontaneously 
aggregate. Also they provided an effective vehicle to improve the culture of 
sensitive cell lines (e.g. endothelial cells) (Bing et al. 1991, Davies 1981) which 
requires specialized conditions to grow. In addition microcarrier beads provided 
an effective way in which to culture different cell types in close proximity. The 
large surface area to volume ratio together with their variety of substrate coatings 
allows cells to proliferate on microcarrier beads in effect creating mini-spheroids. 
As will be shown these seeded microcarrier beads can then adhere to each other 
and form larger spheroid-like structures.
Liquid overlay culture is a relatively old technique which has been widely 
used in the past to generate and study a small numbers of spheroids. By culturing 
cells on an attachment limiting surfaces such as agar, cell-cell aggregation is 
promoted over cell-substratum attachment thus promoting spheroid formation 
(Yuhas et al. 1977). It therefore provides the simplest way of culturing a small 
number of spheroids.
The RCCS is a new and innovative form of optimized suspension culture 
which is designed to mimic microgravity to maintain cells in fluid suspension 
under very low-shear stress conditions (Hammond and Hammond 2001). 
Accordingly, the RCCS largely solves the problems of suspension culture: to 
suspend cells and microcarriers without inducing turbulence, or high degrees of 
shear, while providing adequate nutrition and oxygenation. Due to its low-shear 
and low-turbulence environment it minimizes mechanical cell damage and allows 
dissociated cells to assemble into high fidelity 3-D tissue aggregates, several 
millimetres in size which are largely devoid of necrotic cores, thereby promoting
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cellular differentiation (Hammond and Hammond 2001, Unsworth and Lelkes 
1998).
3-D pre-engineered scaffold serves as a 3-D physical support matrix for 
in vivo cell culture. In essence it simulates the structural and functional role of 
the ECM and its molecules. This method is not a technique to produce spheroids 
as such but it constituted an alternate way of manufacturing a 3-D heterologous 
tumour model for xenograft experiments. In addition, while microcarrier beads 
are inert and stable, these 3-D scaffolds are biodegradable once xenografted in 
vivo and so can help support the creation of a 3-D structure before eventually 
disappearing.
5.2 Microcarrier beads
5.2.1 Introduction
The use of microcarrier beads has provided many advantages to cell culture 
(Clark and Hirtenstein 1981). Conventionally microcarrier bead cultures involve 
growth in rotating vessels to assist in mixing and providing nutrition. A higher 
surface area to volume ratio can be achieved which can be varied by changing 
the microcarrier bead concentration. This leads to high cell densities per unit 
volume with the potential for obtaining higher cell concentrations. Cell 
propagation can be carried out in a single high productivity vessel instead of 
using many low productivity units, thus achieving a better utilization and a 
considerable saving of medium (Gao et al. 1997). Since the microcarrier culture 
is well mixed, it is easy to monitor and control the different environmental 
conditions such as pH, p02, PCO2 etc. In addition, given that the beads settle
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down easily cell sampling, cell harvesting and downstream processing of 
products are easy.
Several factors affect cell adhesion and attachment. The surfaces on 
which the cells are grown as well as the cells themselves are at a physiological 
pH and have either a net negative or a positive charge. The charge density on 
these surfaces rather than their polarity is responsible for attachment and 
spreading o f cells. Cell adhesion also depends on a functional contractile system 
and is mediated by specific cell surface receptors (Hirtenstein et al. 1980). It 
involves multiple contacts with the surface where numerous filopodia are 
formed. They fit into a lattice structure formed by the glycoproteins on the 
substratum. This is followed by cytoplasmic webbing and flattening of the cell 
mass. In this way the cells get attached onto the substratum (Hirtenstein et al. 
1980). Once the cells have attached onto the microcarriers, they grow using the 
nutrients provided in their culture medium. The complexities of this culture 
system are mainly due to the large number o f  parameters affecting cell yield 
(Clark et al. 1980). Medium composition now assumes importance since it 
contains the carbon and nitrogen source, the energy source, growth factors and 
dissolved oxygen and other gases. Besides nutrient limitation, growth of cells is 
also affected by the accumulation of toxic metabolites. Other important 
considerations are environmental factors like pH  and temperature and shear 
sensitivity of the cells, especially in case of microcarrier cultures employing 
spinner bottles (Clark et al. 1980, Clark and Hirtenstein 1981).
A large variety of microcarrier beads are currently available (eg. 
positively-charged DEAE or trimethyl-2-hydroxyaminopropyl groups) in 
different sizes ranging from 95-210pm. The dextran Cytodex 3 (size 133- 
215pm) microcarrier beads coated with denatured porcine-skin collagen bound to
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surface was used. This type was specifically chosen as it was designed to culture 
hard-to-grow cells.
5.2.2 Results
For microcarrier bead seeding, 5 x 106 cells of each type (MCF-7, MHF 3wt and 
HMME 7wt) were added to 5ml of bead containing solution (1.5 x 105) 
separately. The beads and cells were transferred to a 125ml Wheaton Magna Flex 
Spinner Flask, containing 75ml of complete medium, and incubated under 
constant stirring at 30 revolutions per minute (rpm) in a humidified atmosphere 
of 5% (v/v) CO2 at 37°C overnight to attach. The medium was replaced with 
fresh medium every fourth day by letting the beads settle and changing 50ml of 
medium. To add cells in free suspension 5 x 106 of the required cells were 
counted and added to the pre-seeded microcarrier beads in the rotating Spinner 
flask.
To create heterologous co-culture spheroids, cells were added either in 
free cell suspension, as pre-seeded microcarrier beads or using a combination of 
both methods. All the combinations summarized in Tables 5.1a-c were cultured 
for 14 days. In addition a further experiment was carried out in which each cell 
type was used separately to coat a microcarrier bead suspension, and all three cell 
coated microcarrier beads were then mixed in equal proportions and cultured in 
the spinner flask. The following observations were made following their 
preparation by examining them microscopically at daily intervals.
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A)
MCF-7 (CS) HMF 3 wt (CS) HMME 7wt (CS)
MCF-7 (MCB) N/A + +
HMF 3 wt 
(MCB)
+ N/A +
HMME 7wt 
(MCB)
+ + N/A
B)
HMME 7wt (CS) 
+
HMF 3wt (CS)
HMF 3 wt (CS)+ 
MCF-7 (CS)
HMME 7wt (CS) 
+ MCF-7 (CS)
MCF-7 (MCB) + N/A N/A
HMF 3 wt 
(MCB)
N/A N/A +
HMME 7wt 
(MCB)
N/A + N/A
C)
MCF-7 (MCB) HMF 3 wt 
(MCB)
HMME 7wt 
(MCB)
MCF-7 (MCB) N/A + +
HMF 3 wt 
(MCB)
+ N/A +
HMME 7wt 
(MCB)
+ + N/A
Tables 5.1A-C. Table summarizing the combinations of cells used to form 
spheroids. Cells were added either as a free cell suspension (CS) or as cells seeded on 
microcarrier beads (MCB).
Cells when added as a free suspension to the rotating Spinner flasks containing 
pre-seeded microcarrier beads attached to the beads within 12-24 hours. Cells 
originally observed to be in free suspension in the liquid medium at one hour 
post seeding were not visible after 12-24 hours, indicating that they had attached 
to other cells or to microcarrier beads (Figure 5.1).
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Figure 5.1. Microcarrier beads (Cytodex 3, size 133-215 pm). Brightfield mage shows 
microcarrier beads seeded with fibroblasts (HMF 3wt). Arrows point to cells attached to 
the surface of the microcarrier beads. Taken at ><320 magnification.
No one particular combination resulted in a noticeable difference in the rate of 
growth or size of spheroids produced. Initially single or small clusters of pre­
seeded microcarrier beads adhered to other microcarrier beads resulting in 
progressively larger clusters of seeded microcarrier beads (Figure 5.2). 
Progressive increase in the size of these spheroid clusters, when observed daily 
over the 14 day experiment period, under the microscope, indicated that at least 
one of the cell types proliferated when cultured on microcarrier beads. However 
the spheroids broke up into smaller fragments at variable time points leading to 
smaller spheroids. This continued in a cyclical manner, with repeated 
aggregation followed by separation.
As a result of repeated aggregation followed by separation the number 
and size of spheroids obtained after 14 days of culture was too small to utilize as
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xenografts. Thus in an attempt to stabilize the aggregation o f  microcarrier bead 
they were next used in combination with liquid overlay cultures, rather than in 
free suspension.
&
Figure 5.2. Heterologous spheroids manufactured from co-cultures of microcarrier 
beads separately seeded with MCF-7 cells, HMF 3wt and HMME 7wt cell lines at 14 
days. Note the cells binding the microcarrier beads together. Brightfield images taken at 
*80 (left) and *160 (right) magnifications.
5.3 Liquid overlay cultures
5.3.1 Introduction
There has been extensive research describing the mechanisms by which 
the structural architecture o f spheroids induces cell differentiation; increased 
cell-cell and cell-matrix interactions, changes in cell shape, and the development 
of a rich interstitial fluid within cell multilayers which are essential in this regard 
(Durand 1990, Sacks et al. 1989). In contrast, the underlying mechanisms 
governing spheroidal formation remain poorly understood. Many seemingly
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promising cell lines are later found to be unable to self-assemble into spheroids 
(Sutherland 1988).
The simplest method of promoting spheroidal growth is liquid-overlay 
cultures. For cells to grow as 3-D aggregates or spheroids they require conditions 
in which the adhesive forces between the cells are greater than for the substrate it 
is plated on. Cell suspensions are grown in a static culture over an attachment 
limiting surface as agarose or agar (Yuhas et al. 1977). Liquid overlay techniques 
achieve this condition by reducing matrix deposition stimulated by contact with a 
flat surface. This promotes cell-cell attachment over attachment to the substratum. 
With this technique many tumour cell lines will undergo spontaneous homotypic 
aggregation. Spheroid formation can even be induced in tumour cells that do not 
spontaneously aggregate or are difficult to aggregate when cultured in free 
suspension. Essentially, spheroid formation in liquid-overlay cultures follows a 
biphasic process; firstly cells migrate towards each other on the agar and 
aggregate into spheroids. Secondly cell growth results in an increase of spheroid 
size. Cells do not adhere to the substratum but grow and aggregate on it.
Although liquid overlay culture is a relatively old method of 
manufacturing spheroids, with more advanced forms of culturing techniques 
available, they were utilized because they may be more advantageous in 
culturing individual 3-D heterologous spheroids. It was envisaged that a single 
carefully cultured spheroids may be adequate to produce a tumours when 
xenografted into mammary fat pads.
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5.3.2 Results
Two different substrates were used to were used to construct the liquid overlay 
cultures; agar which inhibits substrate attachment and reconstituted basement 
membrane extract matrigel which allows attachment and movement of cells. The 
three cell types were cultured either by plating on or mixing in with one of the 
two different substrates. In a second series of experiment cells were pre-seeded 
on microcarrier beads prior to culture as described in Chapter 5.1. Again these 
were cultured both on and in the two different substrates.
For cultures with cells seeded in the substrates, cell suspensions (approx. 
1 x 104 cells) or pre-seeded microcarrier beads (1 x 104 cells seeded on 5 x 103 
beads) were added and mixed with the substrates (500pl) before being applied to 
a 24-well plate and allowed to gel. Then 2ml of growth medium was added to 
produce the liquid overlay. Following an overnight incubation, medium were 
replaced daily thereafter. For extended cultures (>2 weeks); a further 2 ml of 
fresh medium was added on the second day. This allowed for replacement of 
spent medium at the air liquid interface without disturbing the cellular layer on 
the gel surface.
For culture on the surface of the substrates the above method was 
repeated this time with cells or seeded microcarrier beads plated on the surface 
rather than mixed with the substrates. Both groups were cultured for 14 days.
Following culture several attempts, using various different methods, were 
made at harvesting these 3-D heterologous co-cultures to analyze their cell 
composition and architecture.
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Liquid overlays using agarose
The three cell types when plated on agarose commenced aggregation after 48 
hours by forming loose cell aggregates/clusters. They aggregated very slowly 
taking between 3-7 days to form loose cell clusters, however they did not 
resemble the tight compact architecture of spheroids. The use of microcarrier 
beads did not significantly enhance cell aggregation. Liquid overlays on agarose 
did not produce suitable spheroids for harvesting or xenografting.
Liquid overlays using Matrigel
As an alternative to agar Matrigel was used. This is not an attachment limiting 
substrate but it did promote the aggregation of cells as described. Cells when 
cultured on Matrigel as a mixed cell suspension commenced spheroid formation 
within 24-48 hours. Cells moved along the Matrigel to aggregate into solid 
spheroid like structures with very few free cells remaining un-aggregated. 
Although spheroids did form with and without microcarrier beads, spheroids 
formed with the aid of microcarrier beads were in general larger, faster growing 
and more structurally robust (Figure 5.3).
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Figure 5.3. Brightfield images of heterologous tumour spheroids (containing MCF- 
7, HMF 3wt and HMME 7wt cell lines) manufactured in liquid overlay cultures (A & 
B) and with the aid of microcarrier beads (C & D). Images taken at ><80 and ><160 
magnifications at various time points. Spheroids manufactured with microcarrier beads 
are larger at similar time points as well as being more differentiated demonstrated by 
larger visible sprouting of capillary like vascular structures. Arrows point to capillary like 
structures growing out from the spheroids formed from differentiated human mammary 
endothelial cells.
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Culturing cells, with and without microcarrier beads, in Matrigel produced 
spheroids earlier (24-36 hours), compared to agarose, with larger overall 
spheroid sizes reached. However as expected, the total overall number of 
spheroids produced per well, in both groups, were low (<10/well). Only 
spheroids grown in Matrigel showed evidence of endothelial cell differentiation 
by the large number of capillary like sprouting from the spheroid edges. 
Harvesting spheroids
Three different methods were devised to harvest the heterologous spheroids from 
the matrigel cultures for more detailed histological analysis. The first attempt 
involved emptying the microwells of medium and fixing in formaldehyde 
followed by manually scooping out visible spheroids using a small spatula. This 
method was very labour intensive. However, the greatest problem faced was in 
handling these very fragile and unstable structures. Even the slightest trauma 
would disrupt and disaggregate the spheroids. The second method involved 
cryopreserving the microwell plates, containing the spheroids in the substrate, by 
placing in an -80°C freezer. Although both the agarose and matrigel froze into a 
solid form they were too soft to obtain good quality frozen sections. The third 
method involved encasing the spheroids in hot agarose which gelled to form a 
very hard solid block and then cryopreserving this block to cut under a 
microtome. In order to obtain a sufficiently hard agarose block for sectioning, a 
greater weight per volume of agarose was required (>35% w/v agarose). To 
solubilize such a high agarose content high temperatures (>95°C) were required 
which resulted in thermal damage to the spheroids.
To summarize liquid overlay cultures are well recognised as a method to study 
small numbers of spheroids as opposed to an efficient method of manufacturing 
lots of spheroids. However spheroids manufactured in this way did not have the
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necessary density of cells and/or the structural stability to be used as xenografts. 
Therefore, although relatively simple to manufacture, liquid overlay culture did 
not represent an efficient way of manufacturing 3-D heterologous spheroids for 
xenografting.
5.4 Prefabricated 3-D scaffolds
5.4.1 Introduction
Recently 3-D, biodegradeable, pre-engineered scaffolds have been introduced as 
an improved method of simulating the extracellular matrix (ECM) and providing 
physical/structural support (Figure 5.4). These structures consist of natural 
molecules (collagen composite) or synthetic polymers (D, D-L, L polylactic acid) 
that can be used as a 3-D physical support matrix for in vitro cell culture (Martin 
et al. 1998, Wei Tan et al. 2001) as well as in vivo tissue regeneration (Evans et 
al. 1999, Saito et al. 2001). They function as temporary scaffolds that maintain 
transplanted cells in a defined space and therefore guide new tissue growth and 
organization. They bring great potential in recreating the natural physical and 
structural environment of living tissue (Wei Tan et al. 2001). This is of great 
advantage as ECM molecules have been shown to promote signalling pathways 
that influence key cell functions such as migration, proliferation and 
differentiation. Currently they present one of the most promising experimental 
approaches for regenerating the native structural and functional properties of 
living tissue.
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Figure 5.4. 3-D biodegradable pre-engineered scaffolds. Im a g e s  a re  of a  BD™
T hree  D im ensional O p en -C e ll P o ly lactic  Acid (OPLA ® ) S caffo ld . An o p en -ce ll face tted  
arch itec tu re  is e ffec tive  for culturing  high d en s ity  cell s u s p e n s io n s .  T hey  a re  
approxim ately  5m m  x 3m m  x 0 .0 3 9  c m 3 in s iz e  with a n  a v e r a g e  p o re  s iz e  of 100-200  pm. 
They w eigh 3 .5m g w h en  dry  a n d  h a v e  th e  c a p a c ity  to  a b s o rb  25p l to  g ive a  final w et 
w eight of 45  mg. (Im a g e s  ta k e n  from  BD B io sc ie n c e s)
These scaffolds have been reported to be beneficial in the long-term growth and 
differentiation of a variety of cell types, including epithelial cells e.g.hepatocytes 
(Takezawa et al. 2000), neurons, endothelial cells (Sheridan et al. 2000), 
osteoblasts (Malekzadeh 1998), chondrocytes, (Chu et al. 1997) fibroblasts, and 
smooth muscle cells (Kim et al. 1999). Since tissue and organ function are 
dependent on the presence of an appropriate population of differentiated cells, a 
considerable amount of research has been focused on the development of 3-D 
culture systems for the expansion and differentiation of pluripotent stem cells 
(Solchaga et al. 1999). Recent studies have shown that human microvascular 
endothelial cells transplanted in sponges into SCID mice have been shown to 
organize and differentiate into functional microvessels that anastomose with 
mouse vasculature and become functional human microvessels containing mouse 
blood cells (Schechner et al. 2000, Nor et al. 2000).
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As far as we are aware, there have been no reported studies of human 
breast epithelial cells or tumour cell lines being cultured in these scaffolds. The 
aim of this section was to culture human breast tumour cell lines together with 
human stromal cells in these scaffolds to promote cell differentiation and 
interaction. If successful the ultimate goal was again to transplant these seeded 
scaffolds, which should be more structurally stable than aggregates of cell 
suspensions with and without microcarrier beads, into the mammary fat pads of 
immunodeficient mice to create more realistic xenograft models. Once the 
seeded scaffolds had established the scaffolds should then degrade slowly 
leaving a well differentiated organotypic tumour.
5.4.2 Results
Scaffolds were seeded using two methods: still and dynamic. For the still seeding 
method a cell suspension containing approximately 5.0 x 104-  2.5 x 105 cells (of 
each cell type) in 250pl o f growth medium was added to a scaffold (see Table
5.2 for combinations). The seeded scaffolds were transferred to 96-well plates 
containing 250pl of growth medium. In some experiments the seeded scaffolds 
were coated in matrigel or serum. For dynamic seeding, the seeded scaffolds 
were incubated with gentle agitation (-50-100 rpm) on an orbital shaker at 37°C 
in a gassed incubator for between 2-24 hours depending on the cell type. After 
incubation with agitation was completed, the seeded scaffolds were gently placed 
into a well of a 96-well plate containing 250pl of medium for the remainder of 
the experiment.
Seeded scaffolds were also placed in Matrigel, to further promote growth 
and differentiation. 5.0 X 104 cells were seeded onto the scaffolds using the
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dynamic seeding method and then mixed with 300pl of Matrigel before being 
solidified in wells of a 48-well plate. Liquid overlays were made as described in 
Chapter 2.6.2. Medium was changed every other day. The cells seeded in the 
scaffolds are shown in Table 5.2. At fixed time points (1 and 3 weeks) scaffolds 
were removed and fixed in 4% (w/v) formaldehyde for sectioning and 
histochemistry (Figure 5.5).
Combination of 
cells
In growth medium In Matrigel
1 MCF-7 MCF-7
2 MCF-7 + HMF 3wt MCF-7HMF 3wt
3 MCF-7 + HMME 7wt MCF-7 HMME 7wt
4 MCF-7 + HMME 7wt 
+ HMF 3wt
MCF-7 + HMME 7wt 
+ HMF 3wt
5 MCF-7 V 12 MCF-7 V I2
6 MCF-7 V12+HMF 3wt MCF-7 V12+HMF 3wt
7 MCF-7 V12 + HMME 7wt MCF-7 V12 + HMME 7wt
8 MCF-7 V I2 + HMME 7wt 
+ HMF 3wt
MCF-7 V12 + HMME 7wt 
+ HMF 3wt
Table 5.2. Table summarizing the different combinations of cells seeded on the 
scaffolds. Scaffolds were either cultured in growth medium or in Matrigel for 1 or 3 
weeks. The experiment was repeated at least 3 times with sim ilar results.
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Results from H&E labelling of formaldehyde fixed paraffin embedded scaffolds 
showed no significant difference in cell density between the different 
combinations (Figure 5.5).
Figure 5.5. H&E sections of 3-D scaffolds, seeded with MCF-7, HMF 3wt and 
HMME 7wt cell lines, after 3 weeks in culture. H&E sta in ing  show ed tha t th e  cells 
proliferated in th e  scaffo lds. C ells a re  clearly  visible in th e  cen tre  of th e  scaffolds 
(arrows). Taken a t ><80, *160 an d  ><320 m agn ifica tions respectively.
Furthermore, Matrigel did not provide an observable promotion of cell 
proliferation. H&E sections showed that both in Matrigel and in liquid medium, 
cells were located in the centre of the scaffolds. This was evident by the roughly 
even distribution of cells throughout the scaffold. The densities of cells present in
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the 1 week and 3 week harvested scaffolds were very similar indicating that the 
cells had not significantly proliferated. The density of cells observed in the H&E 
sections at 3 weeks was not as great as that had been reported in other cell types 
(Takezawa et al. 2000, Kim et al. 1999) expected although a quantitative test was 
not performed. The physical structure of the scaffold was still very much intact 
with no evidence of degradation in vitro at 3 weeks. In summary, the scaffolds 
did not provide evidence of adequate cell proliferation or cell aggregation to be 
used as transplantable 3-D heterologous models.
5.5 Rotary cell culture system
5.5.1 Introduction
The NASA developed Rotary cell culture system (RCCS) introduces a 
revolutionary concept in tissue engineering (Figure 5.7). This device provides a 
relatively quiescent environment for 3-D spheroid cell culture with adequate 
mixing for mass transport. By simulating microgravity, cells are maintained in a 
dynamic fluid suspension in liquid media mixed by minimal hydrodynamic 
forces. A culture flask (vessel) rotates whole on its horizontal axis, providing end 
over end mixing of the cells. Fluid turbulence and shear forces are minimized by 
the vessel being completely filled with media and providing aeration through a 
semi-permeable membrane which eliminates bubbles producing hydrodynamic 
forces. Therefore this system successfully integrates cellular co-localization, 3-D 
stromal/epithelial/matrix interactions, and low shear forces.
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Figure 5.6. Operation of the RCCS. T h e  cylindrical c u ltu re  v e s s e l  is filled with cu ltu re  
m edium , an d  th e  ce lls  o r  t i s s u e  p a r tic le s  a r e  a d d e d . All a ir b u b b le s  a r e  re m o v e d  from 
the  cu ltu re  v e s se l. T h e  v e s s e l  is a t ta c h e d  to  th e  ro ta to r  b a s e  a n d  ro ta te d  a b o u t th e  
horizontal ax is (p o w er su p p ly  n o t sh o w n ). C ell a g g r e g a te  p a r tic le s  e s ta b l ish  a  fluid orbit 
within th e  cu ltu re  m ed iu m  in th e  ro ta tin g  v e s s e l .  T h e y  d o  n o t co llide  with th e  w alls o r an y  
o ther p a rts  of th e  v e s s e l .  A s 3-D  t i s s u e s  g ro w  in s iz e , th e  ro ta tio n  s p e e d  is a d ju s te d  to 
c o m p e n sa te  for th e  in c re a s e d  se ttlin g  r a te s  of th e  la rg e r  p a rtic le s . T h e  t is s u e  p artic les  
do m ove en o u g h  w ithin th e  fluid c u ltu re  m e d iu m  to  e x c h a n g e  n u tr ie n ts , w a s te s ,  an d  
d isso lved  g a s e s  a n d  m a k e  c o n ta c t  w ith o th e r  t i s s u e  p a rtic le s . T h e  ce lls  a n d /o r  t is su e  
particles join to  form  la rg e r  t i s s u e  p a r tic le s  th a t  c o n tin u e  th e  d iffe ren tia tion  p ro c e s s . 
O xygen supp ly  a n d  c a rb o n  d io x id e  rem o v a l a r e  a c h ie v e d  th ro u g h  a  g a s -p e rm e a b le  
silicone ru b b e r m e m b ra n e .
Studies have shown that reduced turbulence has profound effects on the physical 
properties of a culture. The spheroids produced were not only larger in size, but 
they were significantly more differentiated than those produced in spinner flasks 
(Goodwin et al 1993, Cherry and Kwon 1990, Croughan and Wang 1991). This 
is a great advantage as higher fluid turbulence in the spinner flask has been 
shown to damage fragile animal cells affecting membrane integrity and 
metabolism (Goodwin et al. 1993). Another advantage of the rotary cell culture 
system is the ability to co-culture multiple cell types in forming 3-D in vitro
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structures. To assist in 3-D structuring, inert scaffold material such as 
microcarrier beads coated in various substrates can be used (Meaney et al. 1998). 
By co-localizing cells in 3-D for an extended period of time, there is an 
opportunity to build tissue with characteristics and differentiation phenotypes 
that are very much different to that grown in 2-D.
5.5.2 Results
Once again, human mammary tumour (MCF-7, T47D, MCF-7 V I2) and stromal 
cell lines (HMME 7wt, HMF 3wt HMF 3wt ras) were either pre-seeded on 
microcarrier beads or mixed as cell suspensions, before being placed in the 
RCCS.
To culture the three different cell types as a cell suspension, 5 x 106 cells 
of each cell type were inserted into either a 50ml or 10ml cylindrical culture 
vessel. The combinations used are summarized in Table 5.3. This was then filled 
completely with growth medium (EGM-2 bullet kit) and then rotated about the 
horizontal axis. Cells were cultured for fixed time points (7 or 14 days) or 
alternatively until the desirable spheroid sizes were manufactured. Spheroids 
meeting the size criteria (l-4mm) were carefully removed from the culture vessel 
through access ports using a syringe. Spheroids were either fixed in 4% (w/v) 
formaldehyde or snap frozen for histology. They were also used for further 
cultures in liquid overlay systems and in vivo xenograft studies. The 
cryopreserved and formaldehyde fixed spheroids were processed for 
immunohistochemistry as described in Chapter 2.7.
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HMF
3wt
HMF 
3wt ras
HMME 
7 wt
HMF 
3wt + 
HMME 
7 wt
HMF 3wt 
ras + 
HMME 
7 wt
MCF-7 + + + + +
MCF-7
V12
+ + + + +
T47D + + + + +
Table 5.3. Table summarizing the different combinations of cells added to the 
RCCS. Cells were added as mixed free cell suspensions.
To pre-seed the microcarrier beads, 5 x 106 cells of each cell type were attached 
to microcarrier beads. The order of cell type seeding was varied to determine the 
most efficient method of manufacturing the heterologous spheroids. As the 
endothelial cell lines were the most sensitive cells of the three they were seeded 
on the microcarrier beads first so that they could establish before the more robust 
fibroblast and tumour cell lines were added. Alternatively the endothelial cells 
were seeded last after the other cell types so that they would benefit from the 
growth factor and matrix provided by the other cells and also because they would 
be closest to the nutrients in the matrigel and medium. All the combinations 
tested are shown in Table 5.4. These cells were cultured as above and harvested 
at 7 and 14 days. The position of the individual cell types within the spheroids 
were identified using cell specific antibody labelling. As described in Chapter 3, 
a pan-cytokeratin antibody was used to label the tumour cells, an anti-vimentin 
antibody for fibroblasts and both anti-CD31/CD34 antibodies to label the 
endothelial cells.
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Combinations 1st 2nd 3rd
1 HMME 7 wt HMF 3wt MCF-7
2 HMME 7 wt HMF 3wt ras MCF-7
3 HMME 7 wt HMF 3wt MCF-7 V12
4 HMME 7 wt HMF 3wt ras MCF-7 V12
5 HMME 7 wt HMF 3wt T47D
6 HMME 7 wt HMF 3wt ras T47D
7 MCF-7 HMF 3wt HMME 7 wt
8 MCF-7 HMF 3wt ras HMME 7 wt
9 MCF-7 V12 HMF 3wt HMME 7 wt
10 MCF-7 V12 HMF 3wt ras HMME 7 wt
11 T47D HMF 3wt HMME 7 wt
12 T47D HMF 3wt ras HMME 7 wt
Table 5.4. Table summarizing the different order and combinations of cells seeded 
on the microcarrier beads prior to culture in the RCCS. Equal numbers of cells were 
seeded on microcarrier beads in the order described above.
When the combination o f cells, as simple cell suspensions, outlined in Table 5.3 
were inserted into the RCCS, spheroid formation was visible macroscopically 
after 48 hours. All of the combinations tested were roughly equal in the rate and 
size of spheroid produced. The maximum size of spheroids harvested at 7 days 
was -1-1.5mm in diameter. At 14 days the largest spheroids were -  2-2.5mm in 
diameter. It is important to note that in this case the spheroids produced were true 
spheroids consisting o f cells only.
When cells pre-seeded on microcarrier beads were inserted into the 
RCCS heterologous spheroids commenced formation within 18-24 hours, with 
small spheroids being visible macroscopically. Two different types of spheroids 
were produced; true spheroids consisting o f cells only and mini-spheroids 
consisting of cells and microcarrier beads (Figure 5.7). The true spheroids 
formed after separating from larger mini-spheroids. Similar to the liquid overlay
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cultures the latter group were significantly larger in size. These mini-spheroids 
increased progressively in numbers and size reaching sizes in excess of 5mm in 
diameter over a period of 7 days (Figure 5.7).
Figure 5.7. Brightfield images of heterologous tumour spheroids (containing MCF- 
7, HMF 3wt and HMME 7wt cell lines) manufactured in the RCCS. Microcarrier beads 
are clearly visible em bedded  in a cellular matrix. M agnification a t x160 and x320.
Microcarrier beads were clearly visible in the tumour spheroids with cells 
proliferating and dividing as indicated by the increasing size of the spheroids. 
Spheroids were harvested either for further culture in matrigel or for processing 
for Immunohistochemical analysis.
Heterologous spheroids of various sizes were harvested after 7 and 14 
days of culture in the RCCS, fixed in formaldehyde and processed for sectioning 
and immunohistochemistry.
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Hematoxylin and eosin (H&E) staining
Paraffin embedded sections of heterologous spheroids (all combinations) were 
harv ested at 7 and 14 days and stained with H&E (Figures 5.8 & 5.9).
A)
Figure 5.8. 3-compartment spheroids harvested at (a) 7 days and (b) 14 days and 
stained with H&E. Note th e  difference in morphology between spheroids harvested at 7 and 
14 days; spheroids at 14 days have a well organised structure. Taken at x160(a) and x80(b) 
magnification.
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The morphology of the heterologous spheroids, consisting of MCF-7, HMF 3wt 
and HMME 7wt cell lines, varied considerably at 7 and 14 days. Spheroids at 14 
days contained more differentiated cells and were more morphologically 
organized (Figures 5.8 and 5.9). Also the three compartment spheroids 
containing the three different cell types were noticeably more differentiated 
morphologically than one and two compartment spheroids.
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B)
Figure 5.9. H&E sections of heterologous tumour spheroids (containing MCF-7, 
HMF 3wt and HMME 7wt cell lines) manufactured in the RCCS and harvested at 7 
and 14 days. N ote th e  lack  of a rch itec tu re  in sp h e ro id s  harv ested  a t 7 d ay s  (a & b) 
com pared to th o se  h a rv e s ted  a t 14 d a y s  (c-f). S ph ero id s form ed on their own and on 
m icrocarrier b e a d s  - arrow  points to  m icrocarrier b e a d s  Note th e  difference in 
architecture a t 7  an d  14 days. F igu res a-d taken  a t x160, e-f taken  at x320 
magnification.
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Epithelial like cells were visibly organized around the periphery of the tumours 
with ECM and other cell types located in the centre. At 7 days there was no 
evidence of structural organization with cells arranged in a random fashion 
resulting in an unorganised mass (Figure 5.9a & b).
Immunohistochemistry
3 compartment heterologous spheroids harvested at 7 and 14 days, containing 
MCF-7, HMF 3wt and HMME 7wt cell lines, were now labelled using cell 
specific antibodies. These were anti-pan-cytokeratin antibody for MCF-7 cells, 
anti-vimentin for fibroblast line HMF 3wt and an anti-CD31 antibody for the 
HMME 7wt endothelial line (Figures 5.10 & 5.11).
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A)
Figure 5.10. Immunohistochemical staining of RCCS manufactured spheroids 
(containing MCF-7, HMF 3wt, HMME 7wt cell lines) for (a) human mammary 
fibroblasts (HMF 3wt) using an antibody against vimentin and (b) for human 
endothelial cells (HMME 7wt) using an antibody against CD31 after 7 days of 
culture. The strom al ce lls  a re  clearly s e e n  to  be  located  centrally  a s  well a s  peripherally 
suggesting  m ovem ent an d  s u b s e q u e n t proliferation of strom al cells in th e  central core of 
the tum our sphero id s. T aken  a t x80 (left) an d  x320  (right) m agnifications.
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Staining of the heterologous spheroids containing MCF-7, HMF 3wt and HMME 
7wt cell lines using human cell specific antibodies (see Chapter 6.2 for list of 
antibodies) demonstrated that the fibroblasts and tumour cells survived in all 
combinations. However, the endothelial cells only survived when they were 
seeded last after the tumour and fibroblasts had established (combinations 7-12 
from Table 5.3) (see Figure 5.11). There was no evidence of survival when they 
were attached to the microcarrier beads first prior to the other cells being added 
(combinations 1-6 from Table 5.3). Cross-sectional staining of the 3- 
compartment spheroids showed that both the endothelial cells and fibroblasts 
migrated within the spheroids and so were located in central and peripheral areas.
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A)
Figure 5.11. Staining for individual cell types in the 3-compartment heterologous 
tumour spheroids after 14 days of culture. Images demonstrate immunoperoxidase 
staining of the three-compartment heterologous spheroids using cell specific markers. 
Figures (a), (b) and (c) represents staining of HMF 3wt, HMME 7wt and MCF-7 cells 
within the heterologous tumour spheroids with antibodies against vimentin, CD31 and a 
pan-cytokeratin respectively. Taken at x160 (left) and x320 (right) magnifications.
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After 14 d a w  ot culture the 3 com partm en t  sphero ids had developed  a well 
organized m orphology, MCI--" cells stained positive only peripherally  (Figure 
5.11c). The centre o f  the sphero ids  conta ined  the stromal cells show n by positive 
stained HMF 3wt and H M M h  7wt stromal cell line-' il mure 5 I k .  & d). The 
remainder o f  the spheroid consis ted  o f  a non cellu lar HCM,
Growth of RCCS m anufactured  heterologous spheroids in 
Matrigel
To promote differentiation further, he tero logous sphero ids  o f  different u / w  to s., 
3.0mm) harvested after 7 o f  culture, in the R C C S. were m ixed  with liquid 
Matrigel before being plated in m icrow ell g row th  plates. The hope was that 3-1) 
Matrigel cultures could induce m orpholog ica l  differentiation o f  breast cancer 
cells in the spheroids. O nce the M atrigel had  gelled appropria te  growth medium 
was added and the plates w ere  incubated  in the appropria te  condition.
Heterologous sphero ids  that had been in culture tor 7 days in 1C F s  with 
the a id oi m icrocarrier beads were harvested  and cultured further in Matrigel. 
The spheroids com m enced  sprouting  o f  capillary  ne tw orks  24 hours after seeding 
in Matrigel (Figure 5.12).
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Figure 5.12. Growth of heterologous tumour spheroids (containing MCF-7, HMF 
3wt and HMME 7wt cell lines), previously manufactured in the RCCS, in Matrigel.
Growth of cells and capillary like vessels are visible extending from the spheroids. 
Magnification x320
Lots of capillary like structures as well as cells were visible growing out away 
from the spheroids. Brightfield images were taken after 5 days in culture (Figure 
5.8). NB: Sometimes tumour cells are known to produce hvphae like tubules. 
However, spheroids formed from tumour cells only (MCF-7) did not form 
capillary like structures in matrigel. As the concentration of growth factors and 
nutrients in the matrigel and or growth medium is considerably higher than in the 
spheroids it is thought that the capillary like networks grew outwards into the 
matrigel rather than inwards to the spheroids.
To summarize, 3-D heterologous spheroids manufactured in the RCCS 
with the aid of microcarrier beads were well differentiated, structurally robust 
and in sufficient supply to be used in future xenograft studies (see Chapter 6 for 
xenograft studies of these spheroids). Moreover, when cultured in 3-D ECM
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conditions they demonstrated good viability with the ability to differentiate and 
form capillary like networks.
5.6 Discussion and conclusion
In recent years breast cancer models, based on 3-D cell culture methods, have 
greatly increased in number due to new culturing techniques emerging from the 
field of tissue engineering, which has lead to improved models. Previously 
spontaneous aggregation, liquid overlay cultures and spinner flasks were the 
most popular methods used to produce 3-D in vitro breast cancer models. More 
recently prefabricated scaffold based cultures, the NASA developed Rotary Cell 
Culture System (RCCS) and pre-engineered collagen scaffold have been 
developed. The design of the RCCS is a vast improvement on the spinner flask in 
that larger more morphologically and functionally differentiated breast cancer 
spheroids can be produced (Goodwin et al. 1993, Cherry and Kwon 1990, 
Croughan and Wang 1991). The scaffold based culture system is gaining in 
popularity as the 3-D matrix is used to promote multilayer growth of cells 
derived from epithelial cancers.
With the many advances in the methods of tissue culturing and 
engineering the purpose of this chapter was to utilize this technology and develop 
a 3-D heterologous organotypic tumour spheroid model in vitro composed of 
human breast cancer and stromal cells. Once a suitable and viable in vitro model 
had been established the aim was to xenograft these heterologous spheroid 
models into immunodeficient mice to produce a self contained human breast 
tumour model.
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A variety of 3-D cell culture techniques were tested to determine their 
suitability to manufacture 3-D heterologous co-culture models. Microcarrier 
beads were useful in that they not only allowed the culture of anchorage 
dependent cells in suspension but they supported the growth of more sensitive 
‘harder to grow’ cells such as endothelial cells. However microcarrier beads in 
suspension culture did meet the necessary requirements as the number of 
spheroids produced was insufficient with those produced being too small to 
contain adequate number of cells. Liquid overlay cultures were primarily 
employed to construct a small number of carefully constructed heterologous 
spheroids so that a single spheroid could be transplanted into one in vivo site (e.g. 
mammary fat pad). However, the spheroids produced did not support the density 
of cells required in addition to being too fragile for in vivo transplantation. 
Finally the 3-D scaffolds represented a potentially good method for tissue 
construction however initial studies did not provide evidence that the human 
tumour or stromal cell lines proliferated in them. Therefore these methods did 
not meet the criteria required.
The Rotary Cell Culture System was chosen as the best method for 
manufacturing heterologous tumour spheroids because it’s many advantages. The 
primary advantage of the RCCS had over either dynamic or static tissue culture 
systems is that its low shear environment allows cells to aggregate, grow three- 
dimensionally, and differentiate. This advantage results in cells or tissues that 
very closely resemble the in vivo tissue equivalent (Hammond and Hammond 
2001, Unsworth and Lelkes 1998). The vessel also supports co-culture efficiently 
by bringing different cell types of different size and density together simply and 
efficiently. It is very simple to expose the suspension cultures to reagents in the 
vessel. Finally, it was simple to use resulting in high productivity of spheroids
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when used with microcarrier beads (Meaney et al. 1998). The rotating-wall 
vessel has been reported to be successful in engineering prostate organoids 
(O’Connor 1999, Zhau et al. 1997), colon carcinoma (Jessup et al. 1997), and 
cartilage (Freed et al. 1997, Vunjak-Novakovic et al. 1999), among other tissues 
(Unsworth and Lelkes 1998).
In the heterologous spheroids manufactured in the RCCS, the three cell 
types grew, multiplied, migrated into clusters, and produced an intracellular 
matrix via the functional interrelationship of cell-to-cell contact. The cells 
differentiated and grew along boundaries characteristic of normal functional 
tissue.
In the present study, we have developed a novel 3-D multi-compartment 
heterologous co-culture system in which human mammary epithelial cells, 
mammary fibroblasts and endothelial cells, seeded as a mixed single cell- 
suspension with the aid of reconstituted basement membrane matrix (Matrigel), 
retain their inherent ability to segregate (or compartmentalize) and organize in a 
3-D manner with formation of a central stromal core composed of fibroblasts and 
functional endothelial cells from and around which epithelial buds emerge. This 
situation bears resemblance to the in vivo situation because, in the mammary 
gland, terminal ductules or acini are set within a rich and specialized stroma that 
defines the lobular unit. This lobular connective tissue is usually loose, possesses 
many capillaries, and is sharply demarcated from the surrounding fat and denser 
fibrous tissue of the structural rather than the functional portion of the breast 
(Page and Anderson 1987). It is interesting to note that the epithelial cells in this 
model demonstrate an example of early morphogenic movement referred to as 
epiboly; which is the process whereby epithelial cells flatten perpendicular to 
their apico-basal axes, accompanied by the lateral expansion of the sheet
spreading as a unit over deeper layers. The term epiboly is generally used to 
describe the movement of epithelial sheets (usually ectoderm cells) which spread 
as a unit (rather than individually) to enclose the deeper layers of the embryos 
(endoderm) (cells move over the surface toward the region of invagination or 
involution) seen in ectoderm formation of amphibians (Keller 1980), sea urchins 
(Trinkaus 1988) and tunicates.
The co-culture system, in the present study, bears physiological relevance 
because not only does it permit the mammary epithelial cells to exhibit a 
homotypic affinity for itself and form an interface with adjacent stromal core or 
compartment as observed in vivo but it also facilitates an arrangement, observed 
in vivo, that is most suitable for functional paracrine interactions between 
epithelial-fibroblast and epithelial-endothelial cells. It must be noted that, 
although the structural and functional organization observed in this model system 
mimics several characteristics of the mammary gland, it is representative not of 
normal mammary gland morphology but rather of alterations occurring during 
early breast cancer. It is important to note that organ specific stromal cells 
produced this effect as a similar study by Shekhar et al. (2001) demonstrated a 
requirement for organ-specific fibroblasts in the induction of epithelial 
morphogenesis.
The tumour and stromal cell lines present in the 3-compartment 
heterologous tumour spheroids interacted with each other to provide in vitro 
tumours that not only survived but proliferated and differentiated. Furthermore 
these spheroids were viable when re-cultured in Matrigel demonstrating the 
production of microcapillary like networks. The latter result is very promising as 
the ability to form differentiated capillary like structures in vitro may suggest that 
these structures could anastomose with host vasculature when xenografted in
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vivo. Having established these viable heterologous tumour spheroids, in vivo 
experiments were set up to xenograft these self contained in vitro tumour units 
into immunodeficient mice (for results see Chapter 6).
2 6 3
Chapter 6 
Xenotransplantation
6.1 Introduction
The concept of the human breast cancer xenograft model is simple; all that is 
involved is growth of human breast cancer cells and cell lines heterotopically 
(subcutaneously) or orthotopically (mammary fat pad) in immunodeficient mice. 
The main advantage xenograft models confer over other animal models is that it 
represents a model system of human origin. As with any model the similarity 
with the original is of paramount importance. However xenograft systems differ 
markedly from human breast cancer in several ways. They contain fewer stromal 
cells and the stroma that does exist is murine in origin, resulting in a chimeric 
tumour. The biology of chimeric rodent/human tumours can differ significantly 
from that of humans resulting in unpredictable growth, differentiation and 
metastatic properties (Hahn and Weinberg 2002, Balmain and Harris 2000). This 
raises issues of which of the two species will be dominant in contributing its 
characteristics to the chimeric tumours. Maybe tumours with a combination of 
the two characteristics will be formed. For example, in contrast to the invasive 
growth pattern of human cancer, mouse mammary tumours tend to be more 
expansile with pushing margins. Many mammary tumours that are known to 
metastasize in mice are regarded as histologically benign by most 
histopathologists (Cardiff 2001).
Unfortunately human breast cancer is one of the most difficult tumours to 
transplant into experimental animals. The reported success rate for human breast 
cancer xenografting is 7% - 20% (Mehta et al. 1993). In comparison the success
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rates of pancreatic/colonic, renal cell, lung and urological carcinomas have been 
reported as 40-60%, 40%, 38-51% and 56% respectively (Cui et al. 2001, 
Angevin et al. 1999, Mourad and Vallieres 1995, Mattem et al. 1985, Okada and 
Yoshida 1984). Not until recent years (Hurst et al. in 1993) were mammary 
tumour xenograft lines which metastasized developed. Recently it has been 
reported that histomorphologically intact primary human breast lesions and 
cancers have been grown in athymic mice (Yang et al. 2000). Furthermore an 
experimental model system has been developed in which dissociated cells from 
surgical breast cancer specimens, after mixing with extracellular matrices, have 
been transplanted into nude mice (Yang et al. 2000). These transplanted cells 
undergo morphogenesis to reflect their original phenotype. This model presents a 
potential in vivo model for analysing specimens of primary human breast lesions 
and cancers. Traditionally established human tumour cell lines, when 
transplanted into immunodeficient mice, have proved to be relatively poor 
predictors of tumour response in humans. These xenograft tumours do not evolve 
in situ and lack the appropriate cellular interactions with the host 
microenvironment.
Until now there has been a distinct lack of a truly representative breast 
cancer model. The recent ability to immortalize fresh primary human mammary 
endothelial cells and fibroblasts by the insertion of the catalytic subunit of human 
telomerase (hTERT) and a mutant (U19A58) variant of simian virus 40 large T 
antigen has resulted in a readily available source of human mammary stromal 
cells. Therefore with the availability of appropriate stromal cells it has now 
become possible to improve xenograft models by incorporating more human 
components. The development of a complex 3 compartment heterologous 
xenograft model incorporating the relevant stromal elements would provide a
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better alternative to currently available chimeric xenograft models. By 
xenografting human breast tumours in combination with human mammary 
fibroblasts and endothelial cells it is envisaged that the immortalized mammary 
stromal cells will provide a viable and much needed tumour microenvironment 
of human origin for tumour proliferation.
Models based on athymic nude mice have been playing an important role 
in evaluating many anti-cancer drugs. However, human tumours were 
transplanted subcutaneously and not at an orthotopically relevant organ site. The 
major problem of this model is that the transplanted tumours are located in an 
environment quite different from where most human tumours locate. Most 
subcutaneously transplanted tumours are surrounded by a pseudocapsule, and 
have little chance to invade and disseminate to the surrounding tissues and rarely 
metastasize, even when highly aggressive tumours have served as the source of 
the xenograft (Cui et al. 2001). However, human tumour cells implanted 
orthotopically in the corresponding organs of nude mice can increase the 
metastatic capability of human tumour cells in nude mice (Cui et al. 2001, 
Angevin et al. 1999, Mourad and Vallieres 1995, Mattem et al. 1985, Okada and 
Yoshida 1984).
The aim of this chapter was two-fold, firstly to investigate whether the 
immortalized stromal cells were tumourigenic in immunodeficient mice which 
would indicate that they have been transformed into a tumourigenic phenotype. 
Secondly, to determine the parameters of their survival and proliferation in vivo 
and also their ability to support and function as stroma to the co-engrafted human 
tumour cells when xenografted orthotopically. Success would allow us to 
develop a more representative model system incorporating more human
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components for vital pre-clinical studies. In order to identify human cells in 
xenografts, cell type specific markers were selected.
6.2 Identification of human mammary epithelial and 
stromal cell markers
In order to identify the three different human cell types: breast epithelial cells, 
endothelial cells and fibroblasts in the context of fixed mixed cell populations 
both in vitro and in vivo, human cell specific antibody markers were chosen and 
staining protocols optimised as in Table 6.1 using both fixed cells in vitro (Figure 
6.1) and tissue sections (Figure 6.2).
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Antigen
(specificity)
Antibody Species Sub-class Dilution Source
Human
CD34
Q/BEND10 Mouse IgGl 1:30
2 min PC
Dako
Human
CD31
JC70A Mouse IgGl 1:30
2 min PC
Dako
Human
Cytokeratin
5,6,8,17,19
MNF116 Mouse IgGl 1:400 
10 min CT
Dako
Human
vimentin
V9 Mouse IgGl 1:800
18 min 
MW
Santa Cruz
Mouse
CD31
PEC AM-1 Rat IgG2a 1:20 Serotec
Vimentin * RV202 Mouse IgGl 1:400 BD
Biosciences
Ki-67 MIB-1 Mouse IgM 1:300 
2 min PC
Dako
SV40 large 
T antigen
PAb 423 Mouse IgGl 1:5 Dako
Table 6.1. Table showing all the antibodies used. Antigen retrieval methods were 
used for formaldehyde fixed paraffin embedded sections only; 2 min PC- 2 minutes 
pressure cooking. 18 min MW - 18 minutes microwaving, 10 min CT - 10 minutes 
chymotrypsin enzyme digestion. Species specificity was confirmed by testing on either 
human or mouse tissues. (*) reacts with both human and mouse vimentin.
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Epithelial cells Endothelial cells Fibroblasts
A)
Figure 6.1. Cells grown on coverslips stained with (a) V9 anti-vimentin, (b) MNF116 
anti-pan-cytokeratin antibody and (c) JC70A anti~CD31 antibody. The antibody 
against CD34 (QBEND/10) showed a similar staining pattern as (c). All primary 
antibodies were visualized using an anti-mouse FITC secondary antibody. Epithelial 
cells were MCF-7, endothelial cells HMME 7wt and fibroblasts HMF 3wt. Magnification 
at *160.
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A)
%
Figure 6.2. Staining of human tonsillar tissue as positive controls. Antibodies 
against (a) human vimentin, (b) human pan-cytokeratin (5,6,8,17,19), (c) human specific 
CD31 and (d) human specific CD34. Magnification a) & b) *160, c) & d) ><80.
In addition, to identify host (murine) endothelial cells and blood vessels a mouse 
specific CD31 antibody was used. Murine fibroblasts were identified using non­
species specific vimentin antibody that recognises the mouse antigen. The human
270
mammary stromal cell lines were further distinguished by SV40 Large T staining 
(Figure 6.3), and stains for the proliferation marker Ki67 using the antibody 
MIB-1 was also optimised for xenograft studies. As an additional means of 
differentiating mouse and human cells the nuclear stain Hoechst 33258 was used. 
This stains mouse nuclei with a characteristic punctuate pattern whereas human 
nuclei are stained homogenously (Figure 6.4).
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Large T
Fibroblasts
Hoechst 33258
Endothelial cells
Epithelial cells
Figure 6.3. Human mammary fibroblasts (HMF 3wt), endothelial cells (HMME 7wt) 
and epithelial cells (MCF-7) cells stained with an anti-large T antibody and also 
with the nuclear stain Hoechst 33258. All primary antibodies were visualized using an 
anti-mouse FITC secondary antibody. Magnification *160.
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Figure 6.4. Hoechst 33258 staining of (a) mouse and (b) human endothelial cells.
Note that mouse nuclei are stained with a punctuate pattern in contrast to a more 
homogenous pattern for human cells. Magnification ><320.
Results showed that the three human cell specific antibodies identified (see Table
6.1) were able to clearly distinguish between the three human cell types in fixed 
cells in vitro (Figure 6.1) and in vivo (Figure 6.2). In addition they were also 
confirmed as having human species specificity. The LT expressing immortalized 
stromal cell lines were also identified by a specific marker against LT (Figure 
6.3). Human cells could also be differentiated from murine cells by the staining 
pattern produced by the nuclear stain Hoechst 33258 (Figure 6.4). Antibodies 
specific for mouse fibroblasts and endothelial cells were also identified and 
tested producing reliable reproducible results. Thus, a panel of reagents for 
confirming cell identity and origin in the context of xenografts was established.
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6.3 Xenografts of immortalized human mammary 
stromal cells
All of the immortalized human mammary stromal cell lines including the 
temperature sensitive and wild LT type variants were xenografted, into 6 week 
old NCR-nu mice primed with slow release oestrogen pellets, to investigate 
whether any of them would give rise to tumours and whether surviving cells if 
any, could be detected immunohistochemically. The stromal cells (5*106) were 
xenografted either heterotopically (subcutaneously, SC) or orthotopically into the 
mammary fat pad (MFP). In addition, the cells were xenografted in either 
standard serum free media (SFM) or in the presence of a basement membrane 
preparation matrigel to potentially enhance take rates. In later experiments the 
immortalized fibroblasts and endothelial cell lines were combined before 
inoculation, including combinations of wild type LT variant cell lines (non 
temperature sensitive) with temperature sensitive lines. Xenograft harvests were 
carried out at 6 and 12 week time points post inoculation.
6.3.1 Xenografts of immortalized human mammary fibroblasts
All of the temperature sensitive and wild type fibroblast cell lines were 
individually xenografted into nude mice. The wild type LT variant of the human 
mammary fibroblast transfected subsequently with the mutant human activated 
ras oncogene Val12 (HMF 3wt ras) was also inoculated either subcutaneously or 
into the mammary fat pads of nude mice in Matrigel. The purpose of the HMF 
3wt ras inoculations was to investigate the tumourigenicity of the immortalized 
fibroblasts following additional expression o f the mutant ras oncogene, as it was
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associated with many of the in v itro  criteria of transformation (see Table 3.8). 
The results for all the fibroblast lines tested are summarized in Table 6.2.
Cell lines Xenograft 
Take Rate 
SFM + SC
Xenograft 
Take Rate 
Matrigel +
SC
Xenograft 
Take Rate 
SFM + MFP
Xenograft 
Take Rate 
Matrigel+MFP
HMF 3A 0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
HMF 3B 0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
HMF 3C 0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
HMF 3D 0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
HMF 3wt 
(wild type)
0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
HMF 3wt ras Not
determined
0/8, 0/8 Not
determined
0/16, 0/16
Table 6.2. Table summarizing the results of the immortalized fibroblast xenografts.
Inoculations were performed in either serum free media (SFM) or extracellular matrix 
Matrigel, subcutaneously (SC) or into the mammary fat pad (MFP). 5x106 cells of each 
cell type in 50^1 of carrier were inoculated into each site. Xenografts were harvested and 
examined at 6 and 12 weeks points for which individual results are recorded. 6 sites 
were inoculated for each time point. The HMF 3wt ras line was only inoculated in 
Matrigel either subcutaneously or into the MFP; for the Matrigel + MFP group, 8 sites 
were inoculated on two separate occasions.
2 7 5
On gross inspection tumours were not visible in any of the fibroblast xenografts. 
Also, from the 8 subcutaneous and 16 paired mammary fat pad (8 on two 
separate occasions) injections of HMF 3wt ras, tumours did not develop in any 
of the mice (Table 6.2). Mammary fat pads and samples of subcutaneous tissues 
taken from the inoculation sites were harvested and either snap frozen for frozen 
sections or fixed in formaldehyde for paraffin sections. Immunohistochemical 
analysis of these sections using both immunoperoxidase and 
immunofluorescence, with an antibody specific for human vimentin (see Chapter
6.2), showed no evidence of surviving cells in any of the groups. 20 
sections/inoculation site were stained. In addition, the sections were stained for 
the presence of the large T antigen, which is present in the immortalized 
fibroblasts. Using an anti-large T antibody all the sections tested were negative. 
Altogether a total of 2.4><108 cells were grafted for each different fibroblast cell 
line, including the HMF 3wt ras cell line, without apparent long term survival or 
tumour formation.
276
6.3.2 Xenografts of immortalized human mammary endothelial 
cells
All of the temperature sensitive and wild type endothelial cell lines were also 
xenografted in the same manner as the fibroblasts. The results are shown in Table
6.3.
Cell lines Xenograft 
Take Rate 
SFM + SC
Xenograft 
Take Rate 
Matrigel +
SC
Xenograft 
Take Rate 
SFM + MFP
Xenograft 
Take Rate 
Matrigel + 
MFP
HM M E2 0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
HM M E7 0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
HMME 7wt 
(wild type)
0/6, 0/6 0/6, 0/6 0/6, 0/6 0/6, 0/6
Table 6.3. Table summarizing the results of the immortalized endothelial cell 
xenografts. Inoculations were performed in either serum free media (SFM) or 
extracellular matrix Matrigel, subcutaneously (SC) or into the mammary fat pad (MFP). 
5x106 cells of each cell type in 50gl of carrier were inoculated into each site. Xenografts 
were harvested and examined at 6 and 12 weeks points for which individual results are 
recorded. 6 sites were inoculated for each time point.
The immortalized endothelial cell lines (wild type LT and temperature sensitive) 
did not give rise to tumours in any of the four group categories, after 6 or 12 
weeks. As with the fibroblast lines, immunoperoxidase and immunofluoresence 
staining showed no evidence of long term survival of the grafted cells, when 10 
sections/inoculation site were stained with a human specific anti-CD31 and 10 
sections/inoculation site with a human specific anti-CD34 antibody. Staining for 
the large T antigen was also negative in all the sections tested. Again a total of 
2.4x108 cells were grafted for each endothelial cell line.
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6.3.3 Xenografts of combined immortalized human mammary 
endothelial cells and fibroblasts
In order to potentially improve survival and provide a more stringent test of 
tumourigenicity, xenograft combinations of endothelial cells and fibroblasts were 
performed (Table 6.4). All the combinations were inoculated, with the aid of 
Matrigel, either subcutaneously or into the MFP. 5 x 106 cells of each cell type 
were inoculated/combination.
Cell lines Xenograft Take Rate 
Matrigel + SC
Xenograft Take Rate 
Matrigel + MFP
HMF 3A + HMME 2 0/6, 0/6 0/6, 0/6
HMF 3A + HMME 7 0/6, 0/6 0/6, 0/6
HMF 3B + HM M E2 0/6, 0/6 0/6, 0/6
HMF 3B + HM M E7 0/6, 0/6 0/6, 0/6
HMF 3C + HMME 2 0/6, 0/6 0/6, 0/6
HMF 3C + HMME 7 0/6, 0/6 0/6, 0/6
HMF 3D + HMME 2 0/6, 0/6 0/6, 0/6
HMF 3D + HMME 7 0/6, 0/6 0/6, 0/6
HMME 7wt (wild type) + 
HMF 3 A
0/6, 0/6 0/6, 0/6
HMF 3wt (wild type) + 
HMME 7
0/6, 0/6 0/6, 0/6
HMME 7wt (wild type) + 
HMF 3wt (wild type)
0/6, 0/6 0/6, 0/6
Table 6.4. Table summarizing the results of the combined immortalized stromal 
cell xenografts. Inoculations were performed in Matrigel either subcutaneously (SC) or 
into the mammary fat pad (MFP). 5x106 cells of each cell type in 50fil of carrier (total) 
were inoculated into each site. Xenografts were harvested and examined at 6 and 12 
weeks points for which individual results are recorded. 6 sites were inoculated for each 
time point.
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Once again no tumours were evident on gross inspection at 6 and 12 weeks. The 
absence of surviving cells was confirmed by immunohistochemical staining 
using human cell specific antibodies and anti-large T antibodies (20 
sections/inoculation site).
In summary, none of the stromal cell lines tested, including the wild type 
lines which might have been expected to survive better at mouse body 
temperature (~38°C), formed tumours. In addition, no surviving cells could be 
detected immunohistochemically. In total, over 5x108 cells of each cell line were 
inoculated, singly or in combination. The inability of the immortalized stromal 
cells to give rise to tumours when xenografted into mice could be due to many 
possible reasons. In addition to the temperature sensitive phenotype of some but 
not all off the lines tested, there are two possible other reasons for the failure to 
produce tumours. These are a residual innate immune response (e.g. natural killer 
cell activity) and the fact that the SV40 large T antigen only results in a partial 
transformation of the stromal cells resulting in a non-tumourigenic phenotype. 
The other possible reasons for their failure to survive could be due to either 
dispersion of cells at the graft site or the absence of other human cell types. The 
lack of support from cells normally present in the tumour or tissue environment 
(i.e. cells not in close proximity or contact) may be a crucial factor. Put simply, 
the stromal cells may need the close contact support of epithelial cells as well as 
other stromal components to survive and proliferate.
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6.4 Xenografts of preformed in vitro multicellular 
spheroids
As described in Chapter 5, heterologous tumour spheroids were manufactured in 
vitro to provide a physiological 3-D environment in which the stromal cells were 
in close proximity both to each other and to the tumour cells. Multicellular 
tumour spheroids have a well organized spherical symmetry of morphological 
and physiological features including complex cell-cell and cell-matrix 
interactions resembling avascular tumour sites and or micrometastatic regions in 
vivo and thus are a very useful model in tumour biology. Heterologous two and 
three compartment tumour spheroids manufactured in the Rotary Cell Culture 
System (RCCS) as described and illustrated in Chapter 5, consisting of the 3 
different cell types combined with Cytodex microcarrier beads were inoculated 
into the mammary fat pads of nude mice in Matrigel. The combinations of cells 
xenografted are shown in Tables 6.5 and 6.6 below. Due to the possible expected 
problems associated with the temperature sensitive lines, which will be close to 
their non permissive temperature (>39°C) in the mouse, only the wild type LT 
lines were used in these experiments.
6.4.1 Heterologous stromal spheroids
Heterologous stromal spheroids consisting of two different combinations of the 
immortalized fibroblasts and endothelial cells, manufactured in the RCCS, were 
inoculated into mammary fat pads of nude mice in Matrigel (Table 6.5). 
Xenograft harvests were carried out at 8 weeks post inoculation.
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Cell lines Xenograft Take Rate 
Matrigel + MFP 
(6 sites per group)
HMF 3wt + HMME 7 wt 0/6
HMF 3wt ras + HMME 7 wt 0/6
Table 6.5. Table summarizing 3-D heterologous stromal cell spheroid xenografts.
Spheroids manufactured from the combination of two different fibroblast cell lines and 
endothelial cells were inoculated into the MFP with Matrigel. Cells were harvested at 8 
weeks.
Both of the heterologous stromal spheroid combinations including the ras 
expressing cells failed to give rise to tumours after 8 weeks (Table 6.5). 
Immunohistochemical analysis of the all the inoculated mammary fat pads (20 
sections/inoculation site), using antibodies against vimentin, CD31/CD34 and 
SV40 LT antigen, demonstrated no evidence of either stromal cell type survival.
6.4.2 Heterologous tumour spheroids 
Tumour spheroids
Three different breast tumour cell lines were xenografted into the mammary fat 
pads of nude mice either as a cell suspension (5X106 cells) or as spheroids (Table 
6.6). All the inoculations were performed in Matrigel. Tumours or mammary fat 
pads were harvested at 8 weeks.
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Cell lines Xenograft Take Rate
Matrigel + MFP (6 sites per group)
Cell suspension Spheroids
MCF-7 6/6 0/6
MCF-7 V12 5/6 0/6
T47D 6/6 0/6
Table 6.6. Table comparing the tumourigenicity of breast tumour cell lines when 
xenografted as spheroids and cell suspensions. Cell suspensions consisted of 5*106 
tumour cells. Tumours or mammary fat pads were harvested at 8 weeks.
Two of the tumour cell lines (MCF-7 and T47D) produced 6 tumours from 6 
inoculations (100%) with the other (MCF-7 V I2) producing 5 out of a possible 6 
inoculations (83%) when xenografted as cell suspensions. Immunohistochemistry 
using a human specific pan-cytokeratin marker confirmed that all the tumours 
produced were of human epithelial cell origin (10 sections/inoculation site). 
However when the same three tumour cell lines were xenografted as pre-formed 
multicellular spheroids none of the inoculations gave rise to tumours. The 
absence of the tumour cell survival in these inoculations was confirmed by 
immunohistochemistry using the same marker (10 sections/inoculation site).
2-compartment heterologous tumour spheroids
In an attempt to improve the success rate of establishment of the tumour cell only 
spheroids, xenograft experiments were performed using 2 compartment 
heterologous tumour spheroids with stromal elements already present in the pre­
formed spheroids. The three breast tumour cell lines were combined with one of 
three different stromal cell lines before being inoculated into the mammary fat 
pads in Matrigel. The preparation and characterization o f the spheroids has been 
described in Chapter 5.5. The different heterologous tumour-stromal 
combinations are shown in Table 6.7.
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Cell lines HMME 7wt HMF 3wt HMF 3wt ras
MCF-7 0/6 0/6 0/6
MCF-7 V12 0/6 0/6 Not determined
T47D 0/6 0/6 Not determined
Table 6.7. Table showing the xenografts of the 2-compartment heterologous 
tumour spheroids. All spheroid combinations were inoculated into the MFP in Matrigel 
(6 sites per group). Mammary fat pads were harvested at 8 weeks.
None of the 2 compartment heterologous tumour spheroid combinations gave 
rise to tumours after 8 weeks. Immunohistochemistry, using human specific 
antibodies described in Chapter 6.2 demonstrated that none of the human cells 
xenografted survived (10 sections/inoculation site).
3-compartment heterologous tumour spheroids
In a final attempt to provide a suitable cellular environment for establishing 
tumour spheroids, the three tumour cell lines were co-grafted as 3 compartment 
spheroids comprising tumour, fibroblast and endothelial cells (Table 6.8).
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Cell lines HMF 3wt + HMME 7wt HMF 3wt ras + HMME 
7wt
MCF-7 0/6 0/6
MCF-7 V12 0/6 Not determined
T47D 0/6 Not determined
Table 6.8. Table summarizing 3-compartment heterologous tumour-stromal cell 
spheroid xenografts. All spheroid combinations were inoculated into the MFP in 
Matrigel (6 sites per group). Mammary fat pads were harvested at 8 weeks.
Neither with HMF 3wt + HMME 7wt combinations or even HMF 3wt ras + 
HMME 7wt were successful in producing tumours. None of the heterologous 3- 
compartment inoculations gave rise to tumours. Again, analysis of all inoculation 
sites, by immunohistochemical analysis, to determine cell survival was negative 
(10 sections/inoculation site).
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6.5 Establishment of heterologous tumour xenografts
6.5.1 Heterologous cell xenografts
The failure of the preformed heterologous tumour spheroids to form tumours did 
not provide a model of stromal-tumour interaction in the context of the 
immortalized stromal lines. One problem associated with the heterologous 
tumour spheroids is that they may not reach an adequate size and hence cell 
numbers necessary for in vivo establishment. To address the issue of whether the 
immortalized human mammary stromal cell lines could support tumour take and 
growth, experiments using cell suspensions, in which tumours cell lines and 
stromal cell lines were mixed at the point of inoculation, were performed. 
Furthermore, the cells numbers inoculated were carefully controlled. Recent 
research has shown that the human breast cell line MCF-7 produced significantly 
faster growing tumours when mixed with carcinoma associated fibroblasts than 
when mixed with normal fibroblasts (Shekhar et al. 2001).
Xenografts using wild type LT human mammary stromal cells 
Cell numbers of breast tumour cell lines (1 x 105), generally insufficient to 
produce tumours when xenografted alone, were xenografted in combination with 
the immortalized human mammary stromal cells to determine whether the 
addition of these cells provided a tumour take advantage. It is generally observed 
that a minimum of 5 x 106 (threshold inoculum) of tumour cells/ inoculation are 
required to consistently produce tumours when xenografted in nude mice.
Tumour cells in the exponential growth phase were harvested and re­
suspended in serum free medium, to give a of dose 1 x 105 cells/inoculation. The 
wild type LT mammary fibroblasts and endothelial cell lines were harvested in 
an identical manner. The stromal cells were then combined with the tumour cell
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lines in either a 1:10 or 1:5 stromal cell to tumour cell ratio (Table 6.9). These 
ratios were chosen to provide a very approximate match to physiological tumour- 
stromal numbers in vivo. In addition to the MCF-7, the YEGF over-expressing 
tumour cell line MCF-7 V12 was also tested (Table 6.10). Controls consisted of 
tumour cell inoculations at the supra-threshold level of 5xl06cells/site. All 
inoculations were carried out in Matrigel into the mammary fat pads and 
harvested at 8 weeks. Tumours were permitted to reach a maximum size of 
8><8mm before being harvested. Inoculation sites were inspected on a daily basis 
in order to identify the time at which the first sign of a palpable mass (a 
successful tumour take) was seen. Harvested tumours or mammary fat pads were 
first measured if tumours were present and then processed for 
immunohistochemical analysis.
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A)
Cell lines Xenograft Take Rate 
(8 sites per group)
Mean tumour volume 
(range) (mm3)
MCF-7 (1 x  105) 1/8 (12.5%) 31.0
MCF-7 (1 x  105) + 
HM F3wt
8/8 (100%) 134.6
(46.8-183.3)
MCF-7 (1 x  105) + 
HMME 7wt
3/8 (37.5%) 75.2
(33.5 -102.1)
MCF-7 (1 x  105) + 
HMF 3wt + HMME 
7wt
6/8 (75%) 192.8
(73.0 -  278.0)
MCF-7 Alone (5 x 106)
8/8 (100%) 66.7
(21.8-104.8)
B)
Cell lines Xenograft Take Rate 
(8 sites per group)
Mean tumour volume 
(range) (mm3)
MCF-7 (1 x  105) 0/8 (0%) N/A
MCF-7 (1 x  105) + 
HMF 3wt
8/8 (100%) 141.2
(65.4-187.3)
MCF-7 (1 x 105) + 
HMME 7wt
4/8 (50%) 74.5
(33.5-115.9)
MCF-7 (1 x  10s) + 
HMF 3wt + HMME 
7wt
7/8 (83.3%) 209.3
(86.7 -  294.0)
MCF-7 (5 x 106)
8/8 (100%) 70.3
(33.5-110.3)
Table 6.9. Heterologous cell xenografts using sub-threshold inocula of breast 
cancer cell line MCF-7 and stromal cells at a ratio of (a) 10:1 and (b) 5:1. Sub­
threshold inoculum was defined as 1x105 cells/inoculation site with supra threshold level 
5x106 cells/inoculation site. All combinations were xenografted in Matrigel and harvested 
at 8 weeks. Tumour volume was calculated as follows: V  = (tt/ 6 ) (  di x d2) 3/2, where di 
and d2 are two perpendicular tumour diameters.
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Cell lines Xenograft Take Rate 
(8 sites per group)
Mean tumour volume 
(range) (mm3)
MCF-7 V12 (1 x 10s) 0/8 (0%) N/A
MCF-7 V12 (1 x 10s) + 
HMF 3wt
6/8 (75%) 187.8
(77.9-225.3)
MCF-7 V12 (1 x 10s) + 
HMME 7wt
2/8 (25%) 72.2
(46.1-140.5)
MCF-7 V12 (1 x 10s) + 
HMF 3wt + HMME 
7wt (10:1:1 ratio)
4/8 (50%) 222.3
(94.4-283.4)
MCF-7 V12 (1 x 10s) + 
HMF 3wt + HMME
7wt (5:1:1 ratio)
5/8 (62.5%) 264.7
(267.8-327.1)
MCF-7 V12 (5x 106)
6/8 (75%) 103.4
43.1-161.0
Table 6.10. Heterologous cell xenografts with sub-threshold inocula of breast 
cancer cell line MCF-7 V12 and stromal cells at a ratio of 10:1. Sub-threshold 
inoculum was defined as 1x105 cells/inoculation site. Stromal cells were xenografted in a 
ratio of 10:1 of each tumour cell to stromal cell type. All combinations were xenografted 
in Matrigel and harvested at 8 weeks. NB. tumours produced were in general larger and 
more hyperaemic than with MCF-7 cell with MCF-7 V12.
Results showed that the addition of stromal cells provided a dramatic growth 
advantage (Tables 6.9 and 6.10). These experiments demonstrate the effect of 
stromal cells on the promotion of tumourigenesis despite their failure to survive 
when grafted alone.
Unlike the heterologous spheroid xenograft experiments, the addition of 
the immortalized stromal cells produced a marked effect on the promotion of 
MCF-7 tumour cell growth when both were combined as cell suspensions. The 
heterologous cell xenografts described above differed significantly from tumour 
cell only xenografts both in the take rate (i.e. efficiency of tumour formation) and
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the latency with which they formed palpable tumours, following orthotopic 
implantation in nude mice. Combining stromal cells at a ratio of 1:5 to tumour 
cells showed no significant difference in take rates compared to a more 
physiological ratio of 1:10 (Table 6.9).
Sub-threshold tumour only xenografts had a poor take rate with tumours 
arising in only 6.25% (1/16 sites) of injection sites. In comparison, the addition 
of fibroblasts produced a significantly enhanced take rate, resulting in a 100% 
take rate (16/16 sites). However, differences were noted in the take rates between 
fibroblasts and endothelial cells or both. In all cases the fibroblasts produced the 
highest overall take rates. While the addition of the endothelial cell lines did 
enhance tumour growth on their own (7/16 sites), this was significantly less than 
the fibroblasts (16/16 sites). The addition of both stromal cell types resulted in a 
take rate of 81.25% (13/16 sites), a take rate in between fibroblasts and 
endothelial cells.
Results using the MCF-7 V I2 tumour cell line were broadly in agreement 
with the original MCF-7 results. Again fibroblasts were most effective (6/8 
sites); endothelial cells (2/8 sites) least effective and the combination of both 
stromal cell types (4/8 sites) somewhere in between. However, there were two 
specific differences to the original MCF-7 cell line: 1) that overall take rates in 
this line were lower, including supra-threshold inoculum controls and 2), the 
tumours that were formed did so more rapidly on the basis of daily observations 
and were more hyperaemic when harvested. Six tumours grew so rapidly that the 
mice had to be sacrificed prematurely before the 8 weeks had elapsed, with three 
mice being sacrificed at 6 weeks.
In all cases heterologous tumours with added wild type LT fibroblasts not 
only grew more rapidly they also grew to significantly larger sizes, compared to
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supra-threshold inoculum controls, within the same experiment period (see Table 
6.11). The addition of fibroblasts reduced the latency period of tumour 
formation. The control groups (supra-threshold tumour cell inocula) displayed 
long latency periods (3-4 weeks) before tumours were visible on gross inspection 
(data not shown). Tumours were first visible at 2 weeks in all the fibroblast 
heterologous xenografts including those combined with endothelial cells. 
However, endothelial cells alone did not reduce the latency period when 
compared to the control group.
Cell lines Take rate Mean
tumour
volume
(range)
(mm3)
Latency
(weeks)
MCF-7
(5 x 106) supra-threshold 
control
8/8 66.7
21.8-104.8
3-4
MCF-7 (1 x 10s) + Fibroblasts 
(10:1)
8/8 134.6
46.8-184.3
<2
MCF-7(1 X 105) + Fibroblasts 
(5:1)
8/8 141.2
65.4-187.3
<2
MCF-7 V12 1 
(5 X 106) supra-threshold 
control
6/8 103.4
43.1 -  161.0
3-4
MCF-7 V12(l x 105) +
Fibroblasts
(10:1)
6/8 187.8
77.9-225.3
<3
Table 6.11. Table comparing supra-threshold control xenografts with the tumour- 
fibroblast combination xenografts. Results taken from Tables 6.9 and 6.10.
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Xenografts using temperature sensitive human mammary stromal cells
As a parallel experiment to the wild type LT heterologous cell xenografts, the 
conditionally immortalized temperature sensitive stromal cell lines were 
xenografted in combination with breast tumour cell lines to determine their effect 
on stromal-tumour interactions (see Table 6.12 for results). As previously 
explained in the introduction a temperature sensitive mutant of SV40 large T 
antigen (U19tsA58) was used to immortalize the stromal cell lines. HMME 2 and 
7 endothelial cell lines were more temperature sensitive than the corresponding 
fibroblasts arresting completely at 36.5°C. The temperature sensitivities for 
growth has previously been characterised by O’Hare et al. (2001). Temperature 
sensitive LT function was essential for the continued proliferation of the stromal 
lines in vitro however a non-permissive temperature of 39.5°C halted growth of 
the cell lines. The body temperature of a mouse is generally around 38°C, but 
this fluctuates greatly with the animals’ surroundings, and so a small increase in 
room temperature could result in loss of temperature sensitive LT functi
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Cell lines Xenograft Take Rate 
(8 sites per group)
Mean tumour volume 
(range) (mm3)
MCF-7(1 x 10s) Alone 0/8 (0%) N/A
MCF-7 (1 x 105) + 
HMF3A
8/8 (100%) 114.7
(63.5-172.0)
MCF-7 (1 x 105) + 
HMME 7
4/8 (50%) 65.2
(31.0 -  116.0)
MCF-7 (1 x 105) + 
HMF 3A + HMME 7
5/8 (62.5%) 178.2
(56.1 -203.6)
MCF-7 (5 x 106) Alone 8/8 (100%) 70.4
(33.5-110.3)
Table 6.12. Heterologous xenografts of sub-threshold inocula of breast cancer cell 
line MCF-7 and temperature sensitive stromal cells at a ratio of 10:1. Sub-threshold 
inoculum was defined as 1x105 cells/inoculation site. Stromal cells were xenografted in a 
ratio of 1:10 of each stromal cell type to tumour. All combinations were xenografted in 
Matrigel and harvested at 8 weeks.
Results (Table 6.12) showed that the addition of the conditionally immortalized 
stromal cells to the tumour cells also resulted in not only a more successful 
tumour take rate compared with sub-threshold tumour only xenografts but they 
also produced quicker growing larger tumours compared with the supra- 
threshold tumour only controls. The addition of temperature sensitive fibroblasts 
produced 8/8 tumours, a 100% take rate; with 4/8 (50%) injection sites leading to 
tumours with the endothelial cells and 5/8 (62.5 %) in the combined stromal cell 
xenografts. It is clear from these results that non-proliferating stromal cells are as 
effective in assisting tumour take rate as the potentially proliferative non­
temperature sensitive (wild type LT variants) equivalents (compare Tables 6.9A 
with 6.12). As the non-temperature sensitive cells could not be detected after 6
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weeks when xenografted alone it is likely that their effects are confined to a short 
term influence on the tumour cells.
Summary
Thus to summarize, the addition of stromal cells supported sub-threshold tumour 
cell inoculates to produce tumours which would not generally have been 
produced. No significant differences in take rates between 1:5 and 1:10 stromal 
cell to tumour cell ratio xenografts were observed. The addition of fibroblasts 
produced better tumour take rates and provided shorter latency periods than the 
endothelial cells. The MCF-7 cell line was more efficient than the MCF-7 V I2 
line at producing tumours, however once the tumours had taken the MCF-7 V I2 
produced faster growing more hyperaemic tumours.
6.6 Histological and immunohistochemical analysis of the 
heterologous cell xenografts
Tumours generated in the mammary fat pads of nude mice by the mixed 
combinations of tumour cells, stromal cells and Matrigel as described above were 
fixed (frozen and formaldehyde) and processed for histology and 
immunohistochemistry after 8 weeks. 8 tumours from each group: tumour cell 
only, 2 and 3 compartment heterologous cell xenografts were harvested and 
analysed extensively. Positive and negative controls were performed on human 
tonsillar/appendix tissue and samples of mouse skin. In addition heterologous 
tumours using the VEGF over expressing tumour cell line MCF-7 V I2 was also 
analysed. 20 sections/tumour were analysed using a variety of staining methods, 
these being haematoxylin and eosin, immunoperoxidase and, direct and indirect 
immunofluorescence for identification of specific human cell types. The
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objective was to see if there were any differences in architecture, general 
histology and cellular composition between tumour cell only and heterologous 
xenografts.
6.6.1 H aem atoxylin and eosin (H & E) staining  
Tumour cell only xenografts (control)
Haematoxylin and eosin (H&E) staining o f tumour cell (MCF-7) only xenografts 
with close examination o f  the centres o f  the tumours demonstrated, although 
occasional foci could be seen, a general lack o f  necrosis was observed indicating 
that the tumours were well vascularized (Figure 6.5). High power images 
demonstrated that they were poorly differentiated carcinomas equivalent to a 
high grade (Grade III) tumour in a patient. The tumours had large, pleomorphic 
nuclei, prominent nucleoli, and several mitotic Figures per high powered field 
(Figure 6.6). The epithelial tumour cells were recognised as solid cords or tubules 
(Figure 6.7).
Figure 6.5. H&E sections of xenografts produced by MCF-7 inoculations. Tum ours  
a re  com prised  of d e n s e ly  p a c k e d  M C F-7 epithelia l cells with only occas io n a l  ev idence  of 
necrosis  (arrow). M agnifica tion  *80.
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Figure 6.6. Haemotoxylin stained sections of xenograft tumours produced by 
MCF-7 inoculations. X e n o g ra f ts  w e r e  poorly d iffe ren tia ted  ce lls  with la rge  pleomorphic 
nuclei and  prom inen t nucleoli visible. M agnifica tion  *320.
Figure 6.7. H&E sections of xenografts produced by MCF-7 inoculations. MCF-7 
epithelial ce lls  a re  eas i ly  r e c o g n is a b l e  a s  co rd s  (arrows). Magnification ><320.
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The tumours that arose from mammary fat pad injections demonstrated invasive 
characteristics, as they infiltrated through several types of adjacent tissue. They 
infiltrated throughout the gland, spreading through adipocyte layers and 
migrating around ducts (Figure 6.8a). They also spread through the thin layers of 
skeletal muscle and the adipose tissue just beneath the skin surrounding the 
mammary fat pad (Figure 6.8b). One mammary gland tumour also showed 
infiltration into the skeletal muscle of the abdominal wall. There was no evidence 
of the equivalent of a desmoplastic response (i.e. extensive tumour-induced 
proliferation) by the host fibroblasts which were relatively few in number and 
present as isolated cells.
No signs of metastatic spread were observed, on gross inspection, in any 
of the tumour bearing mice. H&E staining of sections of the lungs, livers, 
spleens, and kidneys of MCF-7 tumour bearing mice showed no evidence of 
distant metastases (S Clinton, personal communication).
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A) B)
Figure 6.8. H&E sections of MCF-7 xenograft tumours demonstrating invasive 
growth. Tumours (arrow) invaded into adipose tissue (a) with tumour epithelial cells 
(arrow) clearly visible within the adipose tissue (b). They also invaded into local muscle 
(c) beneath the mammary fat pad with striated muscle visible at high power (d). 
Magnification a), b) & d) ><320, c) ><80.
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However tumours produced by the MCF-7 V12 cell line produced were in 
general noticeably more vascular with large vascular lakes (Figure 6.9). As with 
the MCF-7 cell line there was no evidence of metastases either on gross 
inspection or in histological sections of brain, liver and lungs.
A) B)
Figure 6.9. H&E sections of MCF-7 V12 xenograft tumours (VEGF overexpressing 
variant of MCF-7). MCF-7 V12 containing xenografts were noticeably more vascular 
than MCF-7 containing tumours and in some parts showed large (b) vascular lakes 
(arrows). Magnification *80.
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Heterologous cell xenografts
Analysis of 2 and 3 compartment heterologous cell xenografts, by H&E sections, 
showed no significant differences in architecture compared to the tumour cell 
only xenografts (both MCF-7 and MCF-7 V I2 containing xenografts) with again 
the MCF-7 VI2 tumour appearing more vascular.
6.6.2 Immunoperoxidase staining
Formaldehyde fixed paraffin embedded sections of all tumours from each group 
(10 sections/antibody), were labelled using a standard immunoperoxidase 
labelling technique following individual antigen retrieval procedures (see 
Chapter 2.8). As described previously in the methods, antibodies specific for 
human fibroblasts (vimentin), endothelial cells (CD31/CD34) and breast 
epithelial cells (pan-cytokeratin) were used (Table 6.13).
Antigen Antibody Species Sub-class Dilution Sources
CD34 Q/BEND10 Mouse IgGl 1:30
2 min PC
Dako
CD31 JC70A Mouse IgGl 1:30
2 min PC
Dako
Pan-
cytokeratin
MNF116 Mouse IgGl 1:400 
10 min CT
Dako
Vimentin V9 Mouse IgGl 1:800
18 min 
MW
Santa Cruz
Table 6.13. Table showing the human cell specific antibodies and antigen retrieval 
techniques used. PC (pressure cooker), CT (chymotrypsin), MW  (microwave).
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Staining of 3 compartment heterologous xenografts for human endothelial cells 
with anti-CD31/CD34 antibodies, fibroblasts with anti-vimentin and tumour 
epithelial cells with a pan-cytokeratin are shown in Figures 6.10, 6.11 and 6.12.
Figure 6.10. Immunoperoxidase staining of 3-compartment heterologous tumours 
with a human specific antibody against CD31. Sections demonstrated apparent 
stromal staining in some areas (arrows). Anti-CD34 (not shown) and CD31 produced 
similar staining patterns. Magnification ><80 and ><320.
The pattern of staining produced by labelling of endothelial cells and fibroblasts 
using human specific antibodies against CD31/CD34 and vimentin respectively, 
demonstrated that the human stromal cells apparently not only survived but they 
even proliferated to form complex structures (Figure 6.10 and 6.11). Endothelial 
cells lining blood vessels present in the tumours, were clearly labelled by 
positive staining with both human specific anti-CD31 and CD34 markers, 
suggesting that the xenografted human endothelial cells had formed complex 
structures in the form of blood vessels (Figure 6.10). Staining for human specific
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vimentin was also positive with abundant intermixing visible throughout the 
tumour indicating the fibroblasts had also proliferated in vivo (Figure 6.11).
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Figure 6.11. Immunoperoxidase staining of a 3-compartment heterologous tumour 
xenograft with a human specific antibody against vimentin. Note the apparent 
specific staining in (a) but reactivity of epithelial membranes (arrow) in other regions of 
the same section (b) similar to that seen with the pan-cytokeratin staining in Figure 6.12. 
At *80 and *160 magnification.
Immunoperoxidase staining of all tumour xenografts using a human specific pan- 
cytokeratin (MNF116) antibody with antigen retrieval techniques for the 
identification of human epithelial cells showed strong staining throughout the 
tumour, validating the epithelial nature of the tumour (Figure 6.12).
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Figure 6.12. Immunoperoxidase staining of 3-compartment heterologous tumours 
with a human specific antibody against pan-cytokeratin. At high power (b) many 
individual tumour cells are stained just at their edges. Magnification at ><80 and ><320.
Some of the sections shown in the figures were selected as they appeared to 
represent true staining (i.e. cell type specific). However, there were several signs 
of indiscriminate staining in the xenografts, contrasting with the generally clean 
staining of the human tissue controls. Firstly, a significant amount of non­
specific background staining was present in a large proportion (70%) of the 
sections tested some of it typical 'edge effect' but also patches of apparently non­
specific reaction deeper in the xenograft. In several sections tested the staining 
patterns produced by antibodies to vimentin and CD31 were nearly identical, 
indicating that maybe the staining pattern was not cell type specific but rather 
indiscriminate (non-specific). More specifically, high magnification visualization 
of vimentin staining revealed anomalous staining of epithelial cell membranes in 
some sections (Figure 6.11 b).
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6.6.3 Immunofluorescence staining
Due to the variable patterns of staining observed with immunoperoxidase 
labelling, on formaldehyde fixed paraffin tumour sections with antigen retrieval 
techniques, direct and indirect immunofluorescence staining of frozen sections of 
the same tumours were performed to either confirm or refute the results. Frozen 
sections did not require antigen retrieval techniques. The same antibodies 
identified in Table 6.12 were used. In addition all sections were labelled with 
antibodies identifying mouse endothelial cells and a non species specific 
fibroblast marker.
The human mammary stromal cells in the xenografts were labelled using 
either direct (Zenon Alexa fluor dyes) immunofluorescence or indirect 
immunofluorescence using fluorophore conjugated secondary antibodies (TRITC 
or FITC). With the indirect immunofluorescence technique significant 
background fluorescence was encountered using the anti-mouse IgG reacting 
secondary antibodies. For example, while cytokeratin in MCF-7 cells was 
strongly stained and clearly visible, more specific weaker background staining 
was seen in the associated stroma. When sections were stained by the indirect 
method using antibodies against fibroblasts and endothelial cells the only 
reactivity seen was a weak stromal localisation no more intense than when an 
anti-epithelial antibody was used. It is unclear whether or not this represented 
specific staining or reaction of secondary antibodies with mouse IgG in the blood 
and tissue fluids. No differences were seen between vimentin and CD34/31 
staining with this method again suggesting that there were no specifically stained 
human stromal cells present.
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To overcome the problem of non-specific background staining caused by 
secondary antibodies raised against mouse staining mouse tissues in the 
xenograft experiments, the Zenon (Molecular Probes) direct immunofluorescence 
system was, therefore, adopted. This system works as follows: an unlabelled IgG 
is incubated with the Zenon labelling reagent, which contains a fluorophore- 
labeled Fab fragment (A). The labeled Fab fragment binds to the Fc portion of 
the IgG antibody (B), and excess Fab fragment is neutralized by the addition of a 
non-specific IgG (C). The addition of non-specific IgG prevents cross-labeling of 
the Fab fragment in experiments where multiple primary antibodies of the same 
type are present (Figure 2.7 in Chapter 2.8.5). Thus, this system should in theory 
overcome the problem of background staining observed in the sections labelled 
using indirect immunofluorescence techniques.
Controls sections of a primary human breast cancer were used to validate 
the results and check that the system used was able to label the primary 
antibodies chosen for the study (Figure 6.13).
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Figure 6.13. Direct immunofluorescent labelling of controls, consisting of a 
primary human breast cancer, using human specific (a) anti-pan-cytokeratin 
antibody, (b) human specific anti-vimentin and (c) an anti-CD31 antibody. Note that 
human tumour cells are not so tightly packed as the MCF-7 cell xenografts 
Magnification ><80.
Following successful labelling of a primary human breast cancer control (Figure 
6.13) with the Zenon Alexa fluor direct labelling kit, direct immunfluorescence 
labelling of 3-compartment xenografts was now performed. The sections were 
labelled with antibodies specific for human vimentin, CD31/CD34 and a pan- 
cytokeratin. Results are shown in Figure 6.14.
► s . ' O  *  f a  v  s
Figure 6.14. Direct immunofluorescence labelling of 3-compartment heterologous 
xenografts using a human specific pan-cytokeratin marker. At *80, *160 and *320 
magnifications.
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Staining demonstrated that the xenografts were predominantly MCF-7 cells 
surrounded by non cellular connective tissue. Staining for vimentin and CD34 
and or CD31 was negative in all sections tested. These pictures were
representative of the staining pattern seen in both tumour only and heterologous 
cell xenografts.
There was almost no background staining seen in the xenograft sections 
labelled using the Zenon system. The intensity of specific staining (e.g.
cytokeratin in MCF-7 cells) was very similar for that seen using indirect
immunofluorescence methods. This made the assessment of, in particular, 
endothelial cells and fibroblasts markers more robust. In both cases no cells of 
this type were seen despite an extensive immunohistochemical analysis of 20 
sections/tumour harvested at 60 days. The results from direct
immunofluorescence are summarised in Table 6.14.
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Antibodies tested
Tumour
composition
Pan-
cytokeratin
Vimentin CD34 CD31
MCF-7 +ve —ve -ve -ve
MCF-7 
+HMME 7 
(temperature 
sensitive)
+ve -ve -ve -ve
MCF-7 + HMF 
3A (temperature 
sensitive)
+ve -ve -ve -ve
MCF-7 + HMF 
3A + HMME7 
(temperature 
sensitive)
+ve -ve -ve -ve
MCF-7 + 
HMME 7wt
+ve -ve -ve -ve
MCF-7 + HMF 
3wt
+ve -ve -ve -ve
MCF-7 + HMF 
3wt + HMME 
7wt
+ve -ve -ve -ve
MCF-7 V12 +ve -ve -ve -ve
MCF-7 V12 + 
HMME 7wt
+ve -ve -ve -ve
MCF-7 V12 + 
HMF 3wt
+ve -ve -ve -ve
MCF-7 V12 + 
HMF 3wt + 
HMME 7wt
+ve -ve -ve -ve
Table 6.14. Table summarizing the combinations of cells xenografted to produce 
tumours and their staining pattern using direct immunofluorescence. 20 sections 
per xenograft combination were labelled using the antibodies shown above.
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To control for the possibility that the human stromal cells were present but had, 
for example, down-regulated the expression of cell type specific antigens, 
sections were stained for LT antigen, present in the nuclei of all the cell lines 
used in the study. Negative staining using an antibody against SV40 LT antigen 
confirmed the absence of the human cell lines. Also, no evidence of host 
(mouse) fibroblasts was seen in any of the sections studied using the non-species 
specific vimentin antibody. This was validated by using positive controls 
consisting of human tonsillar tissue and mouse skin tissue in which fibroblast 
staining was seen. However, all blood vessels present in the tumours stained 
positive using an anti-CD31 antibody specific to mouse, with blood vessels being 
significantly more abundant near the periphery of the tumours (Figure 6.15).
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Figure 6.15. Fluorescent labelling of mouse endothelial cells in (a) MCF-7 
containing heterologous xenografts and (b) MCF-7 V12 containing heterologous 
xenografts using an anti-CD31 rat antibody specific to mouse. Tumours stained 
negative for human anti-CD31 antibody. MCF-7 V12 containing xenografts were 
noticeably more hyperaemic and vascular compared to the MCF-7 tumours. Blood 
vessels were significantly more abundant near the periphery of the tumours. Taken at 
*80, 160 and *320 magnifications.
Therefore the staining pattern resulting from direct immunofluorescence did not 
correlate with that seen with the immunoperoxidase staining. Direct 
immunofluorescence staining showed that the xenografts were predominantly 
human tumour epithelial cells (MCF-7 or MCF-7 VI2 cells) admixed with host 
connective tissue (ECM) vascularized by murine blood vessels. A summary of 
the positive labellings is demonstrated in Figure 6.16.
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Figure 6.16. Triple immunofluorescence staining of 3-compartment heterologous 
tumours containing MCF-7, HMF 3wt and HMME 7wt cell lines. Alexa fluor dye 
labelling of M CF-7 ce lls  (g reen ) with m o u se  anti-CD 31 labelling of blood v esse ls  (red) 
and th e  n u clea r sta in  H o ec h st 3 3 258  (blue).
6.6.4 Summary and discussion of immunohistochemistry
In summary, immunoperoxidase staining appeared to show, in some sections 
tested, that xenografted immortalized human mammary fibroblasts and 
endothelial cells not only survived but proliferated within the tumours, whereas 
direct and indirect immunofluorescence showed that the human stromal cells did 
not survive beyond 8 weeks and that such stromal cells that were present in the 
xenografts were predominantly mouse blood vessels.
It is generally held that immunoperoxidase staining is a more sensitive 
labelling technique than immunofluorescence. Immunofluorescence labelling 
works by completely saturating the antigens with primary antibodies and then 
saturating the primary antibodies with fluorophore conjugated secondary 
antibodies. Once both reactions are completed to saturation, no further increase
in fluorescence intensity can occur however long the sections are incubated. In 
comparison, immunoperoxidase labelling is not dependent on antigen saturation 
for intensity of labelling as the colour product is the result of an enzymatic 
reaction which only terminates when the chromogen (DAB) is washed off or 
removed. Therefore, this method is should be better at detecting even low levels 
of antigen, which perhaps immunofluorescence may not make evident.
Unlike immunofluorescence labelling immunoperoxidase staining 
presented some very contrasting and variable staining patterns. Although 
apparent specific staining could be seen in certain regions of xenograft sections, 
the rest of the same sections could demonstrate non-specific staining. In some 
sections, CD31/CD34 and vimentin staining were positive even though one or 
the other of these two cell types was not even inoculated. Also the pattern of 
staining resulting from vimentin and CD31/CD34 markers were remarkably 
similar in the many of the sections tested. Furthermore, these same patterns were 
visible in sections of MCF-7 tumour cell only xenografts although fibroblasts 
and endothelial cells were not inoculated. Vimentin staining of fibroblast 
containing xenografts appeared to be specific to stroma at low magnification; 
however at higher magnification it was clearly not restricted to fibroblasts alone. 
Overall, the percentage of non-specific staining areas were much greater than the 
apparently specifically stained regions
There are several other possible reasons for the discrepancy in results 
produced by the two different immunohistochemical staining methods. Firstly, 
the severe conditions required for some antigen retrieval methods may have 
produced false positives due to cellular damage and therefore indiscriminate 
unmasking of antigens. This may explain how appropriate specific staining in 
one region was replaced by non-specific staining in another region in the same
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histological section. However, positive (controls) staining on human tonsillar 
tissue and negative controls consisting of mouse skin samples were not subject to 
these problems even with the same antigen retrieval procedures. Thus the 
problems of interpreting staining with immunoperoxidase seemed confined to the 
xenografts. Furthermore, the Zenon direct immunofluorescence labelling system, 
which bypasses the problems of antigen-antibody species reactivity showed no 
evidence of human stromal cell presence. Thus, two methods which do not suffer 
from the problems of antigen-antibody species reactivity; immunoperoxidase 
controls on human tissue and direct antibody labelling of the xenografts, 
produced the same pattern of staining.
Another possible reason for the discrepancy in results could be that, 
although the human lines were present, they were no longer expressing these 
normally characteristic cell markers. If this was the case, then LT antigen 
staining should have been positive. However it was negative on extensive 
immunohistochemical analysis, again showing that there was no long term 
survival of the grafted human stromal lines despite their clear influence on take 
rates and latency of grafted human breast tumour cell lines (Chapter 6.5.1)
With these results in mind, experiments were next performed to 
investigate how long the stromal cells survived in vivo as part of the heterologous 
xenografts using the direct immunofluorescence method to detect the cells.
6.7 Heterologous tumour harvests at different time points 
- investigation of stromal cell survival
Experiments were conducted in which the 3-compartment heterologous tumours 
(consisting of MCF-7 tumour cells, wild type LT human mammary fibroblasts
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HMF 3wt and endothelial cell line HMME 7wt inoculated orthotopically as 
mixed cell suspensions) were harvested at 2, 4 and 6 week time points for 
immunohistochemical analysis. Two weeks was chosen as the first time point 
because this was the earliest time at which palpable tumours could be detected 
and harvested. Six mammary fat pads were inoculated for each time point with 
20 frozen section samples taken from different levels of all the tumours. These 
were stained for each of the three cell types using the Zenon direct 
immunofluorescence staining method conjugated with human cell type specific 
antibodies. Results of the direct immunofluorescence labelling are shown in 
Figure 6.17.
Figure 6.17. Direct immunofluorescence staining of 3-compartment heterologous 
xenografts containing MCF-7, HMF 3wt and HMME 7wt cell lines at 2, 4 and 6 
weeks post inoculation. At 2 weeks xenografts stained positive for (a) human specific 
pan-cytokeratin (b) and vimentin. At 4 weeks a similar pattern was seen (c & d) as 2 
weeks. However at 6 weeks xenografts stained positive for pan-cytokeratin but no 
vimentin staining was observed. Staining for human specific CD31 and CD34 was 
negative at all time points; images are therefore not shown.
(See next page for figure)
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Immunofluorescence staining for the three different cell types at 2 weeks 
consistently revealed tumours comprising of clusters of proliferating MCF-7 
breast tumour cells with a sparse scattering of the immortalized human mammary 
fibroblasts as visualized by vimentin staining (Figure 6.17). A similar density 
and pattern of vimentin staining was seen in all the 2 week tumour sections tested 
(20 sections/tumour). There was no obvious intermingling of tumour and 
fibroblasts (i.e. the clusters of solid tumour did not contain human fibroblasts 
which were confined to tumour free areas), as demonstrated by staining on 
consecutive sections. Furthermore there did not seem to be an obvious or 
intimate relationship with the distribution of the MCF-7 cell clusters (i.e. 
fibroblasts did not cluster around the tumour cells). Additional staining for 
vimentin using a non-species specific antibody produced a near identical staining 
pattern as the human specific vimentin marker with few if any additional cells 
reacting indicating very little evidence of host (mouse) fibroblast infiltration (i.e. 
it appeared to detect only human cells) (Figure 6.18). Staining was negative for 
human endothelial cells using the anti-CD31/34 antibodies on all sections tested 
demonstrating that endothelial cells had not survived even to two weeks in 
detectable numbers.
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Figure 6.18. Direct immunofluorescence labelling of the 3-compartment 
heterologous cell xenografts (containing MCF-7, HMF 3wt and HMME 7wt cell 
lines) at 2 weeks with (a) human specific anti-vimentin and (b) non species 
specific vimentin on another tissue section. Staining pattern s is identical 
dem onstrating  th a t th e re  is vitually no m o u se  fibroblast p resence .
At the 4 week time point, the tumours had a higher density of MCF-7 cells with 
much less intermingling connective tissue visible (Figure 6.17d). Vimentin 
staining was also much less obvious with much sparser isolated areas of positive 
staining. Again staining for human endothelial cells with anti-CD31 and anti- 
CD34 markers was negative. Finally at 6 weeks (Figure 6.17a), tumours had a 
similar appearance and structure as the xenografts left to grow for 8 weeks. The 
tumours were predominantly composed of tightly packed MCF-7 cells with 
murine vessels and extracellular matrix (as previously demonstrated).
To summarize, human fibroblast lines were clearly more robust than the 
corresponding endothelial cell lines, with signs of survival up to 4 weeks albeit in
relatively small numbers compared with the human tumour cells, unlike 
endothelial cells which showed no evidence of survival even at 2 weeks despite 
their effect on tumour take rates.
6.8 Primary human breast tumour cell xenografts
Successful growth of primary human breast cancer cells in immunodeficient 
mice is reported to be very low (Mehta et al. 1993), quoted to be in the region of 
7-20%. The effect of the addition of stromal cell support was investigated 
because results from the heterologous cell xenograft experiments, presented 
earlier in this chapter, clearly demonstrate that these cells did support and 
promote establishment as xenografts of established cell lines such as MCF-7. To 
test whether that these stromal cells could also support the establishment of 
freshly isolated primary human breast cancer cells in immunodeficient mice the 
following xenografts were carried out.
6.8.1 Heterologous cell xenografts using primary human breast 
tumour cells
Metastatic breast tumour cells (PE 1050) isolated from a large fresh pleural 
effusion of a patient with an aggressive invasive ductal breast carcinoma had 
been previously harvested and frozen for storage. Five attempts at culturing the 
metastatic tumour cells from this patient in vitro, from 5 consecutive pleural 
harvests, had been carried out without success. Cells cultured in the standard 
(DMEM/Ham’s F12 & 10% v/v FCS) medium remained viable in culture for 
periods of up to 2-3 months but with little evidence of proliferation (MJ O’Hare, 
personal communication). The take rates in vivo and in vitro of such freshly
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isolated primary breast tumour cells are well recognised as being very low. 
However with the support provided by relevant human mammary stromal cells; 
fibroblasts and endothelial cells, it was hoped that the primary cells would 
survive and form tumours in vivo as xenografts, since despite their failure to 
survive in the longterm the immortalized stromal cell lines had a very significant 
effect on the establishment of MCF-7 tumour cell line.
PE 1050 cells were thawed quickly by warming in a water bath for 1-2 
hours and then incubated in L I5 medium with 5% (v/v) FCS prior to 
xenografting. The cells were then spun in a centrifuge to obtain a pellet and 
resuspended in 1:1 SFM and matrigel solution for grafting into the mammary fat 
pad. The PE 1050 cells (5><106 cells) were xenografted alone, with HMF 3wt cells, 
with HMME 7wt cells and with a combination of HMF 3wt and HMME 7wt 
cells in each case at a ratio of 10 tumour cells to 1 stromal cell. Six mammary fat 
pads were inoculated per group and harvested at 8 weeks. A total in excess of
Q
1.2x 10 of the primary human tumour cells were inoculated into mice.
Xenografts of the primary human tumour cells PEI 050/stromal cell 
combinations gave rise to one tumour out of a possible 24 sites (Table 6.15).
Cells and cell lines Xenograft Take Rate
(6 sites per group) MFP +Matrigel
PE1050 Alone 0/6
PE1050+ HMF 3wt 1/6 (16.7% )
PE1050 + HMME 7wt 0/6
PE1050+ HMF 3w t + HM M E 7wt 0/6
Table 6.15. Primary breast tumour cell xenografts.
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The tumour was first noticed at 35 days post inoculation. Following the long 
latency period the tumour proliferated rapidly to exceed the permitted 8mm in 
diameter over a period of one week and so was harvested. The single tumour was 
simultaneously processed for immunohistochemistry, in vitro cell culture and 
serial re-engrafting. The contra-lateral negative mammary fat pad together with 
all the other inoculation sites were left to complete the full 8 week experiment 
period. Samples of all the negative mammary fat pads were dissected and 
processed for immunohistochemistry.
6.8.2 In vitro culture and serial xenografts of the primary tumour
The single tumour produced was carefully dissected, washed in PBS and 
processed for serial xenografting in vivo and for in vitro cell culture. Post mortem 
analysis of the tumour bearing mice after 8 weeks showed no evidence of local or 
distant metastases. Gross inspection of the brain, liver, lungs and peritoneal 
cavity was unremarkable.
2 x 2  mm pieces of the original tumour produced were re-grafted back 
into the mammary fat pads of nude mice. This resulted in a take rate of 75% (3/4 
sites) is shown in Table 6.16. Intact tumour pieces were serially re-passaged by 
surgical xenotransplantation a further two times with 100% take rates (Table 
6.16).
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Xenograft 
(Passage number)
Xenograft Take Rate 
(4 sites per group) 
MFP
Tumour pieces (p i) 3/4
Tumour pieces (p2) 4/4
Tumour pieces (p3) 4/4
Table 6.16. Table summarising the serial re-xenotransplantation of the original 
xenograft produced by the combined injection of primary human breast cancer 
cells and human mammary fibroblasts.
Separation and culture o f the tumourigenic cells.
A portion of the original tumour was rinsed in 30ml of HBSS, containing 
lOOU/ml penicillin and lOOpg/ml streptomycin. The tumour was minced into
'j
small pieces (1mm squares) in a 60mm tissue culture dish using sterilized razor 
blades, and then enzymatically digested in 20ml of 1 ml/mg collagenase A 
(Sigma) in L15 medium and 1 mg/ml of bovine trypsin at 37°C for 45 minutes 
with occasional agitation.
Following digestion, DMEM with 10% (v/v) FCS was added and 
centrifuged for 10 minutes at approximately 300*g (1500 rpm) to form a pellet. 
The pellet was then resuspended in 5ml of DMEM with 10% (v/v) FCS and then 
the cellular digest was filtered sequentially through sterile 40pm and 31 pm nylon 
meshes to remove clumps of cells, centrifuged at 400 xg  for 10 minutes to pellet 
cells, and washed twice in DMEM medium with 10% (v/v) FCS. The cell pellet 
was then resuspended in 3ml of DMEM with 10% (v/v) FCS.
The resulting cells were cultured in medium consisting of DMEM, 2mM 
glutamine, 10% (v/v) heat-inactivated FCS, 50umts/ml penicillin, and 50pg/ml 
streptomycin at either 37°C or33.5°C in a humidified incubator in an atmosphere
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of 5% (v/v) CO2 + 95% air. They attached to the tissue culture flasks quickly and 
grew rapidly in culture (Figure 6.19).
Figure 6.19. In vitro culture of cells isolated from the primary heterologous 
tumour. At x80 and *160 magnifications.
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Cell numbers were then bulked up and re-xenografted, as a cell suspension, back 
into the mammary fat pads of nude mice to assess its ability to form tumours 
(Table 6.17). 5xl06 cells were inoculated into each mammary fat pad in serum 
free medium. Results showed that, at 3 different passage numbers, these cells 
produced a take rate of 100% (Table 6.17).
Xenograft 
(Passage number)
Xenograft Take Rate 
(4 sites per group) 
MFP
Cultured cells (pi) 4/4
Cultured cells (p3) 4/4
Cultured cells (p5) 4/4
Table 6.17. Table summarising the serial re-grafting of the original xenograft 
produced by the combined injection of primary human breast cancer cells and 
human mammary fibroblasts as a cell suspension.
This experiment had therefore resulted in a single xenograft tumour that 
subsequently had very high take rates and growth rates when re-grafted directly 
or after culture. This behaviour was so different to that of the original primary 
human breast tumour cell PEI050 cells that further investigation to determine the 
identity of the tumourigenic cells was carried out including histology and 
immunohistochemical examination.
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6.8.3 Histological and immunochemical analysis o f xenograft 
tumour
Tumour analysis with H&E
H&E staining o f the single tumour produced was carried out and results are 
shown in Figure 6.20.
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Figure 6.20. H&E sections of the original xenograft tumour formed by the 
combined injection of primary human breast cancer cells and immortalized 
fibroblasts. Blood vessels with blood are clearly visible (arrows) at *80, *160 and *320 
magnifications.
Staining showed long elongated structures more typical of sarcomas than 
epithelial tumour cells. There were no signs o f lumina, cords or tubular structures
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as seen with the MCF-7 xenografts (Figure 6.21). Vasculature including red 
blood cells was visible in the tumour sections, but less than in the MCF-7 
tumours. There were no signs of local invasioa 
Ultra-thin section
Ultra-thin sections of both the original PEI050 cells and the resulting tumour 
were compared in Figure 6.21.
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Figure 6.21. Ultra-thin sections of the (a & b) original primary human cancer cell 
PE1050 and (c & d) its resulting xenograft tumour. Note the hollow cluster or 
organoid morphology of the original PE1050 cells compared to the 'undifferentiated' 
appearance of the xenograft tumour stained with toluidine blue. Bar: a) 20pm, b) 5pm, c) 
80pm and d) 40pm.
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Immunofluorescence
Immunohistochemical analysis, using direct immunofluorescence, of all the 
sections of the tumour produced, demonstrated positive staining for human 
specific vimentin (Figure 6.22). Staining was negative for human pan-cytokeratin 
MNF116 and a commonly used epithelial membrane antigen (BrEP4). These 
results suggest that the tumour produced was in fact a sarcoma derived from 
fibroblasts HMF 3wt originally inoculated with the PE1050 primary human 
tumour cells. Further studies in vitro confirmed this conclusion 
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Figure 6.22. Immunohistochemical staining of the original primary human tumour 
xenograft (PE1050/HMF 3wt) for (a) human specific vimentin and (b) a human 
specific pan-cytokeratin. All sections were negative for the human pan-cytokeratin and 
epithelial membrane antigen (BrEP4). Magnification *320.
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Analysis of live cells on coverslips using immunofluorescence.
Cells isolated from the original tumour for in vitro culture were plated on 
coverslips in 24 well plates for direct immunofluorescence (Figure 6.23).
A) B)
C)
•L *  r #  •
o t  <
-  . t * V  V
/ £ ;  ^
D)
*  *  € *  t  
b s j f , «
#  A*
' t i t
^  t m * *
► 4  *
* *#  "v** *» •  A
f *  f , * . V  *  > - 4
% •r V >
■KX&  « j ^ .. &
Figure 6.23. Immunofluorescence labelling of cultured cells isolated from the 
primary xenograft tumour. Staining for (a) human specific vimentin and (b) with 
Hoechst 33258 stain are shown as well as (c) SV40 large T staining of the same cells 
with its corresponding (d) Hoechst 33258 staining. All cells were stained on coverslip. 
Note the lack of punctuate staining with Hoechst 33258 (b and d) indicating their non­
mouse origin.
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In correlation with results produced from staining of the original tumour, the 
cells stained positive for human specific vimentin and SV40 large T antibody 
(Figure 6.24). Positive labelling for the large T antigen confirmed that the 
fibroblasts forming the tumour must be a transformed variant of the immortalized 
human mammary fibroblast cell line, HMF 3wt that was originally grafted with 
the primary human tumour cells.
Human origin was further confirmed by the homogenous staining pattern 
observed with Hoechst 33528. Again the cells stained negative for human pan- 
cytokeratin MNF116 and the epithelial membrane antigen (BrEP4). These results 
confirmed that the tumour was a sarcoma derived from a fully transformed 
variant of the immortalized human mammary fibroblast cell line HMF 3wt.
F ig u r e  6 .2 4 .  C e l l s  i s o l a t e d  f r o m  t h e  p r im a r y  tu m o u r  s t a in e d  fo r  a  h u m a n  s p e c i e s  
s p e c i f i c  v im e n t in  a n d  S V 4 0  x ia r g e  T a n t i g e n .  Double immunofluorescence staining 
with vimentin (green) and SV40 LT antigen (red). Magnification x320
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Results from all the previous xenograft experiments have clearly shown that the 
immortalized fibroblast cell line HMF 3wt was not tumourigenic in nude mice 
when inoculated on its own, combined with endothelial cells or in 3-D 
heterologous spheroids. Also the HMF 3wt cell line failed to survive in 
significant numbers when xenografted with a well established human mammary 
tumour cell line MCF-7. However, the results in this section demonstrate that the 
HMF 3wt cell line, in this case, has been transformed into a tumourigenic line 
(HMF 3wtX), a very rare event (>1 in 3x 108). The capacity of these cells to form 
xenografts persisted for up to five passages in culture, indicating that something 
had fundamentally changed resulting in a stable tumourigenic phenotype.
i,
6.9 Discussion and conclusions
To recapitulate, the aim of this chapter was three-fold. Firstly, to investigate 
whether the immortalized stromal cells would produce tumours when 
xenografted into immunodeficient mice, suggesting that they had been 
transformed into a completely tumourigenic phenotype, as a result of LT antigen 
expression. Secondly, if the stromal cells did not form tumour as such, to 
determine their parameters of survival and proliferation in vivo. The third 
objective was to examine their ability to support and function as stroma to co­
engrafted human tumour cells when xenografted orthotopically. Success in the 
last objective would allow us to develop a more representative model system 
incorporating more human components for vital pre-clinical studies.
Hie transformation of a cell line has frequently been assessed by its 
ability to induce tumours when transplanted in vivo into immunodeficient mice, 
such as nudes and SCIDs. Production of tumours would signify complete
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transformation into a fully tumourigenic phenotype. However, it is important to 
recognise that, in this case, if the stromal cell lines had indeed been transformed 
to become neoplastic by the immortalization process, the tumours produced 
would be sarcomas or angiomas. Thus, they would not be representative of the 
stromal cells found in association with human mammary epithelial carcinomas. 
The ideal situation would be the proliferation and differentiation of these non- 
tumourigenic stromal cell lines in vivo when supported by the appropriate stimuli 
i.e. mammary epithelial cell tumours.
6.9.1 Xenografts of immortalized human mammary stromal cell 
lines
Results showed that none of the stromal cell lines, singly or in combination, 
formed tumours (with a single exception) or survived in the longer term (>6 
weeks) when xenografted into the mammary fat pads of nude mice. Furthermore 
immunohistochemical analysis with cell-type specific antibodies showed no
O
evidence of survival at 8 weeks. A total in excess of 2.4x 10 cells of each stromal 
cell line was inoculated in vivo. Cell number inoculations of this quantity should 
have been sufficient to give rise to many tumours if the cells were intrinsically 
tumourigenic.
To enhance the chances of survival and establishment the stromal cell 
lines were inoculated into the mammary fat pads with the aid of an extracellular 
support matrix (Matrigel). The two main reasons behind orthotopic inoculations 
were to keep a) the tumours in a physiological an environment as possible and b) 
overcome the problem of inadequate or inappropriate stromal microenvironment 
in subcutaneous sites for tumour formation. It was also hoped that extracellular 
matrix would support the establishment of the cell lines within the mice, and so
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increase the likelihood of tumour formation when they were grafted with tumour 
cells. Previous studies have reported that altering the tumour microenvironment 
with Matrigel, a complex mixture of extracellular matrix proteins derived from 
the Englebreth-Holm-Swarm sarcoma (Kleinman et al. 1986 ), or stromal 
fibroblasts (normal and tumour associated) enhances the efficiency of tumour 
formation and decreases the tumour latency in other human breast cancer cell 
lines (Noel et al. 1993). In a final attempt to aid establishment the two stromal 
cell lines were combined in Matrigel in order to provide cell-cell and cell-ECM 
interaction.
However, even with these various attempts of enhancing stromal cell 
survival the stromal cells failed to survive. All pertinent factors were precisely 
defined to avoid technical reasons for failure. For example, the number of 
cells/inoculation, total quantity of cells inoculated, use of adjuncts such as 
Matrigel, experimental period and method of inoculations were consistent with 
similar studies by others (Hahn et al. 1999, Elenbass et al. 2001).
There are several possible reasons why the stromal cells did not survive 
when engrafted into nude mice. Firstly, the immortalized stromal cell lines may 
simply not possess the necessary phenotype. Characterization of the 
immortalized stromal cell lines (Chapter 3) demonstrated with the exception of 
the ras variant (see Chapter 3.6) that these cells were only partially transformed 
according to the in vitro criteria. Therefore their inability to form overt tumours 
in vivo is to be expected or even predicted, but that does not explain their failure 
to survive.
There may be a more general explanation for the failure to survive and 
establish, particularly in the temperature sensitive stromal cell lines. It is possible 
that the body temperature of the nude mice approached non-permissive
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temperatures (negative effects on growth in vitro become apparent above 38.5°C, 
disrupting temperature sensitive SV40 large T antigen function). Although the 
body temperature of a mouse is generally around 38°C this fluctuates greatly 
with the animals surroundings (Sage 1981). A temperature of 38°C would 
effectively prevent the conditionally immortalized temperature sensitive lines 
from proliferating and slow down the wild type LT lines’ growth rate. At this 
point the cells could become more susceptible to NK cell activity or self induced 
apoptosis. However, as the wild type LT sensitive stromal cell lines (non­
temperature) also did not survive this does not seem to provide a robust 
explanation.
Another reason may be that even orthotopic inoculations (mammary fat 
pad) are too hostile an environment for exogenous stromal cell growth with 
inadequate support in the form of cell-cell interaction (tumour-stromal cell 
interaction) and or growth factors. The majority of the mouse gland is composed 
of adipocytes with fibroblasts prominent only in narrow sheaths around the ducts. 
In addition the mouse stroma itself provides a foreign microenvironment for the 
xenografted human stromal cells to survive. In the human gland, the ducts are 
embedded in large tracts of connective tissue (composed predominantly of 
fibroblasts) that is adjacent to deeper layers of adipose tissue (Hovey et al. 1999). 
Epithelial cells are never found in the adipose tracts. Human mammary stromal 
cells may therefore require and in turn thrive in the specialized stromal 
microenvironment of the human gland rather than the largely adipose tissue 
microenvironment of the mouse mammary gland. In order to enhance human 
tumour cell xenograft take rates a required number and/or presence of associated 
stromal cells is needed to be present in microenvironment. Lack of sufficient 
stromal cell presence/component can lead to low take rates and long latency
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periods due to the time taken to recruit the necessary host stromal cells to 
commence proliferation (Shekhar et al. 2001). In addition to the inhospitality of 
the mammary fat pad a factor further compounding failure of cell survival could 
be dispersion of cells at the graft site providing inadequate cell—cell interaction 
despite the presence of Matrigel ECM support.
A residual innate immune response provided by functional murine natural 
killer cells (NK) and B lymphocytes, which is known to be present in nude mice, 
may also be a cause of death in the xenografted human stromal cells (Lin et al.
1997). The recessive nu gene, which is responsible for the lack of a thymus, 
when homozygous in mice, produces the nude mouse (<nu/nu). Because it lacks a 
thymus, nude mice cannot generate mature T lymphocytes essential to the 
immune system. Therefore they are unable to mount most types of immune 
responses, including: antibody formation that requires CD4+ helper T cells, cell- 
mediated immune responses, which require CD4+ and/or CD8+ T cells: delayed- 
type hypersensitivity responses (require CD4+ T cells) killing of virus-infected or 
malignant cells (requires CD8+ cytotoxic T cells) graft rejection (requires both 
CD4+ and CD8+ T cells). The absence of functioning T cells prevents nude mice 
from rejecting not only allografts but also xenografts which are grafts of tissue 
from another species. However NK cell activities in nude mice are not 
suppressed which may be a possible explanation for the destruction of the 
xenografted stromal cells. In fact, nude mice have near normal numbers of B 
lymphocytes and normal to elevated numbers of NK cells (Dandekar and 
Perlman 2002, Benveniste et al. 1990, Kennedy et al. 1992).
NK cells are a type of lymphocyte representing a small fraction (-2%) of 
the lymphocytes circulating in the blood. They are neither T cells nor B cells and 
so form a component o f the non-specific immune defence. They are called NK
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cells because they are already specialized to kill certain types of target cells, 
especially host cells that have become infected with virus and host cells that have 
become cancerous (Okumura et al. 1982, Trinchieri 1989, Biron 1997, Scott and 
Trinchieri 1995). Therefore they are able to respond rapidly, thus providing 
another arm of innate immunity. The immortalized stromal cell lines used in the 
present study were generated in such a way that they express both bacterial and 
viral proteins due to their puromycin resistance gene derived from E. coli and 
expression of SV 40 LT antigen. These factors may enhance their susceptibility 
to NK cells. In addition to killing target cells, NK cells secrete cytokines such as 
the anti-viral cytokine IFN-y and the inflammatory cytokine TNF-a. The host 
response to a xenograft is characterized by a large number of infiltrates by 
monocytes and NK cells suggesting an important role of the innate immunity in 
the process of its rejection (Rossini et al. 1999). This response is reported to 
occur within hours and be complete by 12-24 hours. For example in a model 
system by Kim et al. (2002), the abrogation of the ability of nude mice to reject 
xenografted metastatic carcinoma cell lines, by injecting anti-mouse NK cell 
antibodies, underscores the role o f these cells in tumour rejection.
An argument against the NK cell hypothesis is that the co-xenografted 
MCF-7 tumour cells are not destroyed. However, this applies only to supra- 
threshold inoculations (>5*106) because at sub-threshold inoculations tumours 
generally do not form. It is conceivable that at lower cell numbers (sub-threshold 
inoculation) the cells are largely killed shortly after inoculation by NK cells. It is 
perhaps the remaining tumour cells that have survived NK cells activity that give 
rise to tumours. Opposing this argument is the fact the stromal cell lines were 
also inoculated in numbers equivalent to supra-threshold MCF-7 cells (>5xl06) 
but even this did not result in their long term survival. Furthermore, the results
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from the primary human cell tumour xenograft experiments have demonstrated 
that the co-engrafted HMF 3wt cell line survived long enough to generate the 
tumourigenic variant (HMF 3wtX) and form tumours in several consecutive 
xenografts at high frequency. The fact that the HMF 3wtX cells can survive and 
give rise to tumours following xenografting indicates that these immortalized 
stromal cell lines may be able in rare instances, to overcome this residual innate 
immune response and act in the same manner as tumourigenic breast cell lines. 
However, as mentioned in Chapter 6.8.3, this is a very rare event occurring in 
less than 1 in 3xl08 cells inoculated.
The issue of immunodeficiency and a residual immune response could be 
further investigated experimentally. Firstly, the level of NK cell activity could be 
determined, by measuring their numbers in nude mice shortly after xenograft 
inoculations to establish whether there is increased activity at this time. The 
numbers of NK cells present could be determined by using an antibody specific 
for mouse NK cells (Sentman et al. 1989, Newman et al. 1983). Comparison of 
levels between xenografted and non-xenografted mice would provide an 
indication of increased NK activity. In a different approach, irradiation of nude 
mice can suppress NK cell activity and could be a possible simple means of 
testing whether NK cell activity is at the root of the failure of the immortalized 
stromal cells to survive (Feuer et al. 1995). Alternatively, an animal species with 
an overall greater degree of immunodeficiency, including lower NK cell activity, 
could be used. Possible alternative mouse strains are the severe combined 
immunodeficient (SCID) and non-obese diabetic (NOD)/SCID mice both of 
which are more immunodeficient than the nude.
Tumours from other species (rat, cow, human) are more easily 
transplanted into SCID mice and will grow without being rejected (Greiner et al.
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1998). For certain specific tumours (e.g. thyroid), SCID mice showed improved 
transplantability (take rates) over nude mice (Kawai et al. 1998). SCID mice 
have greater levels of immunosuppression compared to nude mice as they lack 
both B and T cell immunity due to a lack of the catalytic subunit of a DNA- 
dependent protein kinase (Bosma et al. 1983).
The NOD/SCID mouse, generated by crossing the SCID mutation onto 
the NOD background, has multiple defects in innate immunity in addition to the 
lack of B and T cell immunity (Shultz et al. 1995). As these mice have defects in 
NK cell activity (Kataoka et al. 1983), as well as defective macrophage (Serreze 
et al. 1993) and complement function (Baxter and Cooke 1993) on a severe T- 
and B-lymphoid-immunodeficient background they may represent an even better 
animal carrier than SCIDs. They have recently been shown to be more successful 
for xenografting ‘difficult’ cells such as progenitor and stem cell transplantations 
(Rice et al. 2000, van der Loo et al. 1998, van Hennik et al. 1999). This is 
probably because the levels of NK cells and macrophages in NOD/SCIDs were 
lower than in SCID mice (Rajan et al. 1994, Greiner et al. 1998).
Another possibility is the beige (bg) mouse which has a recessive 
mutation of chromosome 13 resulting in impaired NK cell activity, specifically 
severe impairment of NK cell cytolysis with decreased chemotaxis of cytotoxic 
T-cells, macrophages, and polymorphonuclear leukocytes macrophages 
(Talmadge et al. 1980). Therefore crossing SCID with beige mice (Mosier et al. 
1993) may provide a model satisfying the criteria of a reduced innate immune 
response on a background of severe B and T cell immunodeficiency.
Nude mice were used as the initial model, in the present study, as they 
have been shown repeatedly to successfully xenograft human breast cancers in 
particular the MCF-7 cell line. Also some studies have shown that SCIDs and
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beige mice are not universally superior to nudes in that breast cancer do not grow 
and disseminate more readily compared to nude mice (Welch 1997). In fact some 
solid tumours, such as breast cancers (cell lines), metastasize more readily in 
nude mice for reasons not known (Welch 1997).
6.9.2 Xenografts of ras transfected immortalized fibroblasts
The purpose of this experiment was to investigate the potential tumourigenicity 
of the immortalized fibroblasts following expression of the activated ras 
oncogene. The wild type LT variant of the immortalized fibroblast cell line HMF 
3wt, already expressing LT and hTERT, was further transformed by H-ras V I2 
to produce the cell line HMF 3wt ras. This cell line was described in Chapter 3 
to have a ‘fully’ transformed phenotype in vitro as shown by its anchorage 
independent growth in soft agar and loss o f contact inhibition of movement and 
growth (MJ O’Hare, personal communication).
Results showed that out of a possible 8><SC and 16xMFP injections (> 2 
xlO8 total cells), tumours failed to develop in any of the mice (Table 6.2). In 
addition, there was again no evidence of survival, on immunohistochemical 
analysis, at 8 weeks. This suggests that the further expression of the ras 
oncogene in this system was insufficient to produce a fully tumourigenic line in 
vivo and that the acquisition of neoplastic growth requires the progressive loss 
cell death signals or gain o f other functions, including the loss of further 
senescence and suppressor functions.
The activated ras gene (H-mvV12), which is mutated in many human 
cancers although rarely mutated in breast cancers (~5% of cases) (Clark and Der 
1995), is an oncogene which has been used successfully to transform certain
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immortalized human cells (fibroblasts and hepatocytes) (Hahn et al. 1999, 
Elenbaas et al. 2001). The most convincing evidence comes from Hahn et al. 
(1999) who have shown that the ectopic expression of the telomerase catalytic 
subunit (hTERT) in combination with two oncogenes (the SV40 LT oncoprotein 
and an oncogenic allele of H-ras) resulted in the direct tumourigenic conversion 
of normal human fibroblast and hepatocytes. The ability of these different cells 
to form colonies in soft agar (a simple, in vitro test for whether cells need to be 
anchored to a solid surface for growth-normal fibroblasts and epithelial cells do, 
where as transformed cells do not) as well as form tumours in nude mice clearly 
showed that only the combination of all three genetic elements was sufficient to 
cause efficient tumour growth. They concluded that the mutations causing 
telomerase to become active can cooperate with other mutations in oncogenes to 
induce full transformation in nude mice.
When the results of the present study were compared with those of Hahn 
et al. (1999) and other similar studies of Elenbaas et al. (2001) and Morales et al. 
(1999) it was noted that the numbers o f cells inoculated (106), site of inoculation 
(SC) and host animal used (nude mice) were consistent throughout the studies. 
Therefore other reasons must exist to explain the discrepancy.
Hahn et al. (1999) showed that the insertion of the two oncogenes and 
hTERT, in the order SV40 LT followed by hTERT and finally the ras V 12 into 
normal human diploid BJ foreskin fibroblasts, and embryonic hepatocytes, 
resulted in fully tumourigenic cell lines both in vitro and in vivo. Elenbaas et al. 
(2001) produced similar results to Hahn et al. (1999) when they inserted the same 
two oncogenes and hTERT in the same order into normal mammary fibroblasts. 
In contrast to these two studies, the HMF 3wt ras cell line, in the present study, 
was generated by inserting hTERT first followed by the two oncogenes LT and
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then ras. This suggests that the order of insertion of the LT oncogene with 
respect to hTERT may be important. Indeed, it has been reported that 
immortalized human mammary endothelial and fibroblast cell lines that received 
hTERT first followed by LT were more chromosomally stable with less 
structural aberration events than the reverse order of gene transduction (Fauth et 
al. 2004). Also, in a not too dissimilar study, Morales et al. (1999), reported that 
they could not transform human fibroblasts using hTERT and ras combined with 
the human papillomavirus-16 E6/E7 viral oncoproteins (which also inactivates 
the retinoblastoma protein and p53). Again hTERT was inserted before the 
E6/E7 viral oncoprotein. Therefore, with the well known fact that the
I
inactivation of p53/retinoblastoma (Rb) functions increases genomic instability 
(leading to mutations), whereas switching on hTERT does not, this study further 
underlines the fact that the large T protein and or the inactivation of p53/Rb may 
perturb additional cellular targets making the order in which the mutations occur 
important.
To test the hypothesis that the order of LT and hTERT insertion, in the 
generation of cell lines, affects their tumourigenic properties the wild type HMF 
3B fibroblast line which was generated by the insertion of LT followed by 
hTERT could be transduced with the ras oncogene and then its tumourigenicity 
determined. If this line is tumourigenic and gives rise to tumours in 
immunodeficient mice the issue of order of oncogene expression could be 
clarified.
Another possible reason for the discrepancy in the present study may be 
that the expression of the potent oncogene H-ras V 12 was insufficient to induce 
a fully malignant phenotype in the HMF 3wt ras cell line. In the study by 
Elenbaas et al. (2001) normal foreskin fibroblasts and human kidney hepatocytes
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had 10-fold and 60-fold over-expressions of the H-rasV12 oncogenes 
respectively compared with endogenously expressed wild-type H-Ras protein. 
The study also showed that expression of H-rasV12 above a critical threshold 
level (approximately >12.5 fold over-expression) is required for tumourigenic 
transformation of cells in the presence of the co-expressed LT and hTERT genes. 
It is clear that the level of ras expression is a critical determinant of 
tumourigenicity (Hahn et al. 1999). However the level of mutant ras in the HMF 
3wt ras cell line was high (~10 fold) compared with endogenous ras levels when 
examined by immunoblotting (K Hardy, personnel communication). Thus the 
level of ras expression seems a less likely explanation of why the HMF 3wt ras 
cell line did not give rise to tumours, although it cannot be ruled out.
6.93 Xenografts of heterologous stromal and tumour spheroids
The purpose of the spheroid xenograft experiments was to enhance establishment 
of the immortalized stromal cells in vivo, by overcoming several obstacles 
encountered in the cell suspension xenografts as described in Chapter 6.9.1. It 
was postulated that a possible cause for the failure of stromal cells to survive in 
vivo could be either dispersion of cells at the graft site and/or the absence of 
other human cell types. The lack of support from cells normally present in the 
tumour or tissue environment (i.e. cells not in close proximity or contact) may be 
a crucial factor. The stromal cells may require the close contact support of 
epithelial cells as well as other stromal components to survive and proliferate. 
Therefore, the stromal lines were inoculated as pre-formed spheroids 
manufactured in vitro containing a combination of stromal-stromal and tumour-
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stromal cells so as to ensure a high concentration of cells at the graft site in a 
form unlikely to disperse.
However, contrary to expectation, spheroid xenografts using two different 
breast tumour cell lines (MCF-7 and T47D), failed to produce tumours. In 
contrast, the suspensions consistently resulted in tumour formation of both cell 
lines (Table 6.6). The inability of the tumour spheroids to give rise to tumours 
could be due to the architectural nature of the spheroids which may not allow 
host vascularization and therefore the influx of host stromal cells. In an attempt 
to overcome this problem, heterologous tumour-stromal spheroids containing 
human stromal cells were manufactured and xenografted. However, these 
heterologous spheroids did not give rise to any tumours. These results were 
surprising as these spheroids when grown in vitro in extracellular matrix 
demonstrated good viability demonstrating proliferation by growth in size as well 
as promotion of endothelial cell differentiation (see Figure 5.5.2).
A possible reason why the heterologous tumour spheroids did not 
produce tumours may be in the fact that they were manufactured in the RCCS. 
One of the key advantages of the RCCS is the promotion of differentiation of 
epithelial cell types such as prostate (O'Connor 1999) and colon (Jessup et al. 
1997) as well as other cell types cartilage (Vunjak-Novakovic et al. 1999, 
Unsworth and Lelkes 1998). This could lead to a relatively more differentiated 
phenotype causing the tumour lines to become less aggressive with regards to 
tumourigenicity with reduced or absent tumourigenic properties. The spheroids 
formed in the RCCS were shown to possess organised morphologies mimicking 
the structural arrangement of well differentiated in vivo tissue (Chapter 5).
In addition, it was unlikely that the required number of living 
tumourigenic cells (supra-threshold level of 5xl06cells/site) were present in the
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spheroids to give rise to successful xenograft establishment. Even if the required 
number of cells had been physically present in the spheroids, due to the very 
nature of the spheroid architecture only the cells in the peripheries of the tumour 
may have been effective as they would be most amenable to host stromal and 
vascular support for survival. In other words the cells at the centre of the 
spheroids may be dormant, less viable or in the process of dying due to 
inadequate host vascularization.
6.9.4 Heterologous 3-compartment cell xenografts
Due to the failure of establishment of the heterologous tumour-stromal 
spheroids, an adequate model of tumour-stromal interaction could not be 
manufactured. Thus, heterologous cell suspension xenografts with strictly 
controlled cell number inoculations were performed. The main purpose of this 
experiment was to determine whether the immortalized human mammary stromal 
cell lines, as a cell suspension, could support tumour establishment and 
proliferation. By providing a more stromal cell-concentrated environment, which 
is a requirement of human tumours, it was hoped that human tumour cell 
proliferation could be further promoted and accelerated. The proliferating tumour 
cells may then reciprocate by providing the necessary support for stromal cell 
survival and growth.
The results showed that the addition of the immortalized stromal 
cells (both the wild type LT and temperature sensitive lines) to sub-threshold 
tumour cell inoculates (MCF-7 and MCF-7 V I2 lines) provided a significant 
growth advantage resulting in a consistent take rate (Table 6.9). Not only did 
these combinations produce better take rates, but the fibroblast cell lines in
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particular promoted shorter latency periods (~2 weeks) compared with the 
controls (i.e. supra-threshold tumour cell only inoculates), which took 3-4 weeks 
to become palpable. Surprisingly, there was no difference in effect between the 
wild type LT and temperature sensitive stromal cell lines in this respect 
suggesting that the mouse body temperature was not high enough to inhibit the 
cells. Results also showed that a ratio low as 1:10 stromal cell to tumour cells 
was sufficient to greatly enhance tumour cell establishment. The VEGF over­
expressing MCF-7 V12 breast tumour cell produced noticeably more vascular 
tumours than the original MCF-7 tumour cell line presumably by stimulating 
growth and differentiation of host endothelial cells. However this stimulation
i.
seemed to only affect the mouse and not the co-xenografted human endothelial 
cells because the latter could not be detected immunohistochemically.
These results concur with the now well recognised fact that human 
tumour cell xenografts, in particular breast, are more successful in terms of take 
rate and latency when extra stromal cells are added (Brouty-Boye et al. 1993, 
Horgan et al. 1987). Also the fact that although only one cell type was injected, 
the tumours (breast and prostate) were histologically complex with a significant 
proportion of the cells being normal stromal cells, including fibroblasts, 
epithelial cells, mast cells and macrophages underlines the requirement for 
stromal cells for support (Tuxhom et al. 2001, Ronnov-Jessen et al. 1996). This 
suggests that a lack of a sufficient stromal cell presence/component will lead to 
poor success and long latency periods due to the time taken to recruit the 
necessary host stromal cells. As the majority of the mouse mammary gland is 
composed of adipocytes, with fibroblasts prominent only in narrow sheaths 
around the ducts, the addition of exogenous stromal components may be required 
to improve or accelerate human tumour xenograft establishment. It is noteworthy
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that there was a virtual absence of host fibroblasts within these heterologous 
xenografts (see Figure 6.18). In the human gland, the ducts are embedded in large 
tracts of connective tissue (composed predominantly of fibroblasts) that are 
adjacent to deeper layers of adipose tissue (Hovey et al. 1999). This may explain 
why, in the present study, the supra-threshold tumour cell-only inoculates had 
long latency periods in comparison to the heterologous inoculates. The question 
remains as to how the added stromal cells produced this enhancement, given that 
that they clearly do not survive very long in vivo.
The precise mechanism of stromal cell stimulation of tumour epithelial 
cell growth is not clear at present, although it may be associated with 
extracellular matrix (ECM) factors. Normal human fibroblasts may enhance 
tumourigenicity by a similar mechanism to Matrigel, which is derived from a 
mouse sarcoma that secretes ECM factors (Kleinman et al. 1986) similar to those 
that are deposited by primary human fibroblasts. Fibroblasts have previously 
been shown to regulate mammary epithelial function through interaction with 
ECM constituents (Haslam 1986, Haslam 1991). However, other studies have 
shown that the latency of tumour formation by MCF-7 xenografts was markedly 
shorter with admixed stromal fibroblasts than with admixed Matrigel (Noel et al. 
1993, Noel and Foidart 1998). This suggests that normal human fibroblasts may 
either secrete different ECM factors to Matrigel or that this effect is mediated 
through additional or different mechanisms. It is likely that the human fibroblasts 
produce human specific ECM. This may explain how the fibroblasts promote 
tumour growth more efficiently than Matrigel, whose role may be limited to 
enhancing the initial establishment of implanted tumour cells in the host tissue. 
The results from the present study support this hypothesis in that while the 
fibroblasts did not survive beyond 2 weeks, probably having a similar duration of
action as Matrigel, their effect on epithelial cell growth was dramatic. 
Furthermore the temperature sensitive lines, which would have tended to take on 
a non-proliferative senescent phenotype at the high temperatures in the mice, 
produced the same effects as the wild type stromal cell lines. This fact and the 
results from Chapter 6.7 suggest that it is the initial short term influence that is 
all important. Therefore, it opens the possibility that an alternative mechanism of 
action other than ECM factors may be the cause.
One such alternative mechanism could be mediated by soluble paracrine 
factors such as cytokines and or growth factors. With stromal cells now well 
recognised as having major roles in epithelial growth and differentiation in adult 
tissues (Cunha et al. 1985), it has been reasoned that stromal cells closest to the 
epithelial cells would be the most likely to be involved in emitting regulatory 
signals in a paracrine manner (Wu et al. 2003). For example fibroblast growth 
factor (Giri et al. 1999, Foster et al. 1999), transforming growth factors a and B 
(Dumont and Arteaga 2000, Akhurst and Balmain 1999) insulin like growth 
factor (IGF) (Singer et al. 1995) and hepatocyte growth factor (Kasai et al. 1996) 
have all been shown to promote epithelial tumour cell progression in both in 
vitro and in vivo model systems. Although potentially any of the growth factors 
derived from breast fibroblasts may function as an important regulator of 
mammary tumour growth, IGFs, and IGF-II in particular which is also produced 
by human fibroblasts, may play a key role in mediating breast tumour growth 
because IGF-II expression has been reported in the stroma of invasive breast 
cancers, but not in normal breast (Singer et al. 1995).
The hypothesis o f a paracrine mediated stimulation of tumour cells by the 
immortalized human mammary stromal cell lines provides a reasonable 
explanation for the dramatic influence on tumour cell growth. Considering this
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hypothesis in conjunction with the issue of NK cell activity it is possible that the 
immortalized stromal cell lines have released growth stimulatory paracrine 
factors (cytokine or growth factors) prior to being selectively destroyed by the 
NK cells in favour of the tumour cells as they are more susceptible (as they 
contain viral and bacterial transgenes). The initial focus of NK cell activity on 
the more susceptible immortalized fibroblasts may divert activity away from the 
tumour cells allowing their proliferation to such an extent which could permit the 
tumour cells to effectively out proliferate NK cell activity. This temporary 
diversion or reprieve from NK cell activity together with the influence of growth 
promoting factors may provide an additional explanation for their dramatic 
growth rates in comparison to tumour cell only inoculates.
6.9.5 Primary human tumour cell xenografts
The results from the present study demonstrated that a combined inoculation of 
primary human breast tumour cells and the immortalized fibroblast cell line 
HMF 3wt cells resulted in the transformation of the HMF 3wt cell line so that it 
not only survived but also proliferated to form tumours in vivo. This is surprising 
as both the HMF 3wt fibroblast cell line and the ras transfected variant HMF 3wt 
ras alone and in combination with established breast tumour cell lines repeatedly 
failed to be tumourigenic in other in vivo xenograft experiments. The new 
tumourigenic fibroblast cell line HMF 3wtX produced was more aggressive than 
the MCF-7 or MCF-7 V12 breast tumour cell lines in terms of in vivo take rate 
and latency rates.
The most likely explanation of this rather rare event is the spontaneous 
mutation in one or a few of the HMF 3wt cells possibly during their routine
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culture or after their inoculation into the nude mice. However the co-inoculated 
primary breast tumour cells, PE 1050, could have played a role. There are 
emerging studies which support the concept of neoplastic transformation of 
tumour associated stromal cells in breast and colon tumours by tumour-epithelial 
interactions (Kurose et al. 2001, Wemert et al. 2001, Moinfar et al. 2000). 
Wemert et al. (2001), for example, demonstrated that frequent genetic alterations 
in non-hereditary invasive human colon and breast cancers (loss of 
heterozygosity (LOH) and TP53 mutations) occur not only in the neoplastic 
epithelial cells, but also in the adjacent fibroblastic stroma and that both 
components can share clonal features. Similarly Kurose et al. (2001) reported 
that out of 41 sporadic invasive adenocarcinomas of the breast examined, the 
great majority of markers (13 chromosomal regions) showed a higher frequency 
of LOH in the neoplastic epithelial compartment than in the stroma, suggesting 
that LOH in neoplastic epithelial cells precedes LOH in surrounding stromal 
cells.
As all stages in this stromal-tumour progression (i.e. primary fibroblasts, 
transformed with hTERT only, transformed with hTERT and LT, transformed 
with hTERT, LT and ras and the tumourigenic HMF 3wtX cells) exists they can 
be compared so as to define what changes have taken place at these five stages. 
One way this could be achieved is using global microarray analysis which will 
define changes in levels of gene expression. Also specific mutations in known 
proto-oncogenes could be studied.
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Chapter 7 
Investigating the role of circulating 
endothelial progenitor cells
7.1 Introduction
Vasculogenesis, the in situ differentiation of primitive endothelial progenitors 
known as angioblasts, into endothelial cells that aggregate into a primary 
capillary plexus, is responsible for the development of the vascular system during 
embryogenesis (Peichev et al. 2000). In contrast, angiogenesis, defined as the 
formation of new blood vessels by a process of sprouting from pre-existing 
vessels, occurs both during embryonic development and in postnatal life (Peichev 
et al. 2000, Watt et al. 1995, Reyes et al. 2002). Until recently, it was believed 
that the formation of the foetal capillary networks from migrating endothelial 
precursor cells was restricted to early embryonic development with blood vessel 
formation in postnatal life being mediated by sprouting of endothelial cells from 
existing vessels (i.e. derived from endothelial cells located in situ). However, 
recent evidence suggests that endothelial stem cells may persist into adult life, 
playing an important role in postnatal endothelialization, whereby they contribute 
to the formation of new blood vessels (Nishikawa et al. 1998, Gehling et al. 
2000, Rafii et al. 1994, Asahara et al. 1997). This in turn suggests that, as during 
development, neo-angiogenesis in the adult may depend at least in part on a 
process of vasculogenesis. Precursors of endothelial cells have been isolated from 
bone marrow and peripheral blood (Peichev et al. 2000, Watt et al. 1995). The 
ontogeny of these endothelial progenitors is unknown.
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Identification of circulating endothelial progenitor cells
A search of unique endothelial markers to facilitate the isolation and 
characterization of circulating endothelial progenitor cells (CEPs), has shown 
that CD 133 is expressed on a subset of CEPs but not on mature differentiated 
endothelial cells. CD 133, also known as AC 133, is a novel 120-kd glycosylated 
polypeptide that contains 5-transmembrane domains with an extracellular N- 
terminus and a cytoplasmic C-terminus (Miraglia et al. 1997, Yin et al. 1997). 
The function of CD 133, which does not share homology with any previously 
described haematopoietic cell surface antigen, is not known. However, isolation 
of a sub-population of CD34+ cells using a monoclonal antibody to human 
CD133 has identified functional CD34+ haematopoietic stem cells that can 
differentiate into mature endothelial cells (Peichev et al. 2000, Reyes et al. 2002). 
Incubation of these non-adherent CD34+CD133+ cells with VEGF, fibroblast 
growth factor (FGF-2) on a substratum of fibronectin or collagen results in their 
proliferation and differentiation into adherent CD133+VEGFR-2+ mature 
endothelial cells. These results suggest that circulating CD34+ cells expressing 
VEGFR-2 and CD 133 comprise a functional population of CEPs cells that may 
play a role in postnatal angiogenesis or vasculogenesis.
One study has demonstrated that human derived CD133+ cells can 
repopulate sheep bone marrow (Yin et al. 1997) and, therefore, can be considered 
pluripotent haematopoietic stem cells. Expression of CD 133 is rapidly down 
regulated in haematopoietic progenitors and stem cells as they differentiate into 
more mature post-mitotic cells (Peichev et al. 2000, Gehling et al. 2000). In fact, 
virtually all mature haematopoietic cells, including mature myeloid, 
megakaryocytes, erythroid, and lymphoid cells and terminally differentiated
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haematopoietic cells, fail to express CD133 (Miraglia et al. 1997, Yin et al. 
1997).
The emerging potential of circulating endothelial progenitor cells
CD34 haematopoietic stem cells can be detected at low numbers in bone 
marrow, foetal liver, and umbilical cord blood. The fact that CD 133 is expressed 
on immature haematopoietic stem and progenitor cells, and is not found on 
mature blood cells provides a valuable method of isolation and tracking.
CEPs can be isolated from adult bone marrow, foetal liver, umbilical-cord 
blood and cytokine-mobilized peripheral blood and have been reported to give 
rise to mature endothelial cells when cultured in vitro (see Table 7.1). Freshly 
isolated CEPs are a reported to be highly motile, non-adherent population of cells 
that express characteristic cell surface markers. Several markers are expressed by 
both CEPs and mature endothelial cells, including VEGFR2 (Gill et al. 2001), 
CD34, PECAM and CXCR4 (Peichev et al. 2000). With this information now 
available it is now feasible to isolate, characterise and study the potential of 
CEPs to differentiate in vitro and in vivo.
CD133-expressing cells in different haematopoietic tissues (1)
% CD34+ % CD133+
Normal bone 
marrow (2)
1.47 ±0.23 (36.3 ±2.2) 0.52 ±0.11
Cord blood (3) 0.37 ±0.06 (51.0 ± 1.6) 0.16 ±0.03
Apheresis (4) 1.75 ±0.31(75.3 ±0.8) 1.37 ±0.27
Table 7.1. Table summarizing the percentage of CD34+and CD133+ cells present in 
different haemopoietic sources. Figures in brackets represent % of CD34 cells also 
expressing CD133+. References 1) de Wynter et al. 1998, 2) Horn et al. 1999, 3) Green 
et al. 2000, 4) Verfaillie 2002.
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Circulating endothelial progenitor cells and their role in cancer
CEPs as detected by CD 133 have been detected at increased frequency in the 
circulation of cancer patients and lymphoma-bearing mice (Mancuso et al. 2001, 
Monestiroli et al. 2001). In addition tumour volume and tumour production of 
VEGF were found to be correlated with CEPs mobilization in the animal model 
system. There is increasing evidence that these cells actually contribute to the 
formation of tumour associated blood vessels. Several studies have shown that 
CEPs when engrafted into immunocompromised mice, incorporate into the 
vasculature of xenotransplanted tumours (Lyden et al. 2001, Reyes et al. 2002, 
Moore 2002, Asahara et al. 1999, Gehling et al. 2000). For example, human 
CD133+/VEGFR2+ cells were isolated from human umbilical cord blood, 
injected in vivo into immunocompromised mice and allowed 2 weeks to engraft. 
Mice were then inoculated with human tumour cells, and the relative 
contributions of donor-derived and host-derived bone marrow cells in the tumour 
vasculature was determined on the basis of immunohistochemical staining for 
human antigens (VEGFR2, CD34 and PECAM). On average, 5-8% of cells in 
the newly formed blood vessels within the tumour tissue were found to be of 
human donor origin (Rafii et al. 2002), indicating that the transplanted donor 
cells contribute to the newly formed vasculature. In another relevant in vivo 
model, it was shown that the neo-intimal surface of left ventricular assist devices 
ranging from 28 days to 6 months old was also colonized with large numbers of 
CD 133+VEGFR-2+ cells determined by dual-colour flow cytometry (Rafii et al. 
1995, Peichev et al. 2000).
The purpose of this chapter was three-fold. The first objective was to 
isolate and characterize CEPS according to methods established in the literature. 
The second objective was to demonstrate that these isolated cells could
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proliferate and differentiate as mature endothelial cells when exposed to the 
appropriate stimuli. The third objective was to determine if such CEPs 
preparations could participate in the vascularization of human tumour cell 
xenografts by incorporating them in multi-compartment xenograft models, 
because of the failure of the differentiated endothelial cells to survive or 
participate in xenograft formation (Chapter 6).
7.2 Isolation, culture, characterization and 
differentiation of circulating endothelial progenitor cells
7.2.1 Isolation of circulating endothelial progenitor cells
Low-density mononuclear cells (LD-MNCs) were extracted from two different 
sources. These were fresh bone marrow aspirates (~50ml) collected from healthy 
donors for allogeneic bone marrow transplantation and cytokine mobilized ‘buffy 
coat residues’, blood samples rich in mononuclear cells obtained from the 
National Blood Transfusion Centre.
LD-MNCs were isolated from fresh bone marrow aspirates and cytokine 
mobilized ‘buffy coat residues’ by layering on a Ficoll-Hypaque gradient. 
Following isolation of LD-MNCs the haemopoietic stem/progenitor cells were 
isolated using positive selection of CD133+ expressing cells using the AC 133 
Cell Isolation Kit (Miltenyi Biotec) and the MS Magnet (MiniMACS™, Miltenyi 
Biotec). Briefly LD-MNCs were added to CD133+ monoclonal antibody 
conjugated super paramagnetic microbeads (AC 133 Cell Isolation Kit), washed 
and processed through a MACS magnetic separation column to obtain a pure 
population of CD133+ cells as shown in materials and methods (Chapter 2.3.2).
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A 500ml bag of ‘buffy coat residue’ provided a yield of approximately 
108 LD-MNCs cells. Isolation of CD133+ cells from this sample resulted in a 
yield of <1% producing approximately 106 CD 133+cells. A typical 50ml marrow 
aspirate produced a smaller yield of between 106-107 LD-MNCs cells. This 
provided a CD133+ cell population of 104-105 CD133+ cells. The isolation 
procedure was earned out on over 10 samples of each source, producing similar 
results each time in terms of yields. These results were consistent with previous 
reports on the isolation of CEPs (Table 7.1).
7.2.2 Culture of circulating endothelial progenitor cells
To induce differentiation into endothelial cells, freshly isolated CD133+ (CEPs) 
cells were plated at 1 x 104 to 2 x 104 cells in 25cm2 fibronectin coated tissue 
culture vessels, in a mix of 60% (v/v) low-glucose DMEM and 40% (v/v) 
MCDB-201 , supplemented with lx  insulin-transferrin-selenium, lx linoleic 
acid-BSA, 10-8 M dexamethasone, 10 "* M ascorbic acid 2-phosphate, lOOU/ml 
penicillin and 100pg/ml streptomycin, lOng/ml VEGF, bFGF-2 lng/ml, 2ng/ml 
IGF-1, and 10% (v/v) FBS as described by Reyes et al. (2002). Cultures were 
maintained at 37°C in a humidified atmosphere of 5% (v/v) CO2 with medium 
changes every 4-5 days.
After 14 days of culture, between 50-60% of the initially non-attached 
cells, had formed isolated colonies each containing an average of 60 cells 
(Figures 7.1a and b), their morphology was characterized by a round central body 
with some cytoplasmic projections. These cells were then cultured for a further 2 
weeks by which time they had proliferated to confluency (Figure 7.1c and d). 
The confluent cultures consisted of a monolayer of ‘spindle-shaped cells,
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sometimes forming a focal area of cell aggregates with typical ‘cobblestone’ 
morphology similar to primary mammary endothelial cells. In some instances, 
cells were sub-cultured using trypsin after day 9 at a 1:4 dilution under the same 
culture conditions. The sub-cultured cells which could be passaged < 5 times 
completed at least 20 population doublings before they ceased to grow and 
eventually died.
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Figure 7.1. Phase contrast micrographs of circulating endothelial progenitor cells 
(CD34+ CD133+) cultured on fibronectin coated tissue culture flasks at (a) 2 days, 
(b) 8 days and 2 weeks (c & d). Figure (d) represents a high power image of (c). a) & c) 
taken at ><80 with c) & d) at ><320 magnification.
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7.2.3 Characterization of circulating endothelial progenitor cells 
Expression of endothelial cell markers
The endothelial cell markers PECAM-1/CD31, CD34 and endothelial progenitor 
cell marker CD 133 were used to characterize CEPs that had been in culture for 2 
and 5 days. Live cells were plated on coverslips in 24-well plates, allowed to 
attach before being fixed in methanol (Figure 7.2). The cells were stained using 
indirect immunofluorescence. In three separate experiments using independent 
cell preparations from both bone marrow and cytokine mobilized blood samples, 
all of the samples taken at 2 days were CD133+ with the majority of cells (>80%) 
staining with the mature endothelial cell marker CD34. However staining for 
CD31 was negative. Preparations from experiments in which cells were cultured 
for longer (5 days) were negative for CD 133, with weak CD34+ (5-37%) staining 
visible. However the cells stained positive for CD31 at 5 days. Therefore CD 133 
expression present at 2 days had disappeared after 5 days, CD34 staining had 
reduced and CD31 had appeared indicating progressive maturation towards an 
endothelial phenotype.
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Figure 7.2. Immunofluorescence staining of CEPs after 5 days of culture using an 
anti-CD31 antibody. CEPs isolated from both bone marrow and cytokine mobilized 
blood were cultured on fibronectin coated tissue culture flasks before being labelled. 
Magnification x80 and x320.
7.2.4 Differentiation analysis of circulating endothelial progenitor 
cells
The ability of mature human microvascular endothelial cells to form a network of 
capillary like structures when cultured on Matrigel is a sign of normal endothelial 
cell differentiation. Therefore the ability of CD133+ cells (CEPs). which had been 
cultured in vitro as described above, to differentiate on Matrigel to form 
microcapillaries was examined. CD133 cells that had been in culture for 5-7 
days following isolation were harvested using trypsin. 1x10^ cells were counted 
and plated on 200pl of pre-prepared Matrigel in 96-well plates (and also 500pl 
on 24-well plates) containing medium and observed for differentiation into 
microcapillary networks (Figure 7.3). Similar to mature human endothelial cells
the CD 133 were seen at first to move to aggregate before forming recognisable 
capillary like networks after 3-4 hours.
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Figure 7.3. Phase contrast micrographs of primitive microcapillary like networks 
formed from CD133+ (CEPs) that had been in culture for 7 days. CD133+ cells were 
isolated from a bone marrow aspirate. Cells isolated from cytokine mobilized blood 
produced similar structures. Images were taken after 12 hours of plating on Matrigel. 
Magnification x80 and x320.
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7.3 Xenotransplantation of CEPs
The purpose of this experiment was to investigate the role of CD133+ cells 
(CEPs) in tumour neo-vascularization by incorporating them as part of the 
heterologous 3-compartment xenograft model. Chapter 6 demonstrated that the 
heterologous tumour xenografts involving the use of immortalized human 
mammary endothelial cells to form human endothelial cell vascularized tumours 
were unsuccessful. With the knowledge that human embryonic stem cells have 
the potential to differentiate into various cell types and, thus, are useful as a 
source of cells for transplantation or tissue engineering, it was postulated that 
inoculating human tumour cell xenografts with endothelial precursor cells, which 
have the ability to differentiate into endothelial cells, would improve the chance 
of producing vasculature of human origin. It was also envisaged that the growth 
factors produced from the xenografted human mammary tumours and fibroblasts 
as well as host/murine cells would provide the necessary growth factors to 
activate and promote endothelial proliferation and differentiation of the CEPs.
7.3.1 Preparation of xenografts
To determine the capacity of CEPs to contribute to tumour angiogenesis and or 
neo-vascularization, CD133+ cells (CEPs) were xenografted in combination with 
the VEGF over-expressing mammary tumour cell line MCF-7 V I2 and/or human 
mammary fibroblasts together into the mammary fat pads in matrigel. Both 
freshly isolated CEPs and adherent cells that had been cultured for <48 hours 
were tested.
Due to the limited number of CEPs available from single isolates, 
experiments utilized cells from both bone marrow and cytokine mobilized blood.
3 5 8
In the first experiment three 500ml ‘buffy coat residue’ bags were processed to 
yield a CD133 cell count of approximately of 3X106 cells. These cells were 
cultured in vitro for 2 days before being harvested for xenotransplantation. Six 
mammary fat pads of 3 mice were inoculated with MCF-7 V12 at a supra- 
threshold number (5X106) and CD133+ cells at a ratio of 10:1. This experiment 
was repeated on a separate occasion but this time with 5X10^  cells of the 
immortalized fibroblast line HMF 3wt was added as well as the CEPs.
In the second series of experiments, three 50ml bone marrow samples 
were also processed to yield a CD133+ cell count of approximately of 2X106 cells 
which were cultured in vitro for 2 days before being harvested and inoculated 
into the mammary fat pads as before. 4 mammary fat pads were inoculated with 
5X105 cells of CD133+ cells and 5><106 of MCF-7 V12 cells together with 5x 105 
cells of HMF 3wt cells. In addition, 1 x106 CEPs from the same preparation were 
xenografted into two mammary fat pads (5X105 CEPs cells/MFP) with MCF-7 
VI2 and HMF 3wt cells in the same ratios as above but this time as freshly 
isolated cells without prior in vitro culture. Results for all the CEPs inoculations 
are shown in Table 7.2.
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Cells and cell lines Xenograft Take Rate 
MFP + Matrigel
MCF-7 V12 + CEPs (2 days in 
culture)
5/6 (blood)
MCF-7 V I2 + HMF 3wt + CEPs (2 
days in culture)
6/6 (blood)
MCF-7 V12 + HMF 3wt + CEPs 
(freshly isolated)
2/2 ( bone marrow)
MCF-7 V12 + HMF 3wt + CEPs (2 
days in culture)
4/4 ( bone marrow)
Table 7.2. Table summarizing the results of circulating endothelial progenitor cell 
xenografts. MCF-7 V12 cells were inoculated in supra-threshold numbers/site (5><106). 
CEPs and fibroblasts (HMF 3wt) were inoculated at a ratio of 1:10 to tumour cells. All 
inoculations were carried out in Matrigel into the MFP. Results are a summary of several 
experiments.
7.3.2 Analysis of xenografts
Xenografts were harvested between 4-6 weeks when a substantially palpable 
tumour was present. In keeping with previous experiments of MCF-7 V I2, 
tumours were visibly hyperaemic. The inoculations gave rise to 17 tumours out 
of a possible 18 inoculations. Extensive immunohistochemical analysis (20 
sections/tumour), using direct immunofluorescence, of the xenografts with 
specific markers for mature human endothelial cells (CD31/CD34) was carried 
out. Results showed very few scattered and isolated fluorescent dots within the 
tumours. However there was no evidence of any significant vascular structure 
staining in the tumours with either the human specific anti-CD31 or CD34 
antibodies. This was consistent throughout sections taken from 4 week and 6 
week old tumours. All blood vessels within the tumours tested stained positive 
using a mouse specific CD31 antibody.
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7.4 Discussion and conclusion
The close similarities in the development of haemopoietic and endothelial cells 
during embryonic life have led to the hypothesis that the two lineages may derive 
from a common precursor called the haemangioblast (Muller et al. 1994, Garcia- 
Porrero et al. 1995, Smith and Glomski 1982). Indeed, recent studies have shown 
circulating CD34+ cells expressing VEGFR-2 and CD 133 comprise a functional 
population of circulating endothelial progenitor cells (CEPs) that may play a role 
in postnatal angiogenesis or vasculogenesis.
The expression of CD 133 on immature haematopoietic stem and 
progenitor cells but not on mature blood cells provided a valuable method of 
isolation and tracking CEPs. The stimuli provided by fibroblast growth factor 
(FGF)-2, vascular endothelial growth factor (VEGF), insulin-like growth factor 
(IGF), fibronectin and/or collagen, have been shown by the present study to 
provide CEPs with the necessary nutrients to differentiate into adherent 
anchorage-dependent endothelial cells in accordance with other studies (Bagley 
et al. 2003, Quirici et al 2001, Kalka et al. 2000, Peichev et al. 2000). As 
reported in the literature, the expression of CD34 and CD 133 diminished with 
maturation and differentiation (Miraglia et al. 1997, Yin et al. 1997, Delia et al. 
1993). Therefore, subsets of CD34+ cells that express CD 133 are truly a 
phenotypic and functional marker of an immature population of haematopoietic 
stem and endothelial progenitor cells.
In summary, bone marrow and cytokine mobilized blood derived CD133+ 
cells can be isolated with a single step of immunomagnetic separation and 
cultured in appropriate conditions, to give rise to an almost pure population of 
endothelial cells, probably derived from ‘putative’ haemangioblasts.
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Role of CEPs in tumour xenograft vascularization
Studies have shown that multi-potential progenitor/stem cells when xenografted 
into immunocompromised mice incorporate into the vasculature of 
xenotransplanted tumours (Lyden et al. 2001, Reyes et al. 2002, Moore 2002, 
Asahara et al. 1999, Gehling et al. 2000). In one particular study, human multi­
potential adult progenitors (MAPC) (bone marrow mononuclear cells depleted of 
CD45+ and glycophorin A+ cells using micromagnetic beads) which had been 
induced to differentiate into endothelial cells in vitro, were injected into 
immunocompromised mice that carried mouse Lewis lung carcinomas. After 5 
days, 30% of the newly formed tumour associated vessels were derived from 
human MAPC-derived endothelial cells. MAPC-derived human endothelial cells 
also contributed to the neovasculature of spontaneously formed lymphomas that 
commonly develop in ageing immunocompromised mice (Reyes et al. 2002). 
Similarly Asahara et al. (1999) engrafted tumour bearing mice with transgenic 
mouse bone marrow cells that were engineered to express a cell marker lacZ 
under the transcriptional regulation of the VEGFR2 and TIE2 endothelial- 
specific promoters. Cells that expressed this marker were detected throughout the 
implanted mouse syngeneic colon tumours, indicating that bone marrow-derived 
cells, such as CEPs, can home to the tumour vasculature and differentiate into 
endothelial cells. None of these studies, however, could prove that recruitment of 
bone marrow-derived cells was absolutely required for tumour growth.
In the present study it was hypothesized that injecting CEPs (CD133+ 
cells) directly into the mammary fat pads of nude mice, with the relevant tumour 
cells and fibroblasts already present, would provide the simplest and most direct 
method for CEPs establishment and differentiation. However, results showed that 
differentiation and incorporation of CEPs as mature endothelial cells into the
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multi-compartment xenograft models was unsuccessful. This was surprising as 
similar type studies in the past indicated that they would incorporate into the neo­
vasculature as summarized as above. Furthermore, the present study introduced 
several novel attempts at optimising the environmental conditions as well as 
enhancing the establishment and growth of the CEPs. For example, the VEGF 
over-expressing cell line MCF-7 V12 was used to promote maturation and 
differentiation into mature endothelial cells whilst the addition of fibroblasts and 
Matrigel was intended to provide additional growth factor and nutritional 
support.
In order to identify the possible causes for the failure of CEPs to 
establish, differences between the present study and other similar type studies 
were examined. There were several possible factors which could affect whether 
the CEPs successfully established or not. These were: origin of progenitor/stem 
cells, cell numbers inoculated, route and site of engraftment, host (animal) type, 
tumour site and type, criteria for identification and duration of experimental 
period. These pertinent features were identified in several similar type studies 
and are shown in Table 7.3.
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Reference Origin & 
Cell
numbers
Origin of
CEPs
Cultured
/fresh
Host
animal
Injection
method/site
Tumour
type&
site
Criteria for 
identification
Duration of 
study
toes et 
12002
Bone
Marrow
2.5 x 105
Multipotent
adult
progenitor
cells
cultured + 
fresh
Tail vein 
injection
NOD / 
SCID
Lewis CD3LCD34,
lung CD36, CD44,
carcinoma HLA class I,
/SC HLA class II,
B2-
microglobulin
, VCAM,
ICAM-1, VE-
cadherin,
H1P12, ZO-1,
MUC18, avB3,
a vB5, B-
catenin, y-
catenin
14 days & 
12 weeks
idling
11L2000
Blood
l * 1 0 c
CD133
LD-MNCs
Cultured
SCID SC
Human
lung
cancer cell 
line A549/ 
SC
CD34,
CD41a,
CD41b,vWF,
VE-Cadherin,
KDR,
P1H12, EN4
5 weeks
\sakara
<111999
Bone
marrow
2 xlO6
LD-MNCs
Fresh
Transgen 
ic mice 
expressin 
g B-
galactosi
dase
Intravenous Mouse
colon
cancer
cells
(MCA38)/
SC
lacZ-
expressing
cells
1 or 3 weeks
.vden et 
42001
Bone
Marrow
1 xlO6
LD-MNCs Idl-Id3
protein
double
knockout
mice
Tail vein 
injection
B6RV2
lymphoma
Intra-
dermal
vWF, 
VEGFR1, 
MOMA-1, 
C D llb , VE- 
Cadherin
14 days
fare et 
42004
Umbilical 
cord blood
1.0 X  106 
per mouse
Human
CD34*
LD-MNCs
Cultured
Tail vein 
injection
SCID
Mouse
glioma
Brain
Cells pre­
labelled with 
a fluorophore 7 & 14 days
Table 7.3. Table summarizing various xenografts studies of endothelial progenitor 
cells.
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The number of CEPs/inoculate and the source of CEPs was ruled out as a 
possible cause of failure as similar numbers of CEPs from both cytokine 
mobilized blood and bone marrow aspirates have been xenografted previously in 
other studies resulting in successful CEPs establishment (see Table 7.3). Both 
sources were used in the present study.
There were, however, some noticeable differences between the present 
study and those reported in the literature. Unlike the present study, SCID and 
NOD/SCID mice were predominantly used as the host with CEPs generally 
being inoculated haematologically, rather than directly into the tumour 
microenvironment. NOD/SCID mice in particular have been shown to provide 
better conditions for stem cell engraftment (Rice et al. 2000, van der Loo et al. 
1998, van Hennik et al. 1999). However, in the present study the hypothesis that 
the residual innate immune responses (e.g. NK cells, macrophages and 
complements) are the cause for the failure to survive is unlikely. This is because 
CEPs are primary cells and not genetically engineered and so do not express 
bacterial and viral proteins like the engineered immortalized endothelial cells. 
Thus, they should be less susceptible to NK cell activity if this was indeed a 
significant factor.
The site of inoculation may be very important in providing the initial 
support required for survival and differentiation. Endothelial precursor cells need 
to adhere to the endothelium to proliferate and so, like many of the studies listed 
in Table 7.3, a haematological implantation method may be more advantageous 
in the establishment of CEPs. The majority of the successful engraftment studies 
injected the CEPs into the vascular system following establishment of tumour 
xenografts and then examined tumour associated blood vessels for CEPs 
differentiated endothelial cells (Reyes et al. 2002, Asahara et al. 1999). The
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recruitment of CEPs to tumour angiogenesis probably represents a multistep 
process, including (a) active arrest and homing of the circulating cells within the 
angiogenic micro vasculature; (b) trans-endothelial extravasation into the 
interstitial space; (c) extravascular formation of cellular clusters; (d) creation of 
vascular sprouts and cellular networks; and (e) incorporation into a functional 
micro vasculature.
In addition, adhesion of CEPs to the tumour vessel endothelium of 
xenografts may be further facilitated by the tumour-specific micro- 
haemodynamics, which are characterized by a much lower blood cell velocity 
(-350 pm/s) and wall shear stress (-4.0 dyne/cm2) when compared with 
physiological conditions in post-capillary venules of non-angiogenic vasculature 
(Vajkoczy et al. 2002, Vajkoczy et al. 2003). The observation that after 
permanent adhesion, CEPs extravasate into the interstitium further indicates 
similar mechanisms underlying CEPs and leukocyte recruitment and migration 
through the endothelial lining. This is in contrast to a non-angiogenic 
microvasculature, where CEPs are arrested by passive plugging of small calibre 
capillaries and remain intravascular (Vajkoczy et al. 2001, Butcher 1991, Menger 
et al. 1996).
In the studies summarized in Table 7.3, CEPs were generally inoculated 
after tumours xenografted into the mice had had sufficient time to establish and 
proliferate. However, in present study as CEPs were inoculated at the same time 
as the tumour cell lines. Consequently, there would be a lag period in which it 
took the tumour cell line to establish and commence vascularization. Thus, the 
attraction of CEPs by angiogenic signals in tumour bearing mice may provide a 
key role in promoting the differentiation and establishment of CEPs. However, 
the molecular and cellular mechanisms underlying CEPs recruitment and
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differentiation are not yet understood, and remain as one of the central issues in 
stem cell biology (Blau et al. 2001). For instance, it is unclear how CEPs 
specifically home to angiogenic sites, which critical steps underlie their 
incorporation into new blood vessels, and how effectively these processes 
compare with the activation of local, pre-existing endothelial cells (Risau 1997). 
Furthermore, little is also known about which tumour types are most susceptible 
and dependent on CEPs and haematopoietic cells for their growth. The present 
study used breast cancer cells, something not attempted in the other reported 
studies. Based on available evidence, mobilization and functional incorporation 
of CEPs into the tumour vasculature is essential for the growth of some tumours; 
lymphomas, Lewis lung carcinoma and colon cancers (Rafii et al. 2002). This 
was concluded because a significant proportion of the tumour vasculature was 
consistently derived from CEPs derived endothelial cells.
Another important difference between the present study and those in 
Table 7.3 is that the experiment period of those studies was generally much 
shorter, with the search for CEPs incorporation beginning much earlier. This 
perhaps may be a crucial factor as a longer time period may have resulted in little 
or no evidence of CEPs presence as they may have changed their expression 
phenotypes or even been replaced by other cells and new vessels (i.e. rapid cell 
turnover in angiogenic vasculatures leading to short cell life). Based on mouse 
tumour models, it seems that these cells are most likely to contribute to the early 
stages of tumour growth, but are only involved in the angiogenic phase.
To conclude therefore, as the hypothesis that the CEPs, too, are being 
destroyed by a remaining immune response is unlikely the most probable 
alternative reason maybe due to inadequate support for endothelial cell growth, 
in terms of nutrition and endothelial cell specific growth factors. Comparison
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with other similar xenograft studies demonstrated that the type of animal (usually 
SCID), site of inoculation (IV) and duration of experiment maybe be crucial 
factors in providing the required nutritional support and growth factors. Having 
said this, the combination of factors released by the co-engrafted tumour cells, 
fibroblasts and growth factor rich Matrigel should have provided sufficient 
growth support.
To test the above hypothesis, freshly isolated CEPs could be injected 
intravenously into SCID or NOD/SCID mice once the MCF-7 cells had 
established in the mammary fat pads. The injected CEPs could then be tracked by 
pre-labelling or looking for specific human endothelial markers at regular earlier 
time points (< 2 weeks). To further improve success, repeated injections of 
greater cell numbers into the vasculature of human breast tumour bearing SCID 
mice could be performed to overcome the problem of cell arrest when trapped in 
small calibre vessels.
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Chapter 8 
Final discussion and future prospects
8.1 Aims of the thesis
The overall aim of this thesis was to develop a more authentic xenograft model 
of human breast cancer by incorporating the relevant and essential constituents of 
a tumour microenvironment: human stromal cells and extracellular matrix. 
Ideally this would be an organotypic, 3-compartment xenograft model of human 
breast cancer in mice comprising solely of human cells. Until now, the great 
hurdle impeding multi-compartment xenograft model development was due to a 
lack of readily available human stromal cells. With the recent availability of a 
series of immortalized human mammary stromal cell lines (O’Hare et al. 2001) it 
has now been possible to commence development of a multi-compartment in 
vivo breast tumour model.
The development of a complex multi-compartment heterologous 
xenograft model incorporating the relevant stromal elements would provide a 
realistic alternative to currently available chimeric xenograft models. If 
successful this model could be utilized as an accurate and credible pre-clinical 
model for the development and testing of new therapeutic strategies, such as 
those that target breast cancer stroma itself.
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8.2 General summary of results
The results of this thesis fall into two broad areas that can be summarised as 
follows:
In vitro
The main purpose of the first results Chapter 3 was to determine whether the 
immortalized human mammary stromal cell lines had retained the basic 
characteristics of normal cellular growth or whether the immortalization 
procedure had transformed the cells. This was performed to assess the suitability 
of the available stromal cell lines for use in the development of tumour-stromal 
xenograft models, and more specifically, to assess the effects and the extent to 
which the SV40 LT antigen had on cell transformation during the 
immortalization process. Characterization of the immortalized stromal cell lines 
demonstrated that the stromal cell lines displayed some of the hallmarks of in 
vitro transformation. However they also retained many of the characteristics of 
normal cells. Therefore, although they could not be strictly regarded as normal 
cells they were also by no means fully transformed. In fact they were much 
closer phenotypically to normal cells than fully transformed cells. The results 
also demonstrated that the each of immortalized human mammary stromal cell 
lines tested was unique, with each line possessing slightly different phenotypic 
properties. The cause of variability between the cell lines (discussed in Chapter 
6) was attributed to the order and timing of hTERT and SV40 LT gene 
transduction (Fauth et al. 2004). However it was also clear from the results that 
the characteristics of the cell lines were not just a manifestation of LT antigen 
expression alone as they had gained other additional properties which made then 
individual.
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Thus it seemed that a useful series of robust and stable human mammary 
stromal cell lines have been generated. Although these cells that possess an 
immortal growth potential, they function essentially like normal cells without 
expressing a typical fully transformed malignant phenotype (Table 3.3). As a 
result they represent a readily available source of essentially normal human 
mammary stromal cells, potentially able to support a tumour microenvironment 
when xenografted in vivo. However, with the available in vitro results it was not 
possible to select a particular cell line as being better suited or more superior for 
the in vivo studies. Their individual characteristics meant that each had to be 
tested separately.
Following characterisation of the available human mammary stromal cell 
lines, the ability of human and host (mouse) endothelial cells to interact to form 
vasculature was investigated (Chapter 4). In vitro differentiation assays 
incorporating the immortalized human mammary microvascular endothelial cells 
and the normal mouse microvascular endothelial cells showed that the two cells, 
from the different species, interacted to form primitive micro-capillary networks. 
These results were very promising in that they indicated that the immortalized 
human mammary endothelial cell line, when xenografted, would interact with 
host endothelial cells to integrate into host vasculature. It, therefore, provided a 
potentially effective means of vascularizing the human tumour cell xenografts 
with human vessels.
The next goal was to bring together the tumour and stromal cells to 
manufacture a 3-D in vitro tumour-stromal co-culture. The rationale was to 
transplant these preformed tumour-stromal units directly into the mammary fat 
pad in order to optimise tumour develop and spread. The availability of the 
immortalized stromal cells, together with increasingly sophisticated 3-D cell
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tissue culturing techniques meant that complex 3-D tumour-stromal models 
could now be created without the limitations associated with monolayer cultures 
and single cell type spheroids (Chapter 5). The 3-compartment heterologous 
tumour-stromal spheroids manufactured in the Rotary Cell Culture System 
demonstrated that more complex organotypic tissues can be manufactured in 
vitro realistically mimicking the 3-D structure and environment of in vivo 
cancers. These 3-D heterologous tumour models incorporating human 
endothelial cells were shown to be viable tissue units capable of growth and 
differentiation in an appropriate environment such as Matrigel. They also 
provided a novel way of promoting tumour-stromal interactions prior to 
xenotransplantation.
As an alternative source of endothelial cells the potential of human 
circulating endothelial progenitor cells (Chapter 7) for vascularizing human 
tumour xenografts with species-specific blood vessels was investigated. CEPs 
could be isolated from bone marrow aspirates and cytokine mobilized blood 
using a simple magnetic bead isolation protocol, with an antibody for CD 133, 
which is a marker specific for CEPs. CEPs, with the appropriate stimuli, 
differentiated into cells that had the same phenotype and characteristics as 
mature endothelial cells. Differentiated CEPs formed primitive micro-capillary 
like networks on Matrigel. These results were promising for the engraftability of 
CEPs in an in vivo setting. If in the future CEPs are found to be a significant 
contributor of tumour vascularization then they may provide a new target for 
chemotherapy.
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In vivo
Results showed that none of the stromal cell lines, singly, in combination or as 
spheroids formed survived or tumours, in the long term (>6 weeks) when 
xenografted into the mammary fat pads of nude mice (Chapter 6). Even when the 
stromal cell lines were inoculated as a part of a 3-compartment xenograft, 
immunohistochemical analysis showed no evidence of survival 8 weeks post 
inoculation. Overall a total in excess of 2.4x108 cells of each stromal cell line 
was inoculated singly or as a mixture in vivo. Generally, cell number inoculations 
of this quantity should have been sufficient to give rise to tumours if the cells 
were intrinsically tumourigenic. Therefore to clarify the survival characteristics 
of the stromal cells 3-compartment tumours were harvested at earlier time points 
(2,4 and 6 weeks). This showed that the fibroblasts survived up to 4 weeks albeit 
in very small numbers. However, the endothelial cells were much more sensitive 
in that they were no evidence of survival after just 2 weeks. Surprisingly the 3- 
compartment heterologous co-culture spheroids previously manufactured in the 
Rotary Cell Culture System also failed to form tumours.
However, the co-engraftment of the immortalized human mammary 
fibroblasts and or endothelial cell lines, with human breast cancer cell lines, as 
mixed cell suspensions had a dramatic effect on the promotion of tumour cell 
take rates including reduction of latency periods. The addition of the stromal cell 
lines to sub-threshold tumour cell inoculates consistently gave rise to tumours, 
which would not ordinarily have formed in the absence of the stromal cells. The 
fibroblasts had the greatest effect with combined inoculations of the fibroblast 
and endothelial cells not producing an additional cumulative effect. Although the 
immortalized stromal cells had a dramatic effect on established breast cancer cell
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lines they did not support the establishment of primary human breast cancer cells 
(PE 1050). In addition, the xenografts of the CEPs were unsuccessful in that they 
also did not survive when inoculated as a combination with tumour and or the 
human mammary fibroblast cell lines.
A surprising positive outcome of the xenograft studies was the full 
transformation of the wild type HMF 3wt fibroblast cell line, on one occasion, 
into a tumourigenic cell line (HMF 3wtX). This resulted when the HMF 3wt 
fibroblast cell line was engrafted with primary human breast cancer cells 
(PE1050). Tumours produced from the HMF 3wtX and PE1050 mixture were 
confirmed as being fibroblastic of human origin expressing the LT antigen, 
originally inserted into derivative immortalized cell line. Not only was this line 
tumourigenic in vivo, it had a near 100% serial re-transplantation rate. Now that 
we have the complete series of fibroblasts ranging from the primary fibroblasts, 
immortalized, immortalized ras oncogene expressing and now the fully 
tumourigenic HMF 3wtX line we can start to investigate the crucial step by step 
changes that have occurred in the original unaltered cells to confer a fully 
transformed malignant phenotype.
8.3 Potential improvements to current models
The failure to establish a fully human humanized xenograft model, in nude mice, 
by using SV40 LT immortalized stromal cells can be attributed to one of two 
possible causes, namely the animal system or the cells used. Therefore, change in 
either one or both of these components of the model system may provide more 
success in the future. Thus, in an attempt to overcome the problems previously 
encountered in developing a fully humanized model several new ideas and
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concepts can be considered. These relate to both the animal hosts and the cells to 
be engrafted.
Animals
Before discussing the advantages and disadvantages of different varieties of 
alternative cells available for use, the most appropriate animal carrier system 
needs to be identified. With the increasingly greater frequency of xenograft 
studies incorporating tumour and stromal stem cells (e.g. CEPs), as well as the 
future prospect of humanized mammary fat pads created from stem cells, the best 
possible animal system for success needs to be designed or discovered. A 
growing number of studies are reporting that NOD/SCID mouse provides the 
best animal carrier system for human stem cell studies (Rice et al. 2000, van der 
Loo et al. 1998, van Hennik et al. 1999). The NOD/SCID mutation results in an 
immunodeficient mouse with multiple defects in adaptive as well as non-adaptive 
immunologic function. This strain of mice lack functional lymphoid cells, serum 
complement activity and show little or no serum immunoglobulin with age. The 
multiple defects in innate and adaptive immunity unique to the NOD/SCID 
mouse provide an excellent in vivo environment for reconstitution with human 
haematopoietic cells.
In addition to its greater level of immunosuppression the systemic 
hormonal environment of NOD/SCID mice during puberty or pregnancy has 
been demonstrated to be sufficient to promote human mammary epithelial cell 
proliferation and lactogenic differentiation (Parmar et al. 2002). The use of 
NOD/SCID mice rather than nude mice now means ectopic oestrogen 
supplementation is not required for mammary epithelial cell proliferation in vivo 
(Parmar et al. 2002). Unlike nude mice, whose reproductive system and thus 
hormonal environment are compromised (Kopf-Maier and Mboneko 1990),
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NOD/SCID female mice are fertile, with a fully functional reproductive system. 
This may suggest that the generally observed graft-host interspecies 
incompatibilities, observed in previous nude mice based studies, originate from 
paracrine heterotypic interactions rather than from incompatibilities in the 
systemic hormonal environment.
This strain of mice can more readily accept and cultivate hard to grow 
cells and so it is possible that they will be more amenable to the growth of the 
SV40 LT immortalized human mammary fibroblasts and endothelial cells. 
Furthermore, as discussed in detail in the discussion of Chapter 6, the residual 
NK cell activity in nude mice (Cudkowicz and Hochman 1979, Kiessling et al. 
1977, Yu et al. 1992) was raised as a significant factor that may have caused the 
death of the immortalized stromal cells. As NOD/SCID mice have little or no 
residual NK cell activity the use of this strain could quickly resolve the issue of 
whether NK cell activity was an important factor. Alternatively the population of 
NK cells in nude mice could be depleted by treatment with anti-asialo-GMl 
antibody as others have demonstrated prior to administration of the human cells 
(Barry et al. 1991, Shpitz et al. 1994, Lacerda et al. 1996).
Stromal cells
Before discussing the alternative cells available for use in the model there is 
another method of testing the hypothesis of NK cell induced cell death in nude 
mice; by changing the method of immortalization. NK cells are attracted to cells 
expressing viral and bacterial proteins. Therefore an alternative method of 
immortalization such as viral or bacterial constituents (e.g. not SV40 LT) may 
provide more success. For example, the human mammary stromal cells could be 
immortalized by other methods such as ionizing radiation and chemical 
carcinogens (Newbold et al. 1982), although these methods are clearly very
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inefficient compared with viral genes used in the present study. These cells will 
not be subject to attack by the NK cells. Presently there are no human adult 
mammary fibroblasts and endothelial cells that have been manufactured in this 
manner. Although human cells apparently immortalized with telomerase only 
have been reported (e.g. BJ foreskin human fibroblasts) these have also been 
engineered using viral type vectors and include bacterial selection markers. 
When selecting alternative cells for use in the development of the 3-compartment 
xenograft model, two important factors must be considered. These are the 
engraftability/survivability in vivo and secondly the authenticity of the cells as 
representative of real tumour associated stroma.
With the recent availability of the tumourigenic mammary fibroblast cell 
line, HMF3wtX, it can now be xenografted in combination with breast tumour 
epithelial and the immortalized endothelial cells. The HMF3wtX fibroblasts have 
been demonstrated to consistently survive in vivo and form tumours. The 
rationale of this study would be to determine whether this line affected breast 
epithelial tumour take rates or whether it would overpower the co-engrafted 
tumour epithelial cells to form a predominantly fibroblast rich sarcoma rather 
than a solid epithelial carcinoma. However if this was the case the growth of the 
HMF 3wtX’s could be attenuated, for example by irradiation or anti-mitotics 
prior to engraftment. Also it could be determined whether the HMF3wtX 
fibroblasts would interact and stimulate the endothelial cell to firstly survive and 
secondly differentiate to form complex structures (e.g. blood vessels) If, 
however, the tumour growth is promoted and the xenograft remains 
predominantly epithelial then we would have developed a truly ‘humanized’ two 
compartment xenograft tumour model. This cell line needs to be characterized in
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more detail to fully determine its authenticity in terms of its retention of normal 
fibroblast function.
It is well recognised that stromal cells found in tumours (e.g. breast, 
prostate etc.) differs from those found in the normal stromal microenvironment. 
Therefore it is important to note that the 3-compartment model described in this 
thesis adopted the use of immortalized normal mammary fibroblasts as opposed 
to tumour associated fibroblasts which may be a crucial factor in determining 
their survival as well as their effect on tumour cell growth. As the technique for 
immortalization is available and easily reproducible the generation of 
immortalized tumour associated mammary fibroblasts and endothelial cells 
would not be too difficult. Hence the use of immortalized tumour associated 
fibroblasts and endothelial cells in the 3-compartment models could provide a 
more physiologically relevant interaction improving their growth and 
authenticity. However such a model would require the use of NOD/SCID mice to 
avoid the problems anticipated with NK cell activity.
As introduced in Chapter 1, both fibroblasts and endothelial cells 
represent a very diverse and heterogeneous population of cells possibly derived 
from multi-potent stem cells capable of organ and tissue specific differentiation. 
For example, cells labelled as common fibroblasts can differentiate into a variety 
of cell types e.g. fat, cartilage, muscle etc. Circulating endothelial progenitor 
cells found in several different types of haemopoietic tissue e.g. bone marrow, 
foetal blood can differentiate into organ specific endothelial cells. Due to the fact 
that CEPs are ontogenically less mature than angioblasts, they can be useful for 
the characterization of endothelial cell commitment and differentiation. Moreover 
the fact that they do form new vessels provides exciting prospects. The 
therapeutic potential of endothelial progenitor cells was recently demonstrated by
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the improved blood flow rates and capillary density following the transplantation 
of endothelial progenitor cells in hind limb ischaemic mice (Kalka et al. 2000). 
In another study by Levenberg et al. (2002) showed that when CEPs were 
transplanted in vivo, into SCID mice, the cells appeared to form microvessels 
containing mouse blood cells. There is clear evidence that these cells have the 
capacity to functionally contribute to the growth of certain tumours (Rafii et al 
2002). By isolating these multi-potential cells and then engrafting into multi­
compartment tumour models we may be able to overcome the problems of cell 
survival and provide an alternative means of introducing stromal elements. 
Furthermore these cells wherever they are placed would differentiate into organ 
specific fibroblasts and endothelial cells enhancing model authenticity.
One important issue that requires clarification is how recruited CEPs and 
pro-angiogenic haematopoietic cells are temporally and spatially related to 
tumour growth. Based on mouse tumour models, it seems that these cells are 
most likely to contribute to the early stages of tumour growth, but are only 
involved in the angiogenic phase. It is also not known whether CEPs are required 
to maintain the long-term integrity of established tumour vessels.
It is also unclear which tumour types are most dependent on CEPs and 
haematopoietic cells for their growth. Based on the available studies, 
mobilization and functional incorporation of CEPs into the tumour vasculature is 
essential for the growth of a few tumour types (e.g. lymphomas, Lewis lung 
carcinoma and colon cancers). Therefore additional studies are required to 
identify the tumour types that are partially or fully dependent on the recruitment 
of CEPs. One possible hypothesis is that unique chemokines/cytokines and 
tissue-specific ECM that are produced by each tumour cell type are the main 
determinants for the recruitment of CEPs. Identification of such unique ECM and
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chemo/cytokines will provide new targets to tailor the treatment of each specific 
malignancy. The ability to target these cells in patients with malignancies is still 
a distant prospect. Further understanding of the biology of CEPs and endothelial 
cells is essential for the development of new methodologies to treat cancer, 
promote vascular healing, provide suitable coating for vascular grafts, and for the 
delivery of toxins to tumour vascular beds.
Tumour cells
Human breast tumours are comprised of phenotypically diverse populations of 
breast cancer cells expressing a variety of cell surface markers including (CD44, 
CD24, and B38.1) (Ahrens et al. 2001, Uchida et al. 2000, Kufe et al. 1983). It 
has, therefore, been hypothesized that only a rare, phenotypically distinct subset 
of cells within breast cancers have the capacity to significantly proliferate and 
form new tumours, but that cells within this subset do so very efficiently (Reya et 
al. 2001). Therefore, the traditional thinking that a large numbers of cells must 
typically be inoculated to give rise to tumours in xenograft models may be 
clumsy and inefficient.
Very recently it has been reported that subsets of immunophenotypically 
distinct (CD44+/CD24) breast cancer cells within primary breast tumours had the 
ability to form new tumours and have enhanced take rate as xenografts (Al-Hajj 
et al. 2003). As few as 100 cells with this phenotype were able to form tumours 
in mice, whereas tens of thousands of breast cancer cells, from the same tumour, 
with alternate phenotypes failed to form tumours. This tumourigenic sub­
population could also be serially passaged: each time cells within this population 
generated new tumours containing additional CD44+CD24/low lineage 
tumourigenic cells as well as the phenotypically diverse mixed populations of 
non-tumourigenic cells present in the initial tumour. It is hoped that by isolating
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these cells from primary breast tumours they can be used to improve xenograft 
take rates as well as accelerate the development of much needed xenograft 
models.
These results, therefore, demonstrate that there is a hierarchy of breast 
cancer cells in which some cells have the ability to proliferate extensively, 
whereas the majority of tumour cells that can be derived from this population 
have only limited proliferative potential in vivo. This sub-population of 
proliferative cells may represent multi-potent epithelial progenitor cells. The 
ability to prospectively identify tumourigenic cancer cells will facilitate the 
elucidation of pathways that regulate their growth and survival. Furthermore, 
because these cells drive tumour development, strategies designed to target this 
population may lead to more effective therapies. Traditionally drug therapies 
have been developed based on their ability to cause tumour regression in animal 
models. Due to the fact that the majority of cancer cells within a tumour may be 
of the non-tumourigenic type, therapies directed at these cells would cause 
tumour regression. However, if therapies fail to target the tumourigenic cells, 
then these cells would persist after therapy and be able to regenerate the tumour, 
resulting in tumour relapse.
It is recognised that normal stem cells have mechanisms that make them 
relatively resistant to cytotoxic drugs, such as increased expression of BCL-2 
family proteins, increased expression of membrane transporters like breast cancer 
drug resistance protein, and multiple drug resistance (Lagasse and Weissman 
1994, 1997, Domen et al. 1998, Zhou et al. 2002). The expression of such 
proteins in tumourigenic breast cancer stem cells may make them inherently 
more resistant to current therapies. The prospective identification of this 
tumourigenic population of cancer cells should allow the identification of
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molecules expressed in these cells that could be targeted to eliminate this crucial 
population of cancer cells, leading to more effective cancer therapies.
8.4 Future prospects
The concepts described above are logical extensions of the work in this thesis 
with a similar but refined strategy. There remain several additional ideas that 
could further enhance the value of human xenograft system for modelling tumour 
development and treatment. These include humanizing the animal immune 
system and humanizing its mammary gland.
Development of a humanized immune system in animals 
A fundamental limitation inherent to all xenograft models is the lack of an 
immune response against the tumour cells. With the development and testing of 
new therapeutic strategies being a key function of these models it is unfortunate 
that the action of therapeutic strategies that incorporate the immune response in 
the fight against cancer will be impaired. For example tumour vaccines and gene 
therapy strategies enlist immune cells to attack and kill tumour cells. As animal 
models used in xenografts are immunodeficient by definition they lack all or a 
significant aspect of their immune function. However, there are several potential 
solutions to the immune response problem in the context of modelling 
immunotherapies. For example, it has been shown that non-disrupted pieces of 
tumour biopsy tissues implanted into SCID mice resulted in the co-engraftment 
of tumours plus tumour infiltrating lymphocytes (TIL), with TILs within the 
tumour graft remaining functional and responding to lymphocyte cytokines 
(Sugiyama et al. 2001). Human peripheral blood lymphocytes, injected 
subcutaneously with a human lung tumour into SCID mice, also engraft and
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display antitumour cytotoxic activity (Iwanuma et al. 1997). One could, 
therefore, envisage the use of immunodeficient mice (e.g. nude or SCIDs) with 
humanized immune systems following engraftment with human bone marrow 
stem cells (Lubin et al. 1991).
Development of a humanized mammary gland in animals
Although the mouse and human mammary glands share a reasonable level of 
similarity they also have some marked differences (Ronnov-Jessen et al. 1996). 
For example, due to the fact that the mouse mammary gland is composed entirely 
of adipocytes with fibroblasts prominent only in narrow sheaths around the ducts, 
whereas in the human gland the ducts are embedded in large tracts of connective 
tissue (composed predominantly of fibroblasts) that are adjacent to deeper layers 
of adipose tissue (Hovey et al. 1999 ), it is reasonable to suggest that the 
environment of the mouse mammary fat pad in mice is quite different to the 
human breast (Neville et al. 1998). Also human mammary epithelial cells are 
never found in the adipose tracts of the breast. Therefore, both human mammary 
stromal and epithelial cells may require and in turn thrive in the specialized 
stromal microenvironment of the human gland rather than the largely adipose 
tissue microenvironment of the mouse mammary gland.
In addition the actions of several steroid and peptide hormones appear to 
be mediated by an array of growth factors, proteases and ECM components 
synthesized by constituents of the mammary fat pad (Hovey et al. 1999). 
Furthermore, mammary adipose tissue represents a significant store of lipid that, 
by itself and through its derivatives, could influence the growth of mammary 
epithelium in diverse ways. In summary the vital role of the mammary fat pad 
during mammary gland development, emphasizes the point that the great species
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differences must be addressed if local growth and morphogenic mechanisms 
within the mammary gland are to be resolved.
In an attempt to overcome these problems cleared mammary fat pads 
were commonly used in early xenotransplantation studies (DeOme 1959). This 
technique took advantage of the fact that the mouse mammary gland is not fully 
developed at 3 weeks of age, making it possible to excise the rudimentary mouse 
mammary epithelium from the fat pad yielding a cleared fat pad devoid of any 
epithelium. However cleared fat pads still contain several other cell types, such 
as fibroblasts, endothelial cells and cells of the immune system, all of which 
could influence mammary gland development. Attempts to recapitulate human 
breast epithelial morphogenesis by introducing human mammary epithelial cells 
into the cleared mammary fat pads of mice have not yielded similar results. 
Unlike their murine counterparts, the introduced human mammary epithelial cells 
fail to colonize these fat pads and thus do not develop into ductal and lobular 
structures (Outzen and Custer 1975, Sheffield 1988) To get round this issue, 
researchers have attempted to recreate functional tissues by transplanting normal 
breast tissue fragments or collagen-embedded dissociated human mammary 
epithelial cells either subcutaneously or beneath the renal capsule of 
immunocompromised nude mice (Parmar et al. 2002, Yang et al. 1994). 
Although the tissue fragments and dissociated cells survive and respond to 
hormone stimulation, no outgrowth or expansion of the transplanted tissues has 
been observed.
For these reasons, one possible way forward would be to develop a new 
protocol for the establishment of human mammary stroma within the mouse 
mammary fat pad, anticipating that the resulting stroma would provide the proper 
environment for the development of human mammary epithelium.
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To be able to study normal breast homeostasis as well as tumourigenesis 
with the ultimate physiological relevance, a model must mimic not just the 
tissues in vivo but the entire organs involved (Bissell and Radisky 2001). In order 
for this to happen we must develop a ‘humanized’ mammary gland by replacing 
mouse mammary gland components with their human counterparts thereby 
reconstructing an organ that is comparable to the human gland in its architecture, 
organization and composition. In attempts to recreate breast tissues in mice past 
studies have attempted to introduce tissue fragments or dissociated mammary 
epithelial cells into the cleared mouse mammary fat pads of 
immunocompromised mice (Outzen and Custer 1975, Sheffield 1988). These 
attempts were unsuccessful in recreating functional, properly differentiated breast 
tissues, presumably due to the inadequate stromal environment provided by the 
mouse mammary fat pad. We now have the relevant cells and techniques (genetic 
and tissue engineering) to create a humanized mammary gland model in mouse, 
specifically in the mammary fat pad. Human mammary stromal fibroblasts 
grafted into the fat pads of nude mice support elaboration of transplanted human 
mammary epithelial cells into an infiltrating ductal tree that is highly 
differentiated and responsive to lactogenic cues (Kuperwasser et al. 2004). Once 
a humanized mammary fat has been established genetically modified epithelial or 
stromal cells can be incorporated thereby providing a model for the controlled 
analysis of specific molecules and pathways in an in vivo context. Furthermore, 
the humanized mouse could be used for other applications such as the 
development of strategies for reconstructing human breast after surgery (Huss 
and Kratz 2001).
Future versions of humanized mammary fat pads could incorporate 
human mammary progenitor cells. The existence of mammary epithelial stem
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cells has been the subject of much debate, but recent evidence demonstrates the 
existence of precursor cells within the luminal epithelial pool (Smith 1996, Stingl 
et al. 1998, Smalley et al. 1999). Recently, (Gudjonnson et al. 2002a) have 
isolated and immortalized a human mammary progenitor cell that gives rise to 
structures that resemble terminal ductal lobular units (TDLU) when implanted 
either in Matrigel or orthotopically into nude mice (Gudjonsson et al. 2002b). 
Thus it seems reasonable that introduction of human progenitor cells in the 
mouse mammary gland may be a useful strategy for generating chimeric animals 
with extensively humanized mammary organs.
Ultimate model
It is natural to assume that the more human components are used the greater the 
resemblance to the human situation. Once these issues are overcome then the 
more complex problems of growth and serum factors as well as hormonal 
influences and dependency have to be addressed. The closer this model 
resembles human breast cancer in vivo the more credible preclinical trials will 
become.
To conclude, as metastasis is the primary cause of mortality in breast 
cancer the ultimate goal is to develop authentic models of local invasion and 
metastases. If and when a fully humanized xenograft model is built containing 
human stroma including human blood vessels, one can commence development 
of chemotherapeutic strategies that target these components that permit local 
invasion and metastases. As these targets within the mouse model will be of 
human origin with typical human antigen expression profiles the relevance of 
this model as a pre-clinical model will be undoubted.
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Appendix I  Source of reagents
Reagent Source
Acetone BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Benzamidine hydrochloride BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
P-mercaptoethanol BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Borate: di-sodium tetraborate AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Bovine serum albumin (BSA) Sigma, Poole, Dorset, UK
Calcium chloride Sigma, Poole, Dorset, UK
Chloroform AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
‘Chloros’ (10%) Sodium hypochlorite Haychlor-Hayes Chemicals 
West Yorkshire, UK
Chymotrypsin Sigma, Poole, Dorset, UK
Citifluor antifadant AF1 Citifluor Ltd, University of Kent, 
Canterbury, Kent, UK
Deoxycholate AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
diaminobenzidine tetrahydrochloride, 3- 
3* diaminobenzidine (DAB)
BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
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Dimethyl Sulphoxide Sigma, Poole, Dorset, UK
DEPC water Sigma, Poole, Dorset, UK
DNTPs Perkin Elmer, via Applied Biosystems, 
Birchwood Science Park, North 
Warrington, UK
DPX mountant BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Dulbecco’s PBS (EDTA) Biowhittaker
EGM-2 Bullitkit Biowhittaker
Eosin BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Ethanol AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
ethylenediaminetetraacetic acid in Ca++ 
and Mg++ free Dulbecco’s PBS 
(EDTA)
Imperial, Andover, Hampshire, UK
Ficoll-Hypaque Sigma, Poole, Dorset, UK
Foetal calf serum (FCS) Imperial, Andover, Hampshire, UK
Formaldehyde AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Glutaradehyde BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Glycine BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Ham’s F12 Biowhittaker
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Hanks balanced salt solution Gibco, via Life Technologies, 
Paisley, Renfrewshire, UK
Harris type haematoxylin Sigma, Poole, Dorset, UK
Hoechst 33258 Hoechst, now Aventis, Strasbourg, 
F67917, Germany
Hydrochloloric acid (HC1) BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Hydrogen peroxide AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Hydrocortisone Sigma, Poole, Dorset, UK
Hydromount National Diagnostics, Hull, 
Humberside, UK
Insulin Sigma, Poole, Dorset, UK
Isopropanol AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
L-glutamine Sigma, Poole, Dorset, UK
Matrigel Becton Dickinson 
Labware, Bedford 
MA, USA
Methanol AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Methylene blue Sigma, Poole, Dorset, UK
O.C.T. compound Tissue-Tek 
RA Lamb Ltd 
Eastbourne, East Sussex
RPMI 1640 Medium Gibco, via Life Technologies,
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Paisley, Renfrewshire, UK
Penicillin Gibco, via Life Technologies, 
Paisley, Renfrewshire, UK
Phenol AnalaR Sigma, Poole, Dorset, UK
Phosphate buffered saline (PBS) Sigma, Poole, Dorset, UK
Sodium chloride AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Sodium citrate AnalaR BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Streptomycin Gibco, via Life Technologies, 
Paisley, Renfrewshire, UK
Trishydroxymethy 1 -methylamine (Tris)- 
HC1
BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Triton-X Sigma, Poole, Dorset, UK
Trypsin Sigma, Poole, Dorset, UK
Tween-20 Organises Sigma, Poole, Dorset, UK
Type III trypsin BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Water HiPerSolv for HPLC BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
Vectabond Vector Laboratories, Orton Southgate, 
Peterborough, UK
Vectasatin universal elite ABC Kit Vector Laboratories, Orton Southgate, 
Peterborough, UK
Xylene AnalaR BDH Laboratory Supplies, Merck,
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Lutterworth, Leicestershire, UK
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Appendix II  Source o f consumables
Consumable Source
Cell lifter Sigma, Poole, Dorset, UK
Coverslips (13mm) BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
0.4 pm pore sized polyethylene 
terephthalate membranes (1.6xl06 
pores /cm2) (Catalog Number 353095, 
BD Falcon™ 0.4 pm pore
BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
ECL Hyperfilm Amersham Life Science, Little 
Chalfont, Buckinghamshire, UK
25 cm2 flasks Falcon, via Becton Dickinson, Cowley, 
Oxford, UK
175cm2 flask Falcon, via Becton Dickinson, Cowley, 
Oxford, UK
Hamilton Syringe Hamilton Company, PO Box 10030, 
Reno, Nevada, USA
24 well plates Gibco, via Life Technologies, 
Paisley, Renfrewshire, UK
2 ml safe-lock tubes BDH Laboratory Supplies, Merck, 
Lutterworth, Leicestershire, UK
15ml tube Falcon, via Becton Dickinson, Cowley, 
Oxford, UK
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Appendix III Source o f equipments and computer programs
Program Source
Anglia Scientific AS300 Microtome Anglia Instruments, Cambridge,UK
Adobe Photoshop v7.0, Adobe Systems Inc., California, 
USA
Axiophot microscope Zeiss, Wellyn Garden City, 
Hertfordshire, UK
Bright Cryostat Huntingdon, Cambridgeshire, England
Centrifuge 5410 for 5000rpm Eppendorf, via Merck Eurolab Ltd, 
Poole, Dorset, UK
Centrifuge IEC Centra MP4R for 
14000rpm
Thermo Quest, Basingspole, 
Hampshire, UK
Coolview 12 cooled Charge Coupled 
Device (CCD) camera
Photonic Science, Newbury, Berkshire, 
UK
High resolution Leaf camera ISS, Greater Manchester, UK
Image-Pro Plus v 4.01, Media Cybernetics, Baltimore, 
Maryland, USA
MRX microplate reader Dynatech Laboratories, Ashford, 
Middlesex, UK
PU8625 UV/VIS Spectrophotometer Philips, Cambridge, Cambridgeshire, 
UK
Personal computer Dell, Bracknell, Berkshire, UK
SCSI interface AHA-2940, Adeptec Inc., California, 
USA
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Shaker Genetic Research Instrumentation, 
Felsted, Essex, UK
Shandon Citadel™ 2000 Tissue 
Processor
Thermoelectron, Bucks
125-ml Wheaton Magna Flex Spinner 
Flask
(Fisher/Wheaton Scientific, Pittsburgh, 
PA)
Snapper frame grabber card Action Imaging, Huntingdon, 
Cambridgeshire, UK
SPSS version 7.5 Illinois 60606, USA
Windows 95 version 4.0 Microsoft, London, East Anglia, UK
125-ml Wheaton Magna Flex Spinner 
Flask
(Fisher/Wheaton Scientific, Pittsburgh, 
PA)
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